page 1 409 clinical guidelines diagnosis treatment manual curative programmes hospitals dispensaries guidance prescribing medecins sans frontieres rights reserved countries reproduction translation adaptation may done without prior permission copyright ownerwere working fix technical issues msf guidelines app affecting offline access page 2 409isbn medecins sans frontieres clinical guidelines diagnosis treatment manual december 2024 9782375852767page 3 409table contents authorscontributors preface abbreviations acronyms chapter 1 symptoms syndromes chapter 2 respiratory diseases chapter 3 gastrointestinal disorders chapter 4 skin diseases chapter 5 eye diseases chapter 6 parasitic diseases chapter 7 bacterial diseases chapter 8 viral diseases chapter 9 genitourinary diseases chapter 10 medical minor surgical procedures chapter 11 mental disorders adults chapter 12 conditions appendices main referencespage 4 409authorscontributors clinical guidelines developed medecins sans frontieres msf would like express sincere gratitude everyone contributed developing guidelines coauthors grace dubois blandine vasseurbinachon cedric yoshimoto contributors gabriel alcoba beatriz alonso mohana amirtharajah haydar alwash catherine bachy roberta caboclo severine caluwaerts cristina carreno arlene chua kate clezy annesophie coutin marcio da fonseca martin de smet eva deplecker carolina echeverri sylvie fagardsultan roopan gill sonia guinovart jarred halton kerstin hanson christian heck caroline henryostian cathy hewison yveslaurent jackson carolina jimenez john johnson rupa kanapathipillai mohamad khalife nadia lafferty amin lamrous james lee helen mccoll natasha mlakar juno min miguel palma isabella panunzi roberta petrucci nicolas peyraud ernestina repetto jean rigal koert ritmeijer julia sander raghda sleit erin stratta alex telnov malcolm townsend clara van gulik specific support given international guidelines publication team editor veronique grouzard language editors mohamed elsonbaty ramadan carolina lopez anna romero layout designer evelyne laissu page 5 409preface guide designed use medical professionals involved curative care dispensary primary hospital tried respond simplest practical way possible questions problems faced field medical staff using accumulated field experience medecins sans frontieres recommendations reference organizations world health organization specialized works field edition touches curative lesser extent preventive aspects main diseases encountered field list incomplete covers essential needs guide used programmes supported medecins sans frontieres also programmes contexts notably integral part emergency health kit medecins sans frontieres also issued french spanish arabic editions editions languages also produced field guide collaborative effort medical professionals many disciplines field experience despite efforts possible certain errors may overlooked guide please inform authors errors detected important remember doubt responsibility prescribing medical professional ensure doses indicated manual conform manufacturer specifications ensure guide continues evolve remaining adapted field realities please send comments suggestions treatment protocols regularly revised please check monthly updatespage 6 409abbreviations acronyms last update october 2023 page 7 409ace angiotensin converting enzyme act artemisininbased combination therapy afb acidfast bacillus alt alanine aminotransferase arv antiretroviral ast aspartate aminotransferase bcg bacillus calmetteguerin bmi body mass index bp blood pressure c degree celsius coamoxiclav amoxicillin clavulanic acid cotrimoxazole sulfamethoxazole trimethoprim crt capillary refill time csf cerebrospinal fluid cmv cytomegalovirus d1 d2 d3 etc day 1 first day day 2 2 day day 3 3 day etcnd rd dl decilitre efast extended focused assessment sonography trauma fbc full blood count g gram hbp high blood pressure hypertension hf heart failure hiv human immunodeficiency virus hr heart ratepage 8 409ig immunoglobulin im intramuscular io intraosseous iu international unit iv intravenous kcal kilocalorie kg kilogram lp lumbar puncture mg milligram miu million international units ml millilitre mmhg millimetre mercury mmol millimole msf medecins sans frontieres nsaid nonsteroidal antiinflammatory drug ors oral rehydration solution salts pcp pneumocystosis pcr polymerase chain reaction po per os oral administration pocus pointofcare ultrasound prbc packedred blood cells rr respiratory rate sam severe acute malnutrition sc subcutaneous smx sulfamethoxazolepage 9 409 smx tmp sulfamethoxazole trimethoprim cotrimoxazole spo2 arterial blood oxygen saturation measured pulse oximetry tab tablet tb tuberculosis tmp trimethoprim world health organization page 10 409chapter 1 symptoms syndromes shock generalised tonicclonic seizures convulsive status epilepticus hypoglycaemia fever pain anaemia dehydration severe acute malnutrition page 11 409shock last updated september 2023 shock condition widespread reduced tissue perfusion inadequate oxygen delivery prolonged shock result cellular dysfunction irreversible organ failure mortality high without early diagnosis treatment clinical features shock suspected patients children accurate bp measurement difficult hypotension late sign shock therefore critically ill childrenshould treated shock present least one following signs lower limb temperature gradient crt 3 seconds weak radial pulse severe tachycardia clinical features may vary according type shock signs hypotension weak pulse low declining blood pressure bp narrow pulse pressure acute onset signs tissue hypoperfusion skin pallor mottled skin sweating cold extremities lower limb temperature gradient capillary refill time crt 3 seconds b lungs tachypnea dyspnoea heart tachycardia often occurs bp decreases kidney oliguria urine output 05 1 mlkghour anuria brain thirst anxiety agitation confusional state apathy altered mental status c b 1 2 page 12 409type specific clinical features risk factors distributive severe vasodilation increased capillary permeability resulting maldistribution blood flowanaphylaxis likely either following 2 criteria develop within minutes hours 3 involvement skin andor mucous membranes eg generalised urticaria itching flushing swollen lipstongueuvula 1 following respiratory symptoms wheeze dyspnoea low bp symptoms endorgan dysfunction hypotonia incontinence severe gastrointestinal symptoms abdominal pain repetitive vomiting hypotension bronchospasm laryngeal involvement stridor vocal changes odynophagia exposure known probable allergen patientrecent exposure allergen eg food sting medicine history anaphylaxis septic shock signs infection fever hypothermia altered mental status dyspnoea persisting hypotension despite fluid resuscitation 4infection recent surgery immunodeficiency cardiogenic cardiac pump failureischaemia chest pain dyspnoea arrhythmia murmur valvular heart diseasehistory cardiac disease advanced age acute heart failure see heart failure adults chapter 12history cardiac disease viral illness immunodeficiency hypovolaemic direct bloodfluid loss fluid sequestration extravascular space resulting decreased intravascular volumehaemorrhagic external bleeding signs symptoms internal bleeding hypotension atrauma recent surgery obstetric haemorrhage nonhaemorrhagic dry mouth absence tears sunken eyesfontanelle low jugular venous pressure jvp altered mental statusprofuse diarrhoea andor vomiting intestinal obstruction obstructive obstruction blood flow heart great vesselspulmonary embolism pe chest pain tachycardia tachypnoea hypoxia deep vein thrombosis dvt leg pain swelling warmthrecent surgery immobilisation cancer history pe dvt tension pneumothorax decreased breath sounds raised jvp weak radial pulse tracheal deviationtrauma invasive medical procedure cardiac tamponade pulsus paradoxus raised jvp narrow pulse pressure muffled heart sounds b trauma immunodeficiency children young adults hypovolaemic shock bp may maintained initially subsequently declines rapidly fluid loss replacedpage 13 409management primary objective shock management restore adequate tissue perfusion demonstrated initial management ongoing care basic life support 1 manage airways breathingbpulsus paradoxus measured taking patients bp expiration inspiration defined decrease 10 mmhg sbp inspiration compared expiration attend patient immediately even type shock known call help move critical care unit possible assess manage airway b breathing c circulation according basic life support see anaphylaxis suspected immediately go specific management take rapid history try determine underlying cause monitor urine output hourly insert urinary catheter hr rr bp temperature crt spo level consciousness 2 perform following tests haemoglobin blood glucose level malaria rapid diagnostic test endemic area see malaria chapter 6 blood culture available blood group children administer ceftriaxone iv one dose 80 mgkg reassess need antibiotic treatment according underlying cause e treat pain see pain chapter 1 returning vital signs crt spo mental status etc normal 2 maintaining mean arterial pressure map 65 mmhg adults higher patient preexisting hypertension f maintaining urine output 05 1 mlkghour take detailed history perform comprehensive physical examination case dehydration see dehydration chapter 1 case blunt thoracic abdominal trauma perform pocus efast exam evaluate pneumothorax free fluid pleural pericardial andor peritoneal spaces refer surgeon required g reevaluate patients condition response treatment every 10 minutes patient stable perform second comprehensive physical examination initiate nutritional support adapted patients needs soon possible reassess regularly patients high protein energy requirements enteral route preferred lay patient back however spinal trauma suspected move patient case anaphylaxis patient may prefer sitting position case altered mental status prepared mask bag needed ventilation remove airway obstruction eg secretions foreign body open airway stand head bed place one hand forehead gently tilt head back simultaneously place fingertips hand chin lift chin suspicion spinal trauma move neck instead place heels hands patients parietal areas use index middle fingers hands push angle mandible anteriorly jaw thrustpage 14 409 2 maintain circulation anaphylaxis repeat 5 minutes poor clinical improvement total 3 im injections repeat bolus signs poor perfusion persist 15 minutes septic shock look source infection possible take specimens culture starting antibiotic treatmentif needed insert oropharyngeal airway auscultate lungs assess ventilation administer 10 15 litresminute oxygen mask maintain spo 94 2 sporemains 94 oxygen see resources allow 2 control bleeding apply direct manual pressure andor compressionhaemostatic dressing wound case massive lifethreatening bleeding extremity eg leg controlled direct pressure apply windlass tourniquet h 5 insert 2 peripheral iv lines catheters 2022g children 1418g adults intraosseous io needle administer ringer lactate rl glucose 5ringer lactate g5rl andor blood following specific management described reassess giving additional fluid therapy monitor fluid overload especially patients risk eg severely malnourished children patients severe malaria heart disease severe anaemia older patients j k maintain normal body temperature unable maintain bp see resources allow remove exposure causal agent administer epinephrine adrenaline im midanterolateral thigh use undiluted solution 1 ml syringe graduated 001 ml 6 children 6 months 01 015 ml children 6 months 5 years 015 ml children 6 12 years 03 ml children 12 yearsand adults 05 ml l monitor hr bp crt clinical response case stridor administer nebulized epinephrine 05 mgkgdose max 5 mg 5 ml 09 sodium chloride 10 15 minutes spo 94 ventilate bag mask 2 administer bolus rl children 10 mlkg quickly possible adults 500 ml quickly possible shock persists 3 im injections epinephrine particular unable maintain bp see ressources allow initial treatment epinephrine iv fluids patients eg patients requiring continuing treatment 2 doses epinephrine im patients ongoing asthma shock may benefit short course corticosteroid therapy patient stable prednisolone po 1 2 mgkg max 50 mg daily morning 3 5 days use iv corticosteroid patient cannot take oral treatment fluid therapy children adolescents 15 years g5rl solution maintenance fluids see appendix 1 adolescents 15 years adults one bolus 250 500 ml rl quickly possible antibiotic treatment start antibiotics according suspected origin infection within 1 hour presentationsee tables 7 page 15 409 source unknown administer broadspectrum antibiotic cover grampositive gramnegative anaerobic bacteria possible take account local epidemiology rates types resistance differentiate community acquired sepsis nosocomial sepsis pathogens rates resistance may different simplify antibiotic treatment narrower spectrum whenever possible reassess treatment daily culture results available adapt treatment accordingly improvement 24 48 hours change oral route however foci eg meningitis require prolonged iv treatment improvement 48 96 hours consider resistant pathogen particular patients immunodeficiency recent last month hospitalisation antibiotic use adapt treatment accordingly measures control infection suspected catheterrelated infection insert new catheter another site remove suspected catheter drain softtissue abscess see cutaneous abscess chapter 10 irrigate debride traumatic wounds refer surgeon needed debridement drainage relieving obstruction etc treatment fever see fever chapter 1page 16 409origin antibiotics alternatives c cutaneous staphylococci streptococci dcloxacillin vancomycin risk factors mrsa e cefazolin vancomycin risk factors mrsa f e pulmonary pneumococci h influenzaeceftriaxone azithromycin gentamicin risk factors mdr gram negative bacteria g clindamycin ciprofloxacin doxycyline intestinal biliary enterobacteria anaerobic bacteria enterococciceftriaxone metronidazole gentamicin risk factors mdr gram negative bacteria ampicillin biliary source g clindamycin ciprofloxacin gynaecological streptococci gonococci anaerobic bacteria e coliceftriaxone metronidazole azithromycinclindamycin gentamicin azithromycin urinary enterobacteria enterococciceftriaxone amikacin risk factors pseudomonas h meropenem amikacin risk factors pseudomonas h central nervous system see bacterial meningitis chapter 7 undeterminedampicillin gentamicin childrenceftriaxone cloxacillin amikacin children ceftriaxone amikacin risk factors pseudomonas adults h clindamycin ciprofloxacin adults conly firstline antibiotic available allergic patients dfor necrotising infections see necrotising infection skin soft tissues chapter 10 erisk factors mrsa prior mrsa infection recent hospitalisation antibiotic use recurrent skin infection chronic wounds invasive device settings high rates mrsa fdo administer severe betalactam allergy grisk factors multiresistant mdr gram negative bacteria recent hospitalisation intensive care unit antibiotic use hrisk factors pseudomonas immunodeficiency recent hospitalisation antibiotic use burns presence invasive device page 17 409antibiotics children 1 month adults amikacin im slow iv injection 3 minutes15 mgkg max 15 g daily 15 mgkg daily ampicillin iv infusion 30 minutes50 mgkg max 2 g every 8 hours 2 g every 6 8 hours 2 g every 4 hours meningitis azithromycin po ngt 10 20 mgkg max 500 mg daily500 mg 1 g daily cefazolin slow iv injection 3 minutes iv infusion 30 minutes25 mgkg max 3 g every 12 hours 2 g every 8 hours ceftriaxone slow iv injection 3 minutes iv infusion 30 minutes80 mgkg max 4 g daily 100 mgkg max 4 g daily meningitis2 g daily 2 g every 12 hours meningitis ciprofloxacin po ngt 15 20 mgkg max 750 mg every 12 hours500 750 mg every 12 hours ciprofloxacin iv infusion 60 minutes10 mgkg max 400 mg every 8 hours400 mg every 8 12 hours clindamycin iv infusion 30 minutes10 mgkg max 600 mg every 8 hours600 900 mg every 8 hours cloxacillin iv infusion 60 minutes25 50 mgkg max 2 g every 6 hours2 g every 6 hours doxycycline po ngt 44 mgkg max 200 mg d1 22 mgkg max 100 mg every 12 hours200 mg d1 100 mg every 12 hours gentamicin im slow iv injection 3 minutes75 mgkg daily 5 mgkg daily meropenem iv infusion 15 30 minutes20 mgkg max 2 g every 8 hours 2 g every 8 hours metronidazole po ngt 10 mgkg max 500 mg every 8 hours500 mg every 8 hours metronidazole iv infusion 30 minutes10 mgkg max 500 mg every 8 hours500 mg every 8 hours vancomycin iv infusion 15 mgkg max 500 mg every 6 15 20 mgkg max 2 g every 12 hourspage 18 409 cardiogenic shock hypovolemic nonhaemorrhagic shock hypovolaemic haemorrhagic shock order prevent lethal trauma triad hypothermia acidosis coagulopathy repeat needed blood available stop rl administer blood immediately start second dose administered iv infusion 8 hours obstructive shock management described point provide temporary stabilization treat cause refer aetiological treatment f60 240 minutes hours administer rl extreme caution monitor closely signs fluid overload adults 100 250 ml 30 minutes subsequent fluid administration based thorough patient assessment including urinary output mental status spo2 vasopressors often required maintain bp see resources allow case acute heart failure see heart failure adults chapter 12 arrhythmias managed according advanced life support techniques appropriate available administer rl children 1 year 30 mlkg 1 hour 70 mlkg 5 hours childrenadolescents 1 14 years 30 mlkg 30 minutes 70 mlkg 25 hours adolescents 15 years adults 250 500 ml quickly possible repeated required adjusted patients condition providing 70 mlkg 25 hours determine blood group needed transfuse quickly possible children 20 kg 20 mlkg whole blood children 20 kg adults adult unit whole blood blood immediately available administer bolus rl caution ie minimize use rl waiting blood children 20 mlkg quickly possible adults 250 500 ml quickly possible warm patient blankets warm room warm iv fluids case trauma presenting within 3 hours administer tranexamic acid slow iv 10 minutes children 15 mgkg max 1 g adults 1 g case postpartum haemorrhage refer guide essential obstetric newborn care msf refer surgery needed pulmonary embolism anticoagulation thrombolysis tension pneumothorax needle decompressionfinger thoracostomy followed insertion chest tube cardiac tamponade pericardial tappage 19 409if resources allow protocols peripheral iv administration titrate according patients clinical situation refer management objectives including bp management manage airways breathing complete airway obstruction endotracheal intubation cricothyroidotomy respiratory failure noninvasive invasive mechanical ventilation maintain circulation unable achieve management objectives particular bp using fluid therapy signs fluid overload present case anaphylaxis shock persists 3 im epinephrine injections vasopressorsinotropes see used following conditions close monitoring critical care unit large peripheral iv catheterproximal forearm central venous catheter io line dedicated infusion n use electric syringe pump control flow rate intensive monitoring drug administration particularly syringe changes infused volumes must accounted recording fluid balance norepinephrine nep tartrate iepinephrine epn adrenaline indicationchildren 2choice adults 1 choicend stchildren 1 choice adults 2 choicest nd preparation diluted solution jchildren add 1 ml 2 mg nep tartrateto 39 ml 09 nacl obtain 005 mgml 50 microgramsml solution children add 2 ml 2 mg epn 38 ml 09 nacl obtain 005 mgml 50 microgramsml solution adults add 2 ml 4 mg nep tartrateto 38 ml 09 nacl obtain 01 mgml 100 microgramsml solution adults add 4 ml 4 mg epn 36 ml 09 nacl obtain 01 mgml 100 microgramsml solution starting rate k01 microgramkgminute rate increasing k increase 005 microgramskgminute every 10 minutes first hour every hour max 1 microgramkgminute rate decreasing k taper doses management objectives attained stop abruptly decrease 005 microgramskgminute every hour i2 mg nep tartrate 1 mg nep base j09 sodium chloride 5 glucose rl used dilution kthe infusion rate calculated follows desired dose microgramkgmin x weight kg x 60 min concentration microgramml ongoing care measure serum potassium magnesium calcium phosphate levels correct abnormalities additional investigations eg xrays laboratory tests may indicated depending aetiology suspectedpage 20 409 referencesfootnotes ahypotension based systolic blood pressure sbp adults sbp 90 mmhg decrease sbp 40 mmhg baseline mean arterial pressure map 65 mmhg shock often accompanied hypotension may also occur normal elevated bp brun back hand toe knee notable temperature change cold foot warm knee positive temperature gradient indicating distal hypoperfusion ccritically illappearing child weak grunting crying drowsy difficult arouse smile disconjugate anxious gaze pallor cyanosis general hypotonia dchildren 1 year 180 bpm children 1 5 years 160 bpm children 5 years 140 bpm efor iv administration ceftriaxone dissolve water injection fmap diastolic bp dbp 13 sbpdbp patient bp 9060 map 60 13 9060 70 gpocus performed interpreted trained clinicians hthe patient receive surgery within 1 hour application windlass tourniquet 1 hour risk ischaemic injury limb surgery possible tourniquet required save patients life left place tourniquet applied 6 hours left place arrival facility capable providing definitive surgical care icrystalloids used colloids eg modified fluid gelatin albumin recommended jremove 50 ml rl 500 ml rl bottle bag add 50 ml 50 glucose remaining 450 ml rl obtain 500 ml 5 glucoserl solution kin case fluid overload sit patient reduce infusion rate minimum administer furosemide iv 05 mgkg children 40 mg adults monitor patient closely 30 minutes assess underlying cardiorespiratory renal disease patient stabilised reassess necessity continuing iv fluids iv fluids still required restart half previous infusion rate monitor closely lif small prepubertal children administer 03 ml epinephrine mfor example methicillinresistant staphylococcus aureus mrsa pseudomonas species gramnegative bacteria extendedspectrum betalactamase esbl activity nwhen using peripheral vein monitor infusion site closely signs extravasation particular young children oif system control volume delivery flow rate eg syringe pump infusion using infusion bag standard paediatric giving set considered extreme situations temporary measure however important consider risks related type administration accidental bolus insufficient dose infusion must constantly monitored prevent even small change prescribed rate 1houston ka george ec maitland k implications paediatric shock management resourcelimited settings perspective feast trial crit care 2018221119 httpsdoiorg101186s1305401819664 2cecconi de backer antonelli et al consensus circulatory shock hemodynamic monitoring task force european society intensive care medicine intensive care med 2014401217951815 httpsdoiorg101007s001340143525z 3cardona v ansotegui ij ebisawa et al world allergy organization anaphylaxis guidance 2020 world allergy organ jpage 21 40920201310100472 published 2020 oct 30 httpsdoiorg101016jwaojou2020100472 4singer deutschman cs seymour cw et al third international consensus definitions sepsis septic shock sepsis3 jama 20163158801810 httpsdoiorg101001jama20160288 5richey sl tourniquets control traumatic hemorrhage review literature world j emerg surg 2007228 published 2007 oct 24 httpsdoiorg10118617497922228 6emergency treatment anaphylaxis guidelines healthcare providers rescuscitation council uk updated 2021 accessed may 31 2023 httpswwwresusorguksitesdefaultfiles2021 05emergency20treatment20of20anaphylaxis20may202021_0pdf 7evans l rhodes alhazzani w et al surviving sepsis campaign international guidelines management sepsis septic shock 2021 intensive care med 2021471111811247 httpsdoiorg101007s0013402106506ypage 22 409generalised tonicclonic seizures convulsive status epilepticus last updated october 2024 generalised tonicclonic seizures involuntary movements sides body associated impaired loss consciousness result abnormal brain activity seizures brief less 5 minutes resolve spontaneously may occur may recur young children seizures frequently occur context fever underlying causes defined febrile seizures seizure lasting longer 5 minutes 2 seizures 5 minutes without complete restoration baseline consciousness seizures defined status epilepticus status epilepticus medical emergency requiring immediate management longer seizure lasts difficult stop greater risk permanent brain damage death pregnancy postpartum period seizures may manifestation eclampsia refer essential obstetric newborn care msf clinical features seizure signs may associated loss urine breathing difficulty cyanosis immediately seizure postictal phase patient experiences fatigue temporary symptoms confusional state headache memory loss focal deficits recovery usually occurs within 30 60 minutesbut may delayed first aid seizure febrile seizures 1 2 contraction muscles including respiratory muscles tonic phase followed rhythmic jerking arms legs clonic phase loss consciousness 3 note time call help protect falls trauma loosen clothing maintain airway place patient recovery position avoid aspiration put anything mouth treat hypoglycaemia present administer glucose unable measure capillary blood glucose immediately see hypoglycaemia chapter 1 depending context administer oxygen available febrile seizures likely see febrile seizures adults thiamine 100 mg iv infusion 100 ml 09 nacl 30 minutes may administered time glucose vitamin b deficiency suspected eg case alcoholrelated seizures 1 seizures stop spontaneously 5 minutes less see postictal managementpage 23 409febrile seizures frequently occur children aged 6 months 5 years fever usually due viral infection signs central nervous system cns infection metabolic disturbances history afebrile seizures may either simple complex status epilepticus case status epilepticus start antiseizure medication asm step 1 firstline asm treatment status epilepticus prehospital setting status epilepticus hospital setting 4 simple febrile seizure defined single generalised seizure without focal signs lasts less 15 minutes recur within 24hour period seizures last less 5 minutes antiseizure treatment required risk subsequent epilepsy low type seizure observe child least full recovery discharge child returns neurological baseline give instructions homebased management symptomatic treatment fever make child comfortable see fever chapter 1 underlying viral infection relevant 4 complex febrile seizure seizure meeting least one following criteria presence focal signs duration 15 minutes multiple seizures within 24hour period 4 cases provide first aid seizure seizure see postictal management seizure lasts 5 minutes recurs within 5 minutes start treatment status epilepticus asms may cause respiratory depression bradycardia hypotension especially children older patients asm administration ventilation equipment ambu mask solutions fluid replacement ready use monitor rr spo hr bp least every 15 minutes stable 2 never administer asms rapid iv injection reduce administration rate event drop rr hr bp administer one following benzodiazepines bzd choice depends situation ie seizures occur prehospital hospital setting case administer 2 doses bzd administer midazolam 5 mgml solution buccal intranasalroute diazepam 5 mgml solution rectal route doses administered see table 1 seizures stop 5 minutes first dose bzd readminister dose seizures stop second dose bzd refer urgently hospital treatment secondline asms seizures stop 1 2 doses bzd refer hospital management aetiologic treatment potential maintenance treatment awaiting transfer monitor vital signs administer oxygen available maintain spo 94 seizures stop see postictal management2page 24 409check whether bzd administered arrival hospital number doses one dose administered give second dose 2 doses administered start step 2 secondline asm treatment prehospital dose bzd administered table 1 dosage benzodiazepines iv io access diazepam 5 mgml solution slow iv injection 3 5 minutes doses administered see table 1 iv io access midazolam 5 mgml solution buccal intranasalroute midazolam 1 mgml solution im route diazepam 5 mgml solution rectal route doses administered see table 1 seizures stop 5 minutes first dose bzd readminister dose seizures stop second dose bzd start step 2 secondline asm treatment seizures recur 6 hours seizures stop restart treatment step 1 firstline asm treatment new seizure less 6 hours seizures stop continue treatment last point eg seizures recur 6 hours first dose bzd readminister dose seizures recur 6 hours 2 doses bzd start step 2 secondline asm treatment seizures stop 1 2 doses bzd recur see postictal management evaluate need maintenance asm treatment age 1 4 months4 12 months1 3 years3 5 years5 9 years 9 12 years 12 years adults weight 3 6 kg6 10 kg10 15 kg15 20 kg20 30 kg30 40 kg 40 kg midazolam buccal intranasal route dose ml 5 mgml solution b 025 ml 04 ml 06 ml 1 ml 12 ml 2 ml 2 ml midazolam im route dose ml 1 mgml solution 06 ml 12 ml 2 ml 3 ml 4 ml 6 ml 10 ml diazepam rectal route dose ml 5 mgml solution c 04 ml 07 ml 12 ml 15 ml 2 ml 2 ml 2 4 ml diazepam slow iv route dose ml 5 mgml solution 025 ml 04 ml 06 ml 1 ml 12 ml 2 ml 2 ml amidazolam buccal route lay patient side withdraw required dose using 1 ml 2 ml syringe remove needle insert tip syringe space gum cheek administer dose slowly pushing syringe plunger bmidazolam intranasal route lay patient back side withdraw required dose using 1 ml 2 ml syringe add additional 01 ml calculated dose account remaining liquid atomising device remove needle attach intranasal atomisation device syringe briskly push syringe plunger spray dose nostril dose split nostrils reduce irritation cdiazepam rectal route lay patient side volumes 1 ml use 1 ml syringe withdraw required dose remove needle insert syringe rectum length 1 3 cm depending age administer dose volumes greater 1 ml use 2 ml syringe attach tip syringe nasogastric tube n8 cut length 2 3 cm administer dose administration hold buttocks together least one minutepage 25 409step 2 secondline asm treatment patients known epilepsy secondline asms indicated choice asm depends patients characteristics age sex pregnancy breastfeeding status comorbidities see table 2 doses administered see table 3 table 2 choice secondline antiseizure medication patients known epilepsydin patients 65 years diazepam rectal exceed 2 ml 10 mg per dose diazepam iv reduce dose half 1 ml 5 mg per dose children seizures stop within 5 minutes second dose bzd adults even seizures stop 1 2 doses bzd unless reversible cause seizure quickly treated eg hypoglycaemia electrolyte disturbances children 1 month 2 years girls 10 years womengirls 2 10 years boys 2 years men first choice levetiracetam lev elevetiracetam levor valproic acid vpa e f second choice phenobarbital pb gphenobarbital pb g third choice phenytoin pht hphenytoin pht h elev used patients caution patients renal impairment heart disorders fvpa contraindicated children 2 years patients hepatic disease women girls may become pregnant every effort made find safer alternative vpa pregnant women girls however prolonged status epilepticus lifethreatening condition mother unborn child vpa asm available use lowest possible dose gpb contraindicated patients severe impairment respiratory renal hepatic function administered caution children older patients patients mild moderate impairment respiratory renal hepatic function hpht contraindicated patients bradycardia atrioventricular block administered caution patients hepatic impairment heart failure cardiac rhythm disorders hypotension seizures stop secondline asm change another secondline asm seizures stop recur 6 hours despite 2 secondline asms transfer patient intensive care unit treatment refractory status epilepticus seizures stop 1 2 secondline asms see postictal management maintenance asm treatment history taking asm dose taken effectiveness missed doses reason eg forgetting interruption due adverse effects shortage medication management administer iv loading dose medication patient usually take see table 2page 26 409step 3 maintenance asm treatment patients may require maintenance treatment loading dose unless child already received loading dose start loading dose see table 3 postictal management frequent causes seizuresif seizures stop continue treatment patients known epilepsy seizures stop 1 2 secondline asms see postictal management maintenance asm treatment children maintenance treatment indicated secondline asm used control seizures unless reversible cause seizure quickly treated eg hypoglycaemia electrolyte disturbances 3 seizures occur within 24hour period focal signs andor impaired consciousness persist beyond expected postictal period known presumed traumatic brain injury within 24 hours injury known presumed epilepsy adults maintenance treatment indicated patients unless reversible cause seizure quickly treated eg hypoglycaemia electrolyte disturbances seizures recur administer maintenance treatment 48 72 hours reassess use oral route nasogastric tube maintenance doses administered see table 3 seizures context head trauma maintenance treatment last 7 days case epilepsy start resume longterm treatment see epilepsy chapter 12 note time end seizure keep patient recovery position maintain airway administer oxygen patients available especially patients received asms maintain spo 94 2 monitor vital signs spo every 15 minutes stable every hour 2 closely monitor rr patient received bzd pb pht hr bp ecg available patient received pht observe seizures soon possible try identify underlying cause treat even patients known epilepsy see frequent causes seizures take detailed history perform full clinical examination looking particularly general status focal signs depending assessment perform following tests available capillary blood glucose especially done seizure check regularly blood glucose necessary rapid diagnostic test malaria endemic areas csf examination lumbar puncture culture white blood cell count serum electrolytes creatinine liver enzymes coagulation tests blood culture note patient return baseline status within 30 60 minutes end seizure febrile seizures young children fever usually context respiratory gastrointestinal viral infection cns infections eg meningitis bacterial meningitis see chapter 7 severe malaria neurocysticercosis trypanosomiasis see chapter 6 cerebral toxoplasmosis cryptococcal meningitis see hiv infection aids chapter 8 metabolic abnormalities eg hypoglycaemia chapter 1 electrolyte disorders hyponatremia hypocalcaemia intoxications eg psychoactive drugs alcohol methanol medications neurotoxic pesticides venoms carbon monoxidepage 27 409dosage secondline antiseizure medications table 3 secondline antiseizure medications loading doses maintenance doses withdrawal cns depressants eg alcohol see agitation acute confusional state chapter 11 opioids benzodiazepines barbiturates use seizureprovoking drugs many drugs may involved eg antidepressants antipsychotics antimicrobials vitamin b deficiencies thiamine pyridoxine particularly patients chronic alcohol consumption epilepsy undiagnosed epilepsy poor adherence treatment ineffective treatment abrupt stop asm head trauma cns tumour stroke sepsis encephalopathy eg hypertensive hypoxicpage 28 409asms loading dose maintenance dose levetiracetam lev 500 mg 5 ml vial 100 mgmlchildren 1 month use diluted solution add 3 ml 300 mg lev 17 ml 09 nacl obtain 20 ml solution containing 15 mg lev per ml administer 40 mgkg max 3 g 10 minutes iv infusion using syringe pump slow iv injection seizures stop end first dose readminister halfdose 20 mgkg max 15 g exceed total dose 60 mgkg 45 g exceed infusion rate 5 mgkgminute12 hours loading dose 7 mgkg every 12 hours po 10 mgkg every 12 hours pochildren 1 5 months children 6 months 15 years adults 60 mgkg max 45 g single dose 15 minutes use diluted solution 15 mgml administered iv infusion using syringe pump use undiluted solution administered iv infusion bag 100 ml 09 nacl exceed infusion rate 5 mgkgminute12 hours loading dose adults 1 15 g every 12 hours po phenobarbital pb 200 mg 1 ml ampoule 200 mgmlchildren 1 month use diluted solution add 1 ml 200 mg pb 9 ml 09 nacl obtain 10 ml solution containing 20 mg pb per ml administer 20 mgkg max 1 g 20 minutes iv infusion using syringe pump available using pediatric infusion set seizures stop end first dose readminister halfdose 10 mgkg exceed infusion rate 1 mgkgminute12 hours loading dose children 1 11 months 5 6 mgkg daily po children 1 5 years 6 8 mgkg daily po children 6 12 years 4 6 mgkg daily po children 12 years 1 3 mgkg daily popage 29 409adults 15 mgkg max 1 g single dose 15 minutes use diluted solution 20 mgml administered iv infusion using syringe pump use undiluted solution administered iv infusion bag 100 ml 09 nacl exceed infusion rate 100 mgminute12 hours loading dose adults 60 180 mg daily po phenytoin pht 250 mg 5 ml ampoule vial 50 mgml use large central peripheral vein use infusion set line 02 micron filter infusion flush catheter 09 nacl limit venous irritation potential incompatibility drugs dilute glucose use line used glucose solutionchildren 1 month 25 kg use diluted solution add 1 ml 50 mg pht 9 ml 09 nacl obtain 10 ml solution containing 5 mg pht per ml administer 20 mgkg max 2 g single dose 20 minutes iv infusion using syringe pump syringe pump available use paediatric infusion set exceed infusion rate 1 mgkgminute12 hours loading dose children 25 mgkg every 12 hours po children 25 kg adults j add undiluted solution 100 ml bag 09 nacl administer 20 mgkg max 2 g single dose iv infusion following rate 1 g 50 kg 20 minutes 1 g 15 g 50 kg 75 kg 30 minutes 15 g 2 g 75 kg 100 kg 40 minutes exceed infusion rate 50 mgminute 12 hours loading dose adults 3 4 mgkg daily poolder patients 65 years adults cardiac disorders add undiluted solution 100 ml bag 09 nacl administer 20 mgkg max 2 g single dose iv infusion following rate 1 g 50 kg 40 minutespage 30 409 1 g 15 g 50 kg 75 kg 60 minutes 15 g 2 g 75 kg 100 kg 80 minutes exceed infusion rate 25 mgminute valproic acid vpa sodium valproate 400 mg 4 ml ampoule 100 mgml kchildren 2 years use diluted solution add 4 ml 400 mg vpa 6 ml 09 nacl obtain 10 ml solution containing 40 mg vpa per ml administer 20 mgkg max 15 g 5 minutes iv infusion using syringe pump slow iv injection seizures stop end first dose readminister dose 20 mgkg max 15 g exceed total dose 40 mgkg 3 g exceed infusion rate 6 mgkgminute6 8 hours loading dose 5 75 mgkg max 600 mg 2 times daily pochildren 2 years adults 40 mgkg max 3 g single dose 10 minutes use diluted solution 40 mgml administered iv infusion using syringe pump use undiluted solution administered iv infusion bag 100 ml 09 nacl exceed infusion rate 6 mgkgminute12 hours loading dose adults 1 g 2 times daily po ireduce dosage patients renal impairment jreduce dosage patients hepatic impairment kfor pregnant woman vpa asm available use lowest possible loading dose option could administer 20 mgkg 5 minutes repeat dose seizures stop end first dosepage 31 409referencesfootnotes athiamine administered time glucose glucose may precipitate wernickes encephalopathy patients chronic alcohol consumption treatment continued 3 5 days thiamine po 100 200 mg daily im 100 mg daily 1lowenstein dh bleck macdonald rl time revise definition status epilepticus epilepsia 1999401120122 httpsdoiorg101111j152811571999tb02000x 2brophy gm bell r claassen j et al guidelines evaluation management status epilepticus neurocrit care 201217323 httpshigherlogicdownloads3amazonawscomneurocriticalcareb8b3b384bfb942afbb55 45973d5054a4uploadedimagesdocumentsguidelinesse_guidelines_ncs_0412pdf 3pottkamper jcm hofmeijer j van waarde ja van putten mjam postictal state know epilepsia 202061610451061 httpsdoiorg101111epi16519 4steering committee quality improvement management subcommittee febrile seizures febrile seizures clinical practice guideline longterm management child simple febrile seizures pediatrics 200812161281 1286 httpsdoiorg101542peds20080939page 32 409hypoglycaemia last update november 2023 hypoglycaemia abnormally low concentration blood glucose severe hypoglycaemia fatal lead irreversible neurological damage blood glucose levels measured whenever possible patients presenting symptoms hypoglycaemia hypoglycaemia suspected blood glucose measurement available glucose another available sugar given empirically always consider hypoglycaemia patients presenting impaired consciousness lethargy coma seizures diagnosis treatment hypoglycaemia neonates refer guide essential obstetric newborn care msf clinical features rapid onset nonspecific signs mild severe depending degree hypoglycaemia sensation hunger fatigue tremors tachycardia pallor sweats anxiety blurred vision difficulty speaking confusion convulsions lethargy coma diagnosis capillary blood glucose concentration reagent strip test blood glucose measurement available diagnosis confirmed symptoms resolve administration sugar glucose symptomatic treatment symptoms improve approximately 15 minutes taking sugar oral route neurological symptoms improve minutes injection check blood glucose 15 minutes still low readminister glucose iv route sugar oral route according patients clinical condition clinical improvement differential diagnoses considered eg serious infection severe malaria meningitis etc epilepsy unintentional alcohol intoxication adrenal insufficiency children cases stabilisation give meal snack rich complex carbohydrates monitor patients hoursnondiabetic patients hypoglycaemia 33 mmollitre 60 mgdl severe hypoglycaemia 22 mmollitre 40 mgdl diabetic patients home treatment 39 mmollitre 70 mgdl 1 conscious patients children teaspoon powdered sugar ml water 50 ml fruit juice maternal therapeutic milk 10 mlkg 10 glucose oral route nasogastric tube adults 15 20 g sugar 3 4 cubes sugar water fruit juice soda etc patients impaired consciousness prolonged convulsions children 2 mlkg 10 glucose slow iv 2 3 minutes adults 1 mlkg 50 glucose slow iv 3 5 minutespage 33 409if patient return full alertness episode severe hypoglycaemia monitor blood glucose levels regularly aetiological treatment referencesother diabetes treat severe acute malnutrition neonatal sepsis severe malaria acute alcohol intoxication etc end prolonged fast replace drugs inducing hypoglycaemia eg quinine iv pentamidine ciprofloxacin enalapril betablockers high dose aspirin tramadol anticipate hypoglycaemia eg administer quinine iv glucose infusion diabetic patients avoid missing meals increase intake carbohydrates necessary adjust dosage insulin according blood glucose levels physical activity adjust dosage oral antidiabetics taking account possible drug interactions footnotes aif readymade 10 glucose solution available remove 100 ml 5 glucose 500 ml bottle bag add 50 ml 50 glucose remaining 400 ml 5 glucose obtain 450 ml 10 glucose solution 1american diabetes association standards care diabetes2023 abridged primary care providers clinical diabetes 2022411431 httpsdoiorg102337cd23as01page 34 409fever last updated december 2023 fever defined axillary temperature higher 375 c fever frequently due infection febrile patient first look signs serious illness try establish diagnosis signs severity infectious causes fever according signs symptomspetechial purpuric rash meningeal signs heart murmur severe abdominal pain dehydration signs severe bacterial infection sepsis critically ill appearance hypothermia altered level consciousness severe tachycardia hypotension tachypnoea respiratory distress seizures bulging fontanel young children signs circulatory impairment shock see shock chapter 1 page 35 409 laboratory examinationssigns symptoms possible aetiology meningeal signs seizures meningitismeningoencephalitissevere malaria abdominal pain peritoneal signs appendicitisperitonitisenteric feversamaebic liver abscess diarrhoea vomiting gastroenteritisenteric fevers jaundice enlarged liver viral hepatitis cough pneumoniameaslestuberculosis persistent eyelid erythema eye pain oedema orbital cellulitis ear pain red tympanic membrane otitis media tender swelling behind ear mastoiditis sore throat enlarged lymph nodes streptococcal pharyngitisdiphtheriaretropharyngeal tonsillar abscessepiglotittis multiple vesicles oral mucosa lips oral herpes dysuria urinary frequency back pain urinary tract infection red warm painful skin erysipelascellulitisnecrotising infections skin soft tissuesabscess limp difficulty walking osteomyelitisseptic arthritis rash measlesdengueviral haemorrhagic feverschikungunya bleeding petechiae epistaxis etc dengueviral haemorrhagic feverssevere malaria joint pain rheumatic feverchikungunyadengue patient ill appearingand persistent fever consider hiv infection tuberculosis according clinical presentation malaria rapid diagnostic test endemic areas case circulatory impairment shock see shock chapter 1 children 1 3 months fever without focus urine dipstick urine culture available blood culture available full blood count fbc availablepage 36 409aetiological treatment symptomatic treatment paracetamol po children 1 month 15 mgkg 3 4 times daily max 60 mgkg daily adults 1 g 3 4 times daily max 4 g daily ibuprofen po children 3 months 12 years 5 10 mgkg 3 4 times daily max 30 mgkg daily children 12 years adults 200 400 mg 3 4 times daily max 1200 mg daily acetylsalicylic acid asa po children 16 years adults 500 mg 1 g 3 4 times daily max 4 g dailylumbar puncture lp meningeal signs signs severe bacterial infection sepsis failure prior antibiotic treatment chest xray available case signs respiratory disease severe infection sepsis children 3 months 2 years fever without focus urine dipstick urine culture available lp meningeal signs signs severe bacterial infection sepsis chest xray available fever 72 hours signs severe bacterial infection sepsis blood culture available fever 72 hours signs severe bacterial infection sepsis fbc available fever 72 hours signs severe bacterial infection sepsis according clinical presentation children 2 years fever without focus urine dipstick urine culture available history urinary tract infection fever 72 hours signs severe bacterial infection sepsis lp meningeal signs signs severe bacterial infection sepsis chest xray available fever 72 hours signs severe bacterial infection sepsis blood culture available fever 72 hours signs severe bacterial infection sepsis fbc available fever 72 hours signs severe bacterial infection sepsis according clinical presentation adults according clinical presentation treat patients positive malaria test see malaria chapter 6 source infection found administer antibiotic treatment accordingly severe infection sepsis circulatory impairment shock hospitalise immediately administer empiric antibiotic treatment see shock chapter 1 continue treatment source infection found adapt antibiotic treatment accordingly source infection found signs severe infection sepsis circulatory impairment shock hospitalise investigations monitoring children 1 3 months children 3 months 2 years negative urine dipstick negative urine culture available malnourished children see severe acute malnutrition chapter 1 patients sickle cell disease see sickle cell disease chapter 12 undress patient wrap children wet towels cloths effective increases discomfort risk hypothermia antipyretics may increase patients comfort prevent febrile convulsions treat 3 days antipyreticspage 37 409prevention complications notes encourage oral hydration continue frequent breastfeeding infants look signs dehydration monitor urine output pregnant breastfeeding women use paracetamol case viral haemorrhagic fevers dengue acetylsalicylic acid ibuprofen contraindicated use paracetamol caution presence hepatic dysfunction footnotes acritically ill appearing child weak grunting crying drowsiness difficult arrouse smile disconjugate anxious gaze pallor cyanosis general hypotoniapage 38 409pain pain results variety pathological processes expressed differently patient depending cultural background age etc subjective experience meaning individual able assess hisher level pain regular assessment intensity pain indispensable establishing effective treatment clinical features pain assessment clinical examination synthesis synthesis information gathered history taking clinical examination allows aetiological diagnosis orients treatment important distinguish pain evaluation scales selfevaluation scale children 5 years adults simple verbal scale svsintensity use simple verbal scale children 5 years adults nfcs flacc scales children less 5 years see pain evaluation scales pattern sudden intermittent chronic rest night movement care procedures etc character burning cramping spasmodic radiating etc aggravating relieving factors etc organ area pain located specific signs underlying disease eg bone osteoarticular pain may caused vitamin c deficiency review systems associated signs fever weight loss etc nociceptive pain presents often acute pain causeeffect relationship usually obvious eg acute postoperative pain burns trauma renal colic etc pain may present different forms neurological exam normal treatment relatively well standardized neuropathic pain due nerve lesion section stretching ischaemia often chronic pain background constant less localized pain paraesthesia burning recurrent acute attacks electric shocklike pain frequently associated disordered sensation anaesthesia hypo hyperaesthesia type pain linked viral infections directly affecting cns herpes simplex herpes zoster neural compression tumors post amputation pain paraplegia etc mixed pain cancer hiv management requires broader approach intensity painno painmild painmoderate painsevere pain scoring 0 1 2 3 write 0 page 39 409 observational evaluation scale children 2 months5 years flacc scale face limb activity cry consolability category scored 0 2 giving final score 0 10 0 3 mild pain 4 7 moderate pain 7 10 severe pain observational evaluation scale children 2 months nfcs scale neonatal facial coding system score 2 signifies significant pain requiring analgesic treatment treatment treatment depends type intensity pain may aetiological symptomatic treatable cause identified treatment symptomatic cases cause found noncurable disease itemsscoring 0 1 2 face particular expression smileoccasional grimace frown withdrawn disinterestedfrequent constant frown clenched jaw quivering chin legs normal position relaxeduneasy restless tense kicking legs drawn activity lying quietly normal position moves easilysquirming shifting back forth tense arched rigid jerking cry cry awake asleepmoans whimpers occasional complaintcrying steadily screams sobs frequent complaints consolabilitycontent relaxed reassured occasional touching hugging talked distractibledifficult console comfort itemsscoring 0 1 brow bulge yes eye squeeze yes nasolabial furrow yes open lips yespage 40 409nociceptive pain classifies analgesics used type pain threestep ladder treatment pain based fundamental concepts treatment acute pain step 1 nonopioid analgesics paracetamol nonsteroidal antiinflammatory drugs nsaids step 2 weak opioid analgesics codeine tramadol combination one two step 1 analgesics recommended step 3 strong opioid analgesics first foremost morphine combination one two step 1 analgesics recommended pain treated correctly correctly evaluated person evaluate intensity pain patient use pain assessment scales invaluable pain evaluation observations recorded patient chart fashion vital signs treatment pain prompt possible recommended administer analgesics advance appropriate eg painful care procedures analgesics prescribed administered fixed time intervals demand oral forms used whenever possible combination different analgesic drugs multimodal analgesia advantageous start analgesic level presumed effective eg event fractured femur start step 3 analgesic treatment dose chosen guided assessment pain intensity also patients response may vary significantly one person another mild pain paracetamol nsaid moderate pain paracetamol nsaid tramadol codeine severe pain paracetamol nsaid morphinepage 41 409 analgesics childrenadults except pregnantbreastfeeding womenremarks level 1paracetamol po 1 month 10 mgkg every 6 8 hours max 40 mgkg daily 1 month 15 mgkg every 6 8 hours max 60 mgkg daily 1 g every 6 8 hours max 4 g dailythe efficacy iv paracetamol superior efficacy oral paracetamol iv route restricted situations oral administration impossible paracetamol iv 1 month 75 mgkg every 6 hours max 30 mgkg daily 1 month 10 kg 10 mgkg every 6 hours max 30 mgkg daily 10 kg 15 mgkg every 6 hours max 60 mgkg daily 50 kg 15 mgkg every 6 hours max 60 mgkg daily 50 kg 1 g every 6 hours max 4 g daily acetylsalicylic acid aspirin po 300 mg 1 g every 4 6 hours max 4 g dailyavoid children less 16 years diclofenac im 75 mg daily treatment must short possible respect contraindications ibuprofen po 3 months 5 10 mgkg every 6 8 hours max 30 mgkg daily 12 years adults200 400 mg every 6 8 hours max 1200 mg daily level 2 codeine po 12 years 30 60 mg every 4 6 hours max 240 mg daily30 60 mg every 4 6 hours max 240 mg dailyadd laxative treatment 48 hours tramadol po 12 years 50 100 mg every 4 6 hours max 400 mg daily50 100 mg every 4 6 hours max 400 mg daily 25 50 mg every 12 hours elderly patients patients severe renal hepatic impairment tramadol im slow iv infusion 12 years 50 100 mg every 4 6 hours max 600 mg daily50 100 mg every 4 6 hours max 600 mg daily level 3morphine po immediate release mir 6 months 015 mgkg every 4 hours ajusted relation pain intensity10 mg every 4 hours ajusted relation pain intensity reduce dose half elderly patients patients renal hepatic impairmentpage 42 409 notes use morphine derivatives rr remain equal greater thresholds indicated respiratory depression must identified treated quickly verbal physical stimulation patient administration oxygen respiratory support bag mask necessary improvement administer naloxone antagonist morphine bolus repeated every minute rr normalises excessive drowsiness resolves 5 microgramskg children 1 3 microgramskg adults add laxative treatment 48 hours morphine po sustained release msrthe daily dose determined initial treatment immediate release morphine mir treatment initiated directly msr 6 months 05 mgkg every 12 hours ajusted relation pain intensitythe daily dose determined initial treatment immediate release morphine mir treatment initiated directly msr 30 mg every 12 hours ajusted relation pain intensity initiate treatment msr elderly patients patients renal hepatic impairment begin treatment mir add laxative treatment 48 hours morphine sc im 6 months 01 02 mgkg every 4 hours01 02 mgkg every 4 hours reduce doses half administer less frequently according clinical response elderly patients patients severe renal hepatic impairment add laxative treatment 48 hoursmorphine iv 6 months 01 mgkg administered fractionated doses 005 mgkg every 10 minutes every 4 hours necessary01 mgkg administered fractionated doses 005 mgkg every 10 minutes every 4 hours necessary morphine effective treatment many types severe pain analgesic effect dosedependent adverse effects often exaggerated obstacle use serious adverse effect morphine respiratory depression may fatal adverse effect results overdose therefore important increase doses gradually respiratory depression preceded drowsiness warning monitor respiratory rate rr children 1 12 months rr 25 respirationsminute children 1 2 years rr 20 respirationsminute children 2 5 years rr 15 respirationsminute children 5 years adults rr 10 respirationsminute morphine codeine always cause constipation laxative prescribed opioid treatment continues 48 hours lactulose po drug choice children 1 year 5 ml daily children 16 years 5 10 ml daily children 714 years 10 15 ml daily adults 15 45 ml dailypage 43 409if patients stools soft stimulant laxative bisacodyl po children 3 years 5 10 mg daily adults 10 15 mg daily preferred children ondansetron po 015 mgkg max 4 mg per dose 3 times daily use metoclopramide children adults haloperidol po 2 mgml oral solution 1 2 mg 6 times daily metoclopramide po 5 10 mg 3 times daily interval least 6 hours dose combine haloperidol metoclopramide treatment nociceptive pain pregnant breastfeeding women neuropathic painnausea vomiting common beginning treatment chronic pain late stage disease cancer aids etc morphine po drug choice may necessary increase doses time according pain assessment hesitate give sufficient effective doses morphine tramadol codeine similar modes action combined buprenorphine nalbuphine pentazocine must combined morphine pethidine tramadol codeine competitive action analgesicspregnancy breastfeeding 05 monthsfrom 6 monthth level 1paracetamol first choicefirst choice first choice aspirin avoid contraindicated avoid ibuprofen avoid contraindicated possible level 2codeine possiblethe neonate may develop withdrawal symptoms respiratory depression drowsiness event prolonged administration large doses end thirdtrimester closely monitor neonateuse caution short period 23 days lowest effective dose monitor mother child event excessive drowsiness stop treatment tramadol possiblethe child may develop drowsiness mother receives tramadol end thirdtrimester breastfeeding administer caution short period lowest effective dose monitor child level 3morphine possiblethe child may develop withdrawal symptoms respiratory depression drowsiness mother receives morphine end third trimester breastfeeding administer caution short period lowest effective dose monitor childpage 44 409commonly used analgesics often ineffective treating type pain treatment neuropathic pain based combination two centrally acting drugs amitriptyline po adults 25 mg daily bedtime week 1 50 mg daily bedtime week 2 75 mg daily bedtime week 3 max150 mg daily reduce dose half elderly patients carbamazepine po adults 200 mg daily bedtime week 1 200 mg 2 times daily week 2 200 mg 3 times daily week 3 given teratogenic risk carbamazepine used women childbearing age covered effective contraception intrauterine device injectable progestogen recommended pregnant women mixed pain mixed pain significant component nociceptive pain cancer aids morphine combined antidepressants antiepileptics chronic pain contrast acute pain medical treatment alone always sufficient controlling chronic pain multidisciplinary approach including medical treatment physiotherapy psychotherapy nursing often necessary allow good pain relief encourage patient selfmanagement coanalgesics combination certain drugs may useful even essential treatment pain antispasmodics muscle relaxants anxiolytics corticosteroids local anaesthesia etcpage 45 409anaemia last updated january 2024 anaemia defined haemoglobin hb level reference values vary depending age sex pregnancy status see table 2 anaemia may caused causes anaemia often interlinked clinical features laboratory table 1 possible diagnoses fbc 1 2 decreased production red blood cells iron deficiency nutritional deficiencies folic acid vitamin b vitamin depressed bone marrow function certain infections hiv visceral leishmaniasis renal failure12 loss red blood cells acute chronic haemorrhage gastrointestinal ulcer ancylostomiasis schistosomiasis etc increased destruction red blood cells haemolysis parasitic malaria bacterial viral hiv infections haemoglobinopathies sickle cell disease thalassaemia intolerance certain drugs primaquine dapsone co trimoxazole nitrofurantoin etc patients g6pd deficiency common signs pallor conjunctivae mucous membranes palms hands soles feet fatigue dizziness dyspnoea tachycardia heart murmur signs decompensation cold extremities altered mental status oedema lower limbs respiratory distress elevated jugular venous pressure cardiaccoronary failure shock significant signs cheilosis glossitis nutritional deficiency jaundice hepatosplenomegaly dark coloured urine haemolysis bleeding maelena haematuria etc signs malaria chapter 6 etc hb levels rapid diagnostic test thick thin blood films areas malaria endemic urinary dipstick check haemoglobinuria haematuria sickle cell disease suspected done blood transfusion rapid diagnostic test sickle scan available emmel test full blood count fbc available guide diagnosispage 46 409 aetiological treatment anaemia indication transfusion anaemias well tolerated corrected simple aetiological treatment aetiological treatment may given alone together transfusion ferrous saltsfolic acid po available ferrous salts po 3 months doses expressed elemental iron folic acid po 4 monthscharacteristics main diagnoses macrocytic deficiency folic acid vitamin b chronic alcoholism 12 microcytic iron deficiency malnutrition chronic haemorrhage chronic inflammation hiv infection cancer thalassaemia normocytic acute haemorrhage renal failure haemolysis reduced number reticulocytesdeficiency iron folic acid vitamin b spinal tumour renal failure 12 increased normal number reticulocyteshaemolysis sickle cell disease thalassaemia eosinophilia ancylostomiasis trichuriasis schistosomiasis hiv infection malignant haemopathies iron deficiency children 1 month 6 years 15 3 mgkg 2 times daily children 6 12 years 65 mg 2 times daily children 12 years adults 65 mg 2 3 times daily age weighttreatment 45 mg5 ml syrup 60 65 mg tablet 1 month 1 year 4 10 kg 15 ml x 2 1 6 years 10 20 kg 25 ml x 2 6 12 years 20 40 kg 1 tab x 2 12 years adults 40 kg 1 tab x 2 3 helminthic infections see schistosomiasis nematode infections chapter 6 folic acid deficiency rarely isolated children 1 year 05 mgkg daily children 1 year adults 5 mg dailypage 47 409blood transfusion indications decide whether transfuse several parameters taken account transfusion indicated carried without delay transfusion thresholds see table 2 volume transfused presence haemorrhagic shock see shock chapter 1 otherwise transfusion volume based presence absence fever point time ordering blood time transfusion repeat necessary depending clinical condition monitoring repeat injection dose 2 hours necessarymalaria see malaria chapter 6 event associated iron deficiency wait 4 weeks malaria treatment prescribing iron supplements suspected haemolytic anaemia stop drug causes haemolysis patients may possibly g6pd deficiency clinical tolerance anaemia underlying conditions cardiovascular disease infection etc rate anaemia develops hb levels b children 3 fever axillary temperature 375 c administer either 15 mlkg packed red blood cells prbc 3 hours 30 mlkg whole blood 4 hours c fever axillary temperature 375 c administer either 10 mlkg prbc 3 hours 20 mlkg whole blood 4 hours c adolescents adults start adult unit prbc whole blood exceed transfusion rate 5 mlkghour monitor patients condition vital signs heart rate blood pressure respiratory rate temperature transfusion 5 minutes start transfusion every 15 minutes first hour every 30 minutes end transfusion transfusion 4 6 hours end transfusion pay attention signs transfusion reaction fluid overload decompensation continuing blood loss children measure hb 8 24 hours end transfusion signs decompensation continuing blood loss signs circulatory overload appear stop temporarily transfusion sit patient upright position administer oxygen administer furosemide slow iv injection children 05 1 mgkg adults 20 40 mg patient stabilised start transfusion 30 minutespage 48 409prevention ferrous saltsfolic acid po available ferrous salts po long risk deficiency persists eg pregnancy malnutrition doses expressed elemental iron table 2 definition anaemia transfusion thresholds iron folic acid deficiency drug supplements 4 children 1 month 12 years 1 2 mgkg daily max 65 mg daily children 12 years adults 65 mg daily age weightprevention 45 mg5 ml syrup 60 65 mg tablet 1 month 1 year 4 10 kg 1 ml 1 6 years 10 20 kg 25 ml 6 12 years 20 40 kg 5 ml 12 years adults 40 kg 1 tab nutritional supplements basic diet insufficient event sickle cell anaemia see sickle cell disease chapter 12 early treatment malaria helminthic infections etcpage 49 409referencespatientshb levels defining anaemiatransfusion thresholds children 26 months 95 gdl hb 4 gdl even signs decompensation hb 4 gdl 6 gdl signs decompensation ongoing blood loss severe malaria serious bacterial infection preexisting heart disease achildren 6 months4 years 11 gdl children 511 years 115 gdl children 1214 years 12 gdl men 15 years 13 gdl hb 7 gdl signs decompensation ongoing blood loss severe malaria serious bacterial infection preexisting heart disease women 15 years 12 gdl pregnant women 11 gdl 1 3 trimester 105 gdl 2 trimester st rd nd 36 weeks hb 5 gdl even signs decompensation hb 5 gdl 7 gdl signs decompensation sickle cell disease severe malaria serious bacterial infection preexisting heart disease 36 weeks hb 6 gdl even signs decompensation hb 6 gdl 8 gdl signs decompensation sickle cell disease severe malaria serious bacterial infection preexisting heart disease aimmediate transfusion required children 2 months 12 years hb 4 gdl 6 gdl sign decompensation ongoing blood loss provided closely monitored including hb measurements 8 24 48 hours transfusion preparation blood grouping etc carried without delay case child needs transfused later footnotes aa coformulated tablet ferrous saltsfolic acid contains 185 mg ferrous fumarate sulfate equivalent 60 mg elemental iron 400 micrograms folic acid 200 mg tablet ferrous fumarate sulfate contains 65 mg elemental iron 140 mg5 ml syrup ferrous fumarate contains 45 mg5 ml elemental iron bbefore transfusing determine recipients potential donors blood groupsrhesus carry screening tests donors blood hiv1 2 hepatitis b c syphilis endemic areas malaria chagas disease caxillary temperature taken time ordering blood immediately prior transfusionpage 50 4091world health organization haemoglobin concentrations diagnosis anaemia assessment severity world health organization 2011 accessed june 26 2023 httpsappswhointirishandle1066585839 2world health organization educational modules clinical use blood world health organization 2021 accessed june 26 2023 httpsappswhointirishandle10665350246 3maitland k olupotolupot p kiguli et al transfusion volume children severe anemia africa n engl j med 20193815420431 httpsdoiorg101056nejmoa1900100 4word health organization daily iron folic acid supplementation pregnant women word health organization geneva 2012 accessed june 26 2023 httpsappswhointirishandle1066577770page 51 409dehydration dehydration results excessive loss water electrolytes body prolonged dehydration compromise organ perfusion resulting shock principally caused diarrhoea vomiting severe burns children particularly susceptible dehydration due frequent episodes gastroenteritis high surface area volume ratio inability fully communicate independently meet fluid needs protocols focused treatment dehydration caused diarrhoea vomiting alternative treatment protocols used children malnutrition see severe acute malnutrition chapter 1 patients severe burns see burns chapter 10 clinical features assessment classification degree dehydration adapted treatment dehydrationhistory diarrhoea andor vomiting concomitant reduced urine output clinical features depend degree dehydration see table features dry mouth absence tears may also noted patients severe dehydration assessed shock tachycardia low blood pressure delayed capillary refill time etc electrolyte disorders may cause tachypnoea muscle cramps weakness cardiac arrhythmia irregular heart rate palpitation confusion andor seizures 1 2 severe dehydration least 2 following signssome dehydration least 2 following signsno dehydration signs severe dehydration mental statuslethargic unconsciousrestless irritable normal radial pulse weak absent palpable easily palpable eyes asunken sunken normal skin pinch bgoes back slowly 2 secondsgoes back slowly 2 secondsgoes back quickly 1 second thirstdrinks poorly able drinkthirst drinks quicklyno thirst drinks normally asunken eyes may normal feature children ask mother childs eyes usual sunken usual bskin pinch assessed pinching skin abdomen thumb forefinger without twisting older people sign reliable normal aging diminishes skin elasticitypage 52 409severe dehydration treatment plan c dehydration treatment plan btreat shock present see shock chapter 1 able drink administer oral rehydration solution ors po whilst obtaining iv access according treatment plan c monitoring infusion rate closely insert peripheral iv line using large caliber catheter 2224g children 18g adults intraosseous needle administer ringer lactate rl 1 2 age first give 30 mlkg c give 70 mlkg children 1 year 1 hour 5 hours children 1 year adults 30 minutes 2 12 hours crepeat radial pulse remains weak absent first bolus case suspected severe anaemia measure haemoglobin treat accordingly see anaemia chapter 1 b soon patient able drink safely often within 2 hours provide ors patient tolerates ors contains glucose electrolytes prevent development complications monitor ongoing losses closely assess clinical condition degree dehydration regular intervals ensure continuation appropriate treatment course treatment patient remains becomes lethargic measure blood glucose level andor treat hypoglycaemia see hypoglycaemia chapter 1 develops muscle crampsweakness abdominal distention treat moderate hypokalaemia 75 potassium chloride syrup 1 mmol kml po 2 days children 45 kg 2 mmolkg 2 mlkg daily according weight daily dose divided 2 3 doses children 45 kg adults 30 mmol 30 ml 3 times daily treatment given inpatient c develops periorbital peripheral oedema reduce infusion rate minimum auscultate lungs evaluate stage dehydration necessity continuing iv rehydration iv rehydration still required continue infusion slower rate observe patient closely iv rehydration longer required change oral treatment ors develops dyspnoea cough bibasal crepitations heard auscultation lungs sit patient reduce infusion rate minimum administer one dose furosemide iv 1 mgkg children 40 mg adults monitor patient closely 30 minutes assess underlying cardiorespiratory renal disease patient stabilised reassess degree dehydration necessity continuing iv rehydration iv rehydration still required restart half previous infusion rate monitor closely iv rehydration longer required change oral treatment ors administer ors according treatment plan b equates 75 mlkg ors given 4 hours 1 dpage 53 409 dehydration prevent dehydration treatment plan treatment diarrhoea addition treatment plan corresponding patients degree dehydration age 4 months4 11 months12 23 months2 4 years5 14 years 15 years weight 5 kg5 79 kg8 109 kg11 159 kg16 299 kg 30 kg quantity ors 4 hours200 400 ml400 600 ml600 800 ml800 1200 ml1200 2200 ml2200 4000 ml encourage additional ageappropriate fluid intake including breastfeeding young children give additional ors loose stool see monitor ongoing losses closely assess clinical condition degree dehydration regular intervals ensure continuation appropriate treatment encourage ageappropriate fluid intake including breastfeeding young children administer ors according treatment plan loose stool 1 2 age quantity ors children 2 years 50 100 ml 10 20 teaspoons children 2 10 years 100 200 ml 12 1 glass children 10 years adults least 250 ml least 1 glass administer aetiologic treatment required administer zinc sulfate children 5 years see acute diarrhoea chapter 3 footnotes aif rl available 09 sodium chloride used bif transfusion required provided parallel iv fluids using separate iv line blood volume administered deducted total volume plan c cif available take blood tests monitor urea electrolyte levels dfor detailed information ors recommendations age weight refer guide management cholera epidemic msfpage 54 409references 1world health organization treatment diarrhoea manual physicians senior health workers 4th rev world health organization 2005 httpsappswhointirishandle1066543209 2world health organization pocket book hospital care children guidelines management common childhood illnesses 2013 httpsappswhointirisbitstreamhandle10665811709789241548373_engpdfsequence1page 55 409severe acute malnutrition last updated february 2024 severe acute malnutrition sam results insufficient energy kilocalories fat protein andor nutrients vitamins minerals etc cover individual needs sam frequently associated medical complications due metabolic disturbances compromised immunity major cause morbidity mortality children globally protocols focused diagnosis management sam children 6 59 months details regarding age group guidance age groups refer national recommendations andor specialised protocols clinical assessment characteristic physical signs diagnostic admission criteria diagnostic criteria sam anthropometric clinical admission criteria sam treatment programmes vary context refer national recommendations medical complications nutritional treatmentin marasmus skeletal appearance resulting significant loss muscle mass subcutaneous fat kwashiorkor bilateral oedema lower limbs sometimes extending parts body eg arms hands face discoloured brittle hair shiny skin may crack weep become infected midupper arm circumference muacmeasures degree muscle wasting muac 115 mm indicates sam significant mortality risk weightforheight zscore whz indicates degree weight loss comparing weight child median weight nonmalnourished children height sex sam defined whz 3 reference child growth standards b presence bilateral pitting oedema lower limbs causes oedema ruled indicates sam regardless muac whz children following severe medical conditions receive hospitalbased medical management pitting oedema extending lower limbs face anorexia observed appetite test severe complications persistent vomiting shock altered mental status seizures severe anaemia clinically suspected confirmed persistent hypoglycaemia eye lesions due vitamin deficiency frequent abundant diarrhoea dysentery dehydration severe malaria pneumonia meningitis sepsis severe cutaneous infection fever unknown origin etc absence conditions children treated outpatients regular followup children sam receive nutritional treatmentpage 56 409routine medical management following provided inpatients outpatients sam nutritional treatment based use specialised nutritious foods enriched vitamins minerals f75 f100 therapeutic milks readytouse therapeutic food rutf nutritional treatment organised phases phase 1 inpatient intends restore metabolic functions treat stabilize medical complications children receive f75 therapeutic milk phase may last 1 7 days children usually enter transition phase children medical complications generally begin phase 1 transition phase inpatient intends ensure tolerance increased food intake continued improvement clinical condition children receive f100 therapeutic milk andor rutf phase usually lasts 1 3 days children enter phase 2 phase 2 outpatient inpatient intends promote rapid weight gain catchup growth children receive rutf phase usually lasts 1 3 days inpatient children discharged outpatient care children without medical complications enter directly phase outpatients outpatient component usually lasts several weeks breastfeeding continued breastfed children drinking water given addition meals especially ambient temperature high child fever receiving rutf antibiotic treatmentfrom d1 unless specific signs infection present amoxicillin po 50 mgkg max 1 g 2 times daily 5 7 days malaria d1 rapid diagnostic test endemic areas treatment malaria according results testing available see malaria chapter 6 intestinal parasitesin transition phase upon outpatient admission albendazole po children 12 23 months 200 mg single dose children 24 months 400 mg single dose vaccination children vaccinated 6 8 months revaccinated ie 2 doses reach 9 months age provided interval 4 weeks first dose respectedin transition phase upon outpatient admission measles vaccine children 6 months 5 years unless document shows child received 2 doses vaccine administered follows one dose 9 months one dose least 4 weeks first dose vaccines included epi check vaccination status refer child vaccination services discharge tuberculosis tb d1 regularly treatment screen tb child screening positive perform complete diagnostic evaluation information refer guide tuberculosis msf hiv infection perform hiv counselling testing unless mother explicitly declines testing children 18 months test mother rapid diagnostic tests mother testing positive request pcr test child children 18 months test child rapid diagnostic testspage 57 409management complications infections severe anaemia diarrhoea dehydration respiratory cutaneous urinary infections common however classic signs infection fever may absent 1 severe infection sepsis suspected children lethargic apathetic suffering acute complication hypothermia hypoglycaemia seizures difficulty breathing shock immediately administer ampicillin iv 50 mgkg every 8 hours gentamicin iv 75 mgkg daily continue treatment unless source infection identified different antibiotic treatment required circulatory impairment shock immediately administer ceftriaxone iv one dose 80 mgkg assess source infection determine antibiotic treatment see also shock chapter 1 transfuse urgently severe anaemia see haemoglobin hb 6 gdl less severe infections assess source infection see fever chapter 1 treat accordingly fever present causes discomfort undress child insufficient administer paracetamol po low dose 10 mgkg 3 times maximum per 24 hours encourage oral fluids including breast milk hypothermia present place child skintoskin mothers body cover warm blanket treat infection check blood glucose level treat hypoglycaemia necessary see hypoglycaemia chapter 1 children kwashiorkor infection cutaneous lesions common may progress soft tissue systemic infection cutaneous infection present stop amoxicillin start amoxicillinclavulanic acid po use formulations ratio 81 71 dose expressed amoxicillin 50 mgkg 2 times daily 7 days children hb 4 6 signs decompensation respiratory distress ongoing blood loss require transfusion within first 24 hours see anaemia chapter 1 volume transfused patient monitoring transfusion preferably use packed red blood cells prbc available monitor closely signs fluid overload see box diarrhoea common therapeutic foods facilitate recovery physiological function gastrointestinal tract amoxicillin administered part routine treatment reduces intestinal bacterial overgrowth diarrhoea generally resolves without additional treatment aetiological treatment necessary see acute diarrhoea chapter 3 zinc supplementation needed children consume recommended amounts therapeutic foods diagnosis dehydration based history clinical features clinical assessment difficult children sam delayed skin pinch test sunken eyes often present even absence dehydration classification degree dehydration adapted children sam see table belowpage 58 409 acute diarrhoea dehydration plan sam acute diarrhoea dehydration plan b sam acute diarrhoea severe dehydration plan c samclinical features 2 following signsno dehydrationsome dehydrationsevere dehydration mental status normal restless irritabilitylethargic unconscious thirstno thirst drinks normallythirsty drinks eagerlyunable drink drinks poorly urine output normal reducedabsent several hours recent frequent watery diarrhoea andor vomitingyes yes yes recent obvious rapid weight lossno yes yes stools neither frequent abundant outpatient oral rehydration solution ors po 5 mlkg loose stool prevent dehydration stools frequent andor abundant inpatient resomalpo nasogastric tube ngt 5 mlkg loose stool prevent dehydration c cases continue feeding breastfeeding encourage oral fluids determine target weight weight onset diarrhoea starting rehydration feasible eg new admission estimate target weight current weight x 106 resomalpo ngt 20 mlkghour 2 hours addition administer 5 mlkg resomal loose stool tolerated c assess 2 hours clinical evaluation weight improvement diarrhoea signs dehydration regress reduce resomal 10 mlkghour signs dehydration andor weight loss known estimated corrected assess every 2 hours signs dehydration andor target weight reached change plan sam prevent dehydration improvement 2 4 hours oral rehydration cannot compensate losses change plan c sam circulatory impairment continue feeding including breastfeeding monitor signs fluid overload see box regardless target weight stop rehydration signs fluid overload appear patients assess circulatory impairment see shock chapter 1 estimate target weight current weight x 11page 59 409 signs fluid overload include plus one following complications complications treated inpatient seemeasure blood glucose level treat hypoglycaemia chapter 1 necessary monitor vital signs signs dehydration every 15 30 minutes monitor urine output monitor signs fluid overload see box circulatory impairment resomal po ngt 20 mlkg 1 hour child alert continue feeding including breastfeeding assess 1 hour improvement change plan b sam keep target weight rehydration pongt tolerated e g vomiting stop resomal administer glucose 5ringer lactate g5rliv infusion 10 mlkghour 2 hours assess 2 hours iv fluids improvement andor vomiting stop g5rl iv infusion change plan b sam improvement still vomiting continue g5rl iv infusion 10 mlkghour 2 hours deterioration circulatory impairment see circulatory impairment administer ceftriaxone iv one dose 80 mgkg subsequent antibiotic treatment depends assessment underlying cause administer g5rl iv infusion 10 mlkghour 2 hours stop resomal child taking assess 1 hour iv fluids improvement vomiting stop iv fluid change plan b sam keep target weight improvement continue g5rl iv infusion 10 mlkghour prepare blood transfusion assess 2 hours iv fluids improvement change plan b sam keep target weight improvement deterioration check hb baseline administer blood transfusion using separate iv line see anaemia chapter 1 volume transfused patient monitoring transfusion transfusing continue g5rl iv infusion 10 mlkghour another 2 hours rr 10 breathsminute compared initial rr hr 20 beatsminute compared initial hr new worsening hypoxia decrease spo 5 2 new onset rales andor fine crackles lung fields new galloping heart rhythm increased liver size must marked liver border pen rehydration new peripheral eyelid oedema hypoglycaemia seizures chapter 1 acute pneumonia chapter 2 stomatitis chapter 3 xerophthalmia vitamin deficiency chapter 5page 60 409discharge criteria general discharge criteria vary context refer national recommendations referenceschildren discharged hospital treated outpatients following criteria met clinically well medical complications controlled able eat rutf observed appetite test reduction absence oedema caregiver feels able provide care outpatient vaccinations date referral vaccination service organised children discharged nutritional treatment following criteria met coexisting medical conditions stable outpatient treatment organised necessary eg dressing changes followup chronic diseases vaccinations date referral vaccination service organised absence oedema whz 2 muac 125 mm least 2 weeks footnotes amuac measured midpoint left upper arm arm relaxed measuring tape contact skin around arm without exerting pressure bfor whz see simplified field tables zscores girls boys httpswwwwhointtoolschildgrowthstandardsstandardsweightforlengthheight cresomal specific oral rehydration solution malnourished children containing less sodium potassium standard ors administered medical supervision avoid overdosing hyponatremia dremove 50 ml ringer lactate rl 500 ml rl bottle bag add 50 ml 50 glucose remaining 450 ml rl obtain 500 ml 5 glucoserl solution 1jones kdj berkley ja severe acute malnutrition infection paediatrics international child health 2014 34sup1 s1s29 httpswwwtandfonlinecomdoifull1011792046904714z000000000218 accessed 24 august 2022page 61 409chapter 2 respiratory diseases acute upper airway obstruction rhinitis rhinopharyngitis common cold acute sinusitis acute pharyngitis diphtheria upper respiratory tract infections croup laryngotracheitis laryngotracheobronchitis epiglottitis bacterial tracheitis otitis acute otitis externa acute otitis media aom chronic suppurative otitis media csom pertussis whooping cough bronchitis acute bronchitis chronic bronchitis bronchiolitis acute pneumonia pneumonia children 5 years age pneumonia children 5 years adults persistent pneumonia staphylococcal pneumonia asthma acute asthma asthma attack chronic asthma pulmonary tuberculosis page 62 409acute upper airway obstruction acute upper airway obstruction caused foreign body aspiration viral bacterial infections croup epiglottitis tracheitis anaphylaxis burns trauma initially stable partial obstruction may worsen develop lifethreatening emergency especially young children clinical features clinical signs severity obstruction management casesobstruction signsdanger signs complete respiratory distress followed cardiac arrest yesimminent completesevere respiratory distress cyanosis spo 90 2 agitation lethargy tachycardia capillary refill time 3 seconds severe stridor abnormal high pitched sound inspiration rest severe respiratory distress severe intercostal subcostal retractions nasal flaring substernal retractions inward movement breastbone inspiration severe tachypnoea moderate stridor agitation moderate respiratory distress mild intercostal subcostal retractions moderate tachypnoeano mild cough hoarse voice respiratory distress examine children position comfortable evaluate severity obstruction according table monitor spo except mild obstruction 2 administer oxygen continuously maintain spo 94 98 90or patient cyanosis respiratory distress 2 pulse oxymeter available least 5 litresminute relieve hypoxia improve respiration hospitalize except obstruction mild intensive care danger signs monitor mental status heart respiratory rate spo severity obstruction 2 maintain adequate hydration mouth possible iv patient unable drinkpage 63 409management foreign body aspiration acute airway obstruction foreign body either completely obstructs pharynx acts valve laryngeal inlet warning signs frequently child 6 months5 years playing small object eating conscience initially maintained perform maneuvers relieve obstruction patient cannot speak cough emit sound heimlich manoeuvre stand behind patient place closed fist pit stomach navel ribs place hand fist press hard abdomen quick upward thrust perform one five abdominal thrusts order compress lungs dislodge foreign body place infant face across forearm resting forearm leg support infants head hand heel hand perform one five slaps back shoulder plates unsuccessful turn infant back perform five forceful sternal compressions cardiopulmonary resuscitation use 2 3 fingers center chest nipples press approximately one third depth chest 3 4 cm repeat foreign body expelled patient resumes spontaneous breathing coughing crying talking patient loses consciousness ventilate perform cardiopulmonary rescucitation tracheostomy unable ventilate differential diagnosis management airway obstructions infectious origin management causes children 1 year adults children 1 year infections symptoms appearancetiming symptoms viral croup stridor cough moderate respiratory difficultyprefers sit progressive epiglottitis stridor high fever severe respiratory distressprefers sit drooling cannot swallow salivarapid bacterial tracheitis stridor fever purulent secretions severe respiratory distressprefers lie flat progressive retropharyngeal tonsillar abscessfever sore throat painful swallowing earache trismus hot potato voiceprefers sit drooling progressive croup epiglottitis tracheitis see upper respiratory tract infections abscess refer surgical drainage anaphylactic reaction angioedema see anaphylactic shock chapter 1 burns face neck smoke inhalation airway oedema see burns chapter 10page 64 409footnotes aif possible better treat patients spo 95 oxygen 2page 65 409rhinitis rhinopharyngitis common cold rhinitis inflammation nasal mucosa rhinopharyngitis inflammation nasal pharyngeal mucosa generally benign selflimited often viral origin however may early sign another infection eg measles influenza may complicated bacterial infection eg otitis media sinusitis clinical features treatment nasal discharge obstruction may accompanied sore throat fever cough lacrimation diarrhoea infants purulent nasal discharge indicative secondary bacterial infection children 5 years routinely check tympanic membranes look associated otitis media antibiotherapy recommended promote recovery prevent complications treatment symptomatic clear nose 09 sodium chloride fever throat soreness paracetamol po 2 3 days fever chapter 1 footnotes afor child place back head turned side instil 09 sodium chloride nostrilpage 66 409acute sinusitis acute sinusitis inflammation one sinus cavities caused infection allergy acute sinus infections viral resolve spontaneously less 10 days treatment symptomatic acute bacterial sinusitis may primary infection complication viral sinusitis dental origin principal causative organisms streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis essential distinguish bacterial sinusitis common rhinopharyngitis see rhinitis rhinopharyngitis antibiotic therapy required case bacterial sinusitis without treatment severe sinusitis children may cause serious complications due spread infection neighbouring bony structures orbits meninges clinical features sinusitis adults sinusitis likely symptoms persist longer 10 14 days worsen 5 7 days severe severe pain high fever deterioration general condition sinusitis children treatment symptomatic treatment antibiotherapy purulent unilateral bilateral discharge nasal obstruction facial unilateral bilateral pain increases bending painful pressure maxillary area behind forehead fever usually mild absent symptoms addition irritability lethargy cough vomiting may present event severe infection deterioration general condition fever 39 c periorbital facial oedema fever pain chapter 1 clear nose 09 sodium chloride adults antibiotherapy indicated patient meets criteria duration severity symptoms oral amoxicillin firstline treatment diagnosis uncertain moderate symptoms 10 days patient reexamined next days start symptomatic treatment rhinopharyngitis viral sinusitis children antibiotic therapy indicated child severe symptoms mild symptoms associated risk factors eg immunosuppression sickle cell disease asthma oral amoxicillin firstline treatment amoxicillin po 7 10 dayspage 67 409 treatments children 30 mgkg 3 times daily max 3 g daily adults 1 g 3 times daily event failure respond within 48 hours therapy amoxicillinclavulanic acid po 7 10 days use formulations ratio 81 71 exclusively dose expressed amoxicillin children 40 kg 25 mgkg 2 times daily children 40 kg adults ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily penicillinallergic patients erythromycin po 7 10 days children 30 50 mgkg daily adults 1 g 2 3 times daily b infants ethmoiditis see periorbital orbital cellulitis chapter 5 sinusitis secondary dental infection dental extraction antibiotic treatment event ophthalmologic complications ophthalmoplegia mydriasis reduced visual acuity corneal anesthesia refer surgical drainage footnotes afor child place back head turned side instil 09 sodium chloride nostril bfor dosage according age weight see erythromycin guide essential drugs msfpage 68 409acute pharyngitis last updated november 2020 acute inflammation tonsils pharynx majority cases viral origin require antibiotic treatment group streptococcus gas main bacterial cause mainly affects children aged 3 14 years acute rheumatic fever arf serious late complication gas pharyngitis prevented antibiotic treatment one main objectives assessing acute pharyngitis identify patients requiring antibiotic treatment clinical features common forms centor criteria patients 14 years probability gas pharyngitis low infectious mononucleosis im due epsteinbarr virus suspected adolescents young adults extreme fatigue generalized adenopathy often splenomegaly erythematous exudative pharyngitis may also associated gonococcal primary hiv infection cases diagnosis mainly prompted patients history forms pharyngitisfeatures common types pharyngitis throat pain dysphagia difficulty swallowing inflammation tonsils pharynx tender anterior cervical lymph nodes without fever specific features depending cause erythematous red throat exudative red throat whitish exudate pharyngitis appearance common viral gas pharyngitis centor criteria help assessment decrease empirical use antibiotics settings rapid testing gas available centor score less 2 rules gas infection nevertheless patients risk factors immunosuppression personal family history arf poststreptococcal complications local general complications use centor score prescribe empirical antibiotic treatment 1 2 criteria score temperature 38 c 1 absence cough 1 tender anterior cervical lymph nodes 1 tonsillar swelling exudate 1 pseudomembranous pharyngitis red tonsilspharynx covered adherent greyish white false membrane see diphtheria chapter 2 vesicular pharyngitis clusters tiny blisters ulcers tonsils always viral coxsackie virus primary herpetic infection ulceronecrotic pharyngitis hard painless syphilitic chancre tonsil tonsillar ulcer soft palpation patient poor oral hygiene malodorous breath vincent tonsillitispage 69 409 peritonsillar retropharyngeal lateral pharyngeal abscess fever intense pain dysphagia hoarse voice trismus limitation mouth opening unilateral deviation uvula treatment spots oral mucosa kopliks spots accompanied conjunctivitis skin rash see measles chapter 8 strawberry red bumpy tongue accompanied skin rash scarlet fever caused gas local complications general complications complications due toxin diphtheria see diphtheria chapter 2 poststreptococcal complications arf acute glomerulonephritis signs serious illness children severe dehydration severe difficulty swallowing upper airway compromise deterioration general condition differential diagnosis epiglottitis see epiglottitis chapter 2 symptomatic treatment fever pain paracetamol ibuprofen po fever chapter 1 centor score 1 viral pharyngitis typically resolves within days weeks im antibiotic treatment centor score 2 scarlet fever antibiotic treatment gas infections 3 singleuse injection equipment available benzathine benzylpenicillin drug choice streptococcus resistance penicillin remains rare antibiotic proven effective reducing incidence rheumatic fever treatment administered single dose benzathine benzylpenicillin im children 30 kg 10 years 600 000 iu single dose children 30 kg 10 years adults 12 miu single dose penicillin v oral reference treatment poor adherence predictable due length treatment phenoxymethylpenicillin penicillin v po 10 days children 1 6 years 250 mg 2 times daily children 6 12 years 500 mg 2 times daily children 12 years adults 1 g 2 times daily children 1 year 125 mg 2 times daily amoxicillin alternative treatment advantage relatively short however cause adverse skin reactions patients undiagnosed im thus avoided im excluded amoxicillin po 6 days children 25 mgkg 2 times daily adults 1 g 2 times daily macrolides reserved penicillin allergic patients resistance macrolides frequent efficacy prevention rheumatic fever studied azithromycin po 3 days children 20 mgkg daily max 500 mg daily adults 500 mg daily gonococcal syphilitic pharyngitis genital gonorrhoea chapter 9 syphilis chapter 9 diphtherial pharyngitis see diphtheria chapter 2 vincent tonsillitis metronidazole amoxicillin peritonsillar retropharyngeal lateral pharyngeal abscess refer surgical drainagepage 70 409 referencesif signs serious illness epiglottitis present children hospitalise 1fine nizet v mandl kd largescale validation centor mcisaac scores predict group streptococcal pharyngitis arch intern med 201217211847852 httpswwwncbinlmnihgovpmcarticlespmc3627733 accessed 20 october 2020 2national institute health care excellence sore throat acute antimicrobial prescribing 2018 httpwwwniceorgukng84 accessed 20 october 2020 3group streptococcal disease centers disease control prevention atlanta ga cdc 2020 httpswwwcdcgovgroupastrepdiseaseshcpstrepthroathtml accessed 20 october 2020page 71 409diphtheria last updated october 2022 diphtheria bacterial infection due corynebacterium diphtheriae spread person person inhalation infected respiratory droplets symptomatic asymptomatic individuals direct contact contaminated objects diphtheria skin lesions infection c diphtheriae incubation period 1 5 days max 10 days time multiplies upper respiratory tract bacteria secretes toxin causes severe local well systemic effects death occur airway obstruction result systemic complications including damage myocardium nervous system caused toxin cases remain infectious 8 weeks initial infection antibiotic treatment reduce infectiousness 6 days vaccination key prevention control diphtheria protects individuals severe disease fewer less severe symptoms prevent spread c diphtheriae clinical disease confer protective immunity vaccination integral part case management clinical features laboratory treatment 1 2 1 2 3 clinical examination respect standard contact droplet precautions handwashing gloves gown mask etc conduct careful examination throat signs respiratory diphtheria pharyngitis rhinopharyngitis tonsillitis laryngitis tough greyish firmly adherent pseudomembranes pharynx nasopharynx tonsils larynx dysphagia cervical adenitis times progressing massive swelling neck airway obstruction possible suffocation infection extends nasal passages larynx trachea bronchi fever generally lowgrade 2 generalised signs due effects toxin cardiac dysfunction tachycardia arrhythmias severe myocarditis heart failure possibly cardiogenic shock see shock chapter 1 3 7 days 2 3 weeks onset disease neuropathies 2 8 weeks onset disease leading nasal voice difficulty swallowing paralysis soft palate vision ocular motor paralysis breathing paralysis respiratory muscles ambulation limb paralysis oliguria anuria acute renal failure differential diagnoses epiglottitis acute pharyngitis chapter 2 stomatitis chapter 3 diagnosis confirmed isolation toxigenic c diphtheriae culture antibiotic susceptibility test swab specimens collected affected areas throat tonsils pharyngeal mucosa soft palate exudate ulcer etc nasopharynx presence toxin confirmed pcr testing detection diphtheria toxin gene isolation patients standard droplet contact precautions medical staffpage 72 409there risk anaphylactic reaction especially patients asthma close monitoring patient essential immediate availability equipment manual ventilation ambu bag face mask intubation ringer lactate epinephrine see shock chapter 1 besredka method inject 01 ml sc wait 15 minutes allergic reaction erythema injection site flat erythema less 05 cm diameter inject 025 ml sc reaction 15 minutes inject rest product im iv depending volume administered doses given function severity illness delay treatment never administer procaine benzylpenicillin iv injection infusion penicillinallergic patients use erythromycin ivdiphtheria antitoxin datderived horse serum administer dat soon possible disease onset wait bacteriological confirmation administer dat close monitoring hospital setting according besredka method assess possibility allergy delay diminish efficacy b 1 clinical signs dose units administration route laryngitis pharyngitis duration 48 hours20 40 000 im iv infusion 250 ml 09 sodium chloride 2 4 hours doses 20 000 unitsrhinopharyngitis 40 60 000 severe disease respiratory distress shock cervical oedema duration 48 hours80 100 000 antibiotic treatment soon possible without waiting bacteriological confirmation 14 days according length treatment recommended national protocol patient swallow azithromycin po firstline children 10 12 mgkg daily max 500 mg daily adults 500 mg daily erythromycin po children 40 kg 10 15 mgkg max 500 mg 4 times daily children 40 kg adults 500 mg 4 times daily phenoxymethylpenicillin penicillin v po children 40 kg 10 15 mgkg max 500 mg 4 times daily children 40 kg adults 500 mg 4 times daily patient cannot swallow start one treatments change soon possible oral route one oral treatments complete 14 days treatment procaine benzylpenicillin im children 25 kg 50 000 iukg 50 mgkg daily max 12 miu 12 g daily children 25 kg adults 12 miu 12 g daily c intubationtracheotomy necessary airway obstruction respiratory failure etc event shock see shock chapter 1 complementary treatment update every patients vaccination status hospital discharge first visit receiving homebased care patient administered dat receive adequate homebased follow hospital discharge wait 3 weeks administration dat vaccinationpage 73 409management close contacts close contacts include household members living roof people directly exposed less one metre nasopharyngeal secretions patient regular basis eg family close friends children class medical personnel 5 days nights prior onset symptoms case benzathine benzylpenicillin never administered iv route azithromycin po erythromycin po 7 days outbreak surveillance measures prevention administer 2 subsequent booster doses containing least 4 weeks apart 4 collect nasal pharyngeal swabs culture starting antibiotic prophylaxis temperature throat examination daily 10 days exclusion school work 48 hours starting antibiotic prophylaxis symptoms respiratory infection appear treat immediately case diphtheria antibiotic prophylaxis benzathine benzylpenicillin im children 30 kg 600 000 iu single dose children 30 kg adults 12 miu single dose check vaccination status less 3 injections received complete vaccination schedule see prevention 3 injections received last injection one year ago administer booster dose immediately 3 injections received last injection less one year ago booster dose immediately necessary suspected case diphtheria defined person pharyngitis rhinopharyngitis tonsillitis andor laryngitis adherent pseudomembrane pharynx nose tonsils andor larynx 1 isolate treat suspect cases without delay collect swab samples starting antibiotic treatment submit case notification public health authorities within 24 hours 1 routine vaccination epi information 3 doses conjugate vaccine containing higher potency formulation diphtheria toxoid soon possible 6 weeks age 4 week intervals booster 12 23 months 4 7 years booster vaccine containing reduced dose diphtheria toxoid 9 15 years 5 catchup vaccination individuals received routine vaccination information children 1 6 years 3 doses conjugate vaccine containing higher potency formulation diphtheria toxoid least 4 weeks apart children 7 years adults including medical staff 3 doses conjugate vaccine containing reduced dose diphtheria toxoid administer minimum interval 4 weeks first second dose interval least 6 months second third dose event outbreak interval may reduced 4 weeks achieve protection quicker 5 footnotes athis guide focuses respiratory diphtheria signs due toxin noted cutaneous diphtheria still significant reservoir c diphtheriae page 74 409referencesbdat reduces mortality given diphtheria patients however supply limited may necessary define criteria reserve dat treatment patients benefit dat administered pregnant women cerythromycin iv infusion 60 minutes children 125 mgkg every 6 hours max 2 g daily adults 500 mg every 6 hours erythromycin powder 1 g reconstituted 20 ml water injection dilute dose erythromycin 10 mlkg 09 sodium chloride children less 20 kg bag 250 ml 09 sodium chloride children 20 kg adults dilute glucose 1world health organization diphtheria vaccinepreventable diseases surveillance standards 2018 httpswwwwhointimmunizationmonitoring_surveillanceburdenvpdwho_surveillancevaccinepreventable_04_diphtheria _r2pdfua1 accessed 11 august 2020 2tiwari tsp wharton chapter 19 diphtheria toxoid plotkin sa orenstein wa offit pa editors vaccines 7th ed philadelphia pa elsevier 2018 p 261275 3truelove sa keegan lt moss wj chaisson lh macher e azman lessler j clinical epidemiological aspects diphtheria systematic review pooled analysis clin infect dis 2020 jun 247118997 httpswwwncbinlmnihgovpmcarticlespmc7312233 accessed 24 november 2020 4pan american health organization world health organization diphtheria americas summary situation 2018 epidemiological update diphtheria 16 april 2018 httpswwwpahoorghqindexphpoptioncom_docmanviewdownloadcategory_slugdiphtheria 098968alias4449716april2018diphtheriaepidemiologicalupdate497itemid270langen accessed 11 august 2020 5world health organization diphtheria vaccine position paper august 2017 weekly epidemiological record 2017 9231417436 httpswwwwhointimmunizationpolicyposition_paperswer_31_diphtheria_updated_position_paperpdfua1 accessed 11 august 2020page 75 409other upper respiratory tract infections croup laryngotracheitis laryngotracheobronchitis epiglottitis bacterial tracheitispage 76 409croup laryngotracheitis laryngotracheobronchitis last updated october 2024 common viral respiratory infection peak incidence amongst children 6 months 3 years clinical features treatment typical barking cough hoarse voice cry inspiratory stridor abnormal high pitched sound inspiration croup considered mild stridor occurs agitation croup considered severe stridor rest especially accompanied respiratory distress wheezing may also present bronchi involved absence inspiratory stridor intercostal subcostal sternal retractions treat symptomatically ensure adequate hydration seek medical attention symptoms worsen eg respiratory difficulty noisy breathing inability tolerate oral fluids stridor present agitation mild croup 1 assure adequate hydration corticosteroids dexamethasone po 015 06 mgkg max 16 mgsingle dose available prednisolone po 1 mgkg single dose keep child observation least 30 minutes oral corticosteroid consider hospitalisation longer observation 4 hours child less 6 months old dehydrated lives far health facility danger signs present stridor rest respiratory distress hypoxia child unable drink admit hospital 1 administer oxygen continuously respiratory distress spo 92 maintain spo 94 98 spo cannot determined least 5 litresminute2 2 2 insert peripheral iv line provide iv hydration epinephrine adrenaline via nebulizer 05 mgkg max 5 mg repeated every 20 minutes danger signs persist see table monitor heart rate nebulization heart rate greater 200 stop nebulization 2 b weight 6 kg 7 kg 8 kg 9 kg 1017 kg dose mg 3 mg 35 mg 4 mg 45 mg 5 mg dose ml 1 mgml 1 ml ampoule 3 ml 35 ml 4 ml 45 ml 5 ml nacl 09 a1 ml 1 ml aadd sufficient nacl 09 obtain total volume 4 45 ml nebulizing chamberpage 77 409epinephrine intended exclusively nebulized administration given iv im croup references corticosteroids dexamethasone po im iv child vomiting 06 mgkg max 16 mg single dose see table c available prednisolone po 1 mgkg single dose weight 68 kg 911 kg 1214 kg 1517 kg dose mg 4 mg 6 mg 8 mg 10 mg dose 2 mg tablet 2 tab 3 tab 4 tab 5 tab dose ml 4 mgml 1 ml ampoule 1 ml 15 ml 2 ml 25 ml suspect bacterial tracheitis critically ill appearing childwith croup improve treatment patient complete airway obstruction intubation possible emergency tracheotomy footnotes aif children easily return hospital case deterioration return symptoms administer 015 mgkg dexamethasone otherwise dose 06 mgkg used balthough licensed indication epinephrine 11000 1 mgml used nebulisation cadminister orally possible order avoid causing agitation child may worsen symptoms dcritically ill appearing child weak grunting crying drowsiness difficult arouse smile disconjugate anxious gaze pallor cyanosis general hypotonia 1pocket book primary health care children adolescents guidelines health promotion disease prevention management newborn period adolescence copenhagen regional office europe 2022 licence cc byncsa 30 igo httpswwwwhointeuropepublicationsiitem9789289057622 2bjornson c russell k vandermeer b klassen tp johnson dw nebulized epinephrine croup children cochrane acute respiratory infections group ed cochrane database syst rev published online october 10 2013 httpsdoiorg10100214651858cd006619pub3 page 78 409epiglottitis bacterial infection epiglottis young children caused haemophilus influenzae hib rare hib vaccine coverage high caused bacteria occur adults clinical features allow child sit comfortable position parents lap force lie may precipitate airway obstruction avoid examination upset child including examination mouth throat treatment rapid less 1224 hours onset high fever typical tripod sniffing position preferring sit leaning forward open mouth anxious appearing difficulty swallowing drooling respiratory distress stridor may present opposed croup hoarse voice cough usually absent critically ill appearing case imminent airway obstruction emergency intubation tracheotomy indicated intubation technically difficult performed anaesthesia physician familiar procedure prepared perform tracheotomy intubation unsuccessful cases insert peripheral iv line provide iv hydration antibiotherapy ceftriaxone slow iv 3 minutes iv infusion 30 minutes avoid im route may agitate child precipitate respiratory arrest children 50 mgkg daily adults 1 g daily iv treatment administered least 5 days clinical condition improvedand oral treatment tolerated change amoxicillinclavulanic acid coamoxiclav po complete total 7 10 days treatment use formulations ratio 81 71 exclusively dose expressed amoxicillin children 40 kg 50 mgkg 2 times daily children 40 kg adult ratio 81 3000 mg daily 2 tablets 500625 mg 3 times daily ratio 71 2625 mg daily 1 tablet 875125 mg 3 times daily b c footnotes acritically ill appearing child weak grunting crying drowsiness difficult arrouse smile unconjugate anxious gaze pallor cyanosis general hypotonia bfor administration iv route ceftriaxone powder reconstituted water injection administration iv infusion dilute dose ceftriaxone 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults cimprovement criteria include fever reduction diminished respiratory distress improved spo improved appetite andor activity2page 79 409bacterial tracheitis bacterial infection trachea children occurring complication previous viral infection croup influenza measles etc clinical features treatment fever critically ill appearing child stridor cough respiratory distress copious purulent secretions opposed epiglottitis onset symptoms gradual child prefers lie flat severe cases risk complete airway obstruction especially young children suction purulent secretions insert peripheral iv line provide iv hydration antibiotherapy ceftriaxone slow iv3 minutes iv infusion 30 minutes administer im route may agitate child precipitate respiratory arrest children 50 mgkg daily adults 1 g daily cloxacillin iv infusion 60 minutes children less 12 years 25 50 mgkg every 6 hours children 12 years adults 2 g every 6 hours iv treatment administered least 5 days clinical condition improvedand oral treatment tolerated change amoxicillinclavulanic acid coamoxiclav po complete 7 10 days treatment epiglottitis b c event complete airway obstruction intubation possible emergency tracheotomy footnotes acritically ill appearing child weak grunting crying drowsiness difficult arrouse smile unconjugate anxious gaze pallor cyanosis general hypotonia bfor administration iv route ceftriaxone powder reconstituted water injection administration iv infusion dilute dose ceftriaxone 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults cimprovement criteria include fever reduction diminished respiratory distress improved spo improved appetite andor activity2page 80 409otitis acute otitis externa acute otitis media aom chronic suppurative otitis media csompage 81 409acute otitis externa diffuse inflammation external ear canal due bacterial fungal infection common precipitants otitis externa maceration trauma ear canal presence foreign body dermatologic diseases eczema psoriasis clinical features treatmentear canal pruritus ear pain often severe exacerbated motion pinna feeling fullness ear clear purulent ear discharge discharge otoscopy remove skin debris secretions auditory canal gentle dry mopping use dry cotton bud small piece dry cotton wool diffuse erythema edema infected eczema ear canal look foreign body visible tympanic membrane normal swelling pain often prevent adequate visualization tympanic membrane remove foreign body present treatment pain paracetamol po chapter 1 pain local treatment remove secretions auditory canal gentle dry mopping use dry cotton bud small piece dry cotton wool consider ear irrigation 09 sodium chloride using syringe tympanic membrane fully visualised intact perforation otherwise ear irrigation contraindicated apply ciprofloxacin ear drops affected ears 7 days children 1 year 3 drops 2 times daily adults 4 drops 2 times dailypage 82 409acute otitis media aom acute inflammation middle ear due viral bacterial infection common children 3 years uncommon adults principal causative organisms bacterial otitis media streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis older children streptococcus pyogenes clinical features treatment amoxicillin po 5 days children 30 mgkg 3 times daily max 3 g daily adults 1 g 3 times dailyrapid onset ear pain infants crying irritability sleeplessness reluctance nurse ear discharge otorrhoea fever signs rhinorrhoea cough diarrhoea vomiting frequently associated may confuse diagnosis hence necessity examining tympanic membranes otoscopy bright red tympanic membrane yellowish rupture imminent presence pus either externalised drainage ear canal tympanic membrane ruptured internalised opaque bulging tympanic membrane combination signs ear pain fever confirms diagnosis aom note following otoscopic findings sufficient make diagnosis aom red tympanic membrane alone evidence bulging perforation suggestive viral otitis context upper respiratory tract infection may due prolonged crying children high fever presence air bubbles fluid behind intact tympanic membrane absence signs symptoms acute infection suggestive otitis media effusion ome complications particularly highrisk children malnutrition immunodeficiency ear malformation include chronic suppurative otitis media rarely mastoiditis brain abscess meningitis cases treatment fever pain paracetamol po chapter 1 ear irrigation contraindicated tympanic membrane ruptured tympanic membrane cannot fully visualised ear drops indicated indications antibiotic therapy antibiotics prescribed children less 2 years children whose assessment suggests severe infection vomiting fever 39 c severe pain children risk unfavourable outcome malnutrition immunodeficiency ear malformation children child reexamined within 48 72 hours preferable delay antibiotic prescription spontaneous resolution probable short symptomatic treatment fever pain may sufficient antibiotics prescribed improvement worsening symptoms 48 72 hours child cannot reexamined antibiotics prescribed children treated antibiotics advise mother bring child back fever pain persist 48 hours choice antibiotherapy amoxicillin firstline treatmentpage 83 409amoxicillinclavulanic acid coamoxiclav po 5 days use formulations ratio 81 71 dose expressed amoxicillin children 40 kg 25 mgkg 2 times daily children 40 kg adult ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily persistence ear drainage alone without fever pain child otherwise improved reduction systemic symptoms local inflammation warrant change antibiotic therapy clean ear canal gentle dry mopping drainage obtained azithromycin po children 6 months 10 mgkg daily 3 daysamoxicillinclavulanic acid used secondline treatment case treatment failure treatment failure defined persistence fever andor ear pain 48 hours antibiotic treatment macrolides reserved rare penicillinallergic patients treatment failure resistance macrolides frequentpage 84 409chronic suppurative otitis media csom chronic bacterial infection middle ear persistent purulent discharge perforated tympanic membrane principal causative organisms pseudomonas aeruginosa proteus sp staphylococcus gram negative anaerobic bacteria clinical features treatment children 1 year 3 drops 2 times daily adults 4 drops 2 times dailypurulent discharge 2 weeks often associated hearing loss even deafness absence pain fever otoscopy perforation tympanic membrane purulent exudate complications consider superinfection aom case new onset fever ear pain treat accordingly consider mastoiditis case new onset high fever severe ear pain andor tender swelling behind ear patient appears significantly unwell consider brain abscess meningitis case impaired consciousness neck stiffness focal neurological signs eg facial nerve paralysis remove secretions auditory canal gentle dry mopping use dry cotton bud small piece dry cotton wool apply ciprofloxacin ear drops drainage obtained approximately 2 weeks max 4 weeks complications chronic mastoiditis medical emergency requires prompt hospitalisation prolonged antibiotherapy covers causative organisms csom ceftriaxone im 10 days ciprofloxacin po 14 days atraumatic cleaning ear canal surgical treatment may required transfer hospital patient needs transferred administer first dose antibiotics meningitis chapter 7page 85 409pertussis whooping cough last updated december 2024 pertussis highly contagious infection respiratory tract caused bacterium bordetella pertussis transmitted via airborne droplets spread infected people coughing andor sneezing particularly within 3 weeks onset cough despite development effective vaccines remains important cause morbidity mortality particularly infants disease endemic worldwide outbreaks common commonly affects children 5 years affect age group reported incidence adolescents adults increasing regions pertussis notifiable disease many countries cases reported local national public health authorities pertussis immunization part vaccination schedules included expanded programme immunization epi clinical features incubation period 7 10 days 21 days illness evolves 3 stages complications may include secondary bacterial pneumonia newonset fever indicator dehydration malnutrition triggered feeding difficulty due cough vomiting seizures encephalopathy sudden death intracranial bleeding petechiae rib fracture hernia rectal prolapse disease severe high risk death infants adolescents adults commonly milder symptoms older adults immunocompromised persons people underlying respiratory conditions risk severe disease hospitalisation pertussis contagious antibiotic treatment beneficial catarrhal stage illness since also period clinical symptoms signs nonspecific necessary maintain high index suspicion clues context include patients compatible symptoms close contact suspected case pertussis outbreak setting management suspected cases antibiotic treatment 1 2 3 catarrhal stage 1 2 weeks may shorter infants 6 months runny nose mild cough lowgrade fever stage disease indistinguishable nonspecific respiratory infections paroxysmal stage 1 6 weeks cough increasing severity occuring characteristic bouts paroxysms series coughs one exhalation followed laboured inspiration causing distinctive gasping sound whoop andor posttussive vomiting lowgrade fever apnoea cyanosis infants prolonged cough sometimes without paroxysms whoop particularly older children adults convalescent stage weeks months paroxysms cough gradually decrease frequency severity 4 page 86 409antibiotic treatment indicated following patientsand started soon pertussis suspected admit following patients hospital infection prevention control measures patients pertussis considered infectious completed 5 days appropriate antibiotics treated 21 days start paroxysmal cough infectious period measures followed 5 patients 1 year age older within 3 weeks onset cough infants pregnant women within 6 weeks onset cough first line azithromycin po 5 dayschildren 6 months 10 mgkg daily children 6 months 10 mgkg max 500 mg d1 5 mgkg max 250 mg daily d2 d5 adults 500 mg d1 250 mg daily d2 d5 alternatives erythromycin po 7 days children 15 mgkg 3 times daily adults 1 g 3 times daily cotrimoxazole po 14 days b children 6 weeks 20 mg smx4 mg tmpkg max 800 mg smx160 mg tmp 2 times daily adults 800 mg smx160 mg tmp 2 times daily aerythromycin alternative azithromycin better tolerated simpler administer shorter treatment duration fewer daily doses buse cotrimoxazole macrolides contraindicated tolerated available avoid first trimester pregnancy risk congenital malformations 36 weeks pregnancy women breastfeeding neonates 0 4 weeks breastfeeding infants premature low birth weight jaundiced ill risk haemolysis jaundice child advise patients seek immediate medical attention signs anaemia jaundice especially regions high prevalence g6pd deficiency patients severe illness eg respiratory distress apnoea cyanosis pneumonia seizures impaired consciousness infants 3 months age monitoring 24 hours per day due risk apnoea patients difficulty feeding drinking 1 hospital single room possible grouping pertussis cases together away patients cohorting standard precautions droplet precautions including patient cough etiquette wearing surgical mask outside room 6 patients avoid contact young children pregnant women avoid congregate settings including childcare school workpage 87 409supportive care hydration nutrition child breastfeeding continue ensure adequate fluid calorie intake give frequent small feedings including coughing bouts posttussive vomiting patients may require nasogastric tube feeding iv maintenance fluids aware ng tube placement might provoke paroxysmal coughing inserted experienced medical staff minimal manipulation weight loss occurred illness consider food supplements several weeks convalescent stage child able eat comfortably respiratory measures children treated outpatients teach parents signs require immediate medical attention eg respiratory difficulty apnoea cyanosis increasing fever seizures impaired consciousness dehydration feeding difficulty contacts prevention place patient semireclining position 30 case apnoea stimulate patient prepared ventilate necessary keep bag mask accessible administer oxygen spo 92 severe respiratory distress recurrent apnoea perform gentle oropharyngeal suctioning required avoid deep suctioning may provoke paroxysmal coughing2 postexposure prophylaxis antibiotic treatment suspect cases recommended regardless vaccination status asymptomatic close contacts facetoface exposure direct contact oral nasal respiratory secretions person suspected pertussis within 3 weeks onset paroxysmal cough 7 asymptomatic exposed people high risk complications come contact people high risk 4 8 pregnant women third trimester risk neonate infants 1 year people immunodepression moderate severe asthma consider people underlying respiratory conditions adults 65 years isolation asymptomatic contacts necessary symptomatic contacts treated suspected pertussis assess whether person uptodate pertussis vaccination according national protocol see prevention pertussis vaccination provides substantial immunity wanes time 1 cases suspected cases contacts uptodate pertussis vaccination begin refer vaccination routine vaccination 3dose primary series polyvalent vaccine containing pertussis antigens age 6 weeks according national protocol booster dose recommended preferably second year life based local epidemiology booster doses may required later life reinforce immunity reduce risk developing pertussis 1 pertussis primary vaccination series interrupted completed rather restarted beginning general vaccinations deferred patients moderate severe illness vaccine administered soon patients condition improved vaccination probably prevent disease person already infected b pertussis substitute postexposure prophylaxis 7 9 page 88 409references 1pertussis vaccines position paper august 2015 wkly epidemiol rec 201535433458 httpsiriswhointbitstreamhandle10665242413wer9035_433458pdf accessed may 17 2024 2guris strebel pm bardenheier b et al changing epidemiology pertussis united states increasing reported incidence among adolescents adults 19901996 clin infect dis 199928612301237 httpsdoiorg101086514776 accessed september 10 2024 3daniels hl sabella c bordetella pertussis pertussis pediatr rev 2018395247257 httpsdoiorg101542pir20170229 accessed september 11 2024 4mbayei sa faulkner miner c et al severe pertussis infections united states 20112015 clin infect dis 2019692218226 httpsdoiorg101093cidciy889 accessed september 13 2024 5centers disease control prevention clinicians pertussis treatment published online august 4 2022 httpswwwcdcgovpertussisclinicaltreatmenthtml accessed april 28 2024 6siegel j rhinehart e jackson chiarello l healthcare infection control practices advisory committee 2007 guideline isolation precautions preventing transmission infectious agents healthcare settings published online july 2023 httpswwwcdcgovinfectioncontrolmediapdfsguidelineisolationhpdf accessed april 282024 7world health organization pertussis vaccinepreventable diseases surveillance standards published online september 5 2018 httpswwwwhointpublicationsmitemvaccinepreventablediseasessurveillancestandardspertussis accessed may 19 2024 8centers disease control prevention pertussis postexposure antimicrobial prophylaxis pep published online august 4 2022 httpswwwcdcgovpertussisphppostexposureprophylaxisindexhtml accessed april 29 2024 9blain skoff cassiday p tondella ml acosta pertussis manual surveillance vaccinepreventable diseases centers disease control prevention 2020chapter 10 httpswwwcdcgovsurvmanualphptableofcontentschapter10pertussishtml accessed may 19 2024page 89 409bronchitis acute bronchitis chronic bronchitispage 90 409acute bronchitis acute inflammation bronchial mucosa commonly viral origin older children caused mycoplasma pneumoniae children 2 years age repetitive acute bronchitis wheezing bronchitis consider asthma see asthma children 2 years age consider bronchiolitis see bronchiolitis clinical features often begins rhinopharyngitis descends progressively pharyngitis laryngitis tracheitis treatment amoxicillin po children 30 mgkg 3 times daily max 3 g daily 5 days adults 1 g 3 times daily 5 daysheavy cough dry beginning becoming productive lowgrade fever tachypnoea dyspnoea pulmonary auscultation bronchial wheezing fever paracetamol po chapter 1 keep patient hydrated humidify air bowl water wet towel children nasal irrigation 09 sodium chloride ringer lactate 4 6 times daily clear airway antibiotherapy useful patients good overall condition rhinopharyngitis influenza antibiotherapy indicated patient poor general condition malnutrition measles rickets severe anaemia cardiac disease elderly patient etc patient dyspnoea fever greater 385 c purulent expectorations secondary infection haemophilus influenzae pneumococcus probablepage 91 409chronic bronchitis chronic inflammation bronchial mucosa due irritation tobacco pollution allergy asthma infection repetitive acute bronchitis may develop chronic obstructive pulmonary disease clinical features patient acute exacerbation chronic bronchitis presents treatmentproductive cough 3 consecutive months per year 2 successive years dyspnoea onset dyspnoea develops several years first exertion becoming persistent pulmonary auscultation bronchial wheeze always exclude tuberculosis onset increase dyspnoea increased volume sputum purulent sputum antibiotic treatment useful treating simple chronic bronchitis antibiotic treatment may useful patients poor general condition acute exacerbations chronic bronchitis see acute bronchitis discourage smoking irritating factorspage 92 409bronchiolitis last updated october 2023 bronchiolitis epidemic seasonal viral infection lower respiratory tract children less 2 years age characterised bronchiolar obstruction respiratory syncytial virus rsv responsible 70 cases bronchiolitis transmission rsv direct inhalation droplets coughing sneezing indirect contact hands materials contaminated infected secretions majority cases bronchiolitis benign resolves spontaneously relapses possible treated outpatient basis severe cases may occur put child risk due exhaustion secondary bacterial infection hospitalisation necessary signscriteria severity present 10 20 cases clinical features rhinopharyngitis dry cough precedes features 24 72 hours fever absent moderate treatment treatment symptomatic obstructive signs symptoms last 10 days cough may persist 2 weeks longer hospitalise children one following criteria consider hospitalisation casebycase basis following situations cases child may treated home provided parents taught carry treatment signs severity lead reconsultationtachypnoea dyspnoea wheezing cough profuse frothy obstructive secretions auscultation prolonged expiration diffuse bilateral wheezes sometimes diffuse fine endinspiratory crackles signs severity significant deterioration general condition toxic appearance pallor greyish colouration apnoea cyanosis check lips buccal mucosa fingernails respiratory distress nasal flaring sternal chest wall indrawing anxiety agitation hypoxia altered level consciousness respiratory rate 60minute decreased signs respiratory distress exhaustion decline respiratory rate 30minute age 1 year 20minute age 3 years exercise caution interpreting signs indicators clinical improvement spo persistently 92 2 sweats tachycardia rest absence fever silence auscultation severe bronchospasm difficulty drinking sucking reduced tolerance exertion presence sign severity preexisting pathology cardiac pulmonary disease malnutrition hiv infection etc associated acute pathology viral gastroenteritis bacterial infection etc age less 3 monthspage 93 409outpatient treatment hospitalisation prevention control risk transmission virus increased hospital settings nasal irrigation 09 nacl feeding demonstrate technique mother small frequent feedings reduce vomiting triggered bouts coughing increased fluids fever andor significant secretions present treat fever chapter 1 handle patient patient little possible avoid unnecessary procedures cases place infant semireclining position 30 nasal irrigation small frequent feeds treatment fever outpatient treatment gentle oropharyngeal suction needed monitor fluid intake normal requirements 80 100 mlkgday 20 25 mlkgday high fever profuse secretions according symptoms humidified nasal oxygen respiratory distress spo 92 2 vomiting significant fatigue sucking fluid requirements may administered nasogastric tube small volumes frequent basis iv route shortest possible time avoid breastfeeding oral feeds children severe tachypnoea prolong ng feeds respiratory compromise iv infusions longer necessary bronchodilator therapy indicated trial treatment may given case severe respiratory distress salbutamol metereddose inhaler 100 microgramspuff 2 3 puffs spacer repeated 2 times interval 30 minutes inhaled salbutamol appears effective relieving symptoms treatment continued 2 3 puffs every 6 hours acute phase gradual reduction recovery takes place trial ineffective treatment discontinued antibiotics indicated unless concern complications secondary bacterial pneumonia children bronchiolitis grouped together away children cohorting infection commonly transmitted hands important prevention measure handwashing contact patients objects surfaces contact patients virus may survive several hours addition staff wear gowns gloves surgical masks contact patients footnotes alie child back head turned side instil 09 nacl nose one nostril timepage 94 409acute pneumonia acute pneumonia viral bacterial pneumococcus haemophilus influenzae staphylococcus atypical bacteria parasitic pneumocystosis infection pulmonary alveolipneumonia children 5 years age pneumonia children 5 years adults persistent pneumoniapage 95 409pneumonia children 5 years age common causes viruses pneumococcus haemophilus influenzae clinical features clinical examination must done calm child order correctly count respiratory rate look signs severity rr 60 breathsminute children 1 months rr 50 breathsminute children 1 11 months rr 40 breathsminute children 12 months 5 years notes consider also treatment severe pneumonia inpatient treatmentcough difficulty breathing fever often high 39 c child may present lowgrade fever may fever often sign serious illness child tachypnoea increased respiratory rate pulmonary auscultation dullness diminished vesicular breath sounds crepitations sometimes bronchial breathing normal pulmonary auscultation signs severity severe pneumonia chest indrawing inferior thoracic wall depresses inspiration superior abdomen expands cyanosis lips oral mucosa fingernails spo 90 2 nasal flaring altered consciousness child abnormally sleepy difficult wake stridor hoarse noise inspiration grunting short repetitive noise produced partial closure vocal cords expiration refusal drink feed children 2 months severe malnutrition malnourished children rr thresholds decreased 5 breathsminute listed chest indrawing significant clearly visible present times observed child upset feeding visible child resting chest indrawing children 2 months age moderate chest indrawing normal thoracic wall flexible soft tissues ribs clavicles depress chest indrawing malaria endemic areas may also cause cough tachypnoea staphylococcal pneumonia patients empyema painful abdominal swelling diarrhoea pneumocystosis children confirmed suspected hiv infection see hiv infection aids chapter 8 tuberculosis child cough fever poor weight gain history close contact tuberculous patient diagnosis refer msf handbook tuberculosis event pneumonia complicated empyema pus pleural spacepage 96 409children 2 months first line treatment combination ampicillin slow iv 3 minutes 10 days gentamicin slow iv 3 minutes im 5 days ampicillin iv route preferred im route may alternative ampicillin available alternatives may cefotaxime slow iv 3 minutes infusion 20 minutes im 10 days doses see meningitis chapter 7 last resort ceftriaxone slow iv3 minutes infusion 30 minutes 60 minutes neonates im 50 mgkg daily 10 days childs condition improveafter 48 hours well administered treatment add cloxacillin iv 10 14 days children 2 months 5 years first line treatment ceftriaxone im slow iv3 minutes 50 mgkg daily ampicillin slow iv 3 minutes im 50 mgkg every 6 hours gentamicin slow iv 3 minutes im 6 mgkg daily ampicillin preferably administered 4 divided doses context permit daily dose must divided least 3 doses treatment administered parenteral route least 3 days clinical condition improvedand oral treatment tolerated switch amoxicillin po 30 mgkg 3 times daily complete 10 days treatment childs condition deteriorates improve 48 hours correct administration add cloxacillin iv 25 50 mgkg every 6 hours clinical improvement 3 days fever switch amoxicillinclavulanic acid coamoxiclav po complete 10 14 days treatment use formulations ratio 81 71 exclusively dose expressed amoxicillin 50 mgkg 2 times daily children 0 7 days 2 kgampicillin 50 mgkg every 12 hours gentamicin 3 mgkg daily 2 kgampicillin 50 mgkg every 8 hours gentamicin 5 mgkg daily children 8 days 1 monthampicillin 50 mgkg every 8 hours gentamicin 5 mgkg daily children 1 month 2 monthsampicillin 50 mgkg every 6 hours gentamicin 6 mgkg daily b c children 0 7 days 2 kg cloxacillin 50 mgkg every 12 hours 2 kg cloxacillin 50 mgkg every 8 hours children 7 days 2 kg cloxacillin 50 mgkg every 8 hours 2 kg cloxacillin 50 mgkg every 6 hours b c page 97 409 childs condition improve 48 hours ceftriaxone cloxacillin consider tuberculosis diagnosis refer guide tuberculosis msf tuberculosis unlikely continue ceftriaxone cloxacillin add azithromycin see atypical pneumonia notes adjuvant therapy use nasogastric tube iv line cannot established children 12 months 5 mlkghour children 12 months 3 4 mlkghour alternate milk water resume normal oral feeding soon possible pneumonia signs severity children 2 months admit child inpatient care treat severe pneumonia children 2 months 5 years treat outpatient except infants amoxicillin po 30 mgkg 3 times daily 5 days followup 48 72 hours sooner childs condition deteriorates malnourished children refer specific protocol event moderatelarge empyema assess drainage required administer antibiotics active pneumococci staphylococci see staphylococcal pneumonia fever paracetamol po chapter 1 infants keep warm install incline head elevated semisitting position clear airway nasal irrigation 09 sodium chloride needed oxygen flow rate required maintain spo 90 pulse oxymeter available minimum 1 litreminute2 maintain adequate hydration nutrition children severe respiratory difficulty place iv line give 70 normal maintenance fluids resume oral feeding soon possible severe respiratory difficulty ability eat normally absence severe respiratory difficulty breastfeed demand milkfood water spoon demand ors required dehydration chapter 1 condition improving continue antibiotic complete treatment c improvement 3 days correct administration add azithromycin see atypical pneumonia condition deteriorating hospitalise treat severe pneumonia footnotes acontact defined living household close regular contact known suspected tuberculous case within last 12 months bthe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used cimprovement criteria include fever reduction diminished respiratory distress improved spo improved appetite andor activity 2page 98 409pneumonia children 5 years adults common causes viruses pneumococcus mycoplasma pneumoniae clinical features sudden onset high fever higher 39 c thoracic pain oral herpes suggestive pneumococcal infection symptoms may confusing particularly children abdominal pain meningeal syndrome etc signs severity severe pneumonia include patients risk include older patients patients heart failure sickle cell disease severe chronic bronchitis immunocompromised patients severe malnutrition hiv infection cd4 200 treatment severe pneumonia inpatient treatment ceftriaxone im slow iv3 minutes children 50 mgkg daily adults 1 g daily treatment given parenteral route least 3 days clinical condition improvedand oral treatment tolerated switch amoxicillin po complete 7 10 days treatment children 30 mgkg 3 times daily max 3 g daily adults 1 g 3 times daily ampicillin slow iv 3 minutes im children 50 mgkg every 6 hours adults 1 g every 6 8 hours ampicillin preferably administered 4 divided doses context permit daily dose must divided least 3 doses treatment given parenteral route least 3 days clinical condition improvedand oral treatment tolerated switch oral route amoxicillin po complete 7 10 days treatment cough without purulent sputum fever thoracic pain tachypnoea pulmonary auscultation decreased vesicular breath sounds dullness localised foci crepitations sometimes bronchial wheeze cyanosis lips oral mucosa fingernails nasal flaring intercostal subclavial indrawing rr 30 breathsminute heart rate 125 beatsminute altered level consciousness drowsiness confusion b b page 99 409if clinical condition deteriorates improve 48 hours correct administration administer ceftriaxone cloxacillin iv infusion children 25 50 mgkg every 6 hours adults 2 g every 6 hours clinical improvement 3 days fever switch amoxicillinclavulanic acid coamoxiclav po complete 10 14 days treatment use formulations ratio 81 71 exclusively dose expressed amoxicillin children 40 kg 50 mgkg 2 times daily children 40 kg adults ratio 81 3000 mg daily 2 tablets 500625 mg 3 times daily ratio 71 2625 mg daily 1 tablet 875125 mg 3 times daily clinical condition improve 48 hours ceftriaxone cloxacillin consider tuberculosis diagnosis refer guide tuberculosis msf tuberculosis unlikely continue ceftriaxone cloxacillin add azithromycin see atypical pneumonia adjuvant therapy pneumonia without signs severity outpatient treatment amoxicillin po children 30 mgkg 3 times daily max 3 g daily 5 days adults 1 g 3 times daily 5 days followup 48 72 hours sooner patients condition deteriorates fever paracetamol po chapter 1 clear airway nasal irrigation 09 sodium chloride needed oxygen flow rate required maintain spo 90 pulse oxymeter available minimum 1 litreminute2 maintain adequate hydration nutrition condition improving continue antibiotic complete treatment b improvement 3 days correct administration add azithromycin see atypical pneumonia condition deteriorating hospitalise treat severe pneumonia footnotes athe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used bimprovement criteria include fever reduction diminished respiratory distress improved spo improved appetite andor activity 2page 100 409persistent pneumonia last update november 2022 patients responding therapy consider atypical pneumonia tuberculosis pneumocystosis hiv infection aids chapter 8 bacteria responsible atypical pneumonia mainly mycoplasma pneumoniae chlamydophila pneumoniae suspected one following antibiotics may used first choice azithromycin po children 10 mgkg max 500 mg daily 5 days adults 500 mg d1 250 mg daily d2 d5 available erythromycin po children 10 mgkg max 500 mg 4 times daily 10 14 days adults 500 mg 4 times daily 10 14 days doxycycline po except pregnant breastfeeding women children 45 kg 2 22 mgkg max 100 mg 2 times daily 10 14 days children 45 kg adults 100 mg 2 times daily 10 14 dayspage 101 409staphylococcal pneumonia pneumonia due staphylococcus aureus affecting young children often poor general condition malnutrition skin lesions etc staphylococcal pneumonia classic complication measles clinical features paraclinical investigations treatment treatment urgent patients deteriorate quickly hospitalise ceftriaxone im slow ivat least 3 minutes 50 mgkg daily cloxacillin iv infusion 60 minutes neonates 0 7 days 2 kg 50 mgkg every 12 hours neonates 0 7 days 2 kg 50 mgkg every 8 hours neonates 8 days 1 month 2 kg 50 mgkg every 8 hours neonates 8 days 1 month 2 kg 50 mgkg every 6 hours children 1 month 25 50 mgkg every 6 hours max 8 g daily clinical improvement 3 days fever drain removal switch amoxicillinclavulanic acid po complete 10 14 days use formulations ratio 81 71 exclusively dose expressed amoxicillin 50 mgkg 2 times daily event large empyema treatment switch oral route 7 days fever treat 3 weeks clindamycin iv may alternative cloxacillin 10 mgkg every 8 hours switch clindamycin po dose according criteria general signs change overall condition pallor high fever hypothermia frequently signs shock presence skin lesions point bacterial entry however skin lesions may absent gastrointestinal signs nausea vomiting diarrhoea painful abdominal distention respiratory signs dry cough tachypnoea signs distress nasal flaring chest indrawing pulmonary auscultation often normal sometimes dullness indicating pleural effusion chest xray available may show multilobar consolidation cavitation pneumatoceles spontaneous pneumothorax antibiotic treatment staphylococcal aetiology cannot confirmed waiting confirmation broad spectrum antibiotic therapy recommended b c fever paracetamol chapter 1 hydration oral route infusion nasogastric tube depending clinical condition oxygen flow rate required maintain spo 90 pulse oxymeter available minimum 1 litreminute2 local disinfection skin lesionspage 102 409clinical evolution significant pleural effusion pleural tap drainage pyopneumothorax insert 2 drains one anterior one posterior without drainage suppurative pleurisy make repetitive taps iv catheter serious risk decompensation pneumothorax suppurative pleurisy pyopneumothorax paediatric ward adequate equipment urgent pleural drainage always available footnotes athe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used bcloxacillin powder injection reconstituted 4 ml water injection dilute dose cloxacillin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults cimprovement criteria include fever reduction diminished respiratory distress improved spo2 improved appetite andor activitypage 103 409asthma last updated june 2023 asthma chronic inflammatory disorder airways associated airway hyperresponsiveness leads recurrent episodes wheezing breathlessness chest tightness coughing episodes usually associated airflow obstruction within lung often reversible either spontaneously treatment factors precipitateaggravate asthma include allergens infection exercise drugs aspirin tobacco etc symptoms sometimes worse night children 5 years initial episodes asthmalike symptoms associated respiratory tract infection symptoms infections wheezing episodes usually become less frequent time children develop asthmaacute asthma asthma attack chronic asthmapage 104 409acute asthma asthma attack last updated june 2023 asthma attack substantial worsening asthma symptoms severity duration attacks variable unpredictable assessment severity asthma attack severity asthma attack must rapidly evaluated following clinical criteria signs necessarily present assessment severity children 2 years adults treatment reassure patient treatment followup depend severity attack patients response mild moderate attack 1 2 3 mild moderate attack severe lifethreatening attack able talk sentences cannot complete sentences one breath breathless talk feed mild moderate increase respiratory rate rrvery high rr children 25 years 40minute children 5 years adults 30minute normal mild increase heart rate hr children 23 years 180minute children 45 years 150minute children 5 years adults 120minute high hr children 23 years 180minute children 45 years 150minute children 5 years adults 120minute spo 90 92 children 25 years 2 spo 90 92 children 25 years 2 criteria severe lifethreatening attack signs lifethreatening attack altered level consciousness drowsiness confusion coma exhaustion silent chest cyanosis arrhythmia hypotension adults place patient 12 sitting position administerpage 105 409severe attack two solutions mixed drug reservoir nebuliser assess symptoms end nebulisation nebuliser use salbutamol mdi dose mild moderate attack ipratropium mdi 20 microgramspuff 4 8 puffs every 20 minutes first hoursalbutamol metereddose inhaler mdi 100 microgramspuff 2 10 puffs every 20 minutes first hour children use spacer use face mask children 3 years single puffs given one time let child breathe 4 5 times spacer repeating procedure spacer also used adults increase effectiveness prednisolone po one dose 1 2 mgkg max 50 mg children 5 years adults oxygen spo 94 2 b attack completely resolved observe patient 1 hour 4 hours live far health centre give outpatient treatment salbutamol mdi 24 48 hours 2 4 puffs every 4 6 hours depending clinical evolution prednisolone po dose daily complete 5 days treatment reassess 1 2 days address identified risk factor reassess need salbutamol longterm treatment patient already receiving longterm treatment reevaluate severity asthma see chronic asthma review compliance correct use medications adjust treatment necessary attack partially resolved continue salbutamol mdi 2 10 puffs every 1 4 hours symptoms subside children 5 years administer one dose prednisolone po symptoms recur within 3 4 hours attack completely resolved proceed symptoms worsen improve treat severe attack hospitalise place patient 12 sitting position c administer oxygen maintain spo 94 98 2 b salbutamol ipratropium nebuliser solutions using nebuliser continue oxygen via nasal cannula nebulisation children 5 years salbutamol 25 mg 125 ml ipratropium 025 mg 1 ml every 20 minutes first hour children 5 11 years salbutamol 25 5 mg 125 25 ml ipratropium 05 mg 2 ml every 20 minutes first hour children 12 years adultssalbutamol 5 mg 25 ml ipratropium 05 mg 2 ml every 20 minutes first hour prednisolone po one dose 1 2 mgkg max 50 mg prednisolone available patient cannot take oral treatment administer children dexamethasone poivim one dose 015 06 mgkg max 16 mg adults hydrocortisone iv 4 mgkg max 100 mg every 6 hours 24 hours symptoms improve one hour transfer intensive care unit insert iv line oxygen maintain spo 94 98 2 b continue salbutamol solution nebuliser without ipratropium corticosteroids administer one dose magnesium sulfate iv infusion 09 sodium chloride 20 minutes monitoring blood pressurepage 106 409 notes referenceschildren 40 mgkg max 2 g adults 2 g symptoms improve continue salbutamol solution nebuliser every 1 4 hours depending symptoms oxygen assess symptoms end nebulisation possible switch salbutamol mdi continue mild moderate attack attack completely resolved observe patient least 4 hours continue treatment salbutamol mdi prednisolone po reassess mild moderate attack pregnant women treatment adults mild moderate asthma attacks administering oxygen reduces risk foetal hypoxia patients irrespective severity asthma attack look underlying lung infection treat accordingly footnotes aif conventional spacer available use 500 ml plastic bottle insert mouthpiece inhaler hole made bottom bottle seal tight possible patient breathes mouth bottle way would spacer use plastic cup instead spacer recommended ineffective bif pulse oxymetry available administer oxygen continuously case moderate severe lifethreatening attack cif signs lifethreatening attack transfer intensive care unit soon possible 1british guideline management asthma national clinical guideline first published 2003 revised edition published july 2019 httpswwwsignacukourguidelinesbritishguidelineonthemanagementofasthma accessed 12 january 2023 2global initiative asthma global strategy asthma management prevention 2022 update httpsginasthmaorgginareports accessed 12 january 2023 3who pocket book primary health care children adolescents guidelines health promotion disease prevention management newborn period adolescence regional office europe 2022 httpswwwwhointeuropepublicationsiitem9789289057622 accessed 12 january 2023page 107 409chronic asthma last updated june 2023 clinical features treatment mainstay longterm treatment inhaled corticosteroids ics longacting beta2 agonists laba labas never used alone always combination ics combination inhalers preferred available addition longterm treatment salbutamol shortacting beta2 agonist saba combination inhalers used reduce bronchoconstriction patient symptomatic treatment started step appropriate initial severity reevaluated adjusted according clinical response intervening severe asthma attack loss control necessitates treatment reassessment inhaler chosen according age children spacer used instructions inhaler technique information asthma attack symptoms provided longterm treatment asthma according severity children 6 years adults asthma suspected patients recurrent respiratory symptoms wheezing chest tightness shortness breath andor cough variable frequency severity duration disturbing sleep causing patient sit breathe symptoms may appear exercise chest auscultation may normal demonstrate diffuse sibilant wheezes personal family history atopy eczema allergic rhinitisconjunctivitis family history asthma increases probability asthma absence exclude asthma patients typical symptoms asthma history disease characteristic asthma considered asthma exclusion diagnoses identified asthma risk factor eg allergen pollution tobacco smoke exposure eliminated possible assessment frequency symptoms limitations daily activities determines treatment 1 2page 108 409symptoms children 6 11 years children 12 years adults intermittent asthma daytime symptoms 2 times monthly normal daily activitiessalbutamol symptomatic beclometasoneformoterol symptomatic beclometasone salbutamol symptomatic mild persistent asthma daytime symptoms 2 times monthly symptoms may affect daily activitiesbeclometasone low dose daily salbutamol symptomaticbeclometasoneformoterol symptomatic beclometasone low dose daily salbutamol symptomatic moderate persistent asthma daytime symptoms days nighttime symptoms weekly symptoms affect daily activitiesbeclometasone low dose salmeterol daily salbutamol symptomatic bbeclometasoneformoterol low dose daily beclometasoneformoterol symptomatic budesonideformoterol low dose daily budesonideformoterol symptomaticor beclometasone low dose salmeterol daily salbutamol symptomatic b severe persistent asthma daily daytime symptoms frequent nighttime symptoms daily activities limited symptomsbeclometasone medium dose salmeterol daily salbutamol symptomaticbeclometasoneformoterol medium dose daily beclometasoneformoterol symptomatic budesonideformoterol low dose daily budesonideformoterol symptomaticor beclometasone medium dose salmeterol daily salbutamol symptomatic c asalbutamol taken beclometasone together combination inhaler available bif salmeterol available use beclometasone mediumdose cif salmeterol available use beclometasone highdosepage 109 409the doses vary according severity asthma find lowest possible effective dose necessary relieve symptoms avoid local systemic adverse effects beclometasone mdi ics cases exceed 2000 micrograms daily number puffs beclometasone depends concentration inhaled aerosol 50 100 250 micrograms per puff salbutamol mdi 100 microgramspuff saba salmeterol mdi 25 microgramspuff laba budesonideformoterol mdi 8045 microgramspuff icslaba combination cases exceed 8 puffs daily beclometasoneformoterol mdi 1006 microgramspuff icslaba combination cases exceed 8 puffs daily restrict exercise exercise trigger asthma attacks administer 1 2 puffs salbutamol beclometasoneformoterol 10 minutes beforehand pregnant women poorly controlled asthma increases risk preeclampsia eclampsia haemorrhage utero growth retardation premature delivery neonatal hypoxia perinatal mortality longterm treatment continued close monitoring children 6 11 years children 12 years adults symptomatic 200 500 micrograms longterm treatment low dose50 100 micrograms 2 times daily100 250 micrograms 2 times daily medium dose 150 200 micrograms 2 times daily300 500 micrograms 2 times daily high dose 500 micrograms 2 times daily children adults 2 4 puffs 4 times daily necessary children 6 11 years 2 puffs 2 times daily max 4 puffs daily children 12 years adults 2 4 puffs 2 times daily max 8 puffs daily children 6 11 years symptomatic 1 puff longterm treatment lowdose 1 puff daily longterm treatment lowdose 1 puff 2 times daily children 12 years adults symptomatic 1 puff longterm treatment lowdose 1 puff 2 times daily longterm treatment mediumdose 2 puffs 2 times dailypage 110 409 symptoms well controlled period 2 3 months check inhalation technique adherence changing stronger treatment symptoms well controlled period least 3 months patient asymptomatic asthma attacks well controlled try stepwise reduction medication references 1global initiative asthma global strategy asthma management prevention 2022 update httpsginasthmaorgginareports accessed 23 january 2023 2who pocket book primary health care children adolescents guidelines health promotion disease prevention management newborn period adolescence regional office europe 2022 httpswwwwhointeuropepublicationsiitem9789289057622 accessed 23 january 2023page 111 409pulmonary tuberculosis pulmonary tuberculosis bacterial infection due mycobacterium tuberculosis spread person person inhalation infected respiratory droplets infection tuberculosis multiplies slowly lungs usually eliminated spontaneously lies dormant 10 cases develop active tuberculosis risk progressing active tuberculosis higher immunocompromised patients certain countries half newly diagnosed tuberculosis patients coinfected hiv information tuberculosis refer guide tuberculosis msf clinical features endemic area diagnosis tuberculosis considered patient consulting respiratory symptoms 2 weeks respond nonspecific antibacterial treatment laboratory treatment pulmonary tuberculosis standard treatment combination four antituberculosis drugs isoniazid rifampicin pyrazinamide ethambutol regimen organised 2 phases initial phase continuation phase lasts 6 months strain drugresistant treatment longer different drug combinations used takes significant investment cure tuberculosis patient medical team uninterrupted treatment lead cure prevent development resistance essential patient understands importance treatment adherence access correct case management treatment completed prevention references 1 prolonged cough 2 weeks without sputum production andor haemoptysis prolonged fever night sweats anorexia weight loss chest pain fatigue differential diagnosis includes pneumonia chronic obstructive pulmonary disease copd lung cancer pulmonary distomatosis flukes chapter 6 melioidosis southeast asia general population xpert mtbrif test simultaneously detects tuberculosis mtb sputum resistance rifampicin rif available perform sputum smear microscopy 2 hiv coinfection suspected diagnosed xpert mtbrif test pointofcare urine lflam lateral flow urine lipoarabinomannan assay 2 bcg vaccination neonates provides 59 protection pulmonary tuberculosis 3 infection control healthcare settings standard precautions airborne precautions confirmed suspected cases close contacts isoniazid preventive therapy 6 monthspage 112 4091world health organization global tuberculosis report 2018 httpsappswhointirishandle10665274453 accessed 21 october 2019 2global laboratory initiative gli model tb diagnostic algorithms 2018 httpwwwstoptborgwggliassetsdocumentsgli_algorithmspdf accessed 21 october 2019 3world health organization weekly epidemiological recordreleve epidemiologique hebdomadaire 23rd february 2018 93rd year23 fevrier 2018 93e annee 8 2018 93 7396 httpswwwwhointimmunizationpolicyposition_papersbcgen accessed 21 october 2019page 113 409chapter 3 gastrointestinal disorders acute diarrhoea shigellosis amoebiasis disorders stomach duodenum gastrooesophageal reflux gastric duodenal ulcers adults dyspepsia stomatitis oral oropharyngeal candidiasis oral herpes infectious causes stomatitis scurvy vitamin c deficiency lesions resulting nutritional deficiency page 114 409acute diarrhoea acute diarrhoea defined least 3 liquid stools per day less 2 weeks clinical features treatment general principles prevention treatment dehydration see dehydration chapter 1 adapted treatment protocols recommended children malnutrition see severe acute malnutrition chapter 1 prevention malnutrition continue unrestricted normal diet breastfed children increase frequency feeds breast milk replace ors ors given feeds zinc supplementationthere 2 clinical types acute diarrhoea diarrhoea without blood caused viruses 60 cases rotavirus enterovirus bacteria vibrio cholerae enterotoxigenic escherichia coli non typhi salmonella yersinia enterocolitica parasites giardiasis diseases malaria acute otitis media respiratory tract infections etc accompanied type diarrhoea diarrhoea blood caused bacteria shigella 50 cases campylobacter jejuni enteroinvasive enterohaemorrhagic escherichia coli salmonella parasites intestinal amoebiasis infectious diarrhoeas transmitted direct dirty hands indirect ingestion contaminated water food contact high mortality rate diarrhoeal diseases even benign due acute dehydration malnutrition prevented adequate rehydration nutrition first assess signs dehydration see dehydration chapter 1 look signs profuse watery diarrhoea cholera enterotoxigenic e coli repeated vomiting cholera fever salmonellosis viral diarrhoea presence red blood stools see also shigellosis amoebiasis chapter 3 patient 5 years severe rapid onset dehydration suspect cholera prevent treat dehydration rehydration consists prompt replacement fluid electrolyte losses required diarrhoea stops administer zinc sulfate children 5 years prevent malnutrition systematically administer antimicrobials certain diarrhoeas require antibiotics see antimicrobial treatment administer antidiarrhoeal drugs antiemetics treat underlying condition malaria otitis respiratory infection etcpage 115 409zinc sulfate given combination oral rehydration solution order reduce duration severity diarrhoea well prevent occurrences 2 3 months treatment zinc sulfate po children 6 months 10 mg 12 tablet daily 10 days children 6 months 5 years 20 mg 1 tablet daily 10 days place halftablet full tablet teaspoon add bit water dissolve give entire spoonful child antimicrobial treatment diarrhoea without blood acute diarrhoeas caused viruses unresponsive antimicrobials antimicrobials beneficial event cholera giardiasis diarrhoea blood prevention referencescholera important part treatment rehydration absence resistance perform antibiotic sensitivity testing beginning outbreak antibiotic treatment shortens duration diarrhoea see guide management cholera epidemic msf giardiasis see intestinal protozoan infections chapter 6 shigellosis frequent cause bloody diarrhoea amoebiasis much less common laboratory diagnosis confirm presence amoebae first line treatment shigellosis chapter 3 amoebiasis antiparasitic treatment motile entamoeba histolytica amoebae found stools correct shigellosis treatment ineffective see amoebiasis chapter 3 breastfeeding reduces infant morbidity mortality diarrhoea severity diarrhoea episodes child weaned preparation storage food associated risk contamination faecal microorganisms discourage bottlefeeding food must cooked well milk porridge must never stored room temperature access sufficient amounts clean water personal hygiene washing hands soap water food preparation eating defecation etc effective methods reducing spread diarrhoea countries high rotavirus diarrhoea fatality rate recommends routine rotavirus vaccination children 6 weeks 24 months age 1 1weekly epidemiological recordreleve epidemiologique hebdomadaire 1st february 2013 88th year1er fevrier 2013 88e annee 5 2013 88 4964 httpswwwwhointwer2013wer8805pdf accessed 02 january 2019page 116 409shigellosis shigellosis highly contagious bacterial infection resulting bloody diarrhoea 4 serogroups shigella dysenteriae sonnei flexneri boydii dysenteriae type 1 sd1 strain causes large scale outbreaks highest case fatality rate 10 patients risk death children 5 years malnourished patients children measles adults 50 years clinical features laboratory shigellosis epidemic context treatment resistance contraindication ciprofloxacin improvement within 48 hours starting firstline treatmentdiarrhoea bright red blood visible stool without fever abdominal rectal pain frequent signs serious illness fever 39 c severe dehydration seizures altered mental status complications frequent sd1 febrile seizures 5 30 children rectal prolapse 3 septicaemia intestinal obstruction perforation moderate severe haemolytic uraemic syndrome confirm causal agent stool culture perform antibiotic sensitivity tests perform monthly culture sensitivity tests antibiotic resistance develop rapidly sometimes course outbreak patients signs serious illness lifethreatening risk factors must admitted inpatients treat patients neither signs serious illness risk factors outpatients antibiotherapy firstline treatment ciprofloxacin po 3 days children 15 mgkg 2 times daily max 1 g daily adults 500 mg 2 times dailyif strain sensitive antibiotic sensitivity test oral administration possible ceftriaxone im 3 days children 50 100 mgkg daily max 1 g daily adults 1 2 g dailyin patients severe infection andor oral administration possible pregnant women bpage 117 409azithromycin po 5 days children one dose 12 mgkg d1 6 mgkg daily d2 d5 adults one dose 500 mg d1 250 mg daily d2 d5 cefixime po 5 days children 8 mgkg daily max 400 mg daily adults 400 mg daily improvement 48 hours starting secondline treatment treat amoebiasis shigellosis epidemic context references 1 2 pain andor fever paracetamol po see pain chapter 1 opioid analgesics contraindicated slow peristalsis supportive therapy nutrition nutritional supplement frequent meals 2500 kcal daily hospitalisation 1000 kcal daily outpatients rehydration administration ors according protocols see dehydration chapter 1 zinc supplement children 5 years see acute diarrhoea chapitre 3 never give loperamide antidiarrhoeal management complications rectal prolapse reduction septicaemia see septic shock chapter 1 etc isolation hospitalised patients school exclusion children treated outpatients hygiene handwashing hygienic preparation storage food home hygiene etc management signs worsen bloody diarrhoea entourage seek medical attention footnotes athis definition excludes blood detected microscope examination stool containing digested blood melaena streaks blood surface normal stool haemorrhoids anal rectal lesion etc bciprofloxacin avoided pregnant women nevertheless ceftriaxone available antibiotics used including ciprofloxacin necessary 1karen l kotloff et al seminar shigellosis lancet volume 391 issue 10122 p801812 february 24 2018 2word health organization pocket book hospital care children guidelines management common childhood illnesses 2013 httpappswhointirisbitstreamhandle10665811709789241548373_engpdfjsessionidce5c46916607ef413aa9fca89b 84163fsequence1 accessed 20 september 2018page 118 409amoebiasis amoebiasis parasitic infection due intestinal protozoa entamoeba histolytica transmission faecaloral ingestion amoebic cysts food water contaminated faeces usually ingested cysts release non pathogenic amoebae 90 carriers asymptomatic 10 infected patients pathogenic amoebae penetrate mucous colon intestinal amoebiasis amoebic dysentery clinical picture similar shigellosis principal cause dysentery occasionally pathogenic amoebae migrate via blood stream form peripheral abscesses amoebic liver abscess common form extraintestinal amoebiasis clinical features investigations treatmentamoebic dysentery diarrhoea containing red blood mucus abdominal pain tenesmus fever moderate fever possibly signs dehydration amoebic liver abscess painful hepatomegaly mild jaundice may present anorexia weight loss nausea vomiting intermittent fever sweating chills change overall condition amoebic dysentery identification mobile trophozoites e histolytica histolytica fresh stool samples amoebic liver abscess indirect haemoagglutination elisa pocus perform efast extended focused assessment sonography trauma examination additional views liver spleen evaluate signs amoebic lesions contact expert local via telemedicine services help interpret images differentiate amoebic abscesses pathologies similar characteristics amoebic dysentery presence cysts alone lead treatment amoebiasis amoebiasis confirmed parasitological stool examination tinidazole po children 50 mgkg daily 3 days max 2 g daily adults 2 g daily 3 days metronidazole po children 15 mgkg 3 times daily 5 days adults 500 mg 3 times daily 5 days laboratory first line treatment dysentery shigellosis treat amoebiasis correct treatment shigellosis ineffective oral rehydration salts ors risk signs dehydration see dehydration chapter 1 amoebic liver abscess tinidazole po treatment 5 days metronidazole po treatment 5 10 dayspage 119 409 footnotes apocus performed interpreted trained clinicianspage 120 409disorders stomach duodenum gastrooesophageal reflux gastric duodenal ulcers adults dyspepsiapage 121 409gastrooesophageal reflux clinical features burning stomachache heartburn generally relieved antacids acid regurgitation often postural sitting forward lying absence dysphagia oesophageal stenosis signs benign treatment first instance encourage patient avoid alcohol tobacco use give aluminium hydroxidemagnesium hydroxide po 400 mg400 mg tablet 1 2 tablets 3 times daily 20 minutes one hour meals 1 tablet painful attacks antacids insufficient omeprazole po 20 mg daily morning 3 days young children drug treatment rest sleep incline 30 45 footnotes aaluminium hydroxidemagnesium hydroxide may decrease intestinal absorption drugs taken time atazanavir chloroquine digoxin doxycycline iron salts gabapentin itraconazole levothyroxine take least 2 hours apart ciprofloxacin take ciprofloxacin 2 hours 4 hours antacids dolutegravir take dolutegravir 2 hours 6 hours antacids velpatasvir take 4 hours apart page 122 409gastric duodenal ulcers adults clinical features burning epigastric pain epigastric cramps meals wake patient night recurrent episodes characteristically last days often accompanied nausea even vomiting common complications perforation bleeding treatment noncomplicated ulcers treatment complicated ulcers perforation perforation considered patients presenting sudden onset intense epigastric pain particularly rigidity abdominal wall risk peritonitis increased perforation occurs full stomach gastrointestinal bleeding passing black stool maelena andor vomiting blood haematemesis 80 cases bleeding stops spontaneouslyfor isolated episode identify patients taking nsaid acetylsalicylic acid stop treatment encourage patients avoid alcohol tobacco use omeprazole po 20 mg daily morning 7 10 days severe recurrent cases dose increased 40 mg daily treatment prolonged 8 weeks patient frequent recurrences unrelated nsaid use require repeated treatment antiulcer drugs see eradication helicobacter pylori start place patient strict fast npo insert nasogastric tube aspirate possible insert intravenous line hydrate ringer lactate treat acute pain see pain chapter 1 omeprazole iv infusion 40 mg daily 20 30 minutes refer surgeon referral possible risk mortality high continue conservative management including maintenance fluid alternate 5 glucose ringer lactate start iv antibiotics see shock chapter 1 3 days patients clinical condition improved cautiously restart oral feeding remove nasogastric tube start po treatment eradicate helicobacter pylori see eradication helicobacter pylori insert nasogastric tube aspiration insert iv line 16g haemodynamic state stable pulse blood pressure normal hydrate ringer lactate monitor keep npo 12 hours active haemorrhage restart oral feeding 12 hours gastric lavage cold water essential may help evaluate persistence bleeding haemorrhage continues haematemesis andor haemodynamic state deteriorates pulse increases bp dropspage 123 409eradication helicobacter pylori peptic ulcers caused helicobacter pylori infection diagnosis ulcer probable treatment eradicate h pylori considered patient frequent attacks requiring repeated andor prolonged treatments antiulcer drugs 8 weeks cases complicated ulcers perforation gastrointestinal bleeding infection confirmed test possible h pylori resistance antibiotics varies globally follow national recommendations available information administer triple therapy 7 days omeprazole po 20 mg 2 times daily clarithromycin po 500 mg 2 times daily amoxicillin po 1 g 2 times daily immunocompromised patients consider mycobacterium avium complex mac infection nontuberculous mycobacterium ntm infection prior starting clarithromycincontaining triple therapy symptoms continue despite treatment consider differential diagnosis gastric cancer refer investigations possible notes intensive care transfusion according severity bleeding see haemorrhagic shock chapter 1 emergency surgical intervention acetylsalicylic acid aspirin nsaid ibuprofen diclofenac etc contraindicated patients suffering history ulcers omeprazole effective po iv footnotes penicillinallergic patients amoxicillin po substituted metronidazole po 500 mg 2 times dailypage 124 409dyspepsia last updated december 2020 clinical features epigastric pain discomfort following meals often accompanied bloating sensation fullness nausea dyspepsia commonly functional diagnosis functional dyspepsia based clinical assessment ruling organic causes gastrooesophageal reflux gastric duodenal ulcers druginduced symptoms gastric cancer possible test helicobacter pylori treatment adults note consider treat possible intestinal parasites see intestinal protozoan infections cestodes nematode infections chapter 6 amoebiasis chapter 3 referencesin case patients test positive h pylori see eradication helicobacter pylori 1 omeprazole po 10 mg daily 4 weeks may help even h pylorinegative patients 2 3 1ford ac mahadeva carbone mf lacy talley nj functional dyspepsia lancet 2020 nov 213961026316891702 2moayyedi pm lacy andrews cn et al acg cag clinical guideline management dyspepsia j gastroenterol 2017 jul11279881013 httpwwwcagacgorgimagespublicationscag_cpg_dyspepsia_ajg_aug2017pdf accessed 24 november 2020 3national institute health care excellence gastrooesophageal reflux disease dyspepsia adults investigation management sept 2014 httpswwwniceorgukguidancecg184chapter1recommendationsinterventionsforfunctional dyspepsia accessed 24 november 2020page 125 409stomatitis stomatitis inflammation mucous membranes mouth caused fungal viral bacterial infection vitamin deficiency injury etc prolonged painful stomatitis may contribute dehydration may cause loss appetite denutrition particularly children infants examine routinely mouth event breast refusal difficulties sucking casesoral oropharyngeal candidiasis oral herpes infectious causes stomatitis scurvy vitamin c deficiency lesions resulting nutritional deficiency maintain adequate hydration feeding offer foods irritate mucosa soft nonacidic use nasogastric tube days pain preventing patient eating keep mouth clean prevent complications recurrencepage 126 409oral oropharyngeal candidiasis infection due candida albicans common infants immunocompromised diabetic patients risk factors include treatment oral antibiotics highdose inhaled corticosteroids clinical features treatment nystatin oral suspension 7 days children adults 400 000 iu daily ie 1 ml oral suspension 100 000 iu 4 times daily miconazole oral gel 7 days children 6 months 2 years 125 ml 4 times daily children 2 years adults 25 ml 4 times daily apply oral suspension nystatin oral gel miconazole meals keep mouth 2 3 minutes swallow young children apply tongue inside cheek show mother treat since cases candidiasis treated home immunocompromised patients see hiv infection aids chapter 8white patches tongue inside cheeks may spread pharynx patients frequent recurrences extensive forms invading esophagus swallowing difficulty pain consider hiv infectionpage 127 409oral herpes infection due herpes simplex virus primary infection typically occurs children aged 6 months 5 years may cause acute gingivostomatitis sometimes severe primary infection virus remains body causes individuals periodic recurrences usually benign herpes labialis clinical features multiple vesicles oral mucosa lips rupture form painful yellowish times extensive ulcers local lesions usually associated general malaise regional lymphadenopathy fever clusters vesicles junction lip skin patients frequent recurrences extensive forms consider hiv infection see hiv infection aids chapter 8 treatment primary herpetic gingivostomatitis immunocompromised patients see hiv infection aids chapter 8 recurrent herpes labialis spontaneous resolution within 7 10 days antiseptic chlorhexidine povidone iodine may applied paracetamol po necessary forms herpes contagious touch lesions wash hands afterwards avoid oral contactprimary herpetic gingivostomatitis recurrent herpes labialis treat pain paracetamol ibuprofen po chapter 1 event severe lesions inability drink significant pain admit child hospital high risk dehydration child presents within first 96 hours symptoms onset aciclovir po 5 7 days children 2 years 200 mg 5 times daily children 2 years adults 400 mg 5 times daily event secondary bacterial infection amoxicillin po 7 dayspage 128 409other infectious causes see pharyngitis chapter 2 diphtheria chapter 2 measles chapter 8 page 129 409stomatitis scurvy vitamin c deficiency clinical features bleeding gums associated infants lower limb pain caused subperiosteal haemorrhage common contexts poor food quality populations completely dependent food aid refugee camps treatment ascorbic acid vitamin c po optimal dose established information children 1 month 11 years 100 mg 3 times daily children 12 years adults 250 mg 3 times daily children 1 month 3 years 100 mg 2 times daily children 4 11 years 250 mg 2 times daily children 12 years adults 500 mg 2 times daily treatment administred least 2 weeks longer symptoms resolve preventive treatment given children adults 50 mg daily long situation requirespage 130 409other lesions resulting nutritional deficiency vitamin deficiencies may provoke mouth lesions angular stomatitis lips glossitis vitamin b riboflavin niacin see pellagra chapter 4 vitamin b pyridoxine deficiencies iron deficiency may also provoke angular stomatitis see anaemia chapter 1 give corresponding vitamins curative doses multivitamins insufficient treat true vitamin deficiencies2 6page 131 409chapter 4 skin diseases dermatology scabies lice pediculosis superficial fungal infections bacterial skin infections impetigo furuncles carbuncles erysipelas cellulitis cutaneous anthrax endemic treponematoses leprosy herpes simplex herpes zoster herpes simplex herpes zoster shingles skin disorders eczema seborrheic dermatitis urticaria pellagra page 132 409dermatology skin diseases particularly infectious skin diseases common must treated individually collectively must also considered indicators sanitary condition population high prevalence infectious skin diseases may reflect problem insufficient water quantity lack hygiene population dermatological examination patients skin disease often present late stage primary lesions specific signs may masked secondary infection cases necessary reexamine patient treating secondary infection order identify treat underlying skin diseaseobserve type lesion macule flat non palpable lesion different colour surrounding skin papule small 1 cm slightly elevated circumscribed solid lesion vesicle 1 cm bulla 1 cm clear fluidfilled blisters pustule vesicle containing pus nodule firm elevated palpable lesion 1 cm extend dermis subcutaneous tissue erosion loss epidermis heals without leaving scar excoriation erosion caused scratching ulcer loss epidermis least part dermis leaves scar scale flake epidermis detaches skin surface crust dried serum blood pus skin surface atrophy thinning skin lichenification thickening skin accentuation normal skin markings look distribution lesions body observe arrangement isolated clustered linear annular ring ask lesions itchy look possible cause insect bites scabies lice parasitic skin infections contact plants animals jewellery detergents etc ask past ongoing treatment topical oral parenteral look local regional signs secondary infection lymphangitis adenopathy erysipelas andor systemic signs fever septicaemia secondary focus consider sanitary conditions family particularly contagious skin diseases scabies scalp ringworm lice check tetanus vaccination statuspage 133 409scabies scabies cutaneous parasitosis due presence mite sarcoptes scabiei hominis within epidermis exists two forms ordinary scabies relatively benign moderately contagious crusted scabies favoured immune deficiency extremely contagious refractory conventional treatment person person transmission takes place chiefly direct skin contact sometimes indirect contact sharing clothing bedding challenge management must include simultaneous treatment patient close contacts time decontamination clothing bedding persons undergoing treatment order break transmission cycle clinical features ordinary scabies older children adults andor typical lesions secondary lesions may coexist specific lesions may entirely masked secondary lesions infants young children crusted norwegian scabies thick scaly erythematous plaques generalised localised resembling psoriasis without itching 50 cases delay diagnosis may lead scabies epidemic treatment cases ordinary scabiesitching worse night suggestive scabies close contacts symptom typical skin lesions scabies burrows common fine wavy lines 5 15 mm corresponding tunnels made parasite within skin burrows often seen interdigital spaces hand flexor aspect wrist may present areolae buttocks elbows axillae back face spared burrows may associated vesicles corresponding entry point parasite skin scabies nodules less common reddishbrown nodules measuring 2 20 mm genitals men persisting effective treatment necessarily indicative active infection secondary skin lesions resulting scratching excoriations crusts superinfection impetigo vesicular eruption often involving palms soles back face limbs secondary infection eczematisation frequent isolated scabies nodules axillae may manifestation examination mothers hands may support diagnosis close contacts patient treated simultaneously even absence symptoms clothing bedding including contacts changed treatment washed 60 c dried sun exposed sunlight 72 hours sealed plastic bag 72 hourspage 134 409topical treatment topical scabicides applied entire body including scalp postauricular areas umbilicus palms soles avoiding mucous membranes face breasts breastfeeding women particular attention paid common infestation sites recommended contact time shortened exceeded patient must wash hands product use product reapplied hands washed children 2 years hands must wrapped prevent accidental ingestion product contact eyes topical scabicides applied broken inflamed skin treatment secondary bacterial infection present initiated 24 48 hours use topical scabicides see impetigo preferred treatment 5 permethrin cream children 2 months adults one application contact time 8 hours rinse thoroughly repeat application 7 days available 25 benzyl benzoate lotion see table dilution depending age contact time number applications oral treatment treatment ivermectin po 200 microgramskg single dose alternative practical topical treatment eg case epidemic treating contacts started right away case secondary infection single dose may sufficient second dose 7 days later reduces risk treatment failure ivermectin recommended children 15 kg pregnant women safety established administration ivermectin patients loiasis carries risk severe neurological complications significant loa loa microfilaraemia present see filariasis chapter 6 ivermectin po single dose children 2 yearschildren 2 12 yearschildren 12 years adultspregnant women dilutionlotion must diluted use 1 part 25 lotion 3 parts waterlotion must diluted use 1 part 25 lotion 1 part wateruse undiluted 25 lotionuse undiluted 25 lotion contact time12 hours 6 hours infants 6 months rinse thoroughly24 hours rinse thoroughly24 hours rinse thoroughly12 hours rinse thoroughly number applications one applicationtwo applications eg 24 hours apart rinse 2 applications 2 successive applications 10 minutes apart first application dried rinse 24 hours one application b page 135 409 treatment effectiveness judged clinical grounds itching may persist 1 3 weeks elimination parasite persistence typical burrows beyond 4 weeks lead suspicion treatment failure insufficient treatment eg scalp included topical treatment patient washed hands treatment period early reinfestation contacts environment treated cases patient contacts retreated persistent itching may due another condition initially masked scabies crusted scabies treatment combines simultaneous administration oral ivermectin topical scabicide regular intervals eg every week 2 3 weeks according severity clinical response crusts softened salicylic acid ointment removed applying local treatment otherwise local treatment ineffective exfoliated skin scales may spread parasite patient isolated treatment staff use protection gloves gowns hand washing contact environment bedding floors surfaces decontaminated weight 15 24 kg 25 35 kg 36 50 kg 51 65 kg ivermectin 3 mg tab 1 tab 2 tab 3 tab 4 tab footnotes atreatment ivermectin patients reserved severe cases alternative exists see crusted scabies bin areas loiasis endemic certain precautions recommended administering ivermectin eg measure loa loa microfilaraemia possible ensure patient history loiasis migration adult worm conjunctiva transient calabar swellings history severe adverse reactions following previous treatment ivermectin doubt use topical treatment preference oralpage 136 409lice pediculosis pediculosis benign contagious parasitic infection due 3 species lice specific humans head lice body lice pubic lice transmission person person occurs direct indirect contact body lice potential vectors relapsing fever chapter 7 typhus eruptive rickettsioses chapter 7 trench fever clinical features treatment head lice body lice mass treatment outbreak apply 30 60 g 2 4 heaped soup spoons 05 permethrin powder inside clothes underclothes contact skin front back neck waistline sleeves socks fully clothed patient rub powder hand leave 12 24 hours treat clothing including headwear bedding plastic bag 05 permethrin powder repeat 8 10 days infestation persistshead lice mainly affect children itching scratch marks nape neck around ears may become secondarily infected impetigo prolonged infestation presence live lice andor live shiny grey nits attached hair shaft within 5 mm scalp body lice mainly affect populations living poor conditions refugees prisoners homeless itching scratch marks back belt line armpits often inflamed infected presence lice nits clothing parasites found body pubic lice considered sexually transmitted infection sti itching scratch marks pubic perianal area hairy areas may also affected armpits thighs eyelashes lice nits base hair shaft rarely visible examine contacts check associated systemic infection body lice sti pubic lice apply lotion scalp dry hair paying particular attention areas behind ears around nape neck reduce exceed recommended duration application 4 dimeticone lotion children 6 months adults leave hair 8 hours rinse thoroughly keep away flames andor intense heat sources including cigarettes application rinsing risk ignition dimeticone available children 2 6 months 1 permethrin lotion children 2 months adults leave hair 10 minutes rinse thoroughly repeat application either treatment 7 days decontaminate combs headwear bedding wash 60 c30 minutes iron dry sun feasible seal plastic bag 2 weeks treat contacts live lice andor live nits treat dead nits alone dull white 1 cm scalppage 137 409individual treatment disinfection clothing bedding head lice pubic lice shave andor apply 1 permethrin lotion hairy areas head lice treat partner time decontaminate clothing bedding head lice repeat application 7 days treatment secondary bacterial infection present begin 24 48 hours local antiparasitic treatment see impetigo local treatment applied later toleratedpage 138 409superficial fungal infections superficial fungal infections benign infections skin scalp nails caused candida albicans dermatophytes clinical features treatment candidiasis candidal diaper dermatitis erythema perianal area peripheral desquamation sometimes pustules secondary infection may develop candidiasis dermatophytoses dermatophytes cause various clinical lesions depending anatomic site involved scalp glabrous hairless skin folds nails buttocks must kept clean ordinary soap water dry avoid humidity according context expose buttocks air change diapers frequently remove plastic pants protect skin zinc oxide ointment diarrhoea present diaper dermatitis severe persistent despite measures consider intestinal infection nystatin po 100 000 iu 4 times daily 20 days candidiasis skin folds miconazole 2 cream one application 2 times daily 2 4 weeks oral candidiasis see stomatitis chapter 3 vulvovaginal candidiasis see abnormal vaginal discharge chapter 9page 139 409anatomic site aclinical features treatment scalp scalp ringworm tinea capitiscommon children depending species one round scaly erythematous plaques ends broken hairs inflammation suppuration crusting peripheral lymphadenopathy kerion permanent hair loss favus scalp ringworms contagious simultaneously examine treat symptomatic contacts shave cut hair short around lesions local treatment 2 times daily clean soap water dry apply miconazole 2 cream whitfields ointment 2 weeks longer necessary administer systemic treatment local treatment alone cure scalp ringworm griseofulvin po 6 weeks minimum 8 12 weeks children 1 12 years 10 20 mgkg daily max 500 mg daily children 12 years adults 500 mg 1 g daily depending severity itraconazole po children 3 5 mgkg daily 4 6 weeks max 200 mg daily adults 200 mg daily 2 4 weeks suppurative lesions treat superinfection see impetigo applying local antifungal treatment painful kerion paracetamol po pregnant lactatingbreastfeeding women oral antifungals contraindicated apply topical treatment miconazole 2 cream whitfields ointment limit spread infection possible treat orally glabrous skin ringworm body tinea corporiserythematous scaly pruritic macule well demarcated raised vesicular border central healing non widespread localised tinea local treatment 2 times daily clean soap water dry apply miconazole 2 cream whitfields ointment 2 4 weeks 2 weeks clinical resolution reserve oral antifungals particularly extensive lesions griseofulvin po 4 6 weeks itraconazole 2 weeks folds interdigital spaces tinea pedis topical treatment oozingpage 140 409tinea pedis athletes foot tinea crurispruritus fissure whitish scales 3andor 4 interdigital spaces groin tinea cruris circumscribed pruritic erythematous plaque pale centre surrounded vesiculo pustules extending outward groinrd th b lesions use miconazole 2 cream use whitfields ointment adermatophytosis may affect nails tinea unguium onychomycosis treatment prolonged 12 18 months griseofulvin thus practice difficult failures relapses frequent bin candidal intertrigo lesions usually located 1st 2nd interdigital spacespage 141 409bacterial skin infections impetigo furuncles carbuncles erysipelas cellulitispage 142 409impetigo impetigo benign contagious infection epidermis due group \xdfhaemolytic streptococcus staphylococcus aureus coinfection common transmission direct contact lack water poor hygiene increase spread primary infections common children secondary infections complicating preexisting pruritic dermatoses lice scabies eczema herpes chickenpox etc common adults clinical features treatment non bullous impetigo classic form flaccid vesicle erythematous skin becomes pustular forms yellowish crust different stages infection may present simultaneously lesion leave scar common sites infection around nose mouth limbs scalp bullous impetigo large flaccid bullae erosions skin anogenital region newborns infants ecthyma ulcerative form impetigo leaves scars form common immunocompromised eg hiv infection malnutrition diabetics alcoholics regardless type impetigo absence fever systemic signs possible complications abscess pyodermitis cellulitis lymphangitis osteomyelitis septicaemia acute glomerulonephritis routinely look signs glomerulonephritis localised non bullous impetigo max 5 lesions single skin area clean soap water dry applying mupirocin 2 mupirocin ointment one application 3 times daily 7 days reassess 3 days response switch oral antibiotic therapy see keep fingernails short avoid touching lesions keep covered gauze possible extensive non bullous impetigo 5 lesions impetigo involving one skin area bullous impetigo ecthyma impetigo abscess immunocompromised patient topical treatment failure clean soap water dry 2 3 times daily keep fingernails short avoid touching lesions keep covered gauze possible incise abscesses present administer oral antibiotic therapy cefalexin po 7 days neonates 7 days 25 mgkg 2 times daily neonates 7 28 days 25 mgkg 3 times daily children 1 month 12 years 25 mgkg 2 times daily children 12 years adults 1 g 2 times daily cloxacillin po 7 days children 10 years 15 mgkg 3 times daily max 3 g daily adults 1 g 3 times daily note newborns lesions located around umbilicus administer cloxacilllin iv patients quarantine school children return school 24 48 hours antibiotic therapypage 143 409 look treat underlying dermatosis lice scabies eczema herpes scalp ringworm ent infection trace treat contacts check proteinuria use urine dipstick 3 weeks infection footnotes penicillinallergic patients resistance macrolides common azithromycin po 3 days children 10 mgkg daily adults 500 mg dailypage 144 409furuncles carbuncles necrotising perifollicular infection usually due staphylococcus aureus risk factors include nasal carriage aureus maceration breaks skin poor hygiene diabetes mellitus malnutrition iron deficiency immunodeficiency clinical features treatment furuncle red warm painful nodule central pustule usually around hair follicle becomes fluctuant discharges core purulent exudate leaves depressed scar occurs frequently thighs groin buttocks armpits neck back fever carbuncle cluster interconnected furuncles sometimes fever peripheral lymphadenopathy leaves depressed scar single furuncle clean soap water 2 times daily cover dry dressing apply warm moist compresses furuncle order encourage drain drainage clean apply dry dressing lesion healed furuncle face multiple furuncles carbuncles immunocompromised patients local care add systematically antibiotic 7 days cefalexin po neonates 7 days 25 mgkg 2 times daily neonates 7 28 days 25 mgkg 3 times daily children 1 month 12 years 25 mgkg 2 times daily children 12 years adults 1 g 2 times daily amoxicillinclavulanic acid coamoxiclav po use formulations ratio 81 71 dose expressed amoxicillin children 40 kg 25 mgkg 2 times daily children 40 kg adults ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily cases wash hand frequently wash bedding footnotes afor penicillinallergic patients clindamycin po children 10 mgkg 3 times daily adults 600 mg 3 times dailypage 145 409erysipelas cellulitis last updated october 2020 acute skin infections due bacteria usually group betahaemolytic streptococcus sometimes staphylococcus aureus including methicillin resistant aureusmrsa enter break skin main risk factors venous insufficiency obesity oedema lymphoedema history erysipelas cellulitis immunosuppression cutaneous inflammation eg dermatosis wound erysipelas superficial infection affecting dermis superficial lymph vessels cellulitis affects deeper tissues deep dermis layers subcutaneous fat generally infections affect lower extremities sometimes face orbital periorbital tissues infected see periorbital orbital cellulitis chapter 5 infection perifollicular see furuncles carbuncles chapter 4 clinical signs paraclinical investigations treatment warm tender swollen welldemarcated erythematous plaque fever lymphadenopathy lymphangitis look portal entry bite ulcer wound intertrigo eczema fungal infection etc case intense pain disproportionate skin lesion hypoesthesia rapidly progressing local signs crepitation skin necrosis critically ill appearing patient consider necrotising fasciitis surgical emergency see necrotising infections skin soft tissues chapter 10 complications septicaemia see septic shock chapter 1 acute glomerulonephritis osteomyelitis septic arthritis main differential diagnoses include contact dermatitis stasis dermatitis due venous insufficiency venous thrombosis erythema migrans characteristic lyme disease ultrasound detect signs cellulitis rule underlying abscess deep vein thrombosis foreign body radiography detect foreign body underlying osteomyelitis gas subcutaneous tissue case necrotising infection nevertheless absence gas rule diagnosis test proteinuria urine dipstick 3 weeks infection look glomerulonephritis cases outline area erythema pen order follow infection bed rest elevation affected area eg leg treatment pain chapter 1 avoid nsaids may increase risk necrotising fasciitis administer antibiotics either orally iv depending severity treat portal entry comorbidities check andor catch tetanus vaccination see tetanus chapter 7 case necrotising fasciitis septic arthritis osteomyelitis urgent transfer surgical centre initiate iv antibiotic treatment awaiting transferpage 146 409 event worsening clinical signs 48 hours antibiotic treatment consider iv route clinical improvement 48 hours afebrile erythema oedema improved switch cefalexin amoxicillinclavulanic acid po doses indicated complete 7 10 days treatment 48 hours change clindamycin po doses indicated complete 7 10 days treatment hospitalize following children younger 3 months critically ill appearing patient local complications debilitated patient chronic conditions elderly risk noncompliance failure outpatient treatment treat patients outpatients b outpatient antibiotherapy cefalexin po 7 10 days children 1 month 12 years 25 mgkg 2 times daily children 12 years adults 1 g 2 times daily amoxicillinclavulanic acid coamoxiclav po 7 10 days use formulations ratio 81 71 dose expressed amoxicillin children 40 kg 25 mgkg 2 times daily children 40 kg adults ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily c inpatient antibiotherapy first line therapy cloxacillin iv infusion 60 minutes children 1 month 12 years 125 25 mgkg every 6 hours children 12 years adults 1 g every 6 hours amoxicillinclavulanic acid coamoxiclav slow iv injection 3 minutes iv infusion 30 minutes dose expressed amoxicillin children 3 months 30 mgkg every 12 hours children 3 months 20 30 mgkg every 8 hours max 3 g daily adults 1 g every 8 hours e clinical improvement 48 hours consider mrsa clindamycin iv infusion 30 minutes children 1 month 10 mgkg every 8 hours adults 600 mg every 8 hours f footnotes athe erythema regress treatment effective erythema spreads consider treatment failure mrsa necrotising infection bcritically ill appearing child weak grunting crying drowsy difficult arouse smile disconjugate anxious gaze pallor cyanosis general hypotonia cfor penicillinallergic patients clindamycin po 7 10 days children 10 mgkg 3 times daily adults 600 mg 3 times daily dfor penicillinallergic patients clindamycin iv infusion children 10 mgkg 3 times daily adults 600 mg 3 times daily ecloxacillin powder injection reconstituted 4 ml water injection dilute dose cloxacillin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adultspage 147 409fdilute dose clindamycin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adultspage 148 409cutaneous anthrax last updated september 2022 anthrax caused bacterium bacillus anthracis primarily affects herbivores sheep goats cows camels horses etc humans may become infected contact broken skin dead sick animal people risk include livestock farmers manipulate skins wool carcasses infected animals disease found eastern europe central asia mediterranean basin africa south america pulmonary acquired inhalation intestinal acquired eating infected meat forms also exist clinical features laboratory treatment uncomplicated cutaneous anthrax doxycycline po except pregnant breastfeeding women children 45 kg 2 22 mgkg max 100 mg 2 times daily children 45 kg adults 100 mg 2 times daily clindamycin po patients allergic firstline antibiotics children 10 mgkg max 600 mg 3 times daily adults 600 mg 3 times daily orpapule pruritic vesicle uncovered skin surfaces face neck arms legs vesicle ulcerates becomes painless black eschar surrounded oedema often associated lymphangitis regional lymphadenopathy following criteria severity lesion located head neck presence systemic symptoms fever malaise headache tachycardia tachypnoea hypotension hyperhypothermia presence extensive oedema multiple extensive bullous lesions vesicular fluid culture drug susceptibility testing rarely available gram stain microscopic examination pcr testing reference laboratory excise eschar daily dry dressings antibiotic treatment 7 10 days firstline antibiotics ciprofloxacin po including pregnant breastfeeding women children children 15 mgkg max 500 mg 2 times daily adults 500 mg 2 times daily alternatives includepage 149 409amoxicillin po penicillins effective documented susceptibility children 30 mgkg max 1 g 3 times daily adults 1 g 3 times daily severe cutaneous anthrax mix two antibiotics infusion bag incompatibility ampicillin iv infusion 30 minutes children 1 month 50 mgkg max 3 g every 6 hours 65 mgkg max 4 g every 8 hours adults 3 g every 6 hours 4 g every 8 hours clindamycin iv infusion change oral treatment soon possible complete 14 days treatment ciprofloxacin clindamycin amoxicillin clindamycin uncomplicated cutaneous anthrax prevention combined antibiotic treatment 14 days firstline ciprofloxacin iv infusion 60 minutes children 10 mgkg max 400 mg every 8 hours adults 400 mg every 8 hours clindamycin iv infusion 30 minutes children 1 month 10 13 mgkg max 900 mg every 8 hours adults 900 mg every 8 hours b b alternative penicillins effective documented susceptibility b intensive care symptomatic treatment shock see shock chapter 1 tracheostomy ventilatory support may necessary antibiotic prophylaxis case known skin exposure treat 10 days po uncomplicated cutaneous anthrax livestock vaccination burial burning animal carcasses footnotes asamples stored including transport time 7 days max cold chain available temperature 30 c bdilute dose ciprofloxacin clindamycin ampicillin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults administer ciprofloxacin slowly clindamycin ampicillinpage 150 409endemic treponematoses endemic treponematoses bacterial infections caused 3 different types treponema treponema pallidum humantohuman transmission may direct indirect 3 endemic treponematoses result positive syphilis serology tphavdrl tests necessary diagnosis clinical laboratory test distinguish different treponematoses diagnosis treatment syphilis see genital infections chapter 9 clinical featurespage 151 409 yaws pinta bejel pathogen treponema pertenue treponema carateum treponema pallidum type geographic distributiontropical humid foreststropical zones latin americaarid areas semidesert middle east africa populationchildren 4 14 yearschildren adults nomadic populations particularly children first stageyaws chancre skin coloured lesion non indurated itchy lower limbs 95 cases peripheral adenopathy spontaneous healing development large yaw surrounded smaller yawsannular erythematous scaly plaques usually uncovered body parts face extremities resemble dermatophytes lesions heal sponta neously leaving scarsdiscrete chancre moist papule commonly mucous membranes dermal folds peripheral adenopathy second stagelesions appear 3 weeks initial chancre occur crops heal spontaneously frambesioma papillomatous lesion vegetal contagious isolated associated yaws round squamous papules contagious osteoperiostitis long bones phalanges nasal process maxilla tibiapintids plaques various colours bluish reddish whitish may occur anywhere body mucous patches mouth common contagious ulcerated round form indurated white coating bleed easily usually occur inside lips cheek tongue labial folds condyloma anogenital region rare cutaneous lesions rare vegetal aspect dermal folds bone destruction identical yaws legs forearms late stage years latency periostitis painful debilitating osteitis ulcerating disfiguring rhinopharyngitis juxtaarticular nodulessymmetrical white patches limbs depigmentation permanent remaining treatmentafter several years latency gummatous lesions skin long bones plantar palmar keratosis juxtaarticular nodules hyper hypopigmented patches pintapage 152 409treatment yaws azithromycin po children adults 30 mgkg single dose max 2 g available benzathine benzylpenicillin im children 10 years 12 miu single dose children 10 years adults 24 miu single dose pinta bejel benzathine benzylpenicillin im yaws patients allergic penicillin doxycycline po except children 8 years pregnant lactating women children 8 years 50 mg 2 times daily 14 days adults 100 mg 2 times daily 14 days notes treatment contacts latent cases treatment administered symptomatic asymptomatic contacts latent cases asymptomatic individuals positive serologic test syphilis endemic zones references 1 2 3 antibiotic treatment cure early stage cases may relieve pain osteitis may ineffective late stage infections syphilis serology remain positive despite clinical cure 1world health organization 2012 yaws recognition booklet communities reprinted changes 2014 httpwwwwhointirishandle1066575360 accessed 15 may 2018 2oriol mitja david mabey yaws bejel pinta last updated may 07 2018 uptodate accessed 15 may 2018 3michael marks anthony w solomon david c mabey endemic treponemal diseases transactions royal society tropical medicine hygiene volume 108 issue 10 1 october 2014 pages 601607 httpsdoiorg101093trstmhtru128 accessed 15 may 2018page 153 409leprosy leprosy chronic bacterial infection due mycobacterium leprae transmitted frequent close contact mainly household members mainly affects young adults 94 reported cases globally bangladesh brazil democratic republic congo ethiopia india indonesia madagascar myanmar nepal nigeria philippines sri lanka united republic tanzania clinical features leprosy considered patient presenting different clinical forms classification systems leprosy ridleyjopling classification classification differentiates 5 forms based bacteriological index forms correlate immunological response leprae patients tuberculoid leprosy tt resistant bacillus infection localised patients lepromatous leprosy extremely sensitive bacillus infection disseminated borderline forms bt bb bl two ends spectrum tt classification order simplify diagnosis promote rapid implementation treatment simplified clinical classification leprosy differentiates 2 forms multibacillary leprosy includes bl bb forms paucibacillary leprosy includes tt bt forms ridleyjopling classification system laboratory 1 hypopigmented erythematous skin lesions partial complete loss sensation touch pain heat infiltrated pigmented nodules initially sensory loss face ear lobes upper lower limbs tender infiltrated hypertrophied peripheral nerve ulnar radial median popliteal tibial etc possible paraesthesia extremities trophic changes perforating ulcer foot paralysis steppage gait deformaties hands feet facial nerve paralysis paucibacillary forms least contagious formsmultibacillary forms contagious forms tuberculoid borderline tuberculoidborderline borderline lepromatouslepromatous tt bt bb bl multibacillary leprosy 5 skin lesions paucibacillary leprosy 1 5 skin lesions laboratory diagnosis based detection acidfast bacilli ziehlneelsen stained nasal smear skin split smear taken ear lobe skin lesion tt leprosy bacilli found practice endemic countries diagnosis based clinical classification number lesionspage 154 409treatment countries leprosy endemic control programme check national recommendations firstline treatment regimens recommended note monthly doses rifampicin clofazimine administered direct observation medical staff whereas daily doses clofazimine dapsone taken patient home rifampicin taken empty stomach improve absorption teach patient recognise quickly report lepra reaction relapse order modify restart treatment leprosy reactions reactions usually occur course treatment patients multibacillary leprosy bl associated immunological response leprae antigens urgent treatment required avoid irreversible disability interrupt ongoing leprosy treatment clinical features treatment agemultibacillary leprosy 5 skin lesionspaucibacillary leprosy 1 5 skin lesions children 10 14 yearsrifampicin po 450 mg monthly clofazimine po 150 mg monthly 50 mg alternate days dapsone po 50 mg dailyrifampicin po 450 mg monthly clofazimine po 150 mg monthly 50 mg alternate days dapsone po 50 mg daily children 15 years adultsrifampicin po 600 mg monthly clofazimine po 300 mg monthly 50 mg daily dapsone po 100 mg dailyrifampicin po 600 mg monthly clofazimine po 300 mg monthly 50 mg daily dapsone po 100 mg daily duration 12 months 6 months reversal reactions exacerbation skin lesions become erythematous oedematous risk ulceration onset worsening numbness skin lesions onset acute painful hypertrophic neuritis erythema nodosum leprosum fever asthenia alteration general state crops purplishred tender subcutaneous nodules warmer surrounding skin reversal reactions prednisolone prednisone po 05 1 mgkg daily 2 weeks reexamine patient every 2 weeks decrease dosage neurological signs recede according clinical response treatment may last 3 6 months example adult week 1 2 40 mg daily 2 3 page 155 409 referencesweek 3 4 30 mg daily week 5 6 20 mg daily week 7 8 15 mg daily week 9 10 10 mg daily week 11 12 5 mg daily erythema nodosum leprosum prednisolone prednisone po reversal reactions 3 months 2 fever paracetamol po see fever chapter 1 1world health organization global leprosy programme global leprosy strategy 20162020 accelerating towards leprosy free world 2016 httpappswhointirisbitstreamhandle106652088249789290225096_enpdfsequence14isallowedy accessed 17 october 2018 2world health organization expert committee leprosy eighth report technical report series n 968 geneva 2012 httpwwwsearowhointentityglobal_leprosy_p rogrammepublications8th_expert_comm_2012pdf accessed 17 october 2018 3world health organization guide eliminating leprosy public health problem leprosy elimination group 2000 httpappswhointirisbitstreamhandle1066566612who_cds_cpe_cee_200014pdfsequence1 accessed 17 october 2018page 156 409herpes simplex herpes zoster herpes simplex herpes zoster shinglespage 157 409herpes simplex recurrent viral infection skin mucous membranes due herpes simplex virus recurrent lesions different presentation primary infection clinical features treatmentrecurrent herpes labialis tingling feeling followed eruption vesicles erythematous base located lips fever blisters around mouth may extend onto face recurrence corresponds reactivation latent virus primary infection associated malaise adenopathy fever carefully consider sites buccal stomatitis chapter 3 genital genital ulcers chapter 9 ophthalmic secondary bacterial infections clean soap water 2 times daily lesions healed patients secondary bacterial infections antibiotic treatment impetigopage 158 409herpes zoster shingles acute viral infection due varicellazoster virus chickenpox primary infection herpes zoster reactivation latent virus clinical features treatmentunilateral neuralgic pain followed eruption vesicles erythematous base follow distribution nerve pathway lesions commonly occur thorax herpes zoster may also develop face risk ophthalmic complications herpes zoster common adults children similar herpes simplex addition systematic analgesics paracetamol po see pain chapter 1 aciclovir po given within first 48 hours eruption lesions indicated severe forms necrotic extensive lesions lesion face may spread eyes see hiv infection aids chapter 8page 159 409other skin disorders eczema seborrheic dermatitis urticaria pellagrapage 160 409eczema acute eczema erythematous plaque pruritic vesicular oozing poorly demarcated crumbly borders chronic eczema erythematous plaque scaly dry poorly demarcated pruritic look cause contact allergic dermatitis fungal bacterial infection distant focus malnutrition ask family history treatment clean soap water 2 times daily acute eczema calamine lotion one application 2 times daily chronic eczema zinc oxide ointment one application 2 times daily look treat preexisting condition scabies lice etc patients secondary infections treat impetigo patients intense pruritus antihistamines days see urticariapage 161 409seborrheic dermatitis seborrheic dermatitis inflammatory chronic dermatosis localized areas rich sebaceous glands dermatosis common infected patients hiv clinical features treatmenterythematous plaques covered greasy yellow scales localized scalp face nose wings eyebrows edge eyelids sternum spine perineum skin folds clean soap water 2 times daily shampooing scalp hydrocortisone 1 cream one application daily 2 times daily affected area thin layer 7 days maximum apply preexisting bacterial infection treat first infection see impetigopage 162 409urticaria last updated july 2022 papules transient erythematous oedematous pruritic resembling nettle stings look cause food drug particularly antibiotic allergy insect bites invasive stage bacterial parasitic infection ascariasis strongylodiasis ancylostomiasis schistosomiasis loiasis viral infection hepatitis b c generalised disease cancer lupus dysthyroidism vasculitis treatment pruritus intense antihistamines days loratadine po children 2 years 30 kg 5 mg 5 ml daily children 30 kg adults 10 mg 1 tab daily event anaphylactic reaction see shock chapter 1page 163 409pellagra pellagra dermatitis resulting niacin andor tryptophane deficiency persons whose staple food sorghum patients malabsorption famine clinical features classically disease three ds dermatitis diarrhoea dementia treatment children adults 100 mg 3 times daily give diet rich protein patient fully cured referencesdark red plaques well demarcated symmetric located exposed areas body forehead neck forearms legs skin becomes scaly pigmented sometimes haemorrhagic bullae gastrointestinal glossitis stomatitis diarrhoea neuropsychiatric symptoms seen serious forms nicotinamide vitamin pp po 1 event epidemic pellagra example refugee camp vital food ration modified add groundnuts dry vegetables order meet daily requirements approximately 15 mg daily adults 1world health organization united nations high commissions refugees pellagra prevention control major emergencies world health organization 2000 httpwwwwhointnutritionpublicationsenpellagra_prevention_controlpdf accessed 23 may 2018page 164 409chapter 5 eye diseases xerophthalmia vitamin deficiency conjunctivitis neonatal conjunctivitis viral epidemic keratoconjunctivitis trachoma periorbital orbital cellulitis pathologies onchocerciasis river blindness loiasis pterygium cataract page 165 409xerophthalmia vitamin deficiency term xerophthalmia covers ocular manifestations vitamin deficiency xerophthalmia progress irreversible blindness left untreated endemic areas vitamin deficiency xerophthalmia affect mainly children particularly suffering malnutrition measles pregnant women disorders due vitamin deficiency prevented routine administration retinol clinical features treatment treat early symptoms avoid development severe complications vision saved provided ulcerations affect less third cornea pupil spared even deficiency already led keratomalacia irreversible loss sight imperative administer treatment order save eye life patient retinol vitamin pothe first sign hemeralopia crepuscular blindness child cannot see dim light may bump objects andor show decreased mobility signs appear gradually conjunctival xerosis bulbar conjunctiva appears dry dull thick wrinkled insensitive bitots spots greyish foamy patches bulbar conjunctiva usually eyes specific sign however always present corneal xerosis cornea appears dry dull corneal ulcerations keratomalacia last severe sign xerophthalmia softening cornea followed perforation eyeball blindness extreme care must taken ophthalmic examination due risk rupturing cornea treatment regardless clinical stage except pregnant women age 200 000 iu capsule children 6 months b50 000 iu 2 drops daily d1 d2 d8 children 6 months 1 year 100 000 iu 4 drops daily d1 d2 d8 children 1 year adults 200 000 iu one capsule daily d1 d2 d8 acapsules must swallowed whole cut end capsule deliver dose directly mouth bvitamin deficiency rare breastfed infants 6 months pregnant women treatment varies according stage illness hemeralopia bitots spots 10 000 iu daily 25 000 iu weekly least 4 weeks exceed indicated doses risk foetal malformationspage 166 409 corneal lesions medical emergency addition immediate administration retinol treat prevent secondary bacterial infections 1 tetracycline eye ointment one application 2 times daily apply eye drops containing corticosteroids protect eye eyepad application prevention avoid excessive dosage record doses administered healthimmunisation card exceed indicated doses vitamin overdose may cause raised intracranial pressure bulging fontanelle infants headache nausea vomiting severe cases impaired consciousness convulsions adverse effects transient require medical surveillance symptomatic treatment needed cornea affected risk blindness outweighs teratogenic risk administer 200 000 iu daily d1 d2 d8 systematically administer retinol po children suffering measles one dose d1 d2 areas vitamin deficiency endemic routine supplementation retinol po age 200 000 iu capsule c children 6 months 50 000 iu 2 drops single dose children 6 months 1 year 100 000 iu 4 drops every 4 6 months children 1 5 years 200 000 iu one capsule every 4 6 months women delivery 200 000 iu one capsule single dose ccapsules must swallowed whole cut end capsule deliver dose directly mouth footnotes afor information countryspecific prevalence vitamin deficiency see httpswwwthelancetcomactionshowpdfpiis2214109x28152900039xpage 167 409conjunctivitis conjunctivitis acute inflammation conjunctiva due bacterial viral infection allergy irritation conjunctivitis may associated measles rhinopharyngitis children absence hygiene effective treatment secondary bacterial infections may develop affecting cornea keratitis clinical features treatment bacterial conjunctivitis viral conjunctivitis allergic conjunctivitis note event foreign body check tetanus immunisation statusneonatal conjunctivitis viral epidemic keratoconjunctivitis clinical signs conjuctivites include redness eye irritation visual acuity affected depending cause abundant purulent secretions eyelids stuck together waking unilateral infection onset bacterial conjunctivitis watery serous secretions itching viral conjunctivitis excessive lacrimation eyelid oedema intense itching allergic conjunctivitis endemic areas turn upper eyelids check signs trachoma see trachoma suspect keratitis patient reports intense pain usually associated conjunctivitis photophobia instill one drop 05 fluorescein check possible ulcerations always check foreign bodies subconjunctival corneal remove administering 04 oxybuprocaine anaesthetic eye drops never give bottle eye drops patient clean eyes 4 times daily boiled water 09 sodium chloride apply eyes 1 tetracycline eye ointment one application 2 times daily 7 days never use corticosteroid drops ointment clean eyes 4 times daily boiled water 09 sodium chloride apply local antibiotics risk secondary bacterial infection see local treatment viral conjunctivitis antihistamines po one 3 days see urticaria chapter 4page 168 409neonatal conjunctivitis conjunctivitis due neisseria gonorrhoeae andor chlamydia trachomatis neonates born mothers genital gonococcal andor chlamydial infections time delivery neonatal conjunctivitis medical emergency without prompt treatment risk corneal lesions visual impairment clinical features treatment symptoms persist 48 hours parenteral treatment alone administer azithromycin po erythromycin po notes prevention apply soon possible preferably within one hour birth 1 tetracycline eye ointment application 1 cm eye referencesunilateral bilateral purulent conjunctivitis first 28 days life clean eyes isotonic sterile solution 09 sodium chloride ringer lactate 4 times daily remove secretions antibiotic treatment neonates conjunctivitis first 28 days life neonates born mothers genital infection purulent cervical discharge time delivery 0 7 days 8 28 days first line ceftriaxone im 50 mgkg single dose max 125 mg ceftriaxone im 50 mgkg single dose max 125 mg azithromycin po 20 mgkg daily 3 days alternatives ceftriaxone contraindicated cefotaxime im 100 mgkg single doseif azithromycin unavailable erythromycin po 125 mgkg 4 times daily 14 days systemic treatment immediately available clean eyes apply 1 tetracycline eye ointment every hour systemic treatment available cases treat genital infection mother partner see genital infections chapter 9 azithromycin erythromycin associated increased risk pyloric stenosis neonates risk higher erythromycin adverse effects monitored 1 2 3 page 169 4091lund et al use macrolides mother child risk infantile hypertrophic pyloric stenosis nationwide cohort study bmj 2014 348 g1908 httpswwwbmjcomcontent348bmjg1908 accessed 16 april 2021 2murchison l et al postnatal erythromycin exposure risk infantile hypertrophic pyloric stenosis systematic review metaanalysis pediatr surg int 2016 dec 3212 11471152 httpswwwncbinlmnihgovpmcarticlespmc5106491 accessed 16 april 2021 3almaramhy hh et al association prenatal postnatal macrolide exposure subsequent development infantile hypertrophic pyloric stenosis systematic review metaanalysis ital j pediatr 2019 feb 4 45120 httpsijponlinebiomedcentralcomarticles101186s1305201906132 accessed 16 april 2021page 170 409viral epidemic keratoconjunctivitis corneal conjunctival lesions treat viral conjunctivitis possible refer ophthalmologist protect eye compress long photophobia lasts remove soon possible necessary administer preventive dose vitamin apage 171 409trachoma trachoma highly contagious keratoconjunctivitis due chlamydia trachomatis disease endemic poorest rural areas africa asia central south america middle east infection usually first contracted early childhood direct indirect contact dirty hands contaminated towels flies absence hygiene effective treatment inflammation intensifies successive infections causing scars deformities upper tarsal conjunctiva resulting ingrowing eyelashes trichiasis cause corneal lesions followed permanent blindness usually adulthood classifies trachoma 5 stages early diagnosis treatment first stages essential avoid development trichiasis associated complications clinical features several stages occur simultaneously treatment 1 2 stage 1 trachomatous inflammation follicular tf presence five follicles upper tarsal conjunctiva follicles whitish grey yellow elevations paler surrounding conjunctiva stage 2 trachomatous inflammation intense ti upper tarsal conjunctiva red rough thickened blood vessels normally visible masked diffuse inflammatory infiltration follicles stage 3 trachomatous scarring ts follicles disappear leaving scars scars white lines bands patches tarsal conjunctiva stage 4 trachomatous trichiasis tt due multiple scars margin eyelid usually upper lid turns inwards entropion eyelashes rub cornea cause ulcerations chronic inflammation stage 5 corneal opacity co cornea gradually loses transparency leading visual impairment blindness stages 1 2 clean eyes face several times per day antibiotic treatment treatment choice azithromycin po children 20 mgkg single dose adults 1 g single dose failing 1 tetracycline eye ointment one application 2 times daily 6 weeks last resort erythromycin po 20 mgkg max 1 g 2 times daily 14 days 3 stage 3 treatment stage 4 surgical treatment waiting surgery regular patient followup possible taping eyelashes eyelid palliative measure help protect cornea certain cases may lead permanent correction trichiasis within months method consists sticking ingrowing eyelashes external eyelid thin strip stickingplaster making sure eyelid open close perfectly replace plaster starts peel usually week continue treatment 3 monthspage 172 409 prevention cleaning eyes face hands clean water reduces direct transmission development secondary bacterial infections referencesnote epilation ingrowing eyelashes recommended since offers temporary relief regrowing eyelashes abrasive cornea stage 5 treatment 1solomon aw et al simplified trachoma grading system amended bull world health organ 20209810698705 httpswwwncbinlmnihgovpmcarticlespmc7652564 accessed 20 april 2021 2thylefors b et al simple system assessment trachoma complications bull world health organ 198765447783 httpswwwncbinlmnihgovpmcarticlespmc2491032 accessed 20 april 2021 3evans jr et al antibiotics trachoma cochrane database syst rev 2019 sep 269cd001860 httpswwwcochranelibrarycomcdsrdoi10100214651858cd001860pub4full accessed 20 april 2021page 173 409periorbital orbital cellulitis periorbital cellulitis common usually benign bacterial infection eyelids arises principally following trauma eyelids insect bite abrasion orbital cellulitis serious infection involving contents orbit fat ocular muscles may lead loss vision brain abscess usually arises secondary spread sinusitis eg complication ethmoid sinusitis periorbital orbital cellulitis common children adults common organisms causing periorbital orbital cellulitis staphylococcus aureus streptococcus pneumoniae streptococci well haemophilus influenzae type b hib children living countries rates immunisation hib remain low clinical features treatment signs common periorbital orbital cellulitis acute eyelid erythema oedema oedema violaceous hue secondary h influenzae case orbital cellulitis pain eye movements ophthalmoplegia paralysis eye movements often diplopia double vision protrusion eye eye bulges socket high fever systemic signs hospitalize following orbital cellulitis children younger 3 months critically ill appearing patient local complications debilitated patient chronic conditions elderly risk noncompliance failure outpatient treatment treat patients outpatients outpatient antibiotic therapy cefalexin po 7 10 days neonates 0 7 days 25 mgkg 2 times daily neonates 8 days 1 month 25 mgkg 3 times daily children 1 month 25 mgkg 2 times daily max 2 g daily children 40 kg adults 1 g 2 times daily amoxicillinclavulanic acid coamoxiclav po 7 10 days use formulations ratio 81 71 exclusively dose expressed amoxicillin children 40 kg 50 mgkg 2 times daily children 40 kg adults ratio 81 3000 mg daily 2 tab 500625 mg 3 times daily ratio 71 2625 mg daily 1 tab 875125 mg 3 times daily b inpatient antibiotic therapy ceftriaxone slow iv3 minutes iv infusion 30 minutes 60 minutes neonates least 5 days children one dose 100 mgkg first day 50 mgkg 2 times daily adults 1 2 g daily cloxacillin iv infusion 60 minutes neonates 0 7 days 2 kg 50 mgkg every 12 hours c e page 174 409 improvement first 48 hours suspicion methicillin resistant aureus replace cloxacillin clindamycin iv infusion 30 minutes neonates 0 7 days 2 kg 5 mgkg every 12 hours neonates 0 7 days 2 kg 5 mgkg every 8 hours neonates 8 days 1 month 2 kg 5 mgkg every 8 hours neonates 8 days 1 month 2 kg 10 mgkg every 8 hours children 1 month 10 mgkg every 8 hours max 1800 mg daily adults 600 mg every 8 hours 5 days change clindamycin po doses complete 7 10 days treatment neonates 0 7 days 2 kg 50 mgkg every 8 hours neonates 8 days 1 month 2 kg 50 mgkg every 8 hours neonates 8 days 1 month 2 kg 50 mgkg every 6 hours children 1 month 25 50 mgkg every 6 hours max 8 g daily children 40 kg adults 2 g every 6 hours clinical improvement patient afebrile erythema oedema improved 5 days change amoxicillinclavulanic acid po doses indicated complete 7 10 days treatment f orbital cellulitis unresponsive iv antibiotics consider abscess transfer patient surgical centre drainage footnotes acritically ill appearing child weak grunting crying drowsy difficult arrouse smile disconjugate anxious gaze pallor cyanosis general hypotonia bfor penicillinallergic patients clindamycin po 7 10 days children 10 mgkg 3 times daily adults 600 mg 3 times daily cfor penicillinallergic patients clindamycin iv infusion doses dfor administration iv route ceftriaxone powder reconstituted water injection administration iv infusion dilute dose ceftriaxone 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults ecloxacillin powder injection reconstituted 4 ml water injection dilute dose cloxacillin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults fdilute dose clindamycin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adultspage 175 409other pathologies onchocerciasis loiasis pterygium cataractpage 176 409onchocerciasis river blindness ocular lesions result invasion eye microfilariae generally develop adults progress blindness absence early treatment clinical features treatment ocular lesions always associated onchocercal skin lesions see onchocerciasis chapter 6 treatment see onchocerciasis chapter 6 ivermectin treatment may improve anterior segment lesions sclerosing keratitis iridocyclitis visual acuity severe lesions chorioretinal lesions optic atrophy continue progress despite treatmentpruritus hemeralopia crepuscular blindness decrease visual acuity narrowing visual field awareness microfilariae visual field patient sees little wiggling worms eyes lesions cornea punctuate sclerosing keratitis iris iridocyclitis posterior segment chorioretinopathy optic atrophy microfilariae within anterior chamber vitreous humor slit lamppage 177 409loiasis clinical features treatment migration adult worm palpebral bulbar conjunctiva white filiform worm measuring 4 7 cm length mobile ocular pruritus lacrimation photophobia eyelid oedema treatment see loiais chapter 6 migration worm often brief duration attempt extract administer anaesthetic drops simply reassure patient event harmless surgical removal likewise futile worm deadcalcifiedpage 178 409pterygium whitish triangular growth fibrovascular tissue extending slowly conjunctiva cornea occurs frequently patients exposed wind dust arid climates never disappears spontaneously clinical features treatment two stages benign pterygium develops slowly reach pupil treatment progressive vascularized pterygium red inflamed growth covers pupil may impair vision clean eye sterile water 09 sodium chloride surgical removal facilities availablepage 179 409cataract opacity lens causes progressive loss visual acuity cataract common tropics occur younger age europe presence cataract eyes leads blindness surgery treatmentpage 180 409chapter 6 parasitic diseases malaria human african trypanosomiasis sleeping sickness american trypanosomiasis chagas disease leishmaniases intestinal protozoan infections parasitic diarrhoea flukes schistosomiases cestodes nematode infections filariasis onchocerciasis river blindness loiasis lymphatic filariasis lf page 181 409malaria malaria parasitic infection due protozoa genus plasmodium transmitted humans bite anopheles mosquitoes transmission transfusion parasite infected blood transplacental transmission also possible 5 species plasmodium cause malaria humans p falciparum p vivax p ovale p malariae p knowlesi species may cause uncomplicated malaria severe malaria defined presence complications almost always due p falciparum less frequently p vivax p knowlesi uncomplicated malaria rapidly progress severe malaria severe malaria may cause death within hours left untreated clinical features malaria always considered patients living coming endemic area presents fever history fever previous 48 hours uncomplicated malaria fever frequently associated chills sweating headache muscular ache malaise anorexia nausea children fever may associated abdominal pain diarrhoea vomiting mild moderate anaemia frequent children pregnant women severe malaria addition patients presenting one following complications hospitalised immediately laboratory parasitological diagnosis diagnosis malaria confirmed whenever possible testing available treatment suspected malaria delayed rapid diagnostic tests rdts rapid tests detect parasite antigens give qualitative result positive negative may remain positive several days weeks following elimination parasites 1 impaired consciousness including coma seizures 2 episodes generalised focal eg abnormal eye movements seizures within 24 hours prostration extreme weakness children inability sit drinksuck respiratory distress rapid laboured breathing slow deep breathing shock cold extremities weak absent pulse capillary refill time 3 seconds cyanosis jaundice yellow discolouration mucosal surfaces mouth conjunctivae palms haemoglobinuria dark red urine abnormal bleeding skin petechiae conjunctivae nose gums blood stools acute renal failure oliguria urine output 12 mlkgday children 400 mlday adults despite adequate hydration 2 page 182 409microscopy thin thick blood films enable parasite detection species identification quantification monitoring parasitaemia blood films may negative due sequestration parasitized erythrocytes peripheral capillaries severe malaria well placental vessels pregnant women note even positive diagnostic results rule causes fever additional examinations haemoglobin hb level measured routinely patients clinical anaemia patients severe malaria blood glucose level measured routinely detect hypoglycaemia patients severe malaria malnutrition see hypoglycaemia chapter 1 treatment malaria due p vivax p ovale p malariae p knowlesi chloroquine cq po children adults day 1 10 mg basekg day 2 10 mg basekg day 3 5 mg basekg general p vivax remains sensitive cq resistance found several countries resistance high 10 countries deregistered cq due p falciparum resistance artemisininbased combination therapy act used instead dosing information see treatment uncomplicated falciparum malaria relapses occur p vivax p ovale due activation dormant parasites liver primaquine po 14 days 025 05 mgkg daily children 15 kg 15 mg daily adults given eliminate parasites initial treatment cq act however treatment recommended patients living areas reinfection unlikely ie nonendemic low transmission areas countries aiming elimination malaria treatment contraindicated individuals g6pd deficiency g6pd deficiency cannot tested individually decision prescribe primaquine must take account prevalence deficiency population treatment uncomplicated falciparum malaria antimalarial treatment pregnancy see antimalarial treatment pregnant women treatment artemisininbased combination therapy actgiven oral route 3 days firstline act chosen according therapeutic efficacy area patient living first line act unavailable contraindicated failed despite correctly administered use another act dosing information see table b c 1 c 1 page 183 409treatment uncomplicated falciparum malaria low malaria endemic areas addition act individuals except children 30 kg pregnant women breastfeeding women infants aged 6 months diagnosed p falciparum malaria given single dose 025 mgkg primaquine reduce risk transmission notes quinine po recommended standard treatment however still remains national protocols quinine po 7 days children adults 50 kg 10 mgkg 3 times daily adults 50 kg 600 mg 3 times daily symptomatic treatment paracetamol po event high fever fever chapter 1 treatment severe malaria patient must hospitalised antimalarial treatment b 3 infants ageweight mentioned table little data efficacy safety acts combinations al asaq dhappq used dose calculated correspond 1016 mgkgdose lumefantrine 10 mgkg daily amodiaquine 20 mgkg daily piperaquine clinical condition young children deteriorate rapidly may preferable start parenteral treatment straight away see b page 184 409during pregnancy see antimalarial treatment pregnant women prereferral treatment patient needs transferred administer transfer either case provide patients especially children sugar prior transfer inpatient treatment drug choice artesunate preferably iv possible im patients shock im route appropriate use artesunate iv artesunate slow iv injection 3 5 minutes possible slow im injection anterior thigh children 20 kg 3 mgkgdose children 20 kg adults 24 mgkgdose treat parenterally least 24 hours 3 doses patient tolerate oral route change complete 3day course act continue parenteral treatment daily patient change oral route without exceeding 7 days parenteral treatment artesunate unavailable artemether may alternative artemether im anterior thigh never administer iv route children adults 32 mgkg admission d1 16 mgkg daily treat parenterally least 24 hours 2 doses patient tolerate oral route change complete 3day course act continue parenteral treatment daily patient change oral route without exceeding 7 days parenteral treatment note patient still parenteral treatment day 5 continue treatment day 7 case necessary start act quinine iv still recommended national protocols may used treatment malaria shock artesunate iv available dose expressed quinine salt adults administer dose quinine 250 ml glucose children 20 kg administer dose quinine volume 10 mlkg glucose administer loading dose patients received oral quinine mefloquine within previous 24 hours start maintenance dose treat parenterally least 24 hours patient tolerate oral route change complete 3day course act available oral quinine complete 7 days quinine treatment continue parenteral treatment patient change oral route without exceeding 7 days parenteral treatmentat community level children 6 years one dose rectal artesunate 10 mgkg children 2 months 3 years 10 kg 1 rectal capsule 100 mg children 3 6 years 20 kg 2 rectal capsules 200 mg dispensary level children adults first dose artesunate unavailable first dose artemether dosing information see one dose admission h0 one dose 12 hours admission h12 one dose 24 hours admission h24 one dose daily loading dose 20 mgkg administered 4 hours keep vein open infusion 5 glucose 4 hours maintenance dose 8 hours start loading dose 10 mgkg every 8 hours alternate quinine 4 hours 5 glucose 4 hourspage 185 409symptomatic treatment management complications hydration maintain adequate hydration guide volume administered per 24 hours oral iv route see appendix 1 adjust volume according clinical condition order avoid dehydration fluid overload risk pulmonary oedema fever paracetamol event high fever fever chapter 1 severe anaemia treatment see anaemia chapter 1 hypoglycaemia treatment see hypoglycaemia chapter 1 notes coma checkensure airway clear measure blood glucose level assess level consciousness event hypoglycaemia blood glucose level cannot measured administer glucose patient respond administration glucose hypoglycaemia detected seizures see seizures chapter 1 address possible causes eg hypoglycaemia fever children respiratory distress oliguria acute renal failurein unconscious prostrated patient case emergency venous access unavailable awaited use granulated sugar sublingual route correct hypoglycaemia e risk hypoglycaemia higher patients receiving iv quinine insert urinary catheter place patient recovery position monitor vital signs blood glucose level level consciousness fluid balance urine output fluid input hourly stable every 4 hours rule meningitis lumbar puncture proceed directly administration antibiotic see meningitis chapter 7 reposition patient every 2 hours ensure eyes mouth kept clean moist etc rapid laboured breathing check pulmonary oedema crepitations auscultation may occur without fluid overload reduce iv infusion rate patient receiving iv therapy nurse semisitting oxygen furosemide iv 1 mgkg children 40 mg adults repeat 1 2 hours necessary associated pneumonia also considered see acute pneumonia chapter 2 slow deep breathing suspected metabolic acidosis look dehydration correct present decompensated anaemia transfuse presentpage 186 409look first dehydration dehydration chapter 1 especially due inadequate fluid intake excessive fluid losses high fever vomiting diarrhoea treat dehydration present aware risk fluid overload acute pulmonary oedema monitor return urine output acute renal failure arf found almost exclusively adults common asia africa insert urinary catheter measure output restrict fluids 1 litreday 30 mlkgday children plus additional volume equal urine output renal dialysis often necessary antimalarial treatment pregnant women uncomplicated p vivax p ovale p malariae p knowlesi malaria patients primaquine given pregnancy uncomplicated falciparum malaria act included table treatment uncomplicated falciparum malaria used trimesters acts available quinine po dosing see treatment uncomplicated falciparum malaria combined clindamycin po possible 10 mgkg 2 times daily 7 days may alternative act primaquine given pregnancy severe malaria artesunate unavailable artemether recommended trimesters quinine iv recommended standard treatment however still remains national protocols prevention pregnant women areas high risk infection p falciparum refer guide essential obstetric newborn care msf areas seasonal malaria transmission particular across sahel subregion seasonal malaria chemoprevention children 5 years reduces mortality administer amodiaquine sp monthly intervals 4 months transmission period 4 malaria endemic areas epidemicprone contexts inpatient facilities including hiv treatment centres feeding centres furnished longlasting insecticidal nets llins information refer guide public health engineering msf see specialised literature information regarding antivector measures prevention travellers footnotes amost rapid tests detect following antigens alone combination hrp2 protein specific p falciparum enzyme pf pldh specific p falciparum enzyme pan pldh common 4 plasmodium species hrp2 may continue detectable 6 weeks parasite clearance pldh remains detectable several days 2 weeks parasite clearance use pan pldh tests first choice hyper holoendemic areas well areas intense seasonal transmission outbreaks complex emergencies contexts hrp2 tests p falciparum 95 hrp2 pldh combination tests p falciparum 95 preferred bif patient vomits within 30 minutes administration readminister full dose patient vomits 30 minutes 1 hour administration readminister half dose severe vomiting precludes oral therapy manage severe malaria see treatment severe malariapage 187 409referencescact combination artemisinin one derivatives eg artesunate artemether another antimalarial different class dif impossible refer patient center capable providing parenteral treatment rectal artesunate given according schedule artesunate slow iv injection h0 h12 h24 daily eplace level teaspoon sugar moistened drops water tongue place patient recovery position repeat 15 minutes patient regained consciousness methods treating hypoglycaemia maintain regular sugar intake monitor 1world health organization guidelines treatment malaria 3rd ed world health organization 2015 httpsappswhointirishandle10665162441 2world health organization compendium malaria guidance prevention diagnosis treatment surveillance elimination 2019 httpsappswhointirishandle10665312082 3world health organization policy brief singledose primaquine gametocytocide plasmodium falciparum malaria 2015 httpswwwwhointmalariapublicationsatozwho_htm_gmp_20151pdfua1 4world health organization policy recommendation seasonal malaria chemoprevention smc plasmodium falciparum malaria control highly seasonal transmission areas sahel subregion africa 2012 httpswwwwhointmalariapublicationsatozsmc_policy_recommendation_en_032012pdfua1page 188 409human african trypanosomiasis sleeping sickness human african trypanosomiasis hat zoonosis caused protozoa trypanosomes transmitted humans bite tsetse fly glossina transmission contaminated blood transfusion transplacental transmission also possible disease found subsaharan africa two forms trypanosoma brucei gambiense hat western central africa trypanosoma brucei rhodesiense hat eastern southern africa clinical features inoculation may followed immediate local reaction trypanosomal chancre chancre arises 50 rhodesiense rarely gambiense gambiense hat rhodesiense hat first stage incubation period shorter 3 weeks disease evolves rapidly symptoms severe patients often die myocarditis 3 6 months without developed signs meningoencephalitic stage practice gambiense rhodesiense hat difficult differentiate eg exist cases acute gambiense infection others chronic rhodesiense infection laboratoryincubation lasts days several years first stage haemolymphatic stage corresponds haematogenous lymphatic dissemination parasite signs include intermittent fever joint pain lymphadenopathy firm mobile painless lymph nodes mainly cervical hepatosplenomegaly skin signs facial oedema pruritus second stage meningoencephalitic stage corresponds invasion central nervous system signs haemolymphatic stage recede disappear varying neurological signs progressively develop sensory disturbances deep hyperaesthesia psychiatric disorders apathy agitation disturbance sleep cycle daytime somnolence alternating insomnia night impaired motor functions paralysis seizures tics neuroendocrine disorders amenorrhoea impotence absence treatment cachexia lethargy coma death diagnosis involves 3 steps gambiense hat screening test diagnostic confirmation stage determination 2 steps rhodesiense hat diagnostic confirmation stage determination recommended screening test tb gambiense infection catt card agglutination test trypanosomiasis detects presence specific antibodies patients blood serum diagnostic confirmation presence trypanosomes lymph node aspirates blood using concentration techniques capillary tube centrifugation technique woo test quantitative buffy coat qbc minianion exchange centrifugation technique maec stage determination detection trypanosomes centrifugation white cell count cerebrospinal fluid lumbar puncture haemolymphatic stage trypanosomes 5 white cellsmm3page 189 409treatment except pregnant women haemolymphatic stage stage gambiense hat pentamidine isetionate deep im children adults 4 mgkg daily 7 10 days patients receive source glucose meal sweet tea one hour injection risk hypoglycaemia remain supine administration one hour injection risk hypotension rhodesiense hat suramin slow iv children adults d1 test dose 4 5 mgkg d3 d10 d17 d24 d31 20 mgkg max 1 g per injection suramin may cause anaphylactic reactions test dose recommended prior starting treatment event anaphylactic reaction test dose patients must given suramin meningoencephalitic stage stage ii administrating trypanocides priority improve patients general condition rehydration treatment malaria intestinal worms malnutrition bacterial infections nonetheless recommended postpone trypanocidal treatment 10 days gambiense hat meningoencephalitic stage evidence trypanosomes 5 white cellsmm3 due toxicity trypanocides detection parasite essential initiating treatment absence parasitological confirmation treatment may nevertheless justified certain cases strong clinical suspicion patients lifethreatening condition strong serological suspicion catt 116 positive population disease highly prevalent 2 several treatment regimens exist check national recommendations local resistance levels treatment must administered close medical supervision patients receiving pentamidine treated outpatients receiving suramin eflornithine without nifurtimox melarsoprol hospitalised treatment patients checked every 6 months clinical examination lumbar puncture examination trypanosomes 24 months look relapse first choice nifurtimoxeflornithine combination therapy nect nifurtimox po children adults 5 mgkg 3 times daily 10 days eflornithine iv infusion 2 hours children adults 200 mgkg every 12 hours 7 days catheter must handled great attention avoid local general bacterial infections thoroughly disinfect insertion site ensure secure catheter fixation protect insertion site sterile dressing systematically change catheter every 48 hours earlier case signs phlebitis second choice eflornithine iv infusion 2 hourspage 190 409 rhodesiense hat melarsoprol slow iv children adults 22 mgkg daily 10 days prednisolone po 1 mgkg daily frequently combined throughout duration treatment treatment pregnant women trypanocides potentially toxic mother foetus risk miscarriage malformation etc however due lifethreatening risk mother risk mothertochild transmission treatment must initiated follows prevention controlchildren 12 years 150 mgkg every 6 hours 14 days children 12 years adults 100 mgkg every 6 hours 14 days event relapse nect eflornithine melarsoprol slow iv children adults 22 mgkg daily 10 days melarsoprol highly toxic reactive encephalopathy coma recurrent prolonged seizures 5 10 treated patients fatal around 50 cases peripheral neuropathy invasive diarrhoea severe skin rash phlebitis etc prednisolone po 1 mgkg daily frequently combined throughout duration treatment haemolymphatic stage pentamidine gambiense hat second trimester suramin rhodesiense hat meningoencephalitic stage treatment depends mothers condition immediately lifethreatening condition treatment nect eflornithine cannot deferred delivery immediately lifethreatening condition pentamidine gambiense hat suramin rhodesiense hat treatment nect eflornithine administered delivery individual protection tsetse fly bites long sleeves trousers repellents keeping away risk areas eg near rivers disease control mass screening treatment patients tb gambiense trypanocide treatment cattle tb rhodesiense vector control using tsetse fly traps insecticidespage 191 409american trypanosomiasis chagas disease chagas disease zoonosis caused protozoa trypanosoma cruzi transmitted humans contact triatomine bug faeces break skin often caused bite triatomine bug mucous membranes transmission contaminated blood transfusion accidental exposure blood mothertochild pregnancy childbirth consumption contaminated food water also possible chagas disease two phases acute phase lasts approximately 4 6 weeks chronic phase lifelong left untreated disease primarily found american continent significantly underdiagnosed clinical features acute phase chronic phase diagnosis laboratory investigations treatment 1 cases asymptomatic transmitted break skin red swelling skin chagoma unilateral painless purplish periorbital oedema romanas sign local lymphadenopathy headache fever rarely multiple lymphadenopathies hepatosplenomegaly myocarditis chest pain dyspnoea meningoencephalitis seizures paralysis many cases remain asymptomatic indeterminate phase 30 cases develop organ damage 2 cardiac lesions conduction disorders dilated cardiomyopathy arrhythmia dyspnoea chest pain heart failure gastrointestinal lesions dilation oesophagus colon ie megaoesophagus megacolon difficulty swallowing severe constipation individuals immunosuppression higher risk developing organ damage general population 1 acute phase identification trypanosoma cruzi direct microscopy fresh blood blood concentrated microhematocrit method case strong clinical suspicion despite definitive diagnosis direct microscopy perform serologic tests delay approximately 1 month see chronic phase chronic phase identification antitrypanosoma cruzi antibodies serologic tests eg enzymelinked immunosorbent assay elisa hemagglutination inhibition assay hai indirect immunofluorescence iif rapid diagnostic test rdt definitive diagnosis two different serological tests performed simultaneously case conflicting results third test recommended b ecg may demonstrate conduction disorders chest abdominal xray may demonstrate cardiomegaly megaoesophagus megacolonpage 192 409aetiologic treatment information symptomatic treatment see seizures chapter 1 pain chapter 1 heart failure chapter 12 prevention referencesacute chronic chagas disease treated either benznidazole nifurtimox however treatment recommended patient already developed cardiac digestive complications close clinical monitoring provided due frequent occurrence adverse effects available blood tests complete blood count liver renal function tests performed treatment protocols vary according country follow national recommendations age dose duration benznidazole po a2 12 years 35 8 mgkg daily 2 divided doses 60 days 12 years adults 45 7 mgkg daily 2 divided doses 60 days nifurtimox po b 3 10 years 15 20 mgkg daily 3 4 divided doses 90 days 11 16 years 125 15 mgkg daily 3 4 divided doses 90 days 17 years adults 8 10 mgkg daily 3 4 divided doses 90 days abenznidazole contraindicated pregnancy breastfeeding patient severe hepaticrenal impairment bnifurtimox contraindicated pregnancy breastfeeding patients severe hepaticrenal impairment history severe mental disorders seizures adverse effects gastrointestinal disturbances agitation sleeping disorders seizure frequent reversible necessarily result discontinuation treatment avoid alcohol fatty meals treatment individual protection bite triatomine bugs use longlasting insecticidal net healthcare settings standard precautions avoid contamination soiled materials potentially infected body fluids blood transfusions advise patients chagas disease donate blood endemic areas screen donor blood trypanosoma cruzi antibodies footnotes afor information geographical distribution cases cruzi infection httpgamapserverwhointmaplibraryfilesmapsglobal_chagas_2009png bif resources limited elisa alone performed result positive second serologic test performed confirm diagnosis starting treatment page 193 4091pan american health organization guidelines diagnosis treatment chagas disease washington dc 2019 httpirispahoorgxmluibitstreamhandle123456789496539789275120439_engpdfsequence6isallowedy 2rassi marinneto j seminar chagas disease lancet volume 375 issue 9723 p13881402 april 17 2010 3centers disease control prevention parasites american trypanosomiasis httpswwwcdcgovparasiteschagas accessed 17 february 2020 4world health organization model prescribing information drugs used parasitic diseases second edition geneva 1995 httpsappswhointirishandle1066541765 accessed 6 may 2020page 194 409leishmaniases leishmaniases group parasitic diseases caused protozoa genus leishmania transmitted bite sandfly 20 species cause disease man clinical features cutaneous mucocutaneous leishmaniasis visceral leishmaniasis visceral leishmaniasis kala azar systemic disease resulting pancytopenia immunosuppression death left untreated postkala azar dermal leishmaniasis macular nodular papular skin rash unknown aetiology particularly face typically occurring apparent cure visceral leishmaniasis laboratory cutaneous mucocutaneous leishmaniasis visceral leishmaniasiscutaneous leishmaniasis endemic 70 countries south central america middle east central asia africa mucocutaneous leishmaniasis occurs latin america rarely africa ethiopia sudan visceral leishmaniasis occurs 60 countries east north africa south central asia southern europe south central america single multiple lesions uncovered parts body erythematous papule begins sandfly bite enlarges nodule extends surface depth form scabbed ulcer ulcers painless unless secondary bacterial fungal infection usually lesions heal spontaneously leaving scar result lifelong protection disease lesions may also spread mucosa mouth nose conjunctiva giving rise mucocutaneous form may cause severe disfigurement prolonged 2 weeks irregular fever splenomegaly weight loss main signs signs include anaemia diarrhoea epistaxis lymphadenopathy moderate hepatomegaly bacterial diarrhoea pneumonia tuberculosis may develop due immunosuppression parasitological diagnosis identification giemsastained parasites smears tissue biopsy edge ulcer useful serological tests parasitological diagnosis identification giemsastained parasites smears splenic bone marrow lymph node aspirationbiopsy splenic aspiration sensitive technique carries theoretical risk potentially fatal haemorrhage serological diagnosis rk39 dipstick test direct agglutination test dat used diagnosis primary visceral leishmaniasis clinically suspect cases diagnosis relapse parasitological confirmationpage 195 409treatment various species leishmania respond differently drugs follow national recommendations information cutaneous mucocutaneous leishmaniasis visceral leishmaniasis visceral leishmaniasis east africa visceral leishmaniasis south asia patients visceral leishmaniasis hydration nutritional support treatment intercurrent infections malaria dysentery pneumonia etc essential tuberculosis andor hiv infection may also present suspected relapse occurs event treatment failurecutaneous lesions generally heal spontaneously 3 6 months treatment indicated lesions persistent 6 months disfiguring ulcerating disseminated forms single lesion lesions start local treatment pentavalent antimonial sodium stibogluconate meglumine antimoniate 1 2 ml infiltrated lesion nodule edges base around crust ulcer repeated every 3 7 days 2 4 weeks healing begins treatment stopped healing continue im treatment pentavalant antimonial 20 mgkg daily 10 20 days restricted severe cases must administered close medical supervision miltefosine po visceral leishmaniasis 28 days effective many forms cutaneous leishmaniasis ulcers often secondarily infected streptococci staphylococci administer suitable antibiotics mucocutaneous forms visceral leishmaniasis firstline treatment pentavalent antimonial im slow iv 20 mgkg daily 17 days paromomycin im 15 mg 11 mg basekg daily 17 days secondline treatment relapse specific vulnerable groups severe disease pregnant women patients 45 years liposomal amphotericin b iv infusion 3 5 mgkg daily 6 10 days total dose 30 mgkg treatment hiv coinfected patients liposomal amphotericin b iv infusion 3 5 mgkg daily 6 10 days total dose 30 mgkg miltefosine po 28 days children 2 11 years 25 mgkg daily children 12 years 25 kg 50 mg daily children 12 years adults 25 50 kg 50 mg 2 times daily adults 50 kg 50 mg 3 times daily firstline treatment liposomal amphotericin b iv infusion 3 5 mgkg daily 3 5 days total dose 15 mgkg liposomal amphotericin b iv infusion 10 mgkg single dose secondline treatment relapse liposomal amphotericin b iv infusion 3 5 mgkg daily 5 8 days total dose 25 mgkgpage 196 409postkala azar dermal leishmaniasis pkdl patients severe disfiguring disease lesions remaining 6 months young children oral lesions interfere feeding treated pkdl east africa pentavalent antimonial im slow iv 20 mgkg daily 17 60 days paromomycin im 15 mg 11 mg basekg daily 17 days liposomal amphotericin b iv infusion 25 mgkg daily 20 days miltefosine po 28 days visceral leishmaniasis may beneficial hiv coinfected patients pkdl south asia liposomal amphotericin b iv infusion 5 mgkg 2 times weekly total dose 30 mgkg prevention insecticidetreated mosquito nets vector control elimination animal reservoir hostspage 197 409intestinal protozoan infections parasitic diarrhoea important intestinal protozoan infections amoebiasis entamoeba histolytica giardiasis giardia lamblia cryptosporidiosis cryptosporidium sp cyclosporiasis cyclospora cayetanensis isosporiasis isospora belli intestinal protozoa transmitted faecaloral route soiled hands ingestion food water contaminated faeces may cause individual cases diarrhoea epidemic diarrhoea outbreaks clinical features laboratory definitive diagnosis relies parasite identification stool specimens trophozoites cysts giardia oocysts cryptosporidium cyclospora isospora two three samples collected 2 3 days apart necessary pathogens shed intermittently treatment amoebiasis gives rise bloody diarrhoea see amoebiasis chapter 3 clinical presentation giardiasis cryptosporidiosis cyclosporiasis isosporiasis similar diarrhoea usually mild selflimiting except children patients advanced hiv disease cd4 200 patients likely develop severe intermittent chronic diarrhoea may complicated malabsorption significant wasting failure gain weight children severe dehydration stools usually watery steatorrhoea pale bulky fatty stools may found event secondary fat malabsorption stools may contain mucus diarrhoea usually associated nonspecific gastrointestinal symptoms abdominal distension cramps flatulence nausea anorexia patients lowgrade fever fever correct dehydration present clinical features management see dehydration chapter 1 causal agent identified stoolpage 198 409 giardiasis tinidazole po single dose children 50 mgkg max 2 g adults 2 g metronidazole po 3 days children 30 mgkg daily adults 2 g daily cryptosporidiosis immunocompetent patients aetiological treatment spontaneous resolution 1 2 weeks cyclosporiasis cotrimoxazole po 7 days children 25 mg smx 5 mg tmpkg 2 times daily adults 800 mg smx 160 mg tmp 2 times daily immunocompetent patients symptoms usually resolve spontaneous 1 3 weeks treatment given case severe prolonged symptoms isoporiasis cotrimoxazole po 7 10 days adults 800 mg smx 160 mg tmp 2 times daily immunocompetent patients symptoms usually resolve spontaneous 2 3 weeks treatment given case severe prolonged symptoms reliable stool examination cannot carried parasitic diarrhoeas cannot differentiated clinical grounds possible distinguish non parasitic diarrhoeas empirical treatment using tinidazole metronidazole cotrimoxazole together succession may tried case prolonged diarrhoea steatorrhoea patients hiv infection see empirical treatment hiv infections aids chapter 8 patients advanced hiv disease cryptosporidiosis cyclosporiasis isosporiasis opportunistic infections effective intervention treatment underlying hiv infection antiretrovirals patients remain high risk dehydrationdeath immunity restoredpage 199 409flukes page 200 409infectionepidemiology clinical featuresdiagnosis treatment lung flukes paragonimus sp distribution southeast asia china parts cameroon nigeria gabon congo colombia peru transmission eating raw freshwater crustaceansthe two prominent symptoms prolonged 2 weeks productive cough intermittent haemoptysis rustybrown sputum endemic areas paragonimosis considered whenever pulmonary tuberculosis suspected clinical radiological features overlap paragonimosis confirmed eggs detected sputum possibly stoolspraziquantel po children 4 years adults 25 mgkg 3 times daily 2 days hepatobiliary flukes fasciola hepatica gigantica distribution worldwide areas sheep cattle raised transmission eating uncooked aquatic plants migration phase asthenia prolonged fever myalgia right upper quadrant pain mild hepatomegaly sometimes allergic signs eg pruritus stage diagnosis rarely considered confirmed serology parasitological examination stools always negative adult flukes present biliary tract presentation resembles cholelithiasis right upper quadrant pain recurrent episodes obstructive jaundice febrile cholangitis diagnosis confirmed parasite eggs detected stools flukes seen biliary tract sonography triclabendazole po children adults 10 mgkg single dose may repeat 24 hours event severe infection opisthorchis felineus asia eastern europe opisthorchis viverrini cambodia laos vietnam thailand clonorchis sinensis china koera vietnam transmission eating rawundercooked freshwater fishabdominal pain diarrhoea heavy infection hepatobiliary symptoms hepatomegaly right upper quadrant pain jaundice episodes febrile cholangitis diagnosis confirmed parasite eggs detected stoolspraziquantel po children 4 years adults 25 mgkg 3 times daily 2 days intestinal flukes fasciolopsis buski india bangladesh southeast asia heterophyes heterophyes southeast asia nile delta metagonimus yokogawai siberia china korea transmission eating uncooked aquatic plants f buskisymptoms limited diarrhoea epigastric abdominal pain massive infection f buski cause oedematous allergic reactions including ascites anasarca diagnosis confirmed parasite eggs detected stoolspraziquantel po children 4 years adults 25 mgkg 3 times daily 1 daypage 201 409 rawundercooked fish speciespage 202 409schistosomiases schistosomiases acute chronic visceral parasitic diseases due 5 species trematodes schistosomes three main species infecting humans schistosoma haematobium schistosoma mansoni schistosoma japonicum schistosoma mekongi schistosoma intercalatum limited distribution humans infected wadingbathing fresh water infested schistosome larvae symptoms occurring phases parasite invasion transient localized itching larvae penetrate skin migration allergic manifestations gastrointestinal symptoms migration schistosomules frequently overlooked general schistosomiasis suspected symptoms established infection become evident species gives rise specific clinical form genitourinary schistosomiasis due haematobium intestinal schistosomiasis due mansoni japonicum mekongi intercalatum severity disease depends parasite load heavily infected patients prone visceral lesions potentially irreversible sequelae children aged 5 15 years particularly risk prevalence parasite load highest age group antiparasitic treatment administered reduce risk severe lesions even likelihood infection clinical featurespage 203 409 parasiteepidemiology aclinical featuresdiagnosis established infection genitourinary schistosomiasiss haematobium distribution africa madagascar arabian peninsulaurinary manifestations endemic areas urinary schistosomiasis suspected patients complain macroscopic haematuria red coloured urine throughout end micturition haematuria frequently associated polyuriadysuria frequent painful micturition patients especially children adolescents urinary symptoms visual inspection urine dipstick test microscopic haematuria urine appears grossly normal indispensible presumptive treatment recommended presence macro microscopic haematuria parasitological confirmation parasite eggs detected urine cannot obtained genital manifestations women symptoms genital infection whiteyellow bloody vaginal discharge itching lower abdominal pain dyspareunia vaginal lesions resembling genital warts ulcerative lesions cervix men haematospermia blood semen left untreated risk recurrent urinary tract infections fibrosiscalcification bladder ureters bladder cancer increased susceptibility sexually transmitted infections risk infertility endemic areas genitourinary schistosomiasis may differential diagnosis genitourinary tuberculosis women sexually transmitted infections especially women history haematuria intestinal schistosomiasiss mansoni distribution tropical africa madagascar arabian peninsula south america especially brazil japonicum distribution china indonesia philippines mekongi distribution parts lao pdr cambodia along mekong river intercalatum distribution parts drc congo gabon cameroon chadnonspecific digestive symptoms abdominal pain diarrhoea intermittent chronic without blood hepatomegaly intercalatum digestive symptoms rectal pain tenesmus rectal prolapse bloody diarrhoea left untreated risk hepatic fibrosis portal hypertension cirrhosis gastrointestinal haemorrhage hematemesis melena etc except intercalatum less pathogenic intestinal schistosomes severe hepatic lesions diagnosis confirmed parasite eggs detected stools absence reliable parasitological diagnosis areas intestinal schistosomiasis common diarrhoea especially bloody diarrhoea abdominal pain andor hepatomegaly may basis presumptive diagnosis treatmentpage 204 409 treatment praziquantel po children 4 years adults references 1 2 b haematobium mansoni intercalatum 40 mgkg single dose 2 doses 20 mgkg administered 4 hours apart japonicum mekongi 2 doses 30 mgkg 3 doses 20 mgkg administered 4 hours apart footnotes afor information geographic distribution schistosomiasis httpswwwwhointschistosomiasisschistosomiasis_201201pngua1 bfor treatment schistosomiasis praziquantel may administered pregnant women 1treatment guidelines medical letter vol 11 suppl drugs parasitic infections 2013 httpswwwuabedumedicinegorgasimagesdocssyllabus201503_parasitesrxparasitesmedicalletter2013pdf accesse 25 may 2020 2centers disease control prevention cdc schistosomiasis resources health professionals 2018 httpswwwcdcgovparasitesschistosomiasishealth_professionalsindexhtmltx accessed 25 may 2020page 205 409cestodes cestodes adult forms cestodes larvaeparasitesclinical featureslaboratorytreatment transmissionprevention taeniasis taenia saginata taenia solium worldwideoften asymptomatic segments expelled stools sometimes gastrointestinal disturbances epigastric abdominal pain nausea diarrhoea laboratory eggs stools collected perianal skin scotch tape method segments stoolspraziquantel po children 4 years adults 5 10 mgkg single dose transmission eating raw undercooked meat preventionbeef saginata pork solium individual cook meat thoroughly collective slaughterhouse monitoring diphyllobothriasis diphyllobothrium latum temperate cold lake areasoften asymptomatic event heavy infection mild gastrointestinal disturbances anaemia due vitamin bdeficiency associated rare neurological sequelae laboratory eggs stools12 praziquantel po children 4 years adults 5 10 mgkg single dose anaemia vitamin b folic acid 12transmission eating raw cooked freshwater fish prevention individual cook fish thoroughly hymenolepiasis hymenolepis nana worldwideoften asymptomatic event heavy infection gastrointestinal disturbances epigastric pain laboratory eggs stoolspraziquantel po children 4 years adults 15 25 mgkg single dose transmission faecal oral route autoinfection prevention individual hand washing nail cutting collective hygiene sanitation water latrines etc apraziquantel may administered pregnant women solium taeniasis indications treatment usually deferred deliverypage 206 409parasites clinical featureslaboratory treatment transmissionprevention cysticercosis taenia solium worldwide laboratory hypereosinophilia blood cerebrospinal fluidmuscular asymptomatic myalgia subcutaneous nodules neurological neurocysticercosis headache convulsions coma etc ocular exophthalmia strabismus iritis etcneurological ocular cysticercosis managed specialized facilities antiparasitic treatment without diagnosis location computerirsed tomography andor magnetic resonance imaging worsen symptoms even threat life neurosurgical treatment requiredtransmission eating food contaminated solium eggs auto infection prevention individual treat solium carriers hygiene cook meat thoroughly hydatid cyst echinococcus granulosus south america north east south africa western europecysts located liver 60 cases lungs 30 cases less frequently sites including brain long asymptomatic period cyst becomes symptomatic complications develop biliary obstruction anaphylactic shock event rupture peritoneal cavity vessels organ febrile painful jaundice event rupture biliary tree etcfirstline treatment surgical excision albendazole po useful addition instead surgery children 2 years adults 60 kg 75 mgkg 2 times daily adults 60 kg 400 mg 2 times daily treatment duration addition surgery preoperatively post operatively continuous course minimum 2 months least two 28day courses drug free interval 14 days inoperable cases 28 day courses drug free intervals 14 days 3 6 months average possibly 1 year b transmission preventiondirect contact dogs indirect water food contaminated dog faeces individual avoid contact dogs collective eliminate stray dogs monitor slaughterhouses balbendazole contraindicated first trimester pregnancypage 207 409nematode infections page 208 409infectionepidemiology clinical featuresdiagnosis treatment ascariasis roundworms ascaris lumbricoides distribution worldwide mainly tropical subtropical transmission ingestion ascaris eggsaduring larval migration loeffler syndrome transient pulmonary symptoms dry cough dyspnoea wheezing mild fever adult worms present intestine abdominal pain distension general diagnosis made adult worms expelled anus occasionally mouth ascaris large 1530 cm cylindrical worms pinkishwhite slightly tapered ends complications ascariasis usually benign massive infestation may cause intestinal obstruction abdominal pain vomiting constipation especially children 5 years worms may accidentally migrate gall bladder liver peritoneum causing jaundice liver abscess peritonitis ascaris eggs may detected parasitological examination stoolsalbendazole po single dose children 6 months adults 400 mg 200 mg children 6 months 10 kg mebendazole po 3 days children 6 months adults 100 mg 2 times daily 50 mg 2 times daily children 6 months 10 kg trichuriasis whipworms trichuris trichiura distribution transmission lumbricoidesain heavy infection abdominal pain diarrhoea massive infection chronic bloody diarrhea tenesmus rectal prolapse due frequent attempts defecate especially children worms may sometimes seen rectal mucosa prolapsed grayish white 35 cm length shape whip thickened body long threadlike extremity trichuris eggs may detected parasitological examination stoolsalbendazole po 3 days children 6 months adults 400 mg daily 200 mg daily children 6 months 10 kg mebendazole po 3 days ascariasis single dose albendazole mebendazole often insufficient ankylostomiase ancylostoma duodenale necator americanus distribution tropical subtropical regions transmission larval skin penetration following contact feet hands contaminated soiladuring larval penetrationmigration cutaneous signs pruritic papulovesicular rash site penetration usually feet pulmonary symptoms similar ascariasis adult worms present intestine mild abdominal pain attachment parasite mucosa leads chronic blood loss anaemia endemic areas antihelminthic treatment recommended patients irondeficiency anaemia hookworm eggs may detected parasitological examination stoolsalbendazole single dose ascariasis much effective mebendazole single dose using mebendazole 3 day treatment ascariasis recommended treatment anaemia chapter 1 strongyloidiasis acute strongyloidiasis first line treatment ispage 209 409strongyloides stercoralis distribution humid tropical regions transmission larval skin penetration auto infectionduring larval penetrationmigration cutaneous signs erythema pruritus site penetration may persist several weeks pulmonary symptoms similar ascariasis larvae present intestine gastrointestinal symptoms bloating abdominal epigastric pain vomiting diarrhoea chronic strongyloidiasis intestinal larvae may reinfect host auto infection penetrating intestinal wall migrating transcutaneously perianal skin chronic infections result prolonged recurrent pulmonary gastrointestinal symptoms transcutaneous migration intestinal larvae gives rise typical rash larva currens mainly anal region trunk sinuous raised linear migrating lesion intensely pruritic moving rapidly 5 10 cmhour lasting several hours days complications hyperinfection massive infestation results exacerbation pulmonary gastrointestinal symptoms possible dissemination larvae atypical locations cns heart etc form occurs mainly patients receiving immunosuppressive therapy eg corticosteroids strongyloides larvae may detected parasitological examination stoolsivermectin po single dose children 15 kg adults 200 microgramskg empty stomach less effective 3day treatment albendazole po trichuriasis may alternative hyperinfections refractory conventional therapy prolonged intermittent multipledose regimens requiredb enterobiasis pinworms enterobius vermicularis distribution worldwide transmission faecaloral route autoinfectionanal pruritus intense night vulvovaginitis girls rare practice diagnosis often made worms seen perianal skin stool heavy infestation pinworms small 1 cm mobile white cylindrical worms slightly tapered ends pinworm eggs may collected anal area scotch tape method detected microscopealbendazole po single dose ascariasis mebendazole po single dose children 6 months adults 100 mg 50 mg children 6 months 10 kg second dose may given 2 4 weeks trichinellosis trichinella sp distribution worldwide particularly frequent asia thailand laos china etcenteric phase 1 2 days ingestion infected meat selflimited episode diarrhoea abdominal pain lasting several daysalbendazole po 10 15 days children 2 years 5 mgkg 2 times daily adultspage 210 409 roundworms whipworms hookworms frequently coinfect host taken account prescribing antihelminthic treatment migrating larvae ancylostoma braziliense caninum hookworms cats dogs also present pruritic inflammatory creeping eruption humans cutaneous larva migrans slower rate progression longer duration several weeks months treatment albendazole 400 mg single dose daily 3 days children 6 months adults 200 mg children 6 months 10 kg ivermectin 200 microgramskg single dosetransmission consumption raw undercooked meat containing trichinella larvae pork warthog bear dog etcmuscular phase 1 week ingestion high fever muscular pain ocular pain eye movement masseters limitation mouth opening throat neck pain swallowing speech trunk limbs facial bilateral periorbital oedema conjunctival haemorrhage subungual haemorrhage headache typical features always present patient may present nonspecific flulike syndrome features dietary habits consuming porkraw meat suggestive symptoms fever 39 c myalgia facial oedema several individuals shared meal eg ceremony hypereosinophilia 1000mm reinforce clinical suspicion3 definitive diagnosis muscle biopsy serology elisa western blot400 mg 2 times daily mebendazole po 10 15 days children 2 years 25 mgkg 2 times daily adults 200 mg 2 times daily plus regardless anti helminthic chosen prednisolone po 05 1 mgkg daily duration treatment bpage 211 409filariasis filariases helminthiases due tissuedwelling nematode worms filariae human human transmission takes place bite insect vector important pathogens outlined table mixed infections common coendemic regions filarial species found 2 principal developmental stages macrofilariae adult worms microfilariae larval offspring treatment depends pathogenic stage species considered targets microfilariae volvulus macrofilariae species classical antifilarial agents include diethylcarbamazine dec ivermectin albendazole doxycycline used solely treatment volvulus lymphatic filarial worms harbour endosymbiotic bacterium wolbachia sensitive doxycyclineonchocerciasis river blindness loiasis lymphatic filariasis lf speciesinfectionslocation macrofilariaelocation microfilariaepathogenic stagepresence wolbachia onchocerca volvulus onchocerciasissubcutaneous nodulesskin eye microfilariae yes loa loa loiasissubcutaneous tissueblood macrofilariae wuchereria bancrofti brugia malayi brugia timori lymphatic filariasislymph vessels blood macrofilariae yespage 212 409onchocerciasis river blindness distribution onchocerciasis linked vector simulium reproduces near rapidly flowing rivers intertropical africa 99 cases latin america guatemala mexico ecuador colombia venezuela brazil yemen clinical features endemic areas following signs alone combination suggestive onchocerciasis laboratory treatment antiparasitic treatmentonchocercomas painless subcutaneous nodules containing adult worms usually found bony prominence iliac crest trochanters sacrum rib cage skull etc measuring several mm cm size firm smooth round oval mobile adherent underlying tissue single multiple clustered acute papular onchodermatitis papular rash sometimes diffuse often confined buttocks lower extremities intensely itchy associated scratch marks often superinfected filarial scabies arises dermal invasion microfilariae late chronic skin lesions patchy depigmentation shins leopard skin skin atrophy areas dry thickened peeling skin lichenification lizard skin visual disturbances ocular lesions see onchocerciasis chapter 5 detection microfilariae skin skin snip biopsy iliac crest skin biopsy positive look loiasis regions loiasis coendemic mainly central africa diethylcarbamazine contraindicated risk severe ocular lesions doxycycline po 200 mg daily 4 weeks possible 6 weeks kills significant percentage adult worms progressively reduces number volvulus microfilariae contraindicated children 8 years pregnant breastfeeding women b ivermectin po drug choice 150 microgramskg single dose 2 dose administered 3 months clinical signs persist repeat treatment every 6 12 months maintain parasite load threshold clinical signs appear ivermectin recommended children 5 years 15 kg pregnant womennd c case coinfection loa loa regions loiasis coendemic ivermectin administered caution risk severe adverse reactions patients high l loa microfilarial load possible test loa loa thick blood film confirm quantify microfilaraemia administer appropriate treatment according microfilarial load see loiasis possible perform thick film examination take history patient patient received previous treatment ivermectin without developing serious adverse reactions see loiasis administer treatment patient never received ivermectin developed signs loiasis migration adult worm conjunctiva calabar swellings administer treatment patient already developed signs loiaisis onchocerciasis significant clinical impact administer ivermectin close supervision see loiasis use alternative doxycycline abovepage 213 409nodulectomy surgical removal onchocercomas nodules benign often deep ablation treat onchocerciasis thus nodulectomy reserved cranial nodules proximity eye risk factor visual compromise nodules cosmetically unacceptable cases refrain nodulectomy nodulectomy performed local anaesthesia appropriately equipped facility case concomitant lymphatic filariasis administer ivermectin first start treatment lymphatic filariasis doxycycline po see lymphatic filariasis one week later footnotes adifferential diagnosis sarcoptic scabies scabies chapter 4 belimination wolbachia reduces longevity fertility macrofilariae thus production new microfilariae within organism civermectin kills microfilariae disrupts production microfilariae adult worms however treatment must administered regular intervals since kill adult wormspage 214 409loiasis distribution loiasis linked vector chrysops forests savannah gallery forests west central africa limits west benin east uganda north sudan south angola clinical features laboratory treatment antiparasitic treatment 1 l loa microfilaraemia 10002000 mfml 28day treatment dec may started using small dose 6 mg d1 ie 18 50 mg tablet 2 times daily double dose every day 200 mg 2 times daily adults 15 mgkg 2 times daily children microfilaraemia symptoms persist second treatment given 4 weeks later dec contraindicated due possible confirmed coinfection volvulus ivermectin 150 microgamskg single dose treats onchocerciasis reduces pruritus frequency calabar swellings treatment may repeated every month every 3 months subconjunctival migration adult worm pathognomonic loa loa infection localised subcutaneous swellings allergic origin transient several hours days painless nonpitting appearing anywhere body frequently upper extremities face often associated localised generalised pruritus calabar swellings onset pruritus absence signs subcutaneous migration adult worm pruritic palpable red cordlike linear lesion sinuous advancing 1 cmhour disappearing rapidly trace migration generally arises following treatment diethylcarbamazine rarely spontaneously detection microfilariae peripheral blood thick film stained giemsa blood specimens collected 10 5 pm quantify microfilaraemia even diagnosis certain since treatment determined intensity parasite load thick film positive look onchocerciasis regions onchocerciasis coendemic mainly central africa diethylcarbamazine dec macrofilaricide available contraindicated patients microfilaraemia 2000 mfml risk severe encephalopathy poor prognosis patients coinfected volvulus risk severe eye lesions pregnant women infants patients poor general condition ivermectin possibly albendazole used reduce microfilaraemia administration dec however ivermectin administration may trigger encephalopathy patients high loa loa microfilaraemia 30 000 mfml doxycycline indicated since loa loa harbour wolbachia managementpage 215 4092 l loa microfilaraemia 2000 8000 mfml reduce microfilaraemia ivermectin 150 microgramskg single dose repeat treatment every month necessary administer dec microfilaraemia 2000 mfml 3 l loa microfilaraemia 8000 30000 mfml treatment ivermectin 150 microgramskg single dose may cause marked functional impairment several days close supervision support family members necessary prescribe paracetamol well 7 days 4 l loa microfilaraemia 30000 mfml extraction macrofilariae subcutaneous migration microfilaria usually results treatment dec worm die beneath skin extracting serves purpose removal adult worm conjunctiva see loasis chapter 5 b loiasis well tolerated preferable refrain treatment disease benign treatment ivermectin may cause severe adverse reactions encephalopathy albeit rarely loiasis significant clinical impact andor patient presents symptomatic onchocerciasis requiring treatment ivermectin 150 microgramskg single dose administered 5 days supervision hospital attempt first reduce l loa microfilaraemia using albendazole 200 mg 2 times daily 3 weeks option l loa microfilaraemia 30 000 mfml treat ivermectin close supervision support dec microfilaraemia 2000 mfml c footnotes afor differential diagnosis see cutaneous larva migrans bpatients may present various pain syndromes unable move without help unable move monitoring necessary determine whether patient manage activities daily living provide assistance necessary patient remains bedridden several days ensure pressure sores develop mobilisation repositioning ca severe reaction may occur d2d3 usually preceded haemorrhages palpebral conjunctiva d1d2 routinely check sign turning back eyelids symptoms post ivermectin encephalopathy reversible prognosis favourable patient correctly managed treatment symptomatic symptoms resolve avoid use steroids due adverse effectspage 216 409lymphatic filariasis lf distribution lf linked mosquito vectors anopheles culex aedes etc 90 lf due w bancrofti 10 brugia spp clinical features laboratory treatment antiparasitic treatmentw bancrofti subsaharan africa madagascar egypt india south east asia pacific region south america caribbean b malayi south east asia china india sri lanka b timori timor acute recurrent inflammatory manifestations adenolymphangitis lymph nodes red warm tender oedema along length lymphatic channel without systemic signs eg fever nausea vomiting inflammation may involve lower limbs external genitalia breast men acute inflammation spermatic cord funiculitis epididymis testicle epididymoorchitis attacks resolve spontaneously within week recur regularly patients chronic disease chronic manifestations lymphoedema oedema lower extremity external genitalia breast secondary obstruction lymphatics macrofilariae oedema reversible initially becomes chronic increasingly severe hypertrophy area affected progressive thickening skin fibrous thickening formation creases initially superficial deep verrucous lesions final stage lymphoedema elephantiasis men increase volume fluid due accumulation within tunica vaginalis hydrocoele lymphocoele chylocoele chronic epididymoorchitis chyluria milky ricewater urine disruption lymphatic vessel urinary tract patients parasitized brugia spp genital lesions chyluria rare lymphoedema usually confined knee detection microfilariae peripheral blood thick film blood specimens collected 9 pm 3 regions loiasis andor onchocerciasis coendemic check coinfection lf diagnosis positive treatment administered acute attack doxycycline po administered prolonged treatment eliminates majority macrofilariae reduces lymphoedema 200 mg daily 4 weeks minimum contraindicated children 8 years pregnant breastfeeding women diethylcarbamazine po single dose 400 mg adults 3 mgkg children may alternative eliminates variable proportion adult worms 40 relieve symptoms prolonged treatment effective single dose therapy addition dec contraindicated patients onchocerciasis loa loa microfilarial load 2000 mfml pregnant breastfeeding womenpage 217 409controlprevention inflammatory manifestations infectious complications surgery may indicated treatment chronic manifestations advanced lymphoedema diversionreconstruction hydrocoele complications chyluria ivermectin weak absent macrofilaricidal effect albendazole used treatment individual cases effect symptoms case confirmed probable coinfection volvulus treat onchocerciasis first administer doxycycline acute attacks bed rest elevation affected limb without bandaging cooling affected limb wet cloth cold bath analgesics antibacterial antifungal cream necessary antipyretics fever paracetamol hydration prevention episodes lymphangitis lymphoedema hygiene affected extremity comfortable footwear immediate attention secondary bacterialfungal infections wounds b established lymphoedema bandaging affected limb day elevation affected extremity removal bandage rest simple exercises flexionextension feet recumbent upright rotation ankles skin hygiene footnotes awhen test results negative clinically suspect case consider detection antigens ict rapid test andor ultrasound inguinal area search filarial dance sign bwash least daily soap water room temperature paying special attention folds interdigital areas rinse thoroughly dry clean cloth nail carepage 218 409chapter 7 bacterial diseases bacterial meningitis tetanus enteric typhoid paratyphoid fevers brucellosis plague leptospirosis relapsing fever borreliosis louseborne relapsing fever lbrf tickborne relapsing fever tbrf eruptive rickettsioses page 219 409bacterial meningitis meningitis acute bacterial infection meninges may affect brain lead irreversible neurological damage auditory impairment bacterial meningitis medical emergency treatment based early parenteral administration antibiotics penetrates well cerebrospinal fluid csf empiric antibiotic therapy administered pathogen cannot identified waiting laboratory results main bacteria responsible vary depending age andor context meningitis nonepidemic context l monocytogenes occasionally responsible meningitis period special conditions meningitis epidemic context sahelian region exclusively eg rwanda angola brazil dry season epidemics meningococcal meningitis neisseria meningitidis c w135 affect children 6 months age adolescents adults regions whether epidemics pathogens found especially young children clinical features clinical presentation depends patients age children 1 year adults children 1 year classic signs meningitis usually absentchildren 0 3 months children 7 days gramnegative bacilli klebsiella spp e coli marcescens pseudomona spp salmonella spp group b streptococcus children 7 days pneumoniae accounts 50 bacterial meningitis children 3 months5 years pneumoniae h influenza b n meningitidis children 5 years adults pneumoniae n meningitidis immunodepressed patients hiv malnourished high percentage gram negative bacilli specially salmonella spp also tuberculosis sickle cell anaemia salmonella spp staphylococcus aureus frequent causes meningitis may related aureus associated skin infection skull fracture fever severe headache photophobia neck stiffness brudzinskis sign neck flexion supine patient results involuntary flexion knees kernigs sign attempts extend knee flexedthigh position met strong passive resistance petechial ecchymotic purpura usually meningococcal infections severe forms coma seizures focal signs purpura fulminans child irritable appears sick fever hypothermia poor feeding vomiting features include seizures apnoea altered consciousness bulging fontanelle crying occasionally neck stiffness purpuric rashpage 220 409laboratory note endemic area essential test severe malaria rapid test thinthick films treatment nonepidemic context antibiotic therapy choice antibiotic therapy dosages according age see table lumbar puncture lp macroscopic examination csf antibiotic therapy initiated immediately lp yields turbid csf microscopic examination gram stain negative examination exclude diagnosis white blood cell count wbc epidemic context meningococcal aetiology confirmed need routine lp new cases pressure aspectwbc leucocytesmm3proteinother tests normal csf clear 5pandy 40 mgdl bacterial meningitis cloudy turbid10020 000 mainly neutrophiles neonates 20 immunocompromised wbc may 100pandy 100500 mgdlgram stain viral meningitisnormal clear10700 mainly lymphocytespandy tb meningitis clear yellowish 500 mainly lymphocytespandy afb cryptococcal meningitis clear 800 mainly lymphocytespandy india ink rapid test detection bacterial antigenspage 221 409 associated skin infectionassociated skin infection including umbilical cord infection first line alternative first line alternative 0 7 days 2 kgampicillin iv 100 mgkg every 12 hours cefotaxime iv 50 mgkg every 12 hoursampicillin iv 100 mgkg every 12 hours gentamicin iv 3 mgkg dailycloxacillin iv 50 mgkg every 12 hours cefotaxime iv 50 mgkg every 12 hourscloxacillin iv 50 mgkg every 12 hours gentamicin iv 3 mgkg daily 0 7 days 2 kgampicillin iv 100 mgkg every 8 hours cefotaxime iv 50 mgkg every 8 hoursampicillin iv 100 mgkg every 8 hours gentamicin iv 5 mgkg dailycloxacillin iv 50 mgkg every 8 hours cefotaxime iv 50 mgkg every 8 hourscloxacillin iv 50 mgkg every 8 hours gentamicin iv 5 mgkg daily 8 days 1 month 2 kgampicillin iv 100 mgkg every 8 hours cefotaxime iv 50 mgkg every 8 hoursampicillin iv 100 mgkg every 8 hours gentamicin iv 5 mgkg dailycloxacillin iv 50 mgkg every 6 hours cefotaxime iv 50 mgkg every 8 hourscloxacillin iv 50 mgkg every 6 hours gentamicin iv 5 mgkg daily 1 3 monthsampicillin iv 100 mgkg every 8 hours ceftriaxone iv 100 mgkg d1 starting d2 100 mgkg daily 50 mgkg every 12 hoursampicillin iv 100 mgkg every 8 hours gentamicin iv 25 mgkg every 8 hourscloxacillin iv 50 mgkg every 6 hours ceftriaxone iv 100 mgkg d1 starting d2 100 mgkg daily 50 mgkg every 12 hourscloxacillin iv 50 mgkg every 6 hours gentamicin iv 25 mgkg every 8 hourspage 222 409duration antibiotherapy 1 according pathogen 2 pathogen unknown additional treatment treatment epidemic context antibiotic therapy context n meningitidis likely pathogen 3 monthsceftriaxone iv children 100 mgkg d1 starting d2 100 mgkg daily 50 mgkg every 12 hours max 4 g dailycloxacillin iv children 40 kg 50 mgkg every 6 hours children 40 kg 2 g every 6 hours ceftriaxone iv children 100 mgkg d1 starting d2 100 mgkg daily 50 mgkg every 12 hours max 4 g daily adults ceftriaxone iv 4 g daily 2 g every 12 hourscloxacillin iv 2 g every 6 hours ceftriaxone iv 4 g daily 2 g every 12 hours haemophilus influenzae 7 days streptococcus pneumonia 1014 days group b streptococcus listeria 1421 days gramnegative bacilli 21 days neisseria meningitidis see antibiotherapy epidemic context children 3 months 2 weeks beyond first sterile csf culture 21 days children 3 months adults 10 days consider extending treatment alternative diagnoses fever persists beyond 10 days hand 7day course ceftriaxone sufficient patients making uncomplicated recovery dexamethasone reduces risk hearing loss patients h influenzae pneumoniae early administration indicated meningitis caused pathogens pathogen unknown except neonates presumed meningococcal meningitis epidemic context dexamethasone iv children 1 month 015 mgkg max 10 mg every 6 hours 2 4 days adults 10 mg every 6 hours 2 4 days treatment started first dose antibiotic otherwise treatment offers benefit 1 2 ensure patient well fed well hydrated infusions nasogastric tube necessary seizures chapter 1 coma prevention bed sores care mouth eyes etcpage 223 409note short treatment single dose ceftriaxone im used children 2 years older adults meningococcal meningitis epidemic 1 confirmed reliable laboratory 2 number cases exceeds management capacities 5day treatment check national recommendations nevertheless essential ensure monitoring cases 24 hours ceftriaxone im children 2 12 years 100 mgkg single dose children 12 years adults 4 g single dose clinical improvement fever 385 c repeated seizures appearance aggravation reduced level consciousness neurological signs 24 hours injection continue treatment ceftriaxone 5 days additional treatment referencesage treatment 3 children 2 monthsceftriaxone ivor im 7 days 100 mgkg daily b children 2 months adultsceftriaxone ivor im 5 days children 2 months 5 years 100 mgkg daily max 2 g daily children 5 years adults 2 g daily b athe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used bfor im administration divide dose 2 injections needed halfdose buttock ensure patient well fed well hydrated infusions nasogastric tube necessary seizures chapter 1 coma prevention bed sores care mouth eyes etc dexamethasone indicated footnotes afor im administration divide dose 2 injections needed halfdose buttock 1d van de beek c cabellos dzupova esposito klein kloek l leib b mourvillier c ostergaard p pagliano hw pfister r c read resat sipahi mc brouwer escmid guideline diagnosis treatment acute bacterial meningitis 2016 httpswwwclinicalmicrobiologyandinfectioncomarticles1198743x16000203pdf 2sheldon l kaplan md bacterial meningitis children dexamethasone measures prevent neurologic complications uptodate accessed 25 february 2019 3world health organization managing meningitis epidemics africa quick reference guide health authorities healthcare workers 2015 httpsappswhointirisbitstreamhandle10665154595who_hse_gar_eri_20104_rev1_engpdfsequence1page 224 409tetanus last updated august 2022 tetanus severe infection due bacillus clostridium tetani found soil human animal waste infection noncontagious clostridium tetani introduced body wound produces toxin whose action central nervous system responsible symptoms tetanus tetanus entirely preventable vaccination occurs people fully vaccinated exposure received adequate postexposure prophylaxis individuals breaks skin mucous membranes carry risk tetanus wounds greatest risk stump umbilical cord neonates puncture wounds wounds tissue loss contamination foreign material soil avulsion crush injuries sites nonsterile injections chronic wounds eg lower extremity ulcers burns bites surgical obstetrical procedures performed nonsterile conditions also carry risk tetanus clinical features generalised tetanus frequent severe form infection presents muscular rigidity progresses rapidly involve entire body muscle spasms painful level consciousness altered children adults neonates treatment hospitalisation needed usually lasts 3 4 weeks correct management reduce mortality even hospitals limited resources general measuresaverage time exposure onset symptoms 7 days 3 21 days muscular rigidity begins jaw muscles difficulty inability open mouth trismus preventing patient speaking eating spreading face fixed smile neck difficulty swallowing trunk restriction respiratory muscles hyperextension spine opisthotonus abdomen guarding limbs flexion upper limbs extension lower limbs muscle spasms painful appear onset muscular rigidity becomes generalised triggered stimuli noise light touch arise spontaneously spasms thoracic laryngeal muscles may cause respiratory distress aspiration 90 cases initial symptoms appear within 3 14 days birth first signs significant irritability difficulty sucking rigidity lips trismus rigidity becomes generalised adults neonate initially sucked cried normally presenting irritability difficulty sucking 3 28 days birth demonstrating rigidity muscle spasms assumed neonatal tetanus ensure intensive nursing care patient dark quiet room blindfold neonates cloth bandagepage 225 409neutralisation toxin human tetanus immunoglobulin im neonates children adults 500 iu single dose injected 2 separate sites inhibition toxin production metronidazoleiv infusion 30 minutes 60 minutes neonates 7 days control rigidity spasms sedation patient diazepam decrease frequency intensity spams without causing respiratory depression dose frequency administration depend patients clinical response tolerance handle patient carefully sedated little possible change position every 3 4 hours avoid bedsores teach family danger signs instruct call nurse slightest respiratory symptom cough difficulty breathing apnoea excessive secretions cyanosis etc establish iv access hydration iv injections gentle suction secretions mouth oropharynx insert nasogastric tube hydration feeding administration oral medications provide hydration nutrition feeds divided 24 hours neonates give expressed breast milk every 3 hours risk hypoglycaemia neonates 0 7 days 15 mgkg d1 24 hours 75 mgkg every 12 hours 8 days 1 month 2 kg doses 8 days 1 month 2 kg 15 mgkg every 12 hours children 1 month 10 mgkg every 8 hours max 1500 mg daily adults 500 mg every 8 hours high risk respiratory depression hypotension using diazepam especially children elderly patients constant close monitoring patients respiratory rate rr oxygen saturation spo essential immediate availability equipment manual ventilation ambu bag face mask intubation suction electric possible ringer lactate2 continuous iv infusion diazepam requires use dedicated vein infusioninjection vein avoid antecubital fossa possible stop treatment abruptly abrupt stop cause spasmspage 226 409count volume infusion diazepam part patients daily fluid intake neonates diazepam emulsion injection 10 mg ampoule 5 mgml 2 ml example neonate weighing 3 kg administration electric syringe 01 mgkghour x 3 kg 03 mghour dilute one 10 mg ampoule diazepam emulsion injection 50 ml 10 glucose obtain solution containing 02 mg diazepam per ml administer 15 mlhour dose mghour dilution mgml dose mlhour ie 03 mghour 02 mgml 15 mlhour electric syringe available diluting diazepam emulsion infusion bag continuous infusion may considered weigh risks associated mode administration accidental bolus insufficient dose infusion monitored closely avoid change however small prescribed rate01 03 mgkg slow iv injection 3 5 minutes every 1 4 hours depending severity persistence spasms long rr 30 despite hourly diazepam spasms persist start continuous infusion diazepam electric syringe 01 05 mgkghour 24 12 mgkg every 24 hours start 01 mgkghour symptoms persist increase 01 mgkghour long rr 30 spite 05 mgkghour symptoms persist dose increased 08 mgkghour long rr 30 diluted diazepam emulsion keep 6 hours children 1 month adultssame doses protocol neonates examplesuse diazepam solution injection 5 mgml 10 mg ampoule 5 mgml 2 ml doses administered long rr 30 children 1 year 25 children 1 4 years 20 children 5 12 years 14 children 12 years 12 adults child weighing 6 kg continuous iv infusion using pediatric infusion set 1 ml 60 drops 01 mgkghour x 6 kg 06 mghour dilute one 10 mg ampoule diazepam solution injection 50 ml 5 glucose 10 glucose child 3 months obtain solution containing 02 mg diazepam per ml administer 3 mlhour dose mghour dilution mgml dose mlhour ie 06 mghour 02 mgml 3 mlhour 3 dropsminute paediatric infusion set mlhour dropsminute adult weighing 60 kg standard adult infusion set 1 ml 20 drops 01 mgkghour x 60 kg 6 mghour dilute 5 ampoules 10 mg diazepam solution 50 mg 250 ml 09 sodium chloride 5 glucose obtain solution containing 02 mg diazepam per ml administer 30 mlhour dose mghour dilution mgml dose mlhour eg 6 mghour 05 mgml 30 mlhour 10 dropsminute aadminister first dose rectally iv cannot placed immediatelypage 227 409when frequency severity spasms decreased start weaning diazepam gradually decrease rate infusion notes treatment pain morphine po via nasogastric tube necessary see pain chapter 1 morphine administered diazepam risk respiratory depression increased thus closer monitoring required morphine longer required wean way diazepam treatment entry point associated infections tetanus vaccination tetanus confer immunity vaccination tetanus must administered patient recovered case neonatal tetanus initiate vaccination mother prevention critical importance given difficulty treating tetanus established 1 postexposure prophylaxiscalculate total daily dose iv diazepam administer orally 4 divided doses 6 hours apart via nasogastric ngtube b give first ng dose decrease rate iv infusion 50 give second ng dose stop iv diazepam infusion withdrawal signsappear wean slowly c diazepam po wean 10 20 original dose daily dose 005 mgkg every 6 hours increase interval every 6 hours every 8 hours 24 hours tolerated wean slowly withdrawal signs appear continue increase interval doses every 8 hours every 12 hours every 24 hours stopping diazepam step 24 hours withdrawal signs appear often smaller doses difficult wean diazepam case slow wean dropping wean eg 5 wean every 24 hours instead 10 wean increasing interval weans eg going every 24 hours every 48 hours patient also receiving morphine wean diazepam first wean morphine nonpharmacological measures reduce withdrawal reduce environmental stimuli swaddle infants frequent feedings infants tetanus remain hypertonic even longer spams search systematically entry wound provide local treatment sedation cleansing deep wounds irrigation debridement cord infection excise debride treat bacterial omphalitis sepsis add metronidazole iv cloxacillin iv cefotaxime iv cloxacillin iv gentamicin iv doses see bacterial meningitis cases cleansing disinfection wound removal foreign body antibiotics prescribed routinely prophylaxis decision administer antibiotic metronidazole penicillin made casebycase basis according patients clinical statuspage 228 409 tetanus vaccine im children adults 05 ml per dose vaccination unknown vaccination status administer least 2 doses interval 4 weeks incomplete vaccination administer one dose ensure longlasting protection administer additional doses complete total 5 doses indicated table human antitetanus immunoglobulin im children adults 250 iu single dose 500 iu wounds 24 hours old inject vaccine immunoglobulin 2 different sites using separate syringe 2 routine vaccination preexposure prophylaxisdepending preexposure vaccination status tetanus vaccine tv immunoglobulin see indications type woundcomplete vaccination 3 doses time since administration last doseincomplete vaccination less 3 doses vaccination unknown status 5 years 510 years 10 years minor clean none nonetv 1 booster doseinitiate complete tv nonetv 1 booster dosetv 1 booster doseinitiate complete tv administer tetanus immunoglobulin children 6 doses total first series 3 doses dtp dtp hepb dtp hepb hib age 1 year administered interval 1 month eg age 6 10 14 weeks dose vaccine containing tetanus toxoid age 12 23 months dose age 4 7 years dose age 12 15 years women childbearing age 5 doses reproductive years series 3 doses td interval least one month first second dose interval least 6 months second third dose two doses minimum interval one year eg pregnancies see table pregnant women woman never vaccinated vaccination status unknown 2 doses tdduring pregnancy reduce risk tetanus mother neonate first soon possible pregnancy second least 4 weeks later least 2 weeks delivery vaccination schedule protects 80 neonates tetanus single dose offers protection page 229 409 dose vaccination schedule adults degree duration protection tv1on first contact health care system soon possible pregnancyno protection tv2 least 4 weeks tv180 1 3 years tv36 months 1 year tv2 following pregnancy95 5 years tv41 5 years tv3 following pregnancy99 10 years tv51 10 years tv4 following pregnancy99 throughout reproductive years footnotes aclindamycin iv 7 days alternative doses see periorbital orbital cellulitis chapter 5 badministration oral diazepam tablets infants calculate exact dose diazepam eg obtain 05 mg diazepam cut scored diazepam 2 mg tablet half along scoring split half crush quarter tablet dissolve expressed breast milk infant formula cwithdrawal signs excessive irritability tremors increased muscle tone frequent yawning poor feeding watery stools sweating dtetanuscontaining vaccine td dtp dtp hepb dtp hepb hib according availability patients agepage 230 409enteric typhoid paratyphoid fevers last updated march 2024 enteric fevers include typhoid fever due salmonella enterica serotype typhi typhi paratyphoid fever due salmonella enterica serotype paratyphi b c paratyphi enteric fevers acquired ingestion water food contaminated excreta symptomatic asymptomatic carriers direct contact dirty hands enteric fevers endemic south central southeast asia subsaharan africa oceania lesser extent latin america effective treatment significantly reduces risk complications death clinical features clinical manifestations typhoid paratyphoid fevers enteric fevers insidious onset vary mild severe clinical diagnosis difficult enteric fevers resembles infections present regions endemic main differential diagnoses malaria brucellosis leptospirosis typhus rickettsiosis sepsis dengue laboratory treatment casesthe characteristic sign prolonged fever gradually increases first week plateaus second week decreases third fourth week nonspecific signs symptoms frequently associated gastrointestinal disturbances abdominal pain constipation diarrhoea vomiting headache malaise chills fatigue non productive cough andor hepatosplenomegaly erythematous maculopapular rash trunk extreme fatigue andor relative bradycardia heart ratetemperature dissociation may present serious complications affect 27 hospitalised patientsand usually occur second third week illness may incude decreased level consciousness intestinal haemorrhage perforation peritonitis shock nephritis pregnant women severe infection may lead foetal complications miscarriage preterm delivery intrauterine death 1 relapse may occur 2 3 weeks recovery usually due antibiotic resistance retreatment required culture typhi paratyphi drug susceptibility test blood stool specimens cases rapid test malaria endemic regions antimalarial treatment needed see malaria chapter 6 widal agglutination test serologic tests rapid diagnostic tests recommended low sensitivity specificity hydrate treat fever chapter 1 fever usually resolves 4 5 days starting effective antibiotic treatment choice antibiotic treatment depends susceptibility strain susceptibility unknown recent data susceptibility strains region check national recommendations informationpage 231 409uncomplicated cases outpatients uncomplicated cases vast majority cases treated oral antibiotic treatment severe cases inpatients cases treated close monitoring antibiotic treatment initially parenteral oral decreasing fever clinical improvement patient tolerate oral treatment additional measures preventionstrains resistant chloramphenicol ampicillinamoxicillin cotrimoxazole multidrugresistant mdr strains present parts world ciprofloxacin used firstline treatment countries however fluoroquinolone resistance endemic asia increasing several parts world 2 ceftriaxone resistance identified several regions 2 mdr strains also resistant fluoroquinolones thirdgeneration cephalosporins extensively drugresistant xdr strains developed 3 firstline antibiotics azithromycin po 7 days including mdr xdr cases pregnant women children 10 20 mgkg max 1 g daily adults 500 mg 1 g daily 1 g d1 500 mg daily cefixime po 10 14 days except thirdgeneration cephalosporin resistance xdr cases children 10 mgkg max 200 mg 2 times daily adults 200 mg 2 times daily alternatives include recent data show susceptibility strains antibiotics region amoxicillin po 14 days children 30 mgkg max 1 g 3 times daily adults 1 g 3 times daily cotrimoxazole po 14 days children 20 mg smx 4 mg tmpkg max 800 mg smx 160 mg tmp 2 times daily adults 800 mg smx 160 mg tmp 2 times daily severe cases include toxic appearance decreased level consciousness medical surgical complication oral administration possible due persistent vomiting start ceftriaxone ivincluding pregnant women children 50 100 mgkg max 4 g daily adults 2 g daily 2 times daily change azithromycin po complete least 7 days treatment suspected confirmed ceftriaxone resistance xdr stains use meropenem iv including pregnant women change azithromycin po complete least 7 days treatment case decreased level consciousness shock dexamethasone iv loading dose 1 mgkg followed 025 mgkg every 6 hours 48 hours total 8 doses treat intensive care unit patients shock significant intestinal haemorrhage suspected perforationperitonitis suspected perforationperitonitis get urgent surgical review add metronidazole ceftriaxone anaerobic bacterial coverage b page 232 409 referenceshygiene measures common diarrhoeas handwashing consumption treated water chlorinated boiled bottled etc washingcooking food etc hospitals patients watery diarrhoea consider disinfection excreta chlorinated solution stools collected buckets vaccination typhoid conjugate vaccine endemic regions vaccine used control typhoid outbreaks protect paratyphoid fever c footnotes athe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used bdo add metronidazole patient receives meropenem meropenem already covers anaerobic bacteria cfor information see typhoid vaccines position paper httpappswhointirisbitstreamhandle10665272272wer9313pdfua1 1cruz espinoza lm mccreedy e holm et al occurrence typhoid fever complications relation duration illness preceding hospitalization systematic literature review metaanalysis clin infect dis 201969suppl 6s43548 httpswwwncbinlmnihgovpmcarticlespmc6821330 accessed 28 june 2022 2browne aj hamadani bhk kumaran eap rao p et al drugresistant enteric fever worldwide 1990 2018 systematic review metaanalysis bmc medicine 202018122 httpsdoiorg101186s1291601914431 accessed 23 february 2022 3klemm ej shakoor page aj qamar fn et al emergence extensively drugresistant salmonella enterica serovar typhi clone harboring promiscuous plasmid encoding resistance fluoroquinolones thirdgeneration cephalosporins mbio 2018 janfeb 91 e0010518 httpswwwncbinlmnihgovpmcarticlespmc5821095 accessed 26 june 2022page 233 409brucellosis last updated september 2022 brucellosis zoonosis mainly affects livestock animals main routes transmission humans brucellosis caused bacteria genus brucella particularly b melitensis sheep goats b abortus cattle b suis pigs disease found worldwide mainly rural areas primary infection relapses may occur 5 15 cases even months end initial treatment infection may become chronic clinical features acute form primary infection diagnosis difficult broad spectrum fluctuating nonspecific clinical manifestations patients unexplained fever brucellosis considered risk factors present consumption unpasteurized milk products exposure livestock eg livestock farmers veterinarians butchers slaughterhouse workers localised form primary infection may progress localised infection even several months years later mainly paraclinical investigations laboratorydigestive ingestion unpasteurized milk unpasteurized milk products infected animal cutaneous direct contact infected animals carcasses infected animals remittent intermittent fever 3940 c associated several signs symptoms chills night sweats joint muscle pain weight loss fatigue malaise headache adenopathies particularly children may associated nonspecific gastrointestinal disorders cough hepato andor splenomegaly arthritis knee orchitis osteoarticular sacroiliac joint often particularly lower limbs joints spine intervertebral disk infection vertebral osteomyelitis genitourinary orchitis epididymitis pulmonary bronchitis pneumonia pleurisy neurological meningitis encephalitis polyneuritis blood culture gold standard diagnosis positive acute phase bacteria grow slowly 7 21 days serological tests rose bengal wright agglutination test indirect immunofluorescence elisa etc provide presumptive diagnoses event neurological signs meningitis lumbar puncture shows clear cerebrospinal fluid csf may contain high white blood cell count high protein concentration csf low csf glucose rule malaria endemic regions rapid test exclude tuberculosis cough 2 weeks sputum smear microscopypage 234 409radiography treatment check national recommendations antibiotic therapy information cotrimoxazole po 6 weeks children 8 years 20 mg smx 4 mg tmpkg max 800 mg smx 160 mg tmp 2 times daily doxycycline po 6 weeks children 8 years 45 kg 2 22 mgkg max 100 mg 2 times daily children 45 kg adults 100 mg 2 times daily rifampicin po 6 weeks children 15 20 mgkg max 600 mg daily adults 600 900 mg daily gentamicin im 2 weeks children adults 5 mgkg daily streptomycin im 2 weeks adults 1 g daily localised forms infection treatment period 6 weeks 4 months depending focus preventionjoint pain hips knees ankles vertebrae sacroiliac joint small erosions destruction joint space narrowing often involves spine particularly lumbar spine causing spondylodiskitis pulmonary signs chest xray often normal may consolidation nodules lymphadenopathy pleural effusion children 8 yearscotrimoxazole rifampicin cotrimoxazole gentamicin children 8 years overdoxycycline rifampicin doxycycline gentamicin adultsdoxycycline rifampicin doxycycline streptomycin gentamicin pregnantbreastfeeding women rifampicin washing hands clothing contact animals boil milk avoid ingestion unpasteurized milk products cook offal thoroughlypage 235 409plague last updated september 2022 plague zoonosis caused gramnegative bacillus yersinia pestis affects many wild domestic mammals particularly rodents plague transmitted man infected animals direct contact inhalation respiratory secretions bite flea infected animals inhalation respiratory secretions individuals pneumonic plague natural foci infection include africa asia north south america parts europe bubonic plague common form usually resulting bite infected flea without prompt treatment bacteria may disseminated haematogenous route producing severe form see high mortality rate following forms plague may primary secondary bubonic plague clinical features see table main differential diagnoses include laboratory managementpneumonic plague rapidly progress respiratory distress shock death without prompt treatment septicaemic plague fulminant illness progress disseminated intravascular coagulation respiratory distress shock death plague meningitis rare severe form plague causes lymphadenitis eg bacterial skin infections tularemia lymphogranuloma venereum chancroid acute pneumonia chapter 2 causes septicaemia see shock chapter 1 meningitis see bacterial meningitis chapter 7 collect pretreatment specimens lymph node aspirate bubonic plague sputum pneumonic plague blood septicaemic plague cerebrospinal fluid plague meningitis send specimensto reference laboratory rapid diagnostic test detection f1 capsular antigen pestis pcr culture pestis drug suceptibility test cases rapid test malaria endemic regions antimalarial treatment needed see malaria chapter 6 start empiric antibiotic treatment 10 14 days soon plague suspected results diagnosis tests available combination 2 antibiotics different classes recommended severe disease plague meningitis pregnant women follow national recommendations according antibiotic resistance patterns known information see table belowpage 236 409treatment suspected casespage 237 409forms plague clinical features antibiotic treatment 1 bubonic fever chills malaise headache lymph node bubo painful usually inguinal one children including 8 years adults doxycycline po gentamicin im iv ciprofloxacin pounder 45 kg 44 mgkg max 200 mg d1 22 mgkg max 100 mg 2 times daily 45 kg 200 mg d1 100 mg 2 times daily children 45 75 mgkg daily adults 5 mgkg daily children 15 mgkg 2 3 times daily max 750 mg 2 times daily 500 mg 3 times daily adults 750 mg 2 times daily pneumonic fever chills malaise headache dyspnea chest pain productive cough purulent bloodstained sputum respiratory distress failure sepsis severe advanced untreated diseasechildren adults mild disease gentamicin im ivas ciprofloxacin po iv severe disease gentamicin ciprofloxacin available gentamicin doxycycline clinical improvement change ciprofloxacin doxycycline po b septicaemic frequently localizing symptoms signs gastrointestinal disturbances abdominal pain vomiting diarrhoea etc often presentas severe pneumonic plague meningitis csigns meningitis children adults chloramphenicol iv ciprofloxacin po iv available gentamicin ciprofloxacin abovechildren 1 12 years 25 mgkg max 1 g every 8 hours children 13 years adults 1 g every 8 hourspage 238 409treatment pregnant women infection prevention control hospitals postexposure prophylaxis contacts event contact distance less 2 meters without appropriate personal protective equipment pneumonic plague patient direct contact infected body fluids tissues plague patient within one week end exposure doxycycline po 7 days children 22 mgkg max 100 mg 2 times daily adults including pregnant women 100 mg 2 times daily ciprofloxacin po 7 days children 20 mgkg max 750 mg 2 times daily adults 500 750 mg 2 times daily pregnant women 500 mg 3 times daily prevention astreptomycin im may alternative gentamicin except pregnant women children 15 mgkg max 1 g every 12 hours adults 1 g every 12 hours buse ciprofloxacin iv oral route possible children 10 mgkg max 400 mg every 8 12 hours adults 400 mg every 8 hours cif plague meningitis develops add chloramphenicol existing regimen continue combined regimen additional 10 days bubonic pneumonic septicaemic plague gentamicin im iv ciprofloxacin po 500 mg 3 times daily iv plague meningitis chloramphenicol iv ciprofloxacin po 500 mg 3 times daily iv bubonic plague isolation standard precautions handwashing gowns gloves eye protection etc respect lymph node aspiration discharge body fluids pneumonic plague isolation single room possible standard precautions plus 48 hours start antibiotic treatment droplet precautions medical mask healthcare workers patients contact aerosolgenerating procedures airborne precautions ffp2 n95 respirators health workers exposed aerosols elimination fleas eg bedding clothing corpse refer guide public health engineering msf flea vector control sanitation rodent reservoir control refer guide public health engineering msf vaccination plague indicated laboratory technicians handling rodents working pestis method controlling epidemic footnotes atransportation specimens 09 sodium chloride requires cold chain failing temperature 30 c triple packaging un3373 labelpage 239 409references 1nelson ca meaneydelman fleckderderian cooley km et al antimicrobial treatment prophylaxis plague recommendations naturally acquired infection bioterrorism response mmwr recomm rep 202170no rr3127 httpswwwcdcgovmmwrvolumes70rrrr7003a1htms_cidrr7003a1_w accessed 25 january 2022page 240 409leptospirosis last update october 2022 leptospirosis zoonosis affects many domestic wild animals mainly rodents particularly rats also dogs cattle etc transmitted humans contact skin lesions mucous membranes eg eyes mouth caused bacteria spirochetes genus leptospira leptospirosis occurs worldwide particularly tropical subtropical regions often outbreaks heavy rainfall flooding clinical features approximately 90 cases asymptomatic mild favourable outcome 5 15 cases present severe form multiple organ dysfunction high mortality rate without prompt treatment mild form severe icterohaemorrhagic form onset days later symptoms worsen renal disorders oliguria polyuria hepatic disorder jaundice widespread haemorrhages purpura ecchymoses epistaxis haemoptysis etc pulmonary signs chest pain cardiac signs myocarditis pericarditis conditions consider include wide range acute febrile illnesses eg freshwater moist soil contaminated urine infected animal indirect contact urine blood body fluids tissues infected animal direct contact acute phase septicaemic sudden onset high fever chills headache myalgia especially calf lumbar pain photophobia ocular pain bilateral conjunctival suffusion affecting bulbar conjunctiva redness without discharge characteristic sign always present may associated gastrointestinal symptoms anorexia abdominal pain nausea vomiting non productive cough lymphadenopathy hepatomegaly sometimes skin rash immune phase signs acute phase regress 5 7 days reappear days usually milder form milder fever less severe myalgia disappear signs meningitis thought immune origin however common phase diagnosis difficult broad spectrum clinical manifestations patients present following considered suspected cases leptospirosis 1 abrupt onset fever chills conjunctival suffusion headache myalgia jaundice one risk factors infection exposure contaminated freshwater eg swimming fishing rice fields flooding infected animals eg crop livestock farmers veterinarians butchers slaughterhouse workers viral haemorrhagic fevers dengue chikungunya zika influenza measles viral hepatitis causes meningitispage 241 409laboratory diagnosis investigations available treatment start empiric antibiotic treatment soon leptospirosis suspected results diagnosis tests available mild form outpatients symptomatic treatment antibiotic treatment children 45 kg 2 22 mgkg max 100 mg 2 times daily children 45 kg adults 100 mg 2 times daily particularly pregnant women children 10 mgkg max 500 mg d1 5 mgkg max 250 mg daily d2 d3 adults 1 g d1 500 mg daily d2 d3 available children 25 mgkg max 1 g 2 times daily adults 1 g 2 times daily antibiotic treatment trigger jarischherxheimer reaction high fever chills fall blood pressure sometimes shock recommended monitor patient 2 hours first dose antibiotic occurrence management severe jarischherxheimer reaction symptomatic treatment shock severe form inpatients symptomatic treatmentmalaria typhoid fever brucellosis rickettsioses collect pretreatment specimens send reference laboratory acute phase first week illness blood andor serum igm screening pcr acute specimen microscopic agglutination test mat immune phase second week illness serum igm screening convalescent specimen mat urine pcr cases rapid test malaria endemic regions antimalarial treatment needed see malaria chapter 6 serum creatinine elevated renal dysfunction full blood count possible neutrophilia thrombocytopenia acute phase anaemia secondary haemorrhage immune phase cerebrospinal fluid immune phase features aseptic meningitis csf see viral meningitis chapter 7 urine mild proteinuria leukocyturia possible microscopic haematuria acute phase rest treatment pain fever paracetamol po chapter 1 acetylsalicylic acid aspirin contraindicated risk haemorrhage doxycycline po 7 days azithromycin po 3 days amoxicillin po 7 days page 242 409 antibiotic treatment children 80 100 mgkg max 2 g daily adults 2 g daily children 50 000 iu 30 mgkg max 2 miu 1200 mg every 6 hours adults 1 2 miu 600 1200 mg every 6 hours prevention referencesspecific management according organs affected oliguria generally responds correction hypovolaemia rest treatment pain fever paracetamol po chapter 1 avoid use paracetamol caution patients hepatic involvement ceftriaxone iv 7 days benzylpenicillin iv 7 days avoid bathing freshwater endemic areas disinfect laundry objects soiled urine infected animal patient vaccination protective clothing professionals risk exposure footnotes afor iv administration ceftriaxone dilute water injection 1world health organization human leptospirosis guidance diagnosis surveillance control world health organization 2003 httpsappswhointirisbitstreamhandle1066542667who_cds_csr_eph_200223pdf20sequence1isallowedy accessed 5 september 2022page 243 409relapsing fever borreliosis relapsing fever fr caused spirochetes genus borrelia transmitted humans arthropod vectorslouseborne relapsing fever lbrf tickborne relapsing fever tbrfpage 244 409louseborne relapsing fever lbrf last updated october 2022 lbrf caused borrelia recurrentis occurs epidemic waves conditions favourable transmission body lice met cold climateseason overcrowding poor sanitation eg refugee camps prisons endemic foci lbrf mainly sudan horn africa especially ethiopia lbrf associated louse borne typhus see eruptive rickettsioses mortality rate untreated lbrf ranges 15 40 clinical features practice applicable epidemiological setting see suspect case lbrf according patient high fever two following symptoms severe joint pain chills jaundice signs bleeding nose bleeding patient high fever responding poorly antimalarial drugs clothing checked presence body lice nits laboratory diagnosis confirmed detection borrelia thick thin blood films giemsa stain blood samples must collected febrile periods spirochetes found peripheral blood afebrile periods addition number circulating spirochetes tends decrease febrile episode treatmentrelapsing fever characterized febrile episodes separated afebrile periods approximately 7 days 4 14 days initial febrile episode lasts 6 days sudden onset high fever axillary temperature 39 c severe headache asthenia diffuse pain muscle joint back pain often associated gastrointestinal disturbances anorexia abdominal pain vomiting diarrhoea splenomegaly common bleeding signs eg petechiae subconjunctival haemorrhage epistaxis bleeding gums jaundice neurological symptoms may observed febrile episode terminates crisis elevation temperature heart rate blood pressure followed fall temperature blood pressure may last several hours following initial febrile episode cycle usually reccurs episode less severe previous one patient develops temporary immunity complications collapse defervescence myocarditis cerebral haemorrhage pregnancy abortion preterm delivery utero foetal death neonatal death antibiotic treatment suspect confirmed cases close contacts doxycycline po children 4 mgkg max 100 mg single dose adults 200 mg single dose erythromycin po children 5 years 250 mg single dose children 5 years adults 500 mg single dosepage 245 409or azithromycin po children 10 mgkg max 500 mg single dose adults 500 mg single dose treatment pain fever paracetamol po prevention treatment dehydration event associated diarrhoea elimination body lice essential control epidemics see pediculosis chapter 4page 246 409tickborne relapsing fever tbrf last update october 2022 tbrfs caused different borrelia species endemic temperate warm regions word especially africa tanzania drc senegal mauritania mali horn africa mainly rural areas tbrf major cause morbidity mortality children pregnant women mortality rate untreated tbrf ranges 2 15 clinical features clinical manifestations complications tbrf similar lbrf central nervous system cns involvement particularly lymphocytic meningitis frequent lbrf number relapses higher clinical diagnosis difficult especially first episode cases occur sporadically rather outbreaks tick bite painless usually unnoticed patient symptoms similar malaria typhoid fever leptospirosis certain arbovirosis yellow fever dengue rickettsiosis meningitis laboratory treatment children 45 kg 22 mgkg max 100 mg 2 times daily children 45 kg adults 100 mg 2 times daily azithromycin po 7 10 days doxycycline contraindicated available children 10 mgkg max 500 mg daily adults 500 mg daily ceftriaxone ivfor 10 14 days pregnant women case cns involvement children 50 75 mgkg max 2 g daily adults 2 g daily antibiotic treatment trigger jarischherxheimer reaction high fever chills fall blood pressure sometimes shock recommended monitor patient 2 hours first dose antibiotic occurrence management severe jarischherxheimer reaction symptomatic treatment shock jarischherxheimer reaction appears occur frequently lbrf tbrf lbrf diagnosis confirmed detection borrelia patients blood repeat examination first smear negative despite strong clinical suspicion cases rapid test malaria endemic regions antimalarial treatment needed see malaria chapter 6 antibiotic treatment doxycycline po 7 10 days treatment pain fever paracetamol po prevention treatment dehydration event associated diarrhoea page 247 409footnotes afor iv administration ceftriaxone dilute water injection onlypage 248 409eruptive rickettsioses last update october 2022 rickettsioses eruptive fevers caused bacteria genus rickettsia transmitted man arthropod vector three main groups distinguished typhus group spotted fever group scrub typhus group clinical features common forms sudden onset fever temperature 39 c severe headache myalgias 3 5 days later onset generalised cutaneous eruption see hypotension nondissociated rapid heart rate variable typhoid state prostration obnubilation confusion extreme asthenia particularly marked typhus forms inoculation eschar painless black crusted lesion surrounded erythematous halo site bite always check significant sign noncutaneous signs vary one form another atypical variable see belowpage 249 409 laboratory detection specific igm group indirect immunofluorescence diagnosis confirmed 2 serological tests interval 10 days practice clinical signs epidemiological context sufficient suggest diagnosis start treatmentgroup typhus spotted fever scrub typhus form epidemic typhusmurine typhusmediterranean spotted feverrocky mountain spotted feverother old world tick borne feversscrub typhus pathogen r prowasekii r typhi r conorii r rickettsii r sibirica r australiso tsutsugamushi vector body lice rat fleas ticks ticks ticks mites reservoir man rats dogs rodents rodents dogs etcrodents occurence epidemic endemic endemic endemic endemic sporadic geographical distributionworldwide conflicts main sites burundirwanda ethiopiaworldwide around mediterranean subsaharan africanorth america central america columbia brazilsouthern africa australia siberiafar east india south pacific area rash maculopapularmaculopapularmaculopapular purpural maculopapular macular eschar 0 0 black necrotic arearare black necrotic areablack necrotic area typhoid state extra cutaneous signscough myalgia meningeal signsgastrointestinal signsmeningeal signsgastrointestinal neurological signs hypotensionvariables meningeal signs case fatality 30 without treatment5 2 5 1 030 complications severe sometimes fatal encephalitis myocarditis hepatitis acute renal failure haemorrhage etcpage 250 409treatment children 45 kg 22 mgkg max 100 mg 2 times daily children 45 kg adults 100 mg 2 times daily severe infections loading dose doxycycline recommended children 45 kg 44 mgkg max 200 mg d1 22 mg kg max 100 mg 2 times daily children 45 kg adults 200 mg d1 100 mg 2 times daily prevention symptomatic treatment hydration po iv patient unable drink fever paracetamol po chapter 1 acetylsalicylic acid aspirin contraindicated due risk haemorrhage antibioticfor 5 7 days 3 days fever disappeared doxycycline po context epidemic typhus doxycycline po choice treatment risk recurrence children 4 mgkg max 100 mg single dose adults 200 mg single dose epidemic typhus control body lice see pediculosis chapter 4 murine typhus control fleas rats spotted fevers avoid tick bites wearing clothing using repellents scrub typhus use repellents chemoprophylaxis doxycycline po 200 mg weekly adults footnotes aunlike borrelioses antibiotic treatment rickettsioses provoke jarischherxheimer reaction however geographical distribution borrelioses rickettsioses may overlap thus reaction may occur due possible co infection see borreliosispage 251 409chapter 8 viral diseases measles poliomyelitis rabies viral hepatitis dengue viral haemorrhagic fevers hiv infection aids page 252 409measles measles highly contagious acute viral infection transmitted airborne route inhalation respiratory droplets spread infected individuals disease mainly affects children 5 years age prevented immunization information refer guide management measles epidemic msf clinical features average incubation period 10 days prodromal catarrhal phase 2 4 days eruptive phase 4 6 days eruptive phase followed skin desquamation 1 2 weeks pronounced pigmented skin skin develops striped appearance practice patient presenting fever erythematous maculopapular rash least one following signs cough runny nose conjunctivitis clinical case measles complications measles cases experience least one complication pneumonia dehydration common immediate causes death case managementhigh fever 3940 c cough coryza nasal discharge andor conjunctivitis red watery eyes kopliks spots tiny bluishwhite spots erythematous base found inside cheek sign specific measles infection may absent time examination observation kopliks spots required diagnosing measles average 3 days onset symptoms eruption erythematous non pruritic maculopapules blanch pressure rash begins forehead spreads downward face neck trunk second day abdomen lower limbs third fourth day rash progresses prodromal symptoms subside absence complications fever disappears rash reaches feet rash fades around fifth day order appeared head feet respiratory ent pneumonia otitis media laryngotracheobronchitis ocular purulent conjunctivitis keratitis xerophthalmia risk blindness gastrointestinal diarrhoea without dehydration benign severe stomatitis neurological febrile seizures rarely encephalitis acute malnutrition provoked aggravated measles postmeasles period admit inpatient children least one major complication inability eatdrinksuck vomiting altered consciousness seizures dehydration severe pneumonia pneumonia respiratory distress cyanosis spo 90 2 acute laryngotracheobronchitis croup corneal lesions pain photophobia erosion opacitypage 253 409if doubt keep child observation hours treatment supportive preventive treatment treatment complicationssevere oral lesions prevent eating acute malnutrition treat outpatient children major complications complications minor complications pneumonia without severe signs acute otitis media purulent conjunctivitis corneal lesions diarrhoea without dehydration oral candidiasis interfere eating isolation isolation hospitalized patients measles cases treated outpatients kept home period treat fever paracetamol fever chapter 1 make child drink high risk dehydration give smaller frequent meals breastfeed frequently every 2 3 hours clear nasopharynx noseblowing nasal lavages prevent secondary respiratory infection improve childs comfort clean eyes clean water 2 times daily administer retinol d1 d2 see xerophthalmia chapter 5 prevent ocular complications children 5 years amoxicillin po 5 days preventive measure reduction respiratory ocular infections event watery diarrhoea without dehydration oral rehydration according plan see dehydration chapter 1 insert nasogastric tube days oral lesions prevent child drinkingpage 254 409 prevention treatment complications severe pneumonia ceftriaxone iv im cloxacillin iv change amoxicillinclavulanic acid po see chapter 2 oxygen cyanosis spo 90 salbutamol expiratory wheezing sibilant rales auscultation cases close monitoring2 pneumonia without severe signsamoxicillin po 5 days croup inpatient monitoring risk worsening keep child calm agitation crying exacerbate symptoms severe croup dexamethasone im 06 mgkg single dose nebulized epinephrine adrenaline 1 mgml ampoule 05 mlkg max 5 ml oxygen cyanosis spo 90 intensive monitoring symptoms resolve2 acute otitis media see otitis chapter 2 dehydration per oral route iv depending degree dehydration oral candidiasis see stomatitis chapter 3 purulent conjunctivitis see conjunctivitis chapter 5 keratitiskeratoconjunctivitistetracycline 1 eye ointment 2 times daily 7 days retinol po one dose d1 d2 d8 see xerophthalmia chapter 5 eye protection pain management see pain chapter 1 topical corticosteroids xerophthalmia see xerophthalmia chapter 5 febrile seizures see seizures chapter 1 chemoprophylaxis contacts vaccination 9 12 months one dose 05 ml recommends second dose 15 18 months respect interval least 4 weeks doses high risk infection overcrowding epidemics malnutrition infants born mother hiv infection etc administer supplementary dose 6 months age continue vaccination schedule children 15 years missed either one doses routine vaccination vaccinated come contact health services check national recommendationspage 255 409footnotes asymptoms hoarse crying voice difficulty breathing highpitched inspiratory wheeze inspiratory stridor characteristic barking cough caused inflammation narrowing larynx croup considered benign moderate stridor occurs child agitated crying disappears child calm child monitored period however general respiratory status deteriorate rapidly croup severe stridor persists rest associated signs respiratory distresspage 256 409poliomyelitis poliomyelitis acute viral infection due poliovirus serotypes 1 2 3 humantohuman transmission direct faecaloral indirect ingestion food water contaminated stool humans reservoir virus principle disease eradicated mass vaccination endemic areas poliomyelitis mainly affect children 5 years fully vaccinated infection affect persons age especially areas population immunity low clinical features laboratory look polio virus stool samples virus excreted one month infection intermittently therefore 2 samples must collected interval 2448 hours within 14 days onset symptoms send stool samples reference laboratory clinical description patient stool samples must stored transported 0 c 8 c treatment outbreak control case acute flaccid paralysis afpup 90 cases asymptomatic present mild symptoms 1 nonparalytic form nonspecific febrile illness muscle pain headache vomiting backache neurological involvement spontaneous recovery usually occurs within 10 days diagnosis rarely made outside epidemic contexts paralytic form less 1 cases nonspecific signs patient develops rapid onset morning evening asymmetrical acute flaccid paralysis predominantly lower limbs ascending progression muscles become soft diminished reflexes sensation maintained disease life threatening paralysis involves respiratory muscles muscles swallowing initial urinary retention common gastrointestinal disturbances nausea vomiting diarrhoea muscle pain meningeal symptoms may also occur 2 hospitalise patients paralytic form rest prevent bed sores bedridden patients give analgesics give im injections patients febrile phase ventilate patients respiratory paralysis physiotherapy lesions stable prevent muscle atrophy contractures care sequelae physiotherapy surgery prosthetics consider patient afp suspected case poliomyelitis send stool samples reference laboratory confirm diagnosis organize vaccination children 5 years living area village neighbouring villages irrespective vaccination status within 14 days laboratory confirmation available vaccine round 0 3 organize two mass vaccination campaigns within 8 weeks laboratory confirmation type vaccine area age groups determined epidemiological data organize mopup doortodoor vaccination campaign wherever monitoring suggests children missed ensure interruption transmission surveillance case afp 100 200 subclinical cases therefore active surveillance detect new cases essential epidemic controlpage 257 409prevention children start routine vaccination late age 3 months dose ipv administered together first dose bopv followed 2 doses bopv alone administered 4 weeks apart also ipv schedule 3 doses administered least 4 weeks apart eg 6 10 14 weeks booster dose least 6 months later ipv eventually completely replace bopv references3 types vaccines exist trivalent injectable inactivated poliovirus vaccine ipv bivalent oral live attenuated poliovirus vaccine bopv containing serotypes 1 3 monovalent oral type 2 vaccine mopv nopv exclusively used responding epidemics vaccination schedule depends epidemiology virus protocols vary according country follow national recommendations information recommends scheduleprimary vaccination endemic risk zones aother zones birth 1 dose bopv b 6 weeks 1 dose bopv 1 dose bopv 10 weeks 1 dose bopv 1 dose bopv 14 weeks 1 dose bopv 1 dose ipv 1 dose bopv 1 dose ipv acountries poliomyelitis endemic zones high risk importation subsequent spread virus bthe first dose bopv administered birth soon possible optimise seroconversion rates subsequent doses induce mucosal protection 1world health organization poliomyelitis polio httpswwwwhointhealthtopicspoliomyelitistabtab_1 accessed 08 june 2021 2centers disease control prevention poliomyelitis 2020 httpswwwcdcgovvaccinespubspinkbookpoliohtml accessed 08 june 2021 3global polio eradication initiative standard operating procedures responding poliovirus event outbreak version 31 world health organization 2020 httpswwwwhointpublicationsiitem9789240002999 accessed 08 june 2021page 258 409rabies rabies viral infection wild domestic mammals transmitted humans saliva infected animals bites scratches licks broken skin mucous membranes endemic areas africa asia 99 cases due dog bites 40 cases children 15 years age symptoms develop rabies effectively prevented postexposure prophylaxis symptoms develop rabies fatal curative treatment care palliative clinical features diagnosis often difficult may history scratch bite exposure licking wounds may healed reliable history may difficult obtain postexposure prophylaxis definitions exposure categories postexposure prophylaxis carried category ii iii exposures treatment wound cases 1 incubation period averages 20 90 days exposure 75 patients shorter severe exposure eg bites face head hands multiple bites longer 20 patients develop symptoms 90 days 1 year 5 1 year exposure prodromal phase itching paraesthesiae neuropathic pain around site exposure nonspecific symptoms fever malaise etc neurologic phase encephalitic form furious form psychomotor agitation hydrophobia throat spasms panic triggered attempting drink sightsoundtouch water aerophobia similar response draft air sometimes seizures patient calm lucid episodes infection evolves paralysis coma paralytic form less common 20 cases progressive ascending paralysis resembling guillainbarre syndrome evolves coma category contact animal licks intact skin exposure category iinibbles exposed skin minor bites scratches without bleedingminor exposure category iiitransdermal bites scratches licks broken skin contamination mucous membranes animals saliva licks direct contact bats asevere exposurepage 259 409prolonged cleansing wound contact site 15 minutes eliminate virus soon possible exposure critical importance skin use soap rinse copiously running water remove foreign material application disinfectant povidone iodine 10 additional precaution take place thorough wound washing mucous membranes eye mouth etc rinse thoroughly water 09 sodium chloride local cleansing indicated even patient presents late according conditiontype wound order avoid inoculating virus deeper tissues wounds either sutured eg superficial non mutilating puncture wounds left open reevaluated 4872 hours view possible closure highly contaminated wounds wounds may compromise function require surgical management exploration removal foreign material excision necrotic tissue copious irrigation sterile 09 sodium chloride ringer lactate local general anaesthesia suturing indicated face rabies immunoglobulin administered several hours wound closure see infected wounds sutured reassessed daily passive active immunisation given duration incubation administration vaccineimmunoglobulin always priority even patients exposed several months previously antirabies serotherapy rabies immunoglobulin indicated intended neutralize virus exposure site given single dose d0 first dose rabies vaccine human rabies immunoglobulin children adults 20 iukg highly purified rabies immunoglobulin fab2 fragments children adults 40 iukg infiltrate rabies immunoglobulin around previously washed wounds ensure injected blood vessel risk shock finger wounds infiltrate cautiously avoid increased pressure tissue compartment compartment syndrome event multiple wounds dilute dose 2 3fold sterile 09 sodium chloride obtain sufficient quantity infiltrate sites exposed infiltrate rabies immunoglobulin wound even already healed mucosal exposures wound rinse rabies immunoglobulin diluted sterile 09 sodium chloride monitor patient injection low risk anaphylactic reaction rabies immunoglobulin available d0 first dose rabies vaccine administered alone administer rabies immunoglobulin soon possible d0 d7 d8 necessary administer rabies immunoglobulin vaccineinduced antibodies begin appear postexposure rabies prophylaxis category iii exposures except patients received full course preexposure prophylaxis rabies see prevention category ii iii exposures immunocompromised patientseven patients received full course preexposure prophylaxis rabies b 1page 260 409a complete prophylaxis series indicated category ii iii exposures started d0 continued completion risk rabies excluded several different types rabies vaccines prepared cell cultures cceev exist vaccines must replace nerve tissue vaccines ntv prophylaxis schedules may vary country country check national recommendations patient must administered full course doses indicated main postexposure prophylaxis regimens notes measures antibiotherapyantibiotic prophylaxis c 1 dateno preexposure prophylaxis unknown prophylaxis status incomplete preexposure prophylaxis complete preexposure prophylaxis ntv im route 1 dose 05 1 ml depending manufacturer id route 1 dose 01 ml b d02 doses 1 dose arm thigh c 1 dose c2 doses 1 dose arm c d3 1 dose2 doses 1 dose arm d7 1 dose 1 dose2 doses 1 dose arm d14 1 dose d21 1 dose aim route two possible schedules zagreb regimen 20101 21 days 4dose essen regimen 11 110 14 28 days im injection administered anterolateral part thigh children 2 years deltoid muscle arm children 2 years adults administer gluteal muscle bid route inject deltoid muscle suprascapular region anterolateral part thigh incorrect id technique results failure postexposure prophylaxis correct id technique cannot assured use im route cas well single dose rabies immunoglobulin d0 indicated dthe last injection administered d14 d28 immunocompromised patients 1 dose d0 1 dose d7 1 dose d21 d28 1 patients received full course preexposure prophylaxis see prevention postexposure regimen 1 dose d0 1 dose d3 im id route 4 doses id route d0 2page 261 409 dosage used treatment prophylaxis treatment choice amoxicillinclavulanic acid coamoxiclav po use formulations ratio 81 71 dose expressed amoxicillin children 40 kg 25 mgkg 2 times daily children 40 kg adults ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily tetanus vaccination serotherapy check prophylaxis status unknown uptodate see tetanus chapter 7 prevention preexposure prophylaxis cceev people risk prolonged stay rabies endemic areas professionals contact animals susceptible carrying virus etc 1 dose im route 2 doses id route d0 d7 infection present infection andno infection local redness oedema serosanguinous purulent drainage locoregional general lymphangitis lymphadenopathy localised cellulitis bone joint infection feverwounds face hands genital region wounds involving joint tendon ligament fracture deep puncture wounds wounds crush injury wounds contaminated requiring debridement wounds correct debridement possible immunocompromised patientsno criteria requiring antibiotic prophylaxis wounds 2448 hours old antibiotherapy po 7 days event local non severe infection 14 days event severe local infection widespread generalised infectionantibiotic prophylaxis po 5 7 days antibiotic prophylaxis footnotes event direct contact bats check national recommendations bfor example hivinfected patients cd4 25 children 5 years 200 cellsmm3 children 5 years adults httpappswhointirisbitstreamhandle10665272371wer9316pdfua1 ceither observation captured animal domestic laboratory diagnosis animal killed recommends 10day observation period animal captured signs rabies develop observation period risk rabies excluded postexposure prophylaxis discontinued laboratory diagnosis dead animal involves sending head specialised laboratory confirms excludes rabies animal laboratory diagnosis negative risk rabies excluded postexposure prophylaxis discontinuedpage 262 409referencesdin penicillinallergic patients children cotrimoxazole 30 mg smx 6 mg tmpkg 2 times daily clindamycin 10 mgkg 3 times daily adults cotrimoxazole 800 mg smx 160 mg tmp 2 times daily doxycycline 100 mg 2 times daily 200 mg daily except pregnant lactating women metronidazole 500 mg 3 times daily 1weekly epidemiological recordreleve epidemiologique hebdomadaire 20 april 2018 93th year20 avril 2018 93e annee 16 2018 93 201220 httpappswhointirisbitstreamhandle10665272371wer9316pdfua1 accessed 25 october 2018 2spencer banerjee animal bites bmj best practice 2018 accessed 25 october 2018page 263 409viral hepatitis last updated october 2021 several viral infections liver grouped heading viral hepatitis hepatitis b c delta e different hepatitis viruses present throughout world prevalence varies country hepatitis b common developing countries vast majority infections occur childhood clinical characteristics five diseases similar enough make differential diagnosis difficult however epidemiological immunological pathological differences patients hepatitis b c may later develop chronic liver disease main characteristics type viral hepatitis summarized table clinical features various forms viral hepatitisasymptomatic forms mild anicteric forms common irrespective causal virus icteric forms insidious sudden onset symptoms varying intensity fever fatigue nausea gastrointestinal disturbance followed jaundice dark coloured urine less claycoloured stool fulminant forms hepatocellular failure severe cytolysis fatal form frequent hepatitis b patients secondary infection virus event pregnant women infected hepatitis e third trimester chronic hepatitis hepatitis b c may lead cirrhosis andor hepatocellular carcinoma hccpage 264 409 hepatitis hepatitis b hepatitis c hepatitis hepatitis e age group riskchildren children young adults young adults young adults transmissionfaecaloral contaminated food water transfusion rarevertical close contact infected person especially intra familial exposure blood transfusion material contaminated blood sexual exposure blood transfusion material contaminated blood sexual low intranasal implements shared intranasal drug users vertical aexposure blood transfusion material contaminated blood sexual possibly vertical afaecaloral contaminated food water incubation period2 6 weeks 4 30 weeks average 10 weeks2 25 weekscoinfection bd hepatitis b secondary infection hepatitis b approximately 5 weeks2 8 weeks fulminant forms02 04 1 3 rare hepatitis bmuch common patients secondary infection hepatitis b patients bd co infection20 mortality pregnant women prognosis chronic formschronicity 02 10 risk inversely related age eg 90 infected age 1 year 5 15 progress cirrhosis hcc possiblechronicity 50 10 25 progress cirrhosis hcc possiblechronicity 5 patients bd co infection 90 secondary infection hepatitis b rapid cirrhosisno chronic formspage 265 409laboratory diagnosis tests investigations elastography fibroscan measures elasticity liver determine stage liver fibrosis scored f0 absence fibrosis f4 cirrhosis treatment treatment chronic active hepatitis b goal treatment reduce risk cirrhosis hcc individual preventionpolyvalent immunoglobulinspecific antihbs immunoglobulin safe sex condomsspecific anti hbs immunoglobulin may effectiveas hepatitis b virus develop bcook meat pork vaccination antihepatitis aantihepatitis b exist antihepatitis bdoes exist collective preventionhygiene sanitationlimit transfusion screen blood prior transfusion single use disposable materialhygiene sanitation avertical transmission transmission virus mother child pregnancy time delivery first 28 days birth hav hdv hev infection detection igm antihav antihdv antihev antibodies respectively hbv infection detection hbsag chronic hepatitis b presence hbsag longer 6 months chronic active hepatitis b detection hbeag andor hbv dna hcv infection detection antihcv antibodies hcv rna chronic hepatitis c viraemia persists longer 6 months alt ast level platelet count creatinine hcv diagnosis hbv viral load decide treatment chronic active hepatitis b apri score evaluation liver fibrosis chronic hepatitis patients ast levelnormal ast level x 100platelet count 10 plateletslitre apri score 1 indicates probable severe fibrosis9 hiv test rest hydration special diet administer drug therapy symptomatic treatment analgesics antipyretics antidiarrhoeals antiemetics etc acute phase may aggravate symptoms evolution hepatitis corticosteroids indicated stop reduce alcohol consumption patients hiv coinfection lifelong antiretroviral therapy hiv includes tenofovir administer tenofovir monotherapy tenofovirpage 266 409treatment chronic hepatitis c case decompensated cirrhosis presence ascites jaundice mental confusion signs gastrointestinal haemorrhage treatment 24 weeks treatment contraindicated pregnancy breastfeeding women childbearing age provide contraceptive start treatment women want contraception vaccination dual therapy lamivudine emtricitabine risk developing hiv drug resistance patients without hiv coinfection treatment indicated event cirrhosis advanced hepatic fibrosis apri score 15 fibroscan f3f4 10 kpa hbsag positive persistently elevated alt ast 2 times normal values 2 samples taken 3 6 months apart persistently elevated alt ast high viral load 20 000 iuml tenofovir po 300 mg tab equivalent 245 mg tenofovir disoproxil lifelong therapy children 12 years adults including pregnant women one tablet daily taken meal 1 genotypes 1 2 3 4 5 6 without cirrhosis compensated cirrhosissofosbuvirvelpatasvir po 400 mg sof100 mg vel tablet 1 tablet daily 12 weeks genotypes 1 2 4 5 6 without cirrhosis compensated cirrhosis genotype 3 without cirrhosissofosbuvirdaclatasvir po 400 mg sof60 mg dcv tablet 1 tablet daily 12 weeks genotype 3 compensated cirrhosis sofosbuvirdaclatasvir po 400 mg sof60 mg dcv tablet 1 tablet daily 24 weeks routine vaccination neonates infants according national vaccination schedule 2 3 dose schedule one dose soon possible birth preferably within first 24 hours life one dose 6 weeks one dose 14 weeks 4 dose schedule one dose soon possible birth preferably within first 24 hours life one dose 6 weeks one dose 10 weeks one dose 14 weeks catchup vaccination unvaccinated individuals 3 dose schedule 016 2 doses 4 weeks apart third dose 6 months first dose postexposure prophylaxis one dose d0 one dose d7 one dose d21 d30 booster dose 12 months first dose footnotes aat birth monovalent hepatitis b vaccine used following doses monovalent tetravalent diphtheria tetanus pertussis hepatitis b pentavalent diphtheria tetanus pertussis hepatitis b haemophilus influenzae vaccine used depending national recommendations infant administered birth dose dose administered anytime first contact healthcare providers time next dose primary schedulepage 267 409references 1world health organization guidelines care treatment persons diagnosed chronic hepatitis c virus infection july 2018 httpappswhointirisbitstreamhandle106652731749789241550345engpdfua1 accessed 21 december 2018 2weekly epidemiological recordreleve epidemiologique hebdomadaire 7 july 2017 92th year 7 juillet 2017 92e annee 27 2017 92 369392 httpappswhointirisbitstreamhandle10665255841wer9227pdfsequence1 accessed 22 november 2018page 268 409dengue last update october 2022 dengue fever arbovirus transmitted humans bite mosquito aedes transmission transfusion contaminated blood transplacental transmission foetus also reported four different serotypes dengue described infection one serotype provides lifelong immunity specific serotype partial shortterm immunity serotypes specific antiviral treatment dengue mainly urban disease present tropical subtropical regions particular asia central south america caribbean outbreaks described eastern africa primary infection may asymptomatic present mild occasionally severe dengue fever subsequent infections increase risk severe dengue clinical features incubation period 4 10 days illness occurs 3 phases febrile phase high fever 39 40 c lasting 2 7 days often accompanied generalized aches maculopapular rash mild haemorrhagic manifestations critical phase third seventh day end febrile phase temperature decreases majority patients dengue without warning signs proceed recovery phase certain patients develop dengue warning signs stage patients higher risk developing severe dengue recovery phase patient improves vital signs normalise gastrointestinal symptoms subside appetite returns times bradycardia generalized prurituspage 269 409major differential diagnoses conditions consider include wide range acute febrile illnesses eg laboratory diagnosissymptoms according severity adapted paho 1 dengue without warning signsfever 2 following symptoms nausea vomiting rash resembling measles generalized aches headache retroorbital pain myalgias arthralgias benign mucocutaneous bleeding petechiae positive tourniquet test epistaxis gingival bleeding leucopenia dengue warning signspresence least one symptoms intense abdominal pain persistent vomiting fluid accumulation ascites pleural effusion mucosal bleeding hepatomegaly 2 cm postural hypotension agitation lethargy increasing haematocrit severe dengue severe fluid accumulation ascites pleural effusion respiratory distress andor shock severe mucocutaneous bleeding severe organ involvement eg transaminases 1000 iulitre myocarditis altered mental status atourniquet test inflate blood pressure cuff upper arm point midway systolic diastolic pressure 5 min test positive 20 petechiae per 25 cm square observed chikungunya zika influenza mononucleosis measles rubella viral haemorrhagic fevers malaria meningococcemia typhoid fever leptospirosis rickettsioses causes sepsis leukaemia ns1 antigen detection febrile phase rapid diagnostic test elisa serum plasma blood antibody detection complex interpretation igm detection 5 6 days onset illness may support confirm diagnosis recent infection igg detection may indicate prior infection vaccination dengue virus closely related virus eg chikungunya zika japanese encephalitis yellow fever pcr may also available reference laboratories cases rapid test malaria endemic regions antimalarial treatment needed see malaria chapter 6page 270 409monitoring disease course treatment patients group outpatients patients warning signs able drink sufficiently normal urine output patients group b inpatients patients following cases poor oral intake warning signshaematocrit hct available full blood count fbc baseline daily possible progressive increase hct warning sign indicates haemoconcentration due increased vascular permeability plasma leakage hct monitored frequently fluid administration patients warning signs end fluid treatment leukopenia thrombocytopenia common improve recovery phase begins leukocytosis may occur severe bleeding liver function tests possible baseline according results bed rest good hydration fever pain paracetamol po usual doses see fever chapter 1 maintaining 6 8 hour interval doses prescribe acetylsalicylic acid ibuprofen nsaids seek medical attention clinical improvement persistent vomiting cold extremities agitation lethargy breathing difficulties absence urine output followup impossible symptoms cannot monitored home patients living far health care facilityliving alone hospitalise observation warning signs acute eg severe dehydation malaria chronic eg diabetes cardiovascular renal haemolytic disease obesity comorbidities risk factors bleeding eg anticoagulation coagulopathy peptic ulcer gastritis treatment nsaids pregnant women patients 1 year 65 years patients difficulty drinking place patient mosquito net encourage oral fluid intake including oral rehydration solution ors needed avoid invasive procedures nasogastric tube im injections minimize risk bleeding fever pain paracetamol po caution without exceeding 2 children 10 mgkg every 6 8 hours adults 500 mg every 6 8 hours case elevated transaminases 10 times upper limit normal administer paracetamol use tepid sponging reducing fever monitor vital signs fluid intake infusion oral urine output every 4 hours b place intravenous line administer children 5 glucose ringer lactate solutionas maintenance fluids according hollidaysegar formula ie 4 mlkghour first 10 kg body weight 2 mlkghour next 10 kg 1 mlkghour additional kg 20 kg c adults ringer lactate 2 3 mlkghour encourage oral intake soon possiblepage 271 409patients group c intensive care unit patients severe dengue requiring emergency treatment managing shock complications eg severe bleeding acidosis coagulopathy prevention referencesmonitor clinical status warning signs general symptoms vital signs capillary refill time iv oral fluid intake urine output hourly least 4 hours every 4 hours patient iv fluid treatment place intravenous line administer bolus ringer lactate children adults 10 mlkg one hour patients 65 years comorbidities 5 mlkg one hour reassess patient improvement first bolus administer second bolus necessary total 3 boluses administered still improvement 3 bolus consider severe dengue patients group c transfer intensive care unit improvement first second third bolus reduce ringer lactate children adults 5 7 mlkghour 2 4 hours patients 65 years comorbidities 5 mlkghour 2 4 hours continuing improvement reduce ringer lactate stop soon possible reduce risk fluid overload children adults 3 5 mlkghour 2 4 hours 2 4 mlkghour 24 48 hours patients 65 years comorbidities 3 mlkghour 2 4 hours 2 mlkghour 24 48 hours patient deteriorates initial improvement resume bolus therapy ringer lactate 3 bolus individual protection long sleeves trousers repellents mosquito net aedes bites day elimination mosquito breeding sites small collections water discarded tires flower pots containers footnotes afor information httpgamapserverwhointmaplibraryfilesmapsglobal_denguetransmission_ithriskmappngua1 badequate urine output least 1 mlkghour children 05 mlkghour adults unavailable ensure patient urinating least every 4 hours cremove 50 ml ringer lactate rl 500 ml rl bottle bag add 50 ml 50 glucose remaining 450 ml rl obtain 500 ml 5 glucoserl solution 1pan american health organization dengue guidelines patient care region americas 2nd edition washington dc paho 2016 httpsirispahoorgbitstreamhandle106652312079789275118900engpdfsequence1isallowedy accessed 23 aug 2022 2pan american health organization guidelines clinical diagnosis treatment dengue chikungunya zikapage 272 409washington dc paho 2022 httpsirispahoorghandle10665255867 accessed 16 aug 2022page 273 409viral haemorrhagic fevers several diseases different aetiologies different modes transmission grouped term present common clinical signs dengue haemorrhagic fever viral haemorrhagic fever described specific chapter see dengue chapter 8 clinical features common syndrome cs fever higher 385 c haemorrhagic symptoms purpura epistaxis haematemesis melaena etc clinical signs often nonspecific severity varies depending aetiologypage 274 409laboratory reservoir vector geographical distributionisolation patientsclinical featuresestimated case fatality rate ebolamarburg bats africastrict isolationcs sudden onset general malaise vomiting diarrhoea6080 lassa arodents west africa bstrict isolationcs general malaise headache muscle pain facial oedema pharyngitis proteinuria reagent strip1520 junin machupo arodents south americaisolationcs vomiting erythema face depending aetiology periorbital oedema cervical adenopathy pharyngitis pharyngitis reddened conjunctivae oedema soft palate generalised petechial rash proteinuria reagent strip1530 omskticks europe asianone 25 crimean congo alivestockticks africa asiastrict isolation520 fhsr hantavirus arodents asia europenone 1 kyasanursmall mammalsticks indianonecs headache muscle pain prostration210 rift valley alivestockmosquitoes africamosquito netsclinical signs isolated fever sc encephalitis retinitis blindness3050 yellow fever aprimatesmosquitoes africa south americamosquito netscs jaundice proteinuria reagent strip oliguria headache1030 aviral haemorrhagic fever epidemic potential bfor information geographic distribution lassa fever httpswwwwhointemergenciesdiseaseslassafevergeographicdistributionpngua1 sample whole blood must send reference laboratory serological diagnosis clinical description patient sample may also sent filter paper easier transport small volume blood allows limited number aetiologies tested protective clothing must worn taking handling sample gown gloves glasses mask etc sample must sent triple packaging system category infectious substancespage 275 409management suspicion haemorrhagic fever isolated case fever haemorrhagic symptoms endemic area confirmed cases ebola marburg lassa crimeancongo fevers epidemics unknown origin plus confirmed cases yellow fever rift valley fever patients report ministry health country treatmentisolation isolation room available use screenspartitions restrict visitors carer strictly necessary must protected gown gloves mask standard precautions majority hospitalacquired infections occurred due lack respect precautions hand washing gloves patient examination touching blood body fluids secretions excretions mucous membranes nonintact skin gowns protect skin prevent soiling clothing consultations activities likely generate splashes sprays blood body fluids secretions excretions surgical mask goggles face shield protect mucous membranes eyes nose mouth activities may generate splashes blood body fluids secretions excretions adequate procedures routine cleaning disinfection objects surfaces rubber gloves handle soiled laundry safe waste management safe injection practices strict isolation reserved area separate patient areas defined circuit entranceexit changing room entranceexit dedicated staff equipmentsupplies use disposable material possible standard precautions droplet precautions contact precautions including personal protective equipment ppe ppe worn systematically prior entry isolation area regardless tasks performed care cleaning distribution meals etc removed leaving isolation area two pairs gloves double gown coverall suit surgical cap hood mask protective glasses impermeable apron rubber boots disinfection surfaces objects clothing bedding chlorine solution safe handling site disposal waste excreta etc event death wash body prompt safe burial dead quickly possible using body bag standard precautions patient mosquito net prevent transmissionpage 276 409prevention referencesaetiological treatment ribavirine lassa fever crimeancongo fever symptomatic treatment fever paracetamol chapter 1 acetylsalicylic acid aspirin contraindicated pain mild paracetamol moderate tramadol severe sublingual morphine see pain chapter 1 dehydration oral rehydration salts andor iv rehydration ringer lactate see dehydration chapter 1 seizures chapter 1 vomiting ondansetron po children 6 months 2 years 2 mg daily children 2 4 years 2 mg 2 times daily children 4 12 years 4 mg 2 times daily children 12 years adults 4 8 mg 2 times daily 1 ebola marburg haemorrhagic fevers invasive procedures must strictly limited health care staff risk contamination inserting maintaining iv lines iv line must well secured patient often confused cannot pull vaccination yellow fever children adults 05 ml single dose 2 routine vaccination children 9 months age along measles vaccine mass vaccination campaign epidemic children 6 months adults pregnant women administer epidemic vaccination rift valley fever epidemic vector control programmes known vectors infection control measures essential cases 1world health organization clinical management patients viral haemorrhagic fever pocket guide frontline health workers interim emergency guidance country adaptation february 2016 httpappswhointirisbitstreamhandle106652055709789241549608_engpdfjsessionid15e17de39631519c2051413dd cbbc8a7sequence1 accessed 11 january 2019 2weekly epidemiological recordreleve epidemiologique hebdomadaire 5 july 2013 88th year 5 juillet 2013 88e annee 27 2013 88 269284 httpswwwwhointwer2013wer8827pdfua1 accessed 10 december 2018page 277 409hiv infection aids last updated january 2024 acquired immune deficiency syndrome aids advanced stage infection human immunodeficiency virus hiv two subtypes hiv identified hiv1 widespread hiv2 latter mainly found west africa hiv2 less virulent less transmissible hiv1 hiv weakens immune system causing deficit cd4 lymphocytes evolution disease world health organization proposed clinical classification hiv infection 4 stages severity adults adolescents children laboratory diagnosis hiv infection cd4 lymphocyte counts cd4 cell depletion marker progression immune depression level cd4 cell count predictor development opportunistic infections neoplasms used orient diagnosis eg cerebral toxoplasmosis cryptococcal meningitis appear cd4 count 100 cellsmm adults clinical symptomssigns present suggesting one infections cd4 count greater equal 200 cellsmm unlikely particular infection present opportunistic infectionsprimary infection acute retroviral syndrome 50 70 newly infected individuals develop seroconversion 15 days 3 months post exposure viral syndrome fever malaise lymphadenopathy asymptomatic hiv infection seroconversion period clinical latency viral latency time period progression hiv infection development severe immune deficiency western countries approximately 10 years period appears shorter developing countries symptomatic hiv infection progressive destruction immune system common severe diseases occur frequently higher mortality seropositive individuals aids stage corresponds development severe opportunistic infections neoplasms biological point view aids defined cd4 count 200 cellsmm without treatment disease progresses rapidly towards death3 1 diagnosis made serological detection antibodies virus virological especially infants testing testing always done voluntarily informed consent hiv test results must strictly confidential order avoid discrimination individual access services offering pretest posttest counselling treatment support diagnosis hiv infection made least 2 different test results 2 different brands clearly positive positive result initial highly sensitive test must confirmed use second highly specific test areas hiv prevalence low diagnosis confirmed 3 positive test results 3 3page 278 409it important screen serious opportunistic infections risk eg testing cryptococcal antigen adults cd4 count 100 cellsmm regardless symptoms treatment hiv infection antiretroviral arv treatment multidrug least 3 antiretroviral therapy art reference treatment eradicate virus slows progression disease improves patients clinical state reducing viral replication consequently increasing cd4 cell count levels beyond threshold opportunistic infections therapeutic classes four major classes arv used principles arv treatment possible combinations exist less commonly used difficult manage criteria arv treatment priority art initiated patients clinical stage 3 4 patients cd4 350 mm however higher cd4 counts initiate art monitoring arv treatment hiv viral load essential tool monitoring effectiveness arv cd4 count useful identifying severely immunosuppressed tests blood count tests liver alat renal function creatinine clearance essential useful detecting adverse effects treatment opportunistic infections progressive immunosuppression hivinfected patients receiving triple therapy patients art poor adherence become increasingly susceptible infections conditions clinical stages 2 3 standard treatments usually effective patients may benefit primary prophylaxis opportunistic infections see primary prophylaxis tuberculosis tb common serious opportunistic infection difficult diagnose hivinfected patients however treatment pain treat patients associated pain see pain chapter 1 prevention hiv infection3 nrti nucleosidenucleotide reverse transcriptase inhibitors zidovudine azt lamivudine 3tc abacavir abc tenofovir tdf emtricitabine ftc nnrti nonnucleoside reverse transcriptase inhibitors efavirenz efv nevirapine nvp etravirine etr hiv2 naturally resistant nnrtis pi protease inhibitors atazanavir atv lopinavir lpv ritonavir rtv darunavir drv ini integrase inhibitors dolutegravir raltegravir daily triple therapy must taken life prevent rapid development resistance important patient understands adherence treatment optimal follow art protocols recommended national hiv program widely used easiest regimens administer 2 nrti 1 nnrti eg tdf3tcefv event treatment failure 3 drugs replaced secondline regimen 2 nrtis 1 pi 3page 279 409sexual transmission reliable method prevention use male female condoms male circumcision decreases significantly risk hiv transmission early diagnosis treatment sexually transmitted infections essential increase transmission hiv see chapter 9 art hiv positive adherent partner protect negative partner hiv infection occupational transmission accidental needle stick injuries injuries contaminated objects contact patients blood unprotected broken skin mucous membranes prevention based use standard precautions avoid contamination soiled material potentially infected body fluids postexposure prophylaxis pep eg event rape occupational accidental exposure blood arv treatment initiated soon possible within 72 hours exposure duration 1 month may reduce risk infection nosocomial transmission prevention nosocomial hiv infection based rational use injections strict respect hygiene sterilization disinfection procedures medical material transfusion strict respect indications transfusion systematic serological screening donors blood two indispensable precautions prevention hiv transmission transfusions transmission injection drug users needle syringe exchange programs disposable needles syringes users reduce risk mothertochild transmission mtct global rate vertical transmission varies 20 40 risk transmission breastfeeding evaluated approximately 12 persists duration breastfeeding prevention opportunistic infections absence arv treatment hivinfected individuals become symptomatic evolve towards aids however opportunistic infections prevented primary prophylaxis hiv infected patients previously contracted opportunistic infection order prevent development opportunistic infections pregnant women hiv transmission mothertochild may reduced art protocol called option b internationally preferred protocol hivinfected pregnant women receive lifelong tripledrug therapy regardless cd4 count clinical stage health prevent transmission child commonly recommended art tdf3tcefv tdfftcefv check national recommendations addition arvs administered newborn programs targeting pregnant women also include preventive measures avoiding artificial rupture membranes systematic episiotomy breastfeeding women exclusive breastfeeding first 6 months life introduction complementary solid foods 6 months gradual cessation breastfeeding age 12 monthspage 280 409 secondary prophylaxis patients develop specific opportunistic infection order prevent recurrence treatment infection completed infections primary prophylaxis pneumocystosis cerebral toxoplasmosis isosporiasis various bacterial infections malariacotrimoxazole po children 50 mg smx 10 mg tmpkg daily adults 800 mg smx 160 mg tmp daily infections secondary prophylaxis comments pneumocystosis cotrimoxazole po children 50 mg smx 10 mg tmpkg daily adults 800 mg smx 160 mg tmp dailyalternative dapsone po children 2 mgkg daily max 100 mg daily adults 100 mg daily toxoplasmosis alternative adults dapsone po 200 mg weekly 50 mg daily pyrimethamine po 75 mg weekly folinic acid po 25 30 mg weekly isosporiasis penicilliosis histoplasmosisitraconazole po adults 200 mg daily cryptococcal meningitisfluconazole po children 6 mgkg daily adults 200 mg daily oral oesophageal candidiasisfluconazole po children 3 6 mgkg daily adults 100 200 mg dailyonly frequent severe recurrences herpes simplex aciclovir po children 2 years 200 mg 2 times daily children 2 years adults 400 mg 2 times dailyonly frequent severe recurrencespage 281 409 page 282 409symptomsdefinitions aetiologiesdiagnosis treatment diarrhoea without blood also see chapter 3diarrhoea defined least 3 liquid stools per day aetiologies parasitic infections isospora belli cryptosporidium microsporidium giardia lamblia entamoeba histolytica bacterial infections shigella salmonella enteritis campylobacter enteritis mycobacterial infections mycobacterium tuberculosis gastrointestinal tb mycobacterium avium complex helminthiasis strongyloides stercoralis viral infections cytomegalovirus cmv causes kaposi sarcoma lymphoma idiopathic hiv infection antiretrovirals especially lopinavir ritonavir1 history clinical examination 2 microscopic examination stool ova parasites 2 3 samples note belli cryptosporidium microsporidium mac cmv unlikely cd4 count 200 cells persistent 2 weeks chronic 4 weeks diarrhoea often associated weight loss dehydration prevention treatment dehydration critical dehydration chapter 1 depending results stool examinations give appropriate treatment laboratory support acute bloody diarrhoea firstline treatment children azithromycin po 20 mgkg daily 5 days ciprofloxacin po 15 mgkg 2 times daily 7 days adults ciprofloxacin po 500 mg 2 times daily 7 days amoebiasis suspected tinidazole metronidazole po amoebiasis chapter 3page 283 409nonbloody persistent chronic diarrhea persistent chronic diarrhoea suggests advanced immunocompromised state patients qualify arvs cd4 count unknown cd4 count arv initiation urgent usually resolve symptoms 14 28 days isospora belli cotrimoxazole po children 40 mg smx 8 mg tmpkg 2 times daily 10 days 25 mg smx 5 mg tmpkg 2 times daily 3 weeks adults 800 mg smx 160 mg tmp 2 times daily 7 10 days 400 mg smx 80 mg tmp 2 times daily 3 weeks cryptosporidium specific treatment hivinfected patients microsporidium albendazole po limited efficacy children 10 mgkg 2 times daily max 800 mg daily 7 days adults 400 mg 2 times daily 2 4 weeks helminthiasis albendazole po 3 days children 6 months 10 kg 200 mg daily children 6 months adults 400 mg daily giardiasis tinidazole metronidazole intestinal protozoan infections chapter 6 improvement contra indications bloody diarrhoea symptomatic treatment loperamide po adults initial dose 4 mg 2 mg liquid stool max 16 mg dailypage 284 409nutrition children continue breastfeed increase daily calorie intake 611 months add 150 kcal daily 1223 months add 200 kcal daily 25 years add 250 kcal daily 69 years add 350 kcal daily 1014 years add 400 kcal daily eliminate fresh milk give porridge prepared rice water soup yoghurts give 25 ml oil per meal child 05 years receive zinc sulfate acute diarrhoea chapter 3 adults increase calorie protein intake least 2 g proteinkg daily food excluded avoid raw food fresh milk foods high fibre encourage small frequent meals oral oesophageal lesionsfungal infections oral candidiasis see stomatitis chapter 3 oesophageal candidiasis pain swallowing dysphagia may result weight loss viral infections oral hairy leukoplakia keratosis lateral sides tongue due epsteinbarr virus oral oesophageal herpes aphthous ulcersclinical examination enough make diagnosis consider severe oral candidiasis pharynx involved oesophageal candidiasis even absence dysphagia mild oral candidiasis nystatin po children adults 100 000 iu 1 ml 4 times daily miconazole oral gel children 6 months2 years 125 ml 4 times daily children 2 years adults 25 ml 4 times daily treatment lasts 7 14 days moderate severe oral candidiasis oesophageal candidiasis fluconazole po children 3 6 mgkg daily adults 50 200 mg daily 400 mg daily necessary treatment lasts 7 14 days oral candidiasis 14 21 days oesophageal candidiasis candidiasis indication prophylaxis cotrimoxazole oral hairy leukoplakia treatmentpage 285 409 oral herpes analgesics paracetamol ibuprofen recurrent extensive forms affecting oesophagus add aciclovir po 7 days children 2 years 200 mg 5 times daily children 2 years adults 400 mg 5 times daily secondary prophylaxis patients frequent recurrences respiratory problems also see chapter 2cough andor thoracic pain andor dyspnoea symptomatic hiv infected patient aetiologies bacterial infections streptococcus pneumoniae haemophilus influenzae staphylococcus aureus mycobacterial infections tuberculosis mac protozoal infections pneumocystis jiroveci pcp fungal infections cryptococcus neoformans histoplasma capsulatum coccidioides immitis aspergillus spp penicillium marneffei viral infections cmv neoplasms kaposi sarcoma nonhodgkins lymphoma1 history clinical examination blood sputum fever 7 days dyspnoea unlikely tb cough 21 days weight loss thoracic pain 15 days dyspnoea likely tb pulmonary auscultation bilateral lobar pneumonia 2 possible look afb sputum b chest xray pcp bilateral interstitial infiltrates tb miliary shadowing large heart pleural effusion enlarged lymph nodes inside chest notes mac pcp cmv fungal infections unlikely patients cd4 count 200 cellsmm staphylococcal pneumonia often associated pyomyositis abscess3 diagnosis treatment upper respiratory tract infections particularly pneumonia see chapter 2 chest xray consistent staphylococcal pneumonia children see staphylococcal pneumonia chapter 2 adults ceftriaxone im slow iv 1 g daily cloxacillin iv 2 g every 6 hours sputum examination afb treat tbpage 286 409others lymphoid interstitial pneumonia pleural effusion often tb pericardial effusion often tb pneumothorax may due pcp sputum examination negative chest xray consistent pcp cotrimoxazole po 21 days children 50 mg smx 10 mg tmpkg 2 times daily adults 1600 smx 320 tmp 3 times daily note symptoms may become worse first phase treatment effectiveness evaluated one week treatment add prednisolone po patients severe pcp hypoxia children start 2 mgkg daily decrease dose following adult example adults 40 mg 2 times daily 5 days 40 mg daily 5 days 20 mg daily 10 days secondary prophylaxis recommended fungal infections cryptococcosis penicilliosis histoplasmosis adults amphotericin b iv 07 1 mgkg daily 2 weeks cryptococcosis penicilliosis 1 2 weeks histoplasmosis fluconazole po 400 mg daily 8 weeks cryptococcosis itraconazole po 200 mg 2 times daily 10 weeks penicilliosis itraconazole po 200 mg 3 times daily 3 days 200 400 mg daily 12 weeks histoplasmosis secondary prophylaxis recommended lymphadenopathy enlarged lymph nodes symptomatic hiv infected patient1 clinical examination look local cause skin dental infection etc tb syphilis treat according aetiology empirical treatment example doxycycline po tb see guide tuberculosis msfpage 287 409persistent generalised lymphadenopathy pgl 2 extrainguinal sites lymph nodes 15 cm enlarged 3 months pgl usually due hiv infection aetiologies hiv infection infections tb syphilis histoplasmosis toxoplasmosis cmv neoplasms kaposi sarcoma lymphoma2 suspected tb lymph node aspiration look afb chest xray note hiv infected patients tb often extrapulmonary 3 suspected syphilis serology 4 examinations negative biopsy useful exclude lymphoma kaposis sarcoma fungal mycobacterial infections see notes patients stage 1 early syphilis benzathine benzylpenicillin im adults 24 miu single dose 12 miu buttock available azithromycin po adults 2 g single dose note patients stage 1 investigation 1 2 3 table treatment required skin lesions also see chapter 4bacterial infections furunculosis impetigo pyoderma axillary hidradenitis pyomyositis syphilis viral infections herpes zoster herpes simplex genital warts molluscum contagiosum fungal infections candidiasis dermatophytoses deep mycoses penicilliosis cryptococcosis histoplasmosis etc neoplasms kaposi sarcoma bacterial infections furunculosis impetigo chronic folliculitis see bacterial skin infections chapter 4 suppurative axillary hidradenitis local treatment doxycycline po 200 mg daily 6 weeks adults pyomyositis antibiotics surgical drainage see pyomyositis chapter 10 primary secondary syphilis see genital ulcers chapter 9page 288 409other skin infections chronic prurigo urticaria severe seborrhoeic dermatitis psoriasis scabies diffuse cutaneous xerosis rash caused medication bed soresviral infections herpes zoster see herpes simplex herpes zoster chapter 4 necrotic extensive forms eruption face ophthalmic zoster add aciclovir within 48 hours onset lesions children iv route 5 10 mgkg every 8 hours 7 days adults oral route 800 mg 5 times daily 7 days herpes simplex see herpes simplex herpes zoster chapter 4 genital warts see venereal warts chapter 9 fungal infections candidiasis 2 miconazole cream one application 2 times daily dermatophytoses see superficial fungal infections chapter 4 treatment kaposi sarcoma ks start promptly art ks tumours oedema ulceration presence extensive oral gastrointestinal pulmonary ks systemic illness chemotherapy skin infections prurigo urticaria see skin disorders chapter 4 seborrhoeic dermatitis whitfields ointment 2 miconazole one application 2 times daily severe inflammation use topical corticosteroid combination miconazole xerosis zinc oxide ointment calamine lotion psoriasis corticosteroids zinc oxide ointment scabies local treatment crusted profuse scabies add ivermectin po see scabies chapter 4 neurological aetiologies history clinical positive malaria test see malariapage 289 409disorders adults infections tb meningitis cryptococcal meningitis cerebral toxoplasmosis neurosyphilis cmv encephalitis hiv encephalopathy progressive multifocal leuko encephalopathy cerebral malaria neoplasms primary cns lymphoma common causes headache unrelated hiv infection sometimes frequent hiv infected patients sinusitis problems accommodation etc adverse effects arvsexamination change mental state focal deficits seizures signs meningeal irritation raised intercranial pressure motor problems ataxia settings cryptococcal infection common screen adults cd4 100 prior initiation art using rapid crag test serum plasma endemic areas check malaria febrile lumbar puncture lp contraindicated elements favour neurosyphilis vdrl positive blood andor csf cells csf high protein csfchapter 6 focal signs treat toxoplasmosis cotrimoxazole po 25 mg smx 5 mg tmpkg 2 times daily 4 6 weeks pyrimethamine po 100 mg morning evening d1 75 100 mg daily sulfadiazine po 2 g 2 3 times daily folinic acid po 15 mg daily 6 weeks secondary prophylaxis recommendedpage 290 409if lp positive bacterial meningitis see chapter 7 tb meningitis see guide tuberculosis msf cryptococcal meningitis amphotericin b iv 1 mgkg daily flucytosine po 25 mgkg 4 times daily 1 week fluconazole po 1200 mg daily 1 week 800 mg daily 8 weeks available amphotericin b iv 1 mgkg daily fluconazole po 1200 mg daily 2 weeks fluconazole po alone 800 mg daily 8 weeks fluconazole po 1200 mg daily flucytosine po 25 mgkg 4 times daily 2 weeks fluconazole po alone 800 mg daily 8 weeks induction phase give fluconazole iv doses patient cannot take oral treatment liposomal amphotericin b 3 mgkg daily 2 weeks may used instead conventional amphotericin b case renal impairment secondary prophylaxis recommended note intracranial pressure icp often raised cryptococcal meningitis lower icp repeated therapeutic punctures drain csf may necessary beginning treatment neurosyphilis benzylpenicillin iv 2 4 miu 12 24 g every 4 hours 14 days ceftriaxone iv im 2 g daily 10 14 days headache unknown origin symptomatic treatment starting step 1 analgesic see pain chapter 1 2 neurological aetiologies good history taking positive malaria test see malariapage 291 409disorders children bacterial meningitis tb meningitis cryptococcal meningitis cerebral toxoplasmosis cmv meningo encephalitis cerebral malariaonly patients acute episodes benefit specific aetiological treatment seizures meningeal syndrome focal signs endemic areas check malaria febrile lumbar puncture lp contraindicatedchapter 6 lp possible treat bacterial meningitis patient febrile andor meningeal syndrome see chapter 7 focal signs treat toxoplasmosis cotrimoxazole po 25 mg smx 5 mg tmpkg 2 times daily 4 6 weeks pyrimethamine po 1 mgkg 2 times daily 2 days 1 mgkg daily sulfadiazine po 40 mgkg 2 times daily folinic acid po 10 mg daily 8 weeks secondary prophylaxis recommendedpage 292 409if lp positive bacterial meningitis see chapter 7 tb meningitis see guide tuberculosis msf cryptococcal meningitis order preference amphotericin b iv 1 mgkg daily flucytosine po 25 mgkg 4 times daily 1 week fluconazole po 12 mgkg daily max 800 mg daily 1 week 612 mgkg daily max 800 mg daily 8 weeks available amphotericin b iv 1 mgkg daily fluconazole po 12 mgkg daily max 800 mg daily 2 weeks fluconazole po alone 612 mgkg daily 8 weeks max 800 mg daily fluconazole po 12 mgkg daily max 800 mg daily flucytosine po 25 mgkg 4 times daily 2 weeks fluconazole po alone 612 mgkg daily max 800 mg daily 8 weeks induction phase give fluconazole iv doses child cannot take oral treatment liposomal amphotericin b 3 mgkg daily 2 weeks may used instead conventional amphotericin b case renal impairment secondary prophylaxis recommended 2 persistent recurrent fevertemperature 38 c chronic lasting 5 days recurrent multiple episodes period 5 days aetiologies1 history clinical examination look ent urinary infection tb skin infection enlarged lymph nodes etc 2 endemic areas check malaria 3 suspected tb look afbpositive malaria test see malaria chapter 6 testing available endemic areas treat malaria suspected meningitis treat according results lp lp available treat bacterial meningitis see chapter 7page 293 409 referencesinfections common childhood diseases severe bacterial infections tb pneumonia typhoid fever septicaemia meningitis endocarditis etc occult bacterial infections sinusitis otitis urinary tract infections opportunistic infections tb mycosis toxoplasmosis malaria neoplasms nonhodgkins lymphoma hiv infection fever caused medication4 chest xray cbc blood cultures urinalysis stool culture serology lumbar puncture lp child treatment consider adverse effects medicationidentified suspected focus infection ent see chapter 2 urinary see chapter 9 etc tb see guide tuberculosis msf footnotes afor information use antiretroviral drugs treating preventing hiv infection recommendations public health approach world health organization second edition 2016 httpappswhointirisbitstream1066520882519789241549684_engpdfua1 1world health organization case definitions hiv surveillance revised clinical staging immunological classification de hivrelated disease adults children 2007 httpwwwwhointhivpubguidelineshivstaging150307pdf accessed 17 may 2018 2word health organization guidelines diagnosis prevention management cryptococcal disease hiv infected adults adolescents children geneva 2018 httpappswhointirisbitstreamhandle106652603999789241550277engpdfsequence1 accessed 17 may 2018page 294 409chapter 9 genitourinary diseases nephrotic syndrome children urolithiasis acute cystitis acute pyelonephritis acute prostatitis genital infections urethral discharge abnormal vaginal discharge genital ulcers lower abdominal pain women upper genital tract infections ugti venereal warts major genital infections summary abnormal uterine bleeding absence pregnancy page 295 409nephrotic syndrome children nephrotic syndrome ns characterized presence oedema heavy proteinuria hypoalbuminemia hyperlipidaemia primary idiopathic ns common cause ns children 1 10 years usually responds corticosteroids secondary ns associated infectious diseases eg postinfectious glomerulonephritis endocarditis hepatitis b c hiv infection malaria schistosomiasis may respond treatment underlying cause children ns increased risk thromboembolism severe bacterial infections particular due pneumoniae malnutrition untreated ns may progress renal failure clinical features oedema worsens may localize back genitals become generalized ascites pleural effusions laboratory treatment typically child presents soft pitting painless oedema varies location based position activity upon awaking child periorbital facial oedema day decreases oedema legs increases oedema differentiated oedema severe acute malnutrition sam sam child presents bilateral pitting oedema feet lower legs vary position oedema extends upwards hands face severe cases usually associated typical skin hair changes see kwashiorkor severe acute malnutrition chapter 1 sam excluded following two criteria must met make clinical diagnosis primary ns presence heavy proteinuria absence associated infections see hepatitis b c hiv infection chapter 8 malaria schistosomiases chapter 6 urine measure protein urinary dipstick three separate voided urine samples first voided urine possible ns proteinuria equal greater equal greater 300 mgdl 30 glitre ns excluded heavy proteinuria consistently present case macroscopic haematuria microscopic haematuria consider glomerulonephritis blood tests available serum albumin concentration less 30 glitre hyperlipidaemia blood urea nitrogen bun creatinine often normal range perform necessary laboratory tests exclude secondary ns hospitalize child initial therapy corticosteroids prednisolone prednisone indicated primary ns starting corticosteroid treatment treat concomitant acute infections pneumonia peritonitis sepsis pharyngitis cellulitispage 296 409 see algorithm total length initial treatment 2 4 months treat infections soon appear routinely give prophylactic antibiotics management complicationsexclude active tuberculosis andor start antituberculous treatment corticosteroid treatment nutrition fluid intake nursing followup saltadded diet restrict fluids risk thrombosis due hypercoagulability oedema severe fluids may initially restricted eg 75 usual intake monitoring urine output encourage child walk play prevent thromboembolism discharge child stable followup least monthly frequently indicated weight urine dipstick visit instruct parent continue saltadded diet seek medical advice case fever abdominal pain respiratory distress signs thromboembolism management infections immunization children 5 years check child received epi vaccines including haemophilus influenzae type b conjugated pneumococcal vaccine endemic area meningococcal conjugate vaccine administer catchup vaccines children 5 years check child received tetanus measles pneumococcal conjugate endemic area meningococcal conjugate vaccine administer catchup vaccines intravascular volume depletion potentially leading shock present despite oedematous appearancepage 297 409signs include decreased urine output one following capillary refill 3 seconds poor skin perfusionmottling cold extremities low blood pressure signs present administer human albumin 5 iv 1 gkg albumin available administer ringer lactate 09 sodium chloride 10 mlkg 30 minutes signs shock present see shock chapter 1 situation diuretics used signs intravascular volume depletion hypovolaemia corrected furosemide po 05 mgkg 2 times daily effective discontinue furosemide creatinine normal administer spironolactone po 1 mgkg 2 times daily dose increased 9 mgkg daily resistant cases ascites diuretics monitor dehydration thromboembolism hypokalaemia specialized advice management including investigations renal biopsy required case steroidresistant ns referral impossible last resort following palliative measure may reduce proteinuria delay renal failure enalapril po 01 03 mgkg 2 times daily start lowest dose increase gradually necessary reduction proteinuria available monitor hyperkalaemia palliative measure prognosis steroidresistant ns poor absence specialized treatment respiratory distress due severe oedema rare children less 1 year 10 years case steroid resistant ns case mixed nephrotic nephritic clinical picture footnotes anephrotic range proteinuria children defined urinary protein excretion greater 50 mgkg daily quantitative measurement protein excretion normally based timed 24hour urine collection however test cannot performed urine dipstick measurements substitutedpage 298 409urolithiasis last updated december 2020 urolithiasis formation passage calculi stones urinary tract clinical features note available ultrasound may demonstrate calculi hydronephrosis treatment note majority calculi pass spontaneously signs significant renal dysfunction secondary infection improve antibiotic treatment consider surgical referralmany calculi cause symptoms may found incidentally radiology exams symptoms arise calculi cause partial complete obstruction andor infection intermittent acute flank pelvic pain renal colic pain severe typically causes nausea vomiting abdomenflank may tender palpation patients typically restless finding comfortable position haematuria andor gravel calculi passed urine fever signs pyelonephritis secondary infection develops see acute pyelonephritis chapter 9 encourage patient drink fluids administer analgesics according intensity pain see pain chapter 1 case secondary infection antibiotic treatment pyelonephritis effectiveness depend passage calculipage 299 409acute cystitis last updated july 2021 cystitis infection bladder urethra affects mainly women girls 2 years age escherichia coli causative pathogen least 70 cases pathogens include proteus mirabilis enterococcus sp klebsiella sp young women staphylococcus saprophyticus clinical features essential rule pyelonephritis symptom burning pain urination alone insufficient make diagnosis see abnormal vaginal discharge investigations perform dipstick analysis nitrites indicate presence enterobacteria leukocytes indicate inflammation urine urine microscopy feasible empirical antibiotherapy administered patients typical signs cystitis positive dipstick urinalysis leukocytes andor nitrites note aside results areas urinary schistosomiasis endemic consider schistosomiasis patients macroscopic haematuria microscopic haematuria detected dipstick test especially children 5 15 years even patient may suffer concomitant bacterial cystitis treatment cystitis girls 2 years cefixime po 8 mgkg daily 3 days amoxicillinclavulanic acid po dose expressed amoxicillin 125 mgkg 2 times daily 3 days cystitis young nonpregnant women fosfomycintrometamol po 3 g single dose nitrofurantoin po 100 mg 3 times daily 5 days burning pain urination urinary urgency frequency children crying passing urine involuntary loss urine fever mild fever flank pain systemic signs symptoms children urine dipstick test dipstick analysis positive nitrites andor leukocytes urinary infection likely women dipstick analysis negative nitrites leukocytes urinary infection excluded microscopyculture dipstick analysis positive recommended carry urine microscopyculture order confirm infection identify causative pathogen particularly children pregnant women pocus cases recurrent cystitis perform fast views evaluate signs urinary tract pathologies dipstick analysis positive nitrites leukocytespage 300 409 cystitis pregnant lactating women fosfomycintrometamol po 3 g single dose nitrofurantoin po contraindicated last month pregnancy 100 mg 3 times daily 7 days cefixime po 200 mg 2 times daily 5 days dipstick analysis negative nitrites positive leukocytes infection may due saprophyticus fosfomycin active pathogen use nitrofurantoin whatever antibiotic used symptoms may persist 2 3 days despite adequate treatment event treatment failure recurrent cystitis ie 34 episodes per year ciprofloxacin po 500 mg 2 times daily 3 days patients recurrent cystitis consider bladder stones urinary schistosomiasis urinary tuberculosis gonorrhoea examine partner footnotes apocus performed interpreted trained clinicianspage 301 409acute pyelonephritis pyelonephritis infection renal parenchyma common women men pathogens causing pyelonephritis causing cystitis see acute cystitis chapter 9 pyelonephritis potentially severe especially pregnant women neonates infants management depends presence signs severity complications risk complications clinical features neonates infant practice urinary tract infection suspected children unexplained fever septic syndrome obvious focus infection older children adults laboratory see acute cystitis chapter 9 treatment symptoms specific fever irritability vomiting poor oral intake palpation lower abdomen may show abdominal tenderness absence fever rule diagnosis hand fever obvious cause may manifestation neonates may present fever hypothermia altered general condition altered conscious state palegrey colour shock signs cystitis burning pain urination urinary urgency frequency etc fever 38 c unilateral flank pain abdominal tenderness nausea andor vomiting common criteria hospital admission patients risk complications children pregnant women men functional structural abnormality urinary tract lithiasis malformation etc severe immunodeficiency patients complicated pyelonephritis urinary tract obstruction renal abscess emphysematous pyelonephritis diabetic patients patients signs severe infection sepsis infection signs organ dysfunction septic shock dehydration nauseavomiting preventing hydration oral treatment clinical improvement 24 hours start oral antibiotherapy women treated outpatients antibiotherapy children children one month ampicillin slow iv 3 minutes 7 10 days children 0 7 days 2 kg 50 mgkg every 12 hours children 0 7 days 2 kg 50 mgkg every 8 hours children 8 days 1 month 50 mgkg every 8 hours gentamicin slow iv 3 minutes 5 days children 0 7 days 2 kg 3 mgkg dailypage 302 409 preferably use combination ampicillin gentamicin cover enterococci pyelonephritis abscess formation emphysematous pyelonephritis may require longer antibiotherapy children 0 7 days 2 kg 5 mgkg daily children 8 days 1 month 5 mgkg daily cefotaxime slow iv 3 minutes 7 10 days children 0 7 days 2 kg 50 mgkg every 12 hours children 0 7 days 2 kg 50 mgkg every 8 hours children 8 days 1 month 50 mgkg every 8 hours children one month ceftriaxone im slow iv3 minutes 50 mgkg daily childs condition improves least 3 days change oral route complete 10 days treatment amoxicillinclavulanic acid po dose expressed amoxicillin children 40 kg 25 mgkg 2 times daily children 40 kg ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily b antibiotherapy adults 1 uncomplicated pyelonephritis ceftriaxone im 1 g single dose gentamicin im 5 mgkg single dose ciprofloxacin po 500 mg 2 times daily 7 days amoxicillinclavulanic acid po dose expressed amoxicillin 10 14 days ratio 81 2000 mg daily 2 tablets 500625 mg 2 times daily ratio 71 1750 mg daily 1 tablet 875125 mg 2 times daily cefixime po 200 mg 2 times daily 400 mg daily 10 14 days pyelonephritis criteria hospital admission ampicillin slow iv 3 minutes 2 g every 6 hours least 3 days gentamicin im 5 mgkg daily 3 days change amoxicillinclavulanic acid po another antibiotic depending antibiotic susceptibility test complete 10 14 days treatment ceftriaxone iv 1 g daily least 3 days gentamicin im 5 mgkg daily 3 days event sepsis change amoxicillinclavulanic acid po another antibiotic depending antibiotic susceptibility test complete 10 14 days treatment b treatment fever pain administer nsaid fever chapter 1 maintain proper hydration 15 litres daily adults especially children risk dehydration treat dehydration present see dehydration chapter 1 management septic shock needed footnotes apyelonephritis rare men bacterial prostatitis suspected event febrile urinary tract infectionpage 303 409referencesbthe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used 1gupta k hooton tm naber kg wullt b colgan r miller lg moran gj nicolle le raz r schaeffer aj soper de infectious diseases society america european society microbiology infectious diseases international clinical practice guidelines treatment acute uncomplicated cystitis pyelonephritis women 2010 update infectious diseases society america european society microbiology infectious diseases clin infect dis 2011525e103 httpsacademicoupcomcidarticle525e103388285 accessed 17 december 2018page 304 409acute prostatitis prostatitis acute bacterial infection prostate common causative pathogen escherichia coli pathogens include proteus mirabilis klebsiella sp pseudomonas aeruginosa enterococcus sp progression chronic prostatitis possible clinical features examination treatment referencesfever often high chills signs cystitis burning urination urinary frequency perineal urethral penile rectal pain urinary retention painful digital rectal examination fluctuant mass case prostatic abscess leukocyturia pyuria possible macroscopic haematuria antibiotic therapy ciprofloxacin po 500 mg 2 times daily 14 days review patient stop treatment signs symptoms completely resolved signs symptoms ongoing continue treatment 14 days 1 symptomatic treatment ensure adequate hydration 15 litres daily treat fever chapter 1 pain chapter 1 refer surgeon case suspected prostatic abscess 1national institute health care excellence nice guideline ng110 prostatitis acute antimicrobial prescribing 2018 httpswwwniceorgukguidanceng110resourcesvisualsummarypdf6544018477 accessed 4 march 2020page 305 409genital infections last updated august 2021 diagnosis treatment genital infections gi present several difficulties clinical features specific many infections asymptomatic laboratory tests available field always reliable mixed infections common sexual partners need treated simultaneously case sexually transmitted infectionsand risk recurrence treatment failure increased hivinfected patients thus introduced syndromic management gi developed standardised case management flowcharts based identification consistent groups signs symptoms syndromes patients treated pathogensinfectionsthat may cause syndrome basic principles gi management special situation sexual violence b look gi patient complains see urethral discharge painful difficult urination dysuriaurethral discharge abnormal vaginal discharge vulvar itchingburning pain intercourse dyspareunia painful difficult urination dysuriaabnormal vaginal discharge genital blisters sores burning sensation vulva perineumgenital ulcers skin growths genital anal area venereal warts lower abdominal pain women lower abdominal pain upper genital tract infections patient effectively treated without laboratory testing tests may help diagnosing vaginal urethral discharge never delay treatment results available within one hour patient treated hisher first encounter health care provider patient sent home without treatment eg waiting laboratory results single dose regimens preferred indicated case urethral discharge abnormal vaginal discharge except candidiasis genital ulcers except herpes sexually transmitted upper genital tract infection sexual partner receive treatment case candidiasis genital herpes venereal warts partner treated symptomatic patients sexually transmitted infections receive information diseases treatment counselled risk reduction hiv testing condoms provided duration treatmentpage 306 409taking consideration physical psychological legal social consequences sexual violence medical care limited diagnosis treatment genital lesions infections care includes listening victims story complete physical examination laboratory tests available completion medical certificate consultation prophylactic curative treatments must proposed patient mental health care necessary irrespective delay event patient arriving consultation care based immediate attention oneonone reception listening necessary followup care view detecting treating psychological andor psychiatric sequelae anxiety depression posttraumatic stress disorder etc see chapter 11 prophylactic treatment priority given risk hiv transmission start antiretroviral therapy early possible patient seen within 48 72 hours exposure see hiv infection aids chapter 8 b risk pregnancy resulting rape administer emergency contraception soon possible ideally within 72 hours rape levonorgestrel po one 15 mg tablet single dose including women receiving hiv postexposure prophylaxis double dose 3 mg patient already taking enzymeinducing drug eg rifampicin carbamazepine certain antiretrovirals rape ulipristal po one 30 mg tablet single dose copper intrauterine device except case active genital infection c prevention sexually transmitted infections single dose azithromycin po 2 g ceftriaxone im 500 mg ceftriaxone available cefixime po 400 mg necessary treatment trichomoniasis may started later treatments tinidazole metronidazole po 2 g single dose tetanus prophylaxis andor vaccination see tetanus chapter 7 wounds vaccination hepatitis b accelerated vaccination schedule see viral hepatitis chapter 8 curative treatment related pathologiesinfections assault recent wounds footnotes agi may sexually transmitted eg gonorrhoea chlamydia eg cases candidiasis bkeep mind schistosoma haematobium endemic areas genital symptoms may also due associated genitourinary schistosomiasis see schistosomiasis chapter 6 cnevertheless 72 120 hours 5 days rape emergency contraception still sufficiently effective administeredpage 307 409urethral discharge last updated august 2022 urethral discharge seen almost exclusively men principal causative organisms neisseria gonorrhoeae gonorrhoea chlamydia trachomatis chlamydia abnormal discharge confirmed performing clinical examination males urethra milked gently discharge visible furthermore specifically check urethral discharge patients complaining painful difficult urination dysuria case management laboratory treatment patient c trachomatis cannot easily identified field laboratory absence validated rapid diagnostic tests treatment empiric men methylene blue gram stained smear urethral swab may used detect gonococci gram negative intracellular diplococci women treatment cervicitis men microscopy urethral smear performed absence gonococci treat chlamydia alone presence gonococci treat chlamydia gonorrhoea laboratory available treat chlamydia gonorrhoea belowpage 308 409 urethral discharge persists reappears 7 days treatment partner sexual partner receives treatment patient whether symptoms present treatment chlamydia treatment gonorrhoea azithromycin po 1 g single dose doxycycline po 100 mg 2 times daily 7 daysplus ceftriaxone im 500 mg single dose ceftriaxone available cefixime po 400 mg single dose verify patient received effective treatment ie one combinations gonococcal resistance possibility another treatment eg cotrimoxazole kanamycin administered retreat gonorrhoea chlamydia rarely resistant effective antibiotic therapy given consider trichomoniasis tinidazole metronidazole po 2 g single dose also consider reinfection footnotes areas lymphatic filariasis endemic careful confuse purulent urethral discharge milky ricewater urine chyluria suggestive lymphatic filariasispage 309 409abnormal vaginal discharge last updated august 2022 abnormal vaginal discharge defined discharge different usual respect colourodourconsistency eg discoloured purulent malodorous abnormal discharge often associated vulvar pruritus pain intercourse dyspareunia painful difficult urination dysuria lower abdominal pain routinely check abnormal vaginal discharge women presenting symptoms abnormal vaginal discharge may sign infection vagina vaginitis andor cervix cervicitis upper genital tract infection abnormal discharge must clinically confirmed inspection vulva speculum exam checking cervicalvaginal inflammation discharge abdominal bimanual pelvic examinations performed routinely women presenting vaginal discharge rule upper genital tract infection lower abdominal pain cervical motion tenderness principal causative organisms case managementin vaginitis gardnerella vaginalis bacteria bacterial vaginosis trichomonas vaginalis trichomoniasis candida albicans candidiasis cervicitis neisseria gonorrhoeae gonorrhoea chlamydia trachomatis chlamydia upper genital tract infections see upper genital tract infectionspage 310 409 cervicitis may difficult diagnose doubt administer treatment cervicitis women abnormal vaginal discharge following risk factors laboratory treatment patient cervicitis treat chlamydia gonorrhoea urethral discharge partner context sexual violence prostitution new partner one partner preceding 3 months xpert molecular pcr tests recommended detection c trachomatis n gonorrhoea microscopic examination fresh wet smear may show mobile vaginalis yeast cells hyphae candidiasis clue cells bacterial vaginosis identification n gonorrhoeae gramstained smear sensitive women recommended page 311 409 bacterial vaginosis trichomoniasis tinidazole po 2 g single dose metronidazole po 2 g single dose case treatment failure tinidazole po 500 mg 2 times daily 5 days metronidazole po 400 500 mg 2 times daily 7 days vulvovaginal candidiasis clotrimazole 500 mg vaginal tab 1 tablet inserted deep vagina bedtime single dose patient extensive vulvar involvement miconazole 2 cream one application vulva 2 times daily 7 days may used combination intravaginal treatment miconazole cream may complement replace treatment clotrimazole treatment partner patient treated vaginitis cervicitis partner receives treatment patient whether symptoms present case vulvovaginal candidiasis partner treated symptomatic itching redness glansprepuce miconazole 2 cream one application 2 times daily 7 daystreatment chlamydia treatment gonorrhoea nonpregnant women azithromycin po 1 g single dose doxycycline po 100 mg 2 times daily 7 daysplus ceftriaxone im 500 mg single dose available cefixime po 400 mg single dose pregnant women azithromycin po 1 g single dose erythromycin po 1 g 2 times daily 500 mg 4 times daily 7 daysplus ceftriaxone im 500 mg single dose available cefixime po 400 mg single dosepage 312 409genital ulcers genital ulcers defined single multiple vesicular ulcerative erosive lesions genital tract without inguinal lymphadenopathy lead consideration sexually transmitted infection principal causative organisms treponema pallidum syphilis haemophilus ducreyi chancroid herpes simplex genital herpes chlamydia trachomatis lymphogranuloma venereum calymmatobacterium granulomatis donovanosisare less frequent case management laboratory laboratory testing available field little value eg syphilis negative rpr vdrl result exclude primary syphilis early stage positive test may reflect previous infection successfully treated patient treatment patient genital herpes local treatment clean area soap water antiviral treatment aciclovir popage 313 409in patients first episode treatment may reduce duration symptoms given within 5 days onset symptoms 400 mg 3 times daily 7 days patients recurrence give dose 5 days treatment effective initiated prodromal phase within 24 hours onset symptoms patients frequent recurrences 6 episodes par year see hiv infection aids chapter 8 syphilis benzathine benzylpenicillin im 24 mui per injection half dose buttock early syphilis primary secondary early latent infection less 12 months duration single dose late latent syphilis infection 12 months duration unknown duration one injection weekly 3 weeks penicillinallergic patients penicillin available erythromycin po 1 g 2 times daily 500 mg 4 times daily 14 days early syphilis 30 days late latent syphilis doxycycline po 100 mg 2 times daily 14 days early syphilis 30 days late latent syphilis azithromycin po 2 g single dose cases early syphilis strain sensitive chancroid azithromycin po 1 g single dose ceftriaxone im 250 mg single dose erythromycin po 1 g 2 times daily 500 mg 4 times daily 7 days fluctuant lymph nodes may aspirated healthy skin required incise drain lymph nodes note treat simultaneously syphilis chancroid frequent cannot correctly distinguished clinical grounds lymphogranuloma venereum erythromycin po 1 g 2 times daily 500 mg 4 times daily 14 days doxycycline po 100 mg 2 times daily 14 days fluctuant lymph nodes may aspirated healthy skin required incise drain lymph nodes donovanosis treatment given complete disappearance lesions usually several weeks otherwise risk recurrence azithromycin po 1 g d1 500 mg daily erythromycin po 1 g 2 times daily 500 mg 4 times daily doxycycline po 100 mg 2 times daily hiv infected patients add gentamicin im 6 mgkg daily treatment partnertreatment pain paracetamol po chapter 1 1 b 2 b bpage 314 409the sexual partner receives treatment patient whether symptoms present except case genital herpes partner treated symptomatic referencesfootnotes alymphogranuloma venereum endemic east west africa india southeast asia south america caribbean donovanosis endemic south africa papua new guinea india brazil caribbean bdoxycycline contraindicated pregnant breastfeeding women 1centers disease control prevention syphilis pocket guide providers 2017 httpswwwcdcgovstdsyphilissyphilispocketguidefinal508pdf 2world health organization guidelines treatment treponema pallidum syphilis geneva 2016 httpappswhointirisbitstreamhandle106652495729789241549806engpdfsequence1 page 315 409lower abdominal pain women upper genital tract infection suspected women lower abdominal pain see upper genital tract infections gynaecological examination routinely performed available pocus perform fast views evaluate free fluid urological abnormalities perform pelvic views evaluate uterine adnexal pathologies consult gynaecologist local via telemedicine services case management inspection vulva speculum examination check purulent discharge inflammation abdominal exam bimanual pelvic exam check pain mobilising cervix footnotes apocus performed interpreted trained clinicianspage 316 409upper genital tract infections ugti last update march 2023 upper genital tract infections bacterial infections uterus endometritis andor fallopian tubes salpingitis may complicated peritonitis pelvic abscess septicaemia ugti may sexually transmitted arise childbirth abortion antibiotic choices directed common pathogens scenario peritonitis pelvic abscess suspected request surgical opinion initiating antibiotic therapy clinical features sexually transmitted infections diagnosis may difficult clinical presentation variable infections childbirth abortion treatment sexually transmitted infectionssuggestive symptoms abdominal pain abnormal vaginal discharge fever dyspareunia menometrorrhagia dysuria infection probable one symptoms associated one following signs cervical motion tenderness adnexal tenderness tender abdominal mass cases present typical clinical picture developing within 2 10 days delivery caesarean section vaginal delivery abortion spontaneous induced fever generally high abdominal pelvic pain malodorous purulent lochia enlarged soft andor tender uterus check retained placenta early stages fever may absent moderate abdominal pain may mild criteria hospitalisation include clinical suspicion severe complicated infection eg peritonitis abscess septicaemia diagnostic uncertainty eg suspicion extrauterine pregnancy appendicitis significant obstacles ambulatory oral treatment improvement 48 hours deterioration within 48 hours outpatient treatment patients may treated ambulatory basis reassessed routinely third day treatment evaluate clinical improvement decrease pain absence fever difficult organise routine followup advise patients return clinic improvement 48 hours treatment sooner condition worsening antibiotic therapy combines 3 antibiotics cover frequent causative organisms gonococci chlamydiae anaerobes ambulatory treatment cefixime po 400 mg single dose ceftriaxone im 500 mg single dosepage 317 409infections childbirth abortion doxycycline po 100 mg 2 times daily 14 days metronidazole po 500 mg 2 times daily 14 days treatment hospital ceftriaxone im iv 1 g daily doxycycline po 100 mg 2 times daily 14 days metronidazole po iv infusion 500 mg 2 times daily 14 days continue triple therapy 24 48 hours signs symptoms improved resolution fever decrease pain continue doxycycline erythromycin metronidazole complete 14 days treatment b iud place removed offer another method contraception analgesic treatment according pain intensity treatment partner single dose treatment gonorrhoea chlamydia urethral discharge whether symptoms present antibiotic therapy treatment must cover frequent causative organisms anaerobes gram negatives streptococci ambulatory treatment early stages amoxicillinclavulanic acid coamoxiclav po 7 days use formulations ratio 81 71 exclusively dose expressed amoxicillin ratio 81 3000 mg daily 2 tablets 500625 mg 3 times daily ratio 71 2625 mg daily 1 tablet 875125 mg 3 times daily amoxicillin po 1 g 3 times daily metronidazole po 500 mg 3 times daily doses 7 days treatment hospital amoxicillinclavulanic acid coamoxiclav iv dose expressed amoxicillin 1 g every 8 hours gentamicin im 5 mgkg daily ampicillin iv 2 g every 8 hours metronidazole iv infusion 500 mg every 8 hours gentamicin im stop antibiotic therapy 48 hours resolution fever clinical signs symptoms penicillinallergic patients use clindamycin iv 900 mg every 8 hours gentamicin case placental retention perform digital curettage manual vacuum extraction refer guide essential obstetric newborn care msf 24 hours initiation antibiotic therapy analgesic treatment according pain intensity patients condition deteriorates fever persists 4872 hours treatment consider possibility complication requiring additional treatment eg pelvic abscess drainage otherwise change antibiotic ceftriaxone doxycycline metronidazole hospitalbased treatment sexually transmitted ugti footnotes pregnantbreastfeeding women erythromycin po 1 g 2 times daily 500 mg 4 times daily 14 days single dose azithromycin effective chlamydia treatment sexually transmitted ugti bthe solvent ceftriaxone im injection contains lidocaine ceftriaxone reconstituted using solvent must never administered iv route iv administration water injection must always used page 318 409venereal warts venereal warts benign tumours skin mucous membranes due certain papilloma viruses hpv clinical features treatment choice treatment depends size location warts treatment may less effective relapses frequent hiv infected patients external warts 3 cm vaginal warts podophyllotoxin 05solution may selfapplied patient event vaginal warts treatment must applied medical staff explain procedure patient apply solution warts using applicator cotton bud sparing surrounding healthy skin allow air dry vaginal warts solution allowed dry speculum withdrawn apply solution 2 times daily 3 consecutive days per week 4 weeks podophyllum preparations contraindicated pregnantor breastfeeding women applied cervical intraurethral rectal oral extensive warts improper use may result painful ulceration external warts 3 cm cervical intraurethral rectal oral warts warts pregnant breastfeeding women surgical excision cryotherapy electrocoagulation venereal warts soft raised painless growths sometimes clustered cauliflower like appearance macules flat warts difficult discern warts external vulva penis scrotum perineum anus andor internal vagina cervix urethra rectum oral cavity hiv infected patients women presence external warts indication speculum examination exclude vaginal cervical warts speculum exam may reveal friable fungating tumour cervix suggestive cancer associated papilloma virus b c footnotes acertain types hpv may cause cancer presence genital warts women indication screen precancerous lesions cervix feasible context visual inspection acetic acid cervical smear available techniques treat lesions identified cryotherapy conisation etc according diagnosis bpodophyllum 10 15 25 resin another preparation much caustic applied medical staff protect surrounding skin vaseline zinc oxide ointment applying resin wash soap water 1 4 hours apply weekly 4 weeks ctreatment warts emergency may deferred alternatives podophyllum preparations available genital warts indication caesarean section uncommon warts interfere delivery risk mothertochild transmission lowpage 319 409major genital infections summary last updated july 2021 page 320 409pathogens infectionsclinical features investigations treatment neisseria gonorrhoeae gonorrhoeain women vaginal discharge cervicitis mucopurulent cervical discharge dysuria 50 infections asymptomatic ugti salpingitis endometritis men purulent urethral discharge sometimes dysuria 5 50 infections asymptomaticbest method pcr xpert available men sensitive enough women gram methylene blue stain intracellular diplococci polymorphonuclear leukocytes 4 per fieldceftriaxone im 500 mg single dose available cefixime po 400 mg single dose treat also chlamydia case upper genital tract infection see ugti chlamydia trachomatis chlamydiain women vaginal discharge cervicitis rarely dysuria 50 infections asymptomatic ugti salpingitis endometritis men mild urethral discharge andor dysuria 90 infections asymptomaticthe best method pcr xpert availableazithromycin po 1 g single dose doxycycline po 200 mg daily 7 days treat also gonococcal infection except gram stain males pcr shows n gonorrhoeae case upper genital tract infection see ugti trichomonas vaginalis trichomoniasisin women yellowgreen vaginal discharge sometimes foul smelling vulvar irritation 10 50 infections asymptomatic men infections asymptomatic produce balanitis urethritis mild discharge sometimes dysuriawet mount fresh vaginal fluid shows motile trichomonas low sensitivity ph urethralvaginal fluid 45tinidazole metronidazole po 2 g single dose bacterial vaginosis gardnerella vaginalis associated bacteriadiagnosis made presence 3 following 4 signs homogenous greywhite adherent vaginal discharge ph vaginal fluid 45 vaginal fluid amine fishy odour especially mixed 10 koh presence clue cells wet mount gram stain vaginal fluidtinidazole metronidazole po 2 g single dose candida albicans candidiasismainly seen women pruritus vulvovaginitis frequently creamy white vaginal discharge sometimes dysuriasaline koh wet mount fresh vaginal fluid shows budding yeast cells pseudohyphaein women clotrimazole 500 mg one vaginal tablet single dosepage 321 409in men balanitisbalanoposthitis inflammation glansprepuce erythema pruritus white pustules rarely urethritisph vaginal fluid normalin men miconazole 2 cream 1 application 2 times daily 7 days herpes simplex virus type 2 genital herpesmany asymptomatic carriers multiple vesicles genitals leading painful ulcerations women affects vulva vagina cervix males penis sometimes urethra primary episodes fever 30 lymphadenopathy 50 recurrences 13 infections shorter milder symptomsdiagnosis culture serology pcr done exclusively reference laboratoryanalgesics local disinfection available aciclovir po primary episode 1200 mg daily 7 days given within 5 days onset lesions recurrent infections dose 5 days given within 24 hours onset lesions treponema pallidum syphilissingle firm painless genital ulcer often unnoticedrprvdrl lack sensitivity specificity may useful following treatment effectiveness decrease titer confirming reinfection rise titer treponemal tests tpha ftaabs rapid tests sd bioline sensitive specificbenzathine benzylpenicillin im 24 miu per injection single dose syphylis 12 months weekly 3 weeks syphilis 12 months unknown duration azithromycin po 2 g single dose erythromycin po 2 g daily 14 days doxycycline po 200 mg daily 14 days treat also chancroid haemophilus ducreyi chancroidpainful single multiple genital ulcer soft chancre bleeds easily touched painful voluminous inguinal lymphadenitis 50 fistulae develop 25 casesh ducreyi bacillus difficult identify microscopy cultureazithromycin po 1 g single dose ceftriaxone im 250 mg single dose ciprofloxacin po 1 g daily 3 days erythromycin po 2 g daily 7 days treat also syphillis b page 322 409human papillomavirus venereal wartssoft raised painless growths sometimes clustered acuminate condyloma macules flat warts warts external vulva penis scrotum perineum anus andor internal vagina cervix urethra rectum oral cavity hiv infected patientsthe diagnosis based clinical features feasible context presence genital warts women indication screen precancerous lesions cervix visual inspection acetic acid cervical smear available techniquesexternal warts 3 cm vaginal warts podophyllotoxin 05 external warts 3 cm cervical intra urethral rectal oral warts warts pregnant breastfeeding women surgical excision cryotherapy electrocoagulation adoxycycline contraindicated pregnant women administered breastfeeding women treatment exceeds 7 days use erythromycin bciprofloxacin avoided pregnant womenpage 323 409abnormal uterine bleeding absence pregnancy last updated october 2021 management pregnancyrelated bleeding refer guide essential obstetric newborn care msf events according clinical examinationheavy menstrual bleeding intermenstrual genital bleeding women childbearing age assess bleeding pregnancyrelated perform pregnancy test rapidly assess severity bleeding perform pelvic examination speculum examination determine origin vagina cervix uterine cavity cause bleeding appearance cervix amount intensity bleeding bimanual examination look cervical motion tenderness uterine enlargement irregularity assess recent trauma surgical history measure haemoglobin possible prevent treat anaemia event signs shock see shock chapter 1 event heavy bleeding start iv infusion ringer lactate monitor vital signs heart rate blood pressure administer tranexamic acid iv 10 mgkg max 600 mg every 8 hours bleeding reduced switch tranexamic acid po 1 g 3 times daily bleeding stops max 5 days 1 bleeding persists andor case contraindication tranexamic acid administer one following two drugs except suspicion cervical endometrial cancer ethinylestradiollevonorgestrel po 003 mg015 mg tab one tablet 3 times daily 7 days medroxyprogesterone acetate po 20 mg 3 times daily 7 days case massive haemorrhage andor lack response medical management surgical management dilation curettage intrauterine balloon last resort hysterectomy event referral surgical facility difficult transport conditions may aggravate bleeding patient iv line andor accompanied family members potential blood donors available pocus perform fast evaluate free fluid andor urological abnormalities perform pelvic views evaluate uterine andor adnexal pathologies friable hard ulcerated hypertrophic mass cervix possible cervical cancer surgical treatment chemotherapy radiation therapy palliative care required depending stage cancer waiting appropriate treatment tranexamic acid po 1 g 3 times daily 5 days max may used reduce bleeding inflammation cervix light moderate bleeding purulent cervical discharge pelvic pain consider cervicitis see abnormal vaginal discharge salpingitis see upper genital tract infectionspage 324 409 note rule causes vaginal bleeding diagnosing functional uterine bleeding consider example poorly tolerated contraceptive endometrial cancer postmenopausal women genitourinary schistosomiasis endemic areas see schistosomiasis chapter 6 referencesenlarged irregular uterus uterine fibroids case failure respond medical treatment surgical management required waiting surgery surgery indicated treat functional uterine bleeding normal uterus cervix possible functional uterine bleeding tranexamic acid po case repeated bleeding combined nsaid ibuprofen po 3 5 days see pain chapter 1 andor one following longterm treatments levonorgestrel intrauterine device ethinylestradiollevonorgestrel po 003 mg015 mg tab one tablet daily medroxyprogesterone acetate im 150 mg every 3 months medroxyprogesterone acetate po 10 mg daily 30 mg daily necessary 21 days monthly b footnotes apocus performed interpreted trained clinicians bunlike treatments drug contraceptive effect 1american college obstetricians gynecologists management acute abnormal uterine bleeding nonpregnant reproductiveaged women obstet gynecol 2013 apr12148916 httpswwwacogorgmediaprojectacogacogorgclinicalfilescommitteeopinionarticles201304managementof acuteabnormaluterinebleedinginnonpregnantreproductiveaged1pdfpage 325 409chapter 10 medical minor surgical procedures dressings treatment simple wound burns cutaneous abscess pyomyositis leg ulcers necrotising infections skin soft tissues venomous bites stings dental infections page 326 409dressings objective dressing wounds promote healing procedure includes cleaning disinfection protection wound respecting rules hygiene wounds need covered dressing eg clean wound sutured several days small dry wound requiring sutures equipment sterile instruments instruments one dressing one patient must wrapped together paper fabric placed metallic box sterilised together limit handling breaks asepsis 5 10 compresses may included set sterile instruments dressing done using sterile gloves renewable supplies organisation care proper organization care helps maintain rules asepsis decreases risk contamination wound transmission organisms one patient another techniqueone kocher pean forceps one dissecting forceps one pair surgical scissors one scalpel excise necrotic tissue cut gauze sutures sterile compresses nonsterile disposable gloves adhesive tape andor crepe gauze bandage sterile 09 sodium chloride sterile water depending wound antiseptic 75 povidone iodine scrub solution 10 povidone iodine dermal solution paraffin compresses analgesics assign one room dressings must cleaned waste removed every day dressing table must disinfected patient dressings may applied bedside patients condition requires use clean disinfected dressing trolley upper tray sterile andor clean material dressing set extra compresses etc lower tray septic material container contaminated instruments sharps disposal container container garbage bag waste prepare necessary material well lit area necessary arrange assistant present wear protective glasses risk projection oozing wound always proceed clean dirty start patients uninfected wounds multiple dressings one patient start cleanest wound procedure may painful give analgesic wait necessary time drug take effect starting procedure settle patient comfortably area privacy respected throughout procedure explain procedure patient obtain cooperation instruments sterile gloves must changed patientspage 327 409removal old dressing observe wound case local signs infection observed look general signs infection fever chills changes overall condition technique cleaning dressing woundto prevent drug interactions use antiseptic care one patient wash hands ordinary soap disinfect alcoholbased hand rub put nonsterile gloves remove adhesive tape bandage superficial compresses proceed gently last compresses stick wound loosen 09 sodium chloride sterile water removal observe soiled compresses significant discharge greenish colour foul odour wound infection likely discard dressing nonsterile gloves waste container case open wound loss cutaneous tissue ulcer colour indicator stage healing process black area necrosis wet dry infected eschar yellow greenish area infected tissue presence pus red area granulation usually sign healing unless hypertrophy however red edges indicate inflammation infection pink area process epithelisation final stage healing begins edges wound case sutured wound existence local signs suppuration pain requires removal one sutures avoid infection spreading local signs include red indurated painful edges drainage pus sutures either spontaneously pressure applied either side wound lymphangitis subcutaneous crepitations around wound wash hands disinfect alcoholbased hand rub open dressing set box checking date sterilisation wrapping intact pick one sterile forceps careful touch anything else pick second forceps help first one make swab folding compress 4 using forceps clean sutured wound clean open wound red granulation clean 09 sodium chloride sterile water remove organic residue work cleanest dirtiest area use clean swab stroke dab dry sterile compress recover sutured wound sterile compresses open wound paraffin compresses dressing extend cm beyond edges wound keep dressing place adhesive tape bandage necrotic infected open wounds clean povidone iodine 75 scrub solution 1 part solution 4 parts sterile 09 sodium chloride sterile water rinse thoroughly dab dry sterile compress available sterile 09 sodium chloride sterile water apply antiseptic 10 povidone iodine dermal solution apply sterile vaseline remove necrotic tissue dressing change wound cleanpage 328 409 principles remain dressing done using instruments sterile gloves subsequent dressingsdiscard sharp materials used appropriate sharps container rest waste waste container quickly possible soak instruments disinfectant wash hands disinfect alcoholbased hand rub clean sutured wound remove initial dressing 5 days wound remains painless odourless dressing remains clean decision recover leave wound uncovered dry often depends context local practices infected sutured wound remove one sutures evacuate pus change dressing least daily open dirty wound daily cleaning dressing change open granulating wound change dressing every 2 3 days except granulation hypertrophic case apply local corticosteroidspage 329 409treatment simple wound simple wound break continuity skin limited depth subcutaneous fatty tissue affect underlying structures muscle bone joints major arteries nerves tendons without significant loss tissue goal treatment assure rapid healing wound without complications sequelae several basic rules apply equipment instruments figures 1a 1d instruments suture one wound one patient must packaged sterilised together suture box set limit handling breaks asepsis renewable supplies technique initial cleaningrapidly treat wounds maintaining rules asepsis order initial procedures cleaning explorationexcision identify wounds need sutured suturing would harmful dangerous immediately suture recent clean simple wounds less 6 hours old delay suturing contaminated wounds andor 6 hours old prevent local abscess general gas gangrene tetanus infections one dissecting forceps one needleholder one pair surgical scissors one pean kocher forceps usually enough one two artery forceps pair farabeuf retractors scalpel may useful contused deep wound local anaesthesia sterile syringe needle 1 lidocaine without epinephrine sterile gloves fenestrated sterile towel sterile absorbable nonabsorbable sutures antiseptic supplies dressings drainage corrugated rubber drain equivalent nylon suture settle patient comfortably area good lighting ensure necessary material prepared explain procedure patient ensure cooperation patient young child arrange assistant hold child necessary wear suitable clothing sterile gloves wounds gown protective glasses risk projection bleeding wound start washing wound prolong cleaning wound particularly soiled use ordinary soap 75 povidone iodine scrub solution water rinse necessary use sterile brush cleaning running water preferable cleaning immersionpage 330 409exploration wound excision immediate suturing simple wound delayed suturing simple wound healing second intention infected woundsif wound infected patient general signs infection fever chills changes overall condition systemic antibiotic therapy may required administer antibiotics least one hour prior starting care wash hands put sterile gloves disinfect wound surrounding area 10 povidone iodine cover wound fenestrated sterile towel local anaesthetic infiltrate 1 lidocaine edges wound wait least 2 minutes anaesthetic take effect proceed carefully superficial deepest parts wound explore extent wound necessary aided assistant consider anatomical location wound look injury underlying structures clinical examination limb must include evaluation sensitivity motor functioning well tendons order orient surgical exploration wound communicates fracture open fracture wound close joint may joint wound wound hands feet may affect nerves andor tendons wound close major artery may arterial wound even longer bleeding look remove foreign bodies event significant pain bleeding exploration must completed operating room goal excision remove nonviable tissue favours proliferation bacteria infection wound may require little excision clean excision extensive wound bruised irregular extensive limit excision skin around wound particularly facial wounds subcutaneous fat tissue doubtful viability generously excised order leave well vascularised tissue immediate suturing may serious consequences patient precautions prevent infection promote healing taken decision suture immediately taken cleaning exploration satisfactory excision following conditions met simple wound 6 hours old devitalised contused tissue wound may long 24 hours old face scalp upper limbs hands bites local treatment see rabies chapter 8 bullet shell mine shrapnel wounds immediately sutured wounds fill conditions immediately sutured cleaning exploration excision simple dressing applied open wound cleaning removal remaining necrotic tissue completed daily dressing changes 72 hours signs local infection wound may suturedpage 331 409if wound meet conditions cleanliness described wound cannot sutured heal either spontaneously healing secondary intention require skin graft wound clean significant loss tissue figures 1 basic instruments figures 2 hold instruments figure 1a kocher forceps straight toothed figure 1b kelly forceps curved nontoothed figure 1c small artery forceps curved nontoothed figure 1d farabeuf retractors page 332 409figures 3 wound debridement done sparingly limited excision severely contused lacerated tissue clearly becoming necrotic figure 2a always mount surgical blade using needle holder change blade new procedure figure 2b dissecting forceps held palm hand rather thumb index finger toothed dissecting forceps used skin figure 2c insert thumb ring finger handle needle holder scissors stabilize instrument using index fingerpage 333 409figures 4 practising making knots using forceps figure 3a debridement contused ragged wound straightening wound edges scalpel conservative facial wounds figure 3b excision edges aponeurosis prevent necrosis figure 3c excision contused musclepage 334 409 figure 4a loop suture around needle holder one direction remember direction loop grasp loose end needle holder pull loop make first knot lower knot closes wound figure 4b second loop opposite direction least 3 knots needed make suture alternating form one direction figure 4c principle first knot lies flat figure 4d second knot opposite direction figure 4e figure 4fpage 335 409figures 5 particular problemsgrasp loose end needle holder figure 4g fist flat knot slide knot towards wound using hand holding loose end holding end needle holder tighten knot without causing tissue ischaemia figure 4h figure 4i second knot opposite directionpage 336 409figure 6 closing corner figure 7 closure skin simple interrupted sutures nonabsorbable sutures figure 5a figure 5b suture deep wide figure 5c figure 5d suture shallow edges invaginated figure 5e poor lining edges figure 5f make knot directly wound page 337 409burns last updated august 2022 burns cutaneous lesions caused exposure heat electricity chemicals radiation cause significant pain may threaten survival andor compromise function classification burns severe burns one following parameters minor burns involving less 10 bsa children 15 adults absence risk factors evaluation burns extent burns lundbrowder table percentage body surface area according age involving 10 body surface area bsa children 15 adults inhalation injury smoke hot air particles toxic gas etc major concomitant trauma fracture head injury etc location face hands neck genitaliaperineum joints risk functional deficit electrical chemical burns burns due explosions age 3 years 60 years significant comorbidities eg epilepsy malnutritionpage 338 409 table helps accurately calculate bsa involved according patients age eg burn face anterior trunk inner surface lower arm circumferential burn left upper arm child 2 years age 85 13 15 4 27 bsa depth burnslocation 1 year 14 years 59 years 1015 years adults head 19 17 13 10 7 neck 2 2 2 2 2 anterior trunk 13 13 13 13 13 posterior trunk 13 13 13 13 13 right buttock 25 25 25 25 25 left buttock 25 25 25 25 25 perineumgenitalia 1 1 1 1 1 right upper arm 4 4 4 4 4 left upper arm 4 4 4 4 4 right lower arm 3 3 3 3 3 left lower arm 3 3 3 3 3 right hand 25 25 25 25 25 left hand 25 25 25 25 25 right thigh 55 65 85 85 95 left thigh 55 65 85 85 95 right leg 5 5 55 6 7 left leg 5 5 55 6 7 right foot 35 35 35 35 35 left foot 35 35 35 35 35page 339 409apart firstdegree burns painful erythema skin absence blisters deep burns thirddegree burns carbonization possible upon initial examination determine depth burns differentiation possible d8d10 evaluation presence inhalation injury dyspnoea chest wall indrawing bronchospasm soot nares mouth productive cough carbonaceous sputum hoarseness etc treatment severe burns initial management admission patient stabilized superficial burn d8d10 deep burn d8d10 sensation normal pain insensitive diminished sensation colour pink blanches pressure white red brown black blanch pressure texture smooth supple firm leathery appearance minimal fibrinous exudate granulation tissue evident bleeds incisedcovered fibrinous exudate little bleeding incised healing heals spontaneously within 5 15 daysvery deep burn always requires surgery spontaneous healing intermediate burn may heal spontaneously 3 5 weeks high risk infection permanent sequelae ensure airway patent highflow oxygen even spo normal 2 establish iv access unburned skin possible intraosseous access iv access possible ringer lactate rl 20 mlkg first hour even patient stable morphine sc 02 mgkg step 1 step 2 analgesics effective event chemical burns flush copious amounts water 15 30 minutes avoiding contamination healthy skin attempt neutralize chemical agent remove clothes adherent burn take history burn injury mechanism causative agent time etc assess burn injury extent depth carbonization ocular burns burns risk secondary functional deficits circumferential burns extremities chest neck wear face mask sterile gloves examination assess associated injuries fractures etc protect patient keep warm cleansterile sheet survival blanket insert urinary catheter burns involve 15 bsa case electrical burns burns perineumgenitaliapage 340 409notes ii general measures first 48 hours resuscitative measures intravenous replacement fluid correct hypovolaemia fluid electrolyte requirements first 48 hours according age note increase replacement volumes 50 3 mlkg x bsa first 8 hours event inhalation injury electrical burn burns 50 bsa limit calculation 50 bsa formula provides guide adjusted according systolic arterial pressure sap urine output avoid fluid overload reduce replacement fluid volumes urine output exceeds upper limit target endpoints iv replacement fluidsinsert nasogastric tube burns involve 20 bsa operating room carrying dressing procedure calculate initiate fluid electrolyte requirements first 24 hours intensive monitoring level consciousness heart rate blood pressure spo respiratory rate rr hourly temperature urine output every 4 hours2 additional testing haemoglobin blood group urine dipstick test prepare patient first dressing procedure operating room burns bleed initial stage check haemorrhage haemoglobin level normal low burns alone alter level consciousness case altered consciousness consider head injury intoxication postictal state epileptic patients clinical manifestations electrical burns vary significantly according type current look complications arrhythmia rhabdomyolysis neurological disorders children 12 years children 12 years adults 0 8 h 2 mlkg x bsa rl maintenance fluidper hour x 8 h 2 mlkg x bsa rl 8 24 h 2 mlkg x bsa rl maintenance fluidper hour x 16 h 2 mlkg x bsa rl 24 48 h daily maintenance iv fluid requirementsminus oral fluids milk broth gavage feeds include drinking water calculation 40 mlkg rl minus oral fluids include drinking water calculation amaintenance fluid alternate rl 5 glucose 4 mlkgh first 10 kg body weight 2 mlkgh next 10 kg 1 mlkgh additional kg 20 kg 30 kgpage 341 409 patients oliguria despite adequate fluid replacement dopamine iv 5 15 microgramskgminute iv pump epinephrine iv 01 05 microgramskgminute iv pump stop infusion 48 hours fluid requirements met oral route gavage respiratory care analgesia see pain management nutrition start feeding early beginning h8 patients risk rhabdomyolysis event deep extensive burns electrical burns crush injuries extremities infection control nonelectrical burns electrical burns children 1 yearchildren 112 yearschildren 12 yearsadultsall ages ap mmhg sap 60 sap 70 90 2 x age sap 100 age appropriate sap urine output 1 2 mlkgh 1 15 mlkgh 05 1 mlkgh 1 2 mlkgh cases continuous inhalation humidified oxygen chest physiotherapy emergency surgical intervention necessary tracheotomy chest escharotomy administer corticosteroids effect oedema predisposition infection specific treatment direct bronchopulmonary lesions daily needs adults calories 25 kcalkg 40 kcal bsa proteins 15 2 gkg high energy foods nrg5 plumpynut f100 milk necessary bsa 20 normal food inadequate nutritional requirements administered according following distribution carbohydrates 50 lipids 30 proteins 20 provide 510 times recommended daily intake vitamins trace elements enteral feeds preferred oral route nasogastric tube necessary bsa 20 start small quantities d1 increase progressively reach recommended energy requirements within 3 days assess nutritional status regularly weigh 2 times weekly reduce energy loss occlusive dressings warm environment 2833 c early grafting management pain insomnia depression monitor myoglobinuria dark urine urine dipstick tests present induce alkaline diuresis 48 hours 20 ml 84 sodium bicarbonate per litre rl obtain output 1 2 mlkghour administer dopamine furosemidepage 342 409precautions infection paramount importance healing complete infection one frequent serious complications burns treatments iii local treatment regular dressing changesprevent infection decrease heat fluid losses reduce energy loss promote patient comfort dressings occlusive assist relieving pain permit mobilisation prevent contractures basic principles techniquehygiene precautions eg sterile gloves handling patients rigorous wound management dressing changes early excision separate new patients 7 days burn convalescent patients 7 days burn administer antibiotherapy absence systemic infection infection defined presence least 2 4 following signs temperature 385 c 36 c tachycardia tachypnoea elevation white blood cell count 100 substantial decrease number white blood cells event systemic infection start empiric antibiotherapy cefazolin iv children 1 month 25 mgkg every 8 hours adults 2 g every 8 hours ciprofloxacin po children 1 month 15 mgkg 2 times daily adults 500 mg 3 times daily local infection absence signs systemic infection requires topical treatment silver sulfadiazine applied children 2 months omeprazole iv d1 children 1 mgkg daily adults 40 mg daily tetanus vaccination see tetanus chapter 7 thromboprophylaxis low molecular weight heparin sc beginning 48 72 hours postinjury physiotherapy d1 prevention contractures analgesia necessary intentional burns suicide attempt aggression appropriate psychological followup rigorous adherence principles asepsis dressing changes require morphine administration nonanaesthetised patient first dressing procedure performed operating room general anaesthesia following operating room general anaesthesia bedside morphine time first dressing procedure shave hairy areas armpit groin pubis burns involve adjacent tissues scalp anteriorly case facial burns entirely case cranial burns cut nails clean burn povidone iodine scrub solution 1 volume 75 povidone iodine 4 volumes 09 sodium chloride sterile water scrub gently compresses taking care avoid bleeding remove blisters forceps scissors rinse 09 sodium chloride sterile water dry skin blotting sterile compresses apply silver sulfadiazine directly hand wear sterile gloves uniform layer 35 mm burned areas except eyelids lips children 2 months adultspage 343 409frequency monitoring iv surgical care emergency surgical interventions burn surgery v pain management burns require analgesic treatment pain intensity always predictable regular assessment paramount use simple verbal scale svs children 5 years adults nfcs flacc scales children 5 years see pain chapter 1 morphine treatment choice moderate severe pain development tolerance common burn patients requires dose augmentation adjuvant treatment may complement analgesic medication eg massage therapy psychotherapy continuous pain experienced restapply greasy dressing jelonet petrolatum gauze using back forth motion use circular movement cover sterile compresses unfolded single layer never encircle limb single compress wrap crepe bandage loosely applied elevate extremities prevent oedema immobilise extension routinely every 48 hours daily event superinfection certain areas eg perineum distal ischaemia burned limb main complication first 48 hours assess signs ischaemia cyanosis pallor extremity dysaesthesia hyperalgia impaired capillary refill monitor daily pain bleeding progression healing infection escharotomy case circumferential burns arms legs fingers order avoid ischaemia circumferential burns chest neck compromise respiratory movements tracheotomy event airway obstruction due oedema eg deep cervicofacial burns tracheotomy performed burned area tarsorrhaphy event ocular deep eyelid burns surgery associated injuries fractures visceral lesions etc excisiongrafting deep burns operating room general anaesthesia d5 d6 excision necrotic tissue eschar simultaneous grafting autografts thin skin intervention entails significant bleeding risk involve 15 bsa surgery early excisiongrafting feasible default process sloughinggranulationreepithelisation sloughing occurs spontaneously due action sulfadiazine petrolatum gauze dressings necessary mechanical surgical debridement necrotic tissue followed granulation may require surgical reduction case hypertrophy risk infection high process prolonged 1 month moderate pain paracetamol po tramadol po see pain chapter 1 moderate severe pain paracetamol po sustained release morphine po see pain chapter 1 page 344 409acute pain experienced care analgesics given addition given continuous pain note doses morphine adults dosing children 1 year halved children less 1 year quartered infants less 3 months chronic pain rehabilitation period minor burns patients severe burns oral drugs poorly absorbed digestive tract first 48 hours morphine administered sc route significant medical interventions extensive burns general anaesthesia operating room limited nonsurgical interventions dressings painful physiotherapy mild moderate pain 60 90 minutes giving care tramadol po see pain chapter 1 rarely allows treatment completed comfortably event treatment failure use morphine moderate severe pain 60 90 minutes giving care immediate release morphine po initial dose 05 1 mgkg effective dose usually around 1 mgkg maximum dose morphine sc initial dose 02 05 mgkg effective dose usually around 05 mgkg maximum dose pain management using morphine dressing changes bedside requires trained nursing team availability immediate release oral morphine naloxone close monitoring level consciousness rr heart rate spo every 15 min first hour following dressing change routine monitoring2 assessment pain intensity sedation intervention 1 hour thereafter necessary equipment ventilation mask manual suction gentle handling patient times adjustment morphine doses subsequent dressings pain intensity svs 0 1 continue dose svs score 2 increase dose 25 50 pain control remains inadequate dressing change carried operating room anaesthesia take advantage residual analgesia following dressing changes carry physiotherapy last resort morphine unavailable facilities give general anaesthesia safe setting trained staff resuscitation equipment recovery room adding ketamine im analgesic doses 05 1 mgkg reinforces analgesic effect paracetamol tramadol combination given dressing change treatment guided selfevaluation pain intensity utilises paracetamol andor tramadol patients may develop neuropathic pain see pain chapter 1 associated pain physiotherapy mobilization treated acute pain treat outpatients wound care dressings silver sulfadiazine children 2 months adults petrolatum gauze except first degree superficial burns pain paracetamol tramadol usually effectivepage 345 409footnotes aopen technique naked burn patient mosquito net water immersion therapy obsolete longer usedpage 346 409cutaneous abscess cutaneous abscess collection pus within dermis subcutaneous tissue commonly due staphylococcus aureus clinical features paraclinical investigations radiography case suspected osteomyelitis septic arthritis treatment equipment anaesthesia analgesia see pain chapter 1 technique incision figure 8apainful red shiny nodule without fluctuance suppuration surrounding cellulitis see erysipelas cellulitis chapter 4 regional adenopathy fever may present complications osteomyelitis septic arthritis septic shock see shock chapter 1 treatment surgical incision drainage aseptic conditions ie sterile consumables instruments antiseptic skin preparation refer surgeon cutaneous abscess located anterior lateral neck central triangle face hand perirectal region breast adjacent major blood vessels eg femoral artery involving joint bone antibiotic therapy signs systemic infection extensive surrounding cellulitis individuals risk factors eg immunosuppression diabetes antibiotic therapy see erysipelas cellulitis chapter 4 sterile scalpel sterile curved nontoothed artery forceps kelly type sterile disposable gloves compresses antiseptic solution 09 sodium chloride 5 10 ml syringe small approximately 5 cm well delineated abscess adults use local anaesthesia 1 lidocaine without epinephrine 10 mgml 15 20 ml larger approximately 5 cm deep poorly delineated abscess adults abscess children consider procedural sedation general anaesthesia ketamine im 10 mgkgpage 347 409digital exploration figure 8b washing abundant washing cavity using syringe filled 09 sodium chloride drainage figure 8c necessary deep abscesses insert drain failing gauze wick base cavity possible fix edge incision single suture drain withdrawn progressively 3 5 days removed completelyhold scalpel thumb middle finger dominant hand index finger presses handle hold abscess thumb index finger hand scalpel blade perpendicular skin incision made single stroke along long axis abscess incision must long enough finger inserted figure 8a incision scalpel explore cavity index finger breaking loculi single cavity remain evacuate pus foreign body present explore edges cavity exploration also allows assessment extent abscess depth location respect underlying structures arterial pulsation possible contact underlying bone last case seek surgical advice figure 8b exploration cavity breaking loculipage 348 409dressing cover sterile compresses figure 8c drain fixed skinpage 349 409pyomyositis pyomyositis infection muscle almost always due staphylococcus aureus commonly affects muscles limbs torso infections may occur simultaneously multiple sites risk factors include immunosuppression concurrent aureus infection malnutrition trauma injection drug use risk mortality significant treatment delayed clinical features paraclinical investigations treatment equipment anaesthesia cutaneous abscess chapter 10 techniquesigns symptoms local exquisite muscle tenderness oedema giving muscles woody texture palpation systemic regional adenopathy fever pyomyositis psoas muscle patient keeps hip flexed experiences pain hip extension abscess right side clinical signs appendicitis pain right iliac fossa complications septic emboli endocarditis septic arthritis septic shock see shock chapter 1 pocus assists characterisation abscess rule deep venous thrombosis radiography may demonstrate foreign body signs osteomyelitis osteosarcoma immobilise limb systematic antibiotic therapy see erysipelas cellulitis chapter 4 adapt analgesics pain level see pain chapter 1 apply compresses soaked 70 alcohol 2 times daily max 3 times daily prevent burns skin incision drainage treatment surgical incision drainage aseptic conditions sterile consumables instruments antiseptic skin preparation following rules incision drainage abscesses see cutaneous abscess chapter 10 muscle abscesses often deeper abscesses result aspiration large bore needle may necessary locate abscess needle aspiration insufficient treatment even pus evacuated followed surgical incision drainage case pyomyositis psoas muscle start antibiotics refer surgeon generous incision along axis limb site abscess avoiding underlying neurovascular stuctures incise skin subcutaneous tissues muscular fascia scalpel figure 9a dissect muscle fibres nontoothed forceps kelly type round tipped scissors insert instrument finger muscle purulent cavity reached instrument used insertion keep instrument closed perpendicular muscle fibres withdraw gently scissors forceps slightly open keeping instrument perpendicular fibres figure 9b abscess found deep may necessary refer surgeonpage 350 409 figures 9 surgical incisiondrainage pyomyositis use forefinger explore cavity break loculi evacuate pus figure 9c wash abundantly 09 sodium chloride insert large drain fix drain edge wound using single suture remove drain 5 day figure 9dth figure 9a long incision figure 9b dissection muscle using kelly forceps insert closed withdraw instrument slightly open figure 9c exploration evacuation pus finger figure 9d drain fixed skin footnotes apocus performed interpreted trained clinicianspage 351 409leg ulcers daily local treatment systemic treatmentleg ulcers chronic losses cutaneous tissue common tropical regions resulting varied aetiologies vascular venous andor arterial insufficiency bacterial leprosy buruli ulcer mycobacterium ulcerans phagedenic ulcer yaws syphilis parasitic dracunculiasis guineaworm disease leishmaniasis metabolic diabetes traumatic trauma often precipitating factor combined another underlying cause history disease complete clinical examination paying particular attention neurological examination determine peripheral neuropathy caused leprosy diabetes usually leads aetiological diagnosis ulcers may become complicated either local regional secondary infections abscess lymphadenopathy adenitis osteomyelitis erysipela pyodermitis generalised infection septicaemia tetanus many years evolution skin cancer bathe leg 10 15 minutes nadcc rinse boiled water remove necrotic black fibrinous yellowish tissue using compresses excise tissue scalpel apply clean ulcer little discharge 10 povidone iodine vaseline dirty ulcer little discharge silver sulfadiazine limited area monitor systemic adverse effects oozing ulcer 10 povidone iodine alone extensive oozing ulcer multiple ulcers diluted povidone iodine 14 10 povidone iodine 34 09 sodium chloride clean water one minute rinse 09 sodium chloride clean water reduce risk transcutaneous iodine absorption cover dry sterile dressing treatment analgesics event pain adapt level dosage individual see pain chapter 1 give systemic antibiotics case secondary infection see bacterial skin infections chapter 4 phagedenic ulcer early stages antibiotics may useful often ineffective chronic stages doxycycline po except children 8 years pregnant lactating women children 8 years 4 mgkg daily adults 200 mg daily metronidazole po children 10 mgkg 3 times daily adults 500 mg 3 times daily 7 days antibiotherapy effective continue doxycycline metronidazole treatment duration varies according clinical evolution treat cause complementary therapy elevate legs cases venous andor lymphatic insufficiencypage 352 409tetanus prophylaxis appropriate see tetanus chapter 7 skin graft ulcer extensive clean red flat skin grafts often necessary surgical excision heal phagedenic buruli ulcerspage 353 409necrotising infections skin soft tissues invasive infections soft tissues skin subcutaneous tissue superficial deep fascia muscles include necrotising cellulitis necrotising fasciitis myonecrosis gas gangrene etc clinical presentation depends causative organism stage progression group streptococcus frequently isolated staphylococcus aureus enterobacteriaceae anaerobic bacteria including clostridium sp delay treatment minor wound certain types wounds gunshot wounds stabbings open fractures non sterile intramuscular injectionscircumcisions certain infections varicella omphalitis favours development necrotising infection patient risk factors include immunosuppression diabetes malnutrition advanced age necrotising infection surgical emergency high mortality rate clinical features laboratory paraclinical investigations radiography may demonstrate gas muscles along fascia planes rule foreign body osteomyelitis osteosarcoma treatment prompt surgical management accompanied iv antibiotic therapy essential reduce high mortality refer immediately surgeon start resuscitation necessary see shock chapter 1 initial signs symptoms include erythema oedema pain disproportionate appearance infection location depends portal entry may difficult differentiate necrotising infections nonnecrotising infections see erysipelas cellulitis chapter 4 systemic signs infection fever tachycardia etc may present lesions progress rapidly despite antibiotic therapy development typical signs necrotizing infection haemorrhagic blisters necrosis cold bluish blackish hypoaesthetic macules signs late infection crepitus palpation fetid odour gas gangrene signs severe systemic infection see shock chapter 1 available following tests help identify early necrotising infection white blood cell count 15 000mm3 4000mm3 serum creatinine 141 micromollitre serum glucose 10 mmollitre 180 mgdl 33 mmollitre 60 mgdl however normal results exclude necrotising infection obtain specimens bacterial culture operating room blood cultures possible emergency surgical treatment debridement drainage wide excision necrotic tissue rapid amputation necessary surgical reevaluation within 24 36 hours check eventual progression necrosis need debridementpage 354 409 cloxacillin iv infusion 60 minutes children 40 kg 50 mgkg every 6 hours children 40 kg adults 3 g every 6 hours ceftriaxone slow iv 3 minutes iv infusion 30 minutes children 1 month 100 mgkg daily adults 2 g daily clindamycin iv infusion 30 minutes neonates 0 7 days 2 kg 5 mgkg every 12 hours neonates 0 7 days 2 kg 5 mgkg every 8 hours neonates 8 days 1 month 2 kg 5 mgkg every 8 hours neonates 8 days 1 month 2 kg 10 mgkg every 8 hours children 1 month 10 13 mgkg every 8 hours max 2700 mg daily adults 900 mg every 8 hours amoxicillinclavulanic acid coamoxiclav slow iv injection 3 minutes iv infusion 30 minutes children less 3 months 50 mgkg every 12 hours children 3 months 40 kg 50 mgkg every 8 hours max 6 g daily children 40 kg adults 2 g every 8 hours iv antibiotic therapy least 14 days depending clinical response cloxacillin ceftriaxone clindamycin amoxicillinclavulanic acid clindamycin doses see b c treatments deep vein thrombosis prophylaxis appropriate management pain see pain chapter 1 early nutritional support footnotes acloxacillin powder injection reconstituted 4 ml water injection dilute dose cloxacillin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults bfor administration iv route ceftriaxone powder reconstituted water injection administration iv infusion dilute dose ceftriaxone 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults cdilute dose clindamycin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults ddilute dose amoxicillinclavulanic acid 5 mlkg 09 sodium chloride children less 20 kg bag 100 ml 09 sodium chloride children 20 kg adults dilute glucosepage 355 409venomous bites stings snake bites envenomation clinical manifestations management bites envenomations described table event coagulation abnormalities continue monitor daily coagulation returns normal patients prepared anaphylactic reaction despite potential severity shock usually easily controlled coagulation disorders serious neurological disorders clinical signs treatment 50 bites dry bites ie envenomation occurred event venom injected severity envenomation depends species amount venom injected location bite bites head neck dangerous weight general condition age individual serious children rare snake involved identified however observation clinical signs may orient diagnosis management two major syndromes identified neurological disorders evolve towards respiratory muscle paralysis coma common manifestations elapid envenomation cobra mamba etc extensive local lesions intense pain inflammation oedema necrosis coagulation abnormalities common manifestations viperid crotalid rattle snake envenomation early diagnosis monitoring coagulation abnormalities based whole blood clotting tests performed dry tube patients arrival every 4 6 hours first day take 2 5 ml whole blood wait 30 minutes examine tube complete clotting coagulation abnormality incomplete clotting clotting coagulation abnormality susceptibility bleeding aetiological treatment based administration snake antivenom serum clear clinical manifestations envenomation coagulation abnormalities observed antivenom sera effective rarely available verify local availability difficult store antivenom serum administered early possible iv infusion 09 sodium chloride using poorly purified serum slow iv event severe envenomation serum known well purified repeat antivenom serum administration 4 6 hours symptoms envenomation persist asymptomatic patients bites without signs envenomation normal coagulation monitoring must continue least 12 hours 24 hours preferredpage 356 409time since biteclinical manifestationspossible aggressortreatment bite 0 fang marks pain site bite strict rest immobilisation limb splint slow diffusion venom wound cleansing tetanus prophylaxis tetanus chapter 7 observe manifestations envenomation dispensary level prepare patient evacuation referral centre envenomation 1030 minuteshypotension myosis excessive salivation sweating dysphagia dyspnoea local paraesthesia paresiselapids insert peripheral iv line iv antivenom serum soon possible inflammatory syndrome intense pain extensive regional oedemaviperids crotalidsinsert peripheral iv line iv antivenom serum soon possible analgesics iv po antiinflammatories b b 30 minutes 5 hourscobra syndrome bilateral eyelid drooping trismus respiratory muscle paralysis shockelapids intubation assisted ventilation see shock chapter 1 30 minutes 48 hourshaemorrhagic syndome epistaxis purpura haemolysis disseminated intravascular coagulation shockviperids crotalidsmonitor coagulation blood clotting test dry tube transfusion fresh blood event severe anaemia see shock chapter 1 6 hours moreno signs changes coagulation non venomous snakes snake bite without envenomation reassure patient send home 12 hours tissue necrosis remove blisters clean daily non occlusive dressings surgical intervention necrosis depending extent lesions stabilise minimum 15 days atourniquets incisionsuction cauterisation ineffective may dangerous bdo use acetylsalicylic acid aspirinpage 357 409scorpion stings envenomation spider bites envenomation well general measures listed treatment includes administration 10 calcium gluconate slow iv event muscle spasms children 5 ml per injection adults 10 ml per injection administered 10 20 minutes incision debridement necrotic tissue recommended useful may impair healing hymenoptera stings honeybees wasps hornetsin case clinical evidence infection drainage abscess amoxicillinclavulanic acid coamoxiclav 7 10 days case cellulitis infections relatively rare often associated traditional treatment nosocomial transmission unnecessary premature surgery cases sting causes local effects including pain oedema erythema management includes strict rest wound cleansing analgesics po tetanus prophylaxis see tetanus chapter 7 patients significant pain infiltrate area around sting local anaesthetic 1 lidocaine observe 12 hours general signs appear event severe envenomation hypertension excessive salivation sweating hyperthermia vomiting diarrhoea muscle pain respiratory difficulties seizures rarely shock aetiological treatment use scorpion antivenom sera controversial effective may poorly tolerated due insufficient purification practice countries scorpion envenomations severe north africa middle east central america amazonia check local availability antivenom sera follow national recommendations criteria administration severity envenomation age patient severe children time elapsed since sting exceed 2 3 hours time elapsed 2 3 hours benefit antivenom serum poor comparison risk anaphylaxis contrast envenomation snakes symptomatic treatment event vomiting diarrhoea excessive sweating prevention dehydration oral rehydration salts especially children event muscle pain 10 calcium gluconate slow iv children 5 ml per injection adults 10 ml per injection administered 10 20 minutes event seizures diazepam may used caution risk respiratory depression increased envenomated patients see seizures chapter 1 treatment usually limited wound cleansing strict rest analgesics po tetanus prophylaxis see tetanus chapter 7 severe envenomations rare two main clinical syndromes neurotoxic syndrome black widow spider severe muscle pain tachycardia hypertension nausea vomiting headache excessive sweating signs develop 24 hours resolve spontaneously days necrotic syndrome recluse spider local tissue lesions possible necrosis ulceration mild general signs fever chills malaise vomiting usually resolve days present haemolysis may sometimes life threateningpage 358 409 children 1 ml syringe available use diluted solution ie add 1 mg epinephine 9 ml 09 sodium chloride obtain 01 mgml solution 110 000 children 6 years 15 ml children 6 12 years 3 ml repeat 5 minutes clinical improvement patients circulatory collapse deteriorate despite receiving im epinephrine use iv epinephrine doses see anaphylactic shock chapter 1 local care remove embedded sting bee clean soap water calamine lotion pruriginous children adults one application 3 4 times daily thin layer analgesics necessary paracetamol po event anaphylactic reaction epinephrine adrenaline im use undiluted epinephrine solution 11000 1 mgml 1 ml syringe graduated 001 ml children children 6 years 015 ml children 6 12 years 03 ml children 12 years adults 05 ml footnotes athere considerable delay decrease coagulation factors less 30 minutes bite first signs bleeding bleeding site bite andor development serosanguinous blisters may appear 3 days bite conversely bleeding may resolve prior normalization coagulation parameterspage 359 409dental infections infection arising secondary complication inflammation dental pulp severity treatment dental infections depend evolution localised infected tooth extended adjacent anatomical structures diffuse infections clinical features treatment infection localised tooth surroundings acute dental abscess infections extending adjacent anatomical structures acute dentoalveolar abscess local spreading acute dental abscess surrounding bone tissue notes dental procedure delayed local anaesthesia possible due inflammation significant trismus start antibiotherapy dental procedure must completed following days improvement within 48 72 hours dental procedure change antibiotic start new procedure tooth infections extending cervicofacial tissuesintense continuous pain examination swelling limited gum surrounding infected tooth purulent exudate may present draining either root canal periodontal ligament loosening tooth gingival fistula signs infection extending adjacent anatomical structures general signs infection treatment treatment surgical source infection inaccessible antibiotics root canal therapy disinfection root canal possible extraction tooth pain paracetamol ibuprofen po see pain chapter 1 painful gingival buccal swelling warm tender skin developing ripe abscess intense pain trismus particularly infection posterior tooth presence general signs fever fatigue cervical lymphadenopathy patients acute gangrenous cellulitis crepitations palpation treat infection extending cervicofacial tissues see treatment first surgical incision drainage pus extraction tooth antibiotic treatment 5 days following procedure amoxicillin po children 25 mgkg 2 times daily adults 1 g 2 times daily pain paracetamol ibuprofen po see pain chapter 1 extremely serious cellulitis rapidly spreading cervical facial tissue necrosis signs septicaemia treatment treatment intensive care unit high dose antibiotic treatment see necrotising infections skin soft tissues extraction toothpage 360 409chapter 11 mental disorders adults anxiety insomnia agitation acute confusional state delirium posttraumatic stress disorder depression psychotic disorders acute psychotic episode chronic psychoses bipolar disorder page 361 409anxiety last updated november 2021 patient suffering anxiety anxiety common feature depression posttraumatic stress disorder psychosis also occur isolation associated mental disorders anxiety symptoms often occur immediately difficult life event medically unexplained symptoms frequent refugees people exposed adversity certain cultures may expression psychological distress management try determine source anxiety reassure patient without minimising distress symptoms necessary use simple relaxation techniques alleviate symptoms symptoms exacerbated eg tachycardia feeling suffocation fear dying going crazy agitation conversely prostration may necessary administer diazepam 5 10 mg po 10 mg im repeated one hour required acute severe anxiety may justify short course max 2 3 weeks diazepam po 25 5 mg 2 times daily reducing dose half last days treatment moderate anxiety lasting 2 weeks administer firstline treatment hydroxyzine po 25 50 mg 2 times daily max 100 mg daily improvement 1 week diazepam po 25 5 mg 2 times daily max 2 weeks symptoms recur treatment discontinuation resume diazepam hydroxyzine reevaluate possible depression posttraumatic stress disorder generalised anxiety lasts 2 months improve psychosocial interventions antidepressant prescribed fluoxetine paroxetine po 20 mg daily continued 2 3 months symptoms resolve stop gradually 2 weekspsychological symptoms pervasive worries eg fear serious illness fear clearlydefined object phobias behavioural changes nervousness avoidance behaviour selfisolating tendency irritability physical symptoms eg dry mouth lump throat sometimes medically unexplained symptoms eg feeling malaise hot flashes chills diffuse pain concentration difficulties sleep problems difficulty getting sleep recurrent nightmares footnotes afor example case hyperventilation use technique controls respiratory rate get patient comfortable position eyes closed help focus breathing becomes calmer regular threephase breathing cycles inhalation count three exhalation count three pause count three etcpage 362 409insomnia last updated november 2021 complaints may difficulty falling remaining asleep waking early morning nightmares fatigue symptoms occur least three times week least one month management insomnia related organic cause treat cause eg administer analgesics pain insomnia related use alcohol drugs medication management depends substance involved insomnia related particular life event eg bereavement short term treatment sedative may useful promethazine po 25 mg daily bedtime 7 10 days promethazine available hydroxyzine po 25 mg daily bedtime 7 10 days last resort risk addiction diazepam po 2 5 mg daily bedtime 7 days max insomnia persists reevaluate patient insomnia common feature depression depression posttraumatic stress disorder posttraumatic stress disorder anxiety disorders anxiety cases underlying disorder addressed footnotes athe main drugs known cause sleep problems corticosteroids beta blockers levodopacarbidopa fluoxetine levothyroxine etcpage 363 409agitation last updated november 2021 people recently experienced violent events anxiety depression psychotic disorders delirium may periods psychomotor agitation agitation common acute intoxication alcoholpsychostimulant drugs withdrawal syndrome certain drugs may cause agitation selective serotonin reuptake inhibitors ssris levodopa mefloquine efavirenz etc agitation may accompanied oppositional violent fleeing behaviour management clinical evaluation best performed pairs calm setting without persons familyfriends depending situation essential check signs delirium present priority identify cause treat see acute confusional state may necessary administer diazepam 10 mg po reduce agitation conduct clinical exam without oversedating patient patient violent dangerous urgent sedation required diazepam im 10 mg repeated 30 60 minutes necessary physical restraint used certain circumstances strictly following procedure place avoid diazepam agitation related acute alcohol intoxication case delirium risk respiratory depression use haloperidol see acute confusional state alcoholic patients experience withdrawal symptoms within 6 24 hours stop drinking withdrawal syndrome taken consideration patients hospitalised therefore forced stop drinking abruptly early phase predelirium tremens symptoms include irritability general feeling malaise profuse sweating shaking treatment consists diazepam po 10 mg every 6 hours 1 3 days reduce stop 7 days oral hydration 3 litres water daily thiamine im slow iv 100 mg 3 times daily least 3 days agitation associated anxiety see anxiety associated psychotic disorders see psychotic disorderspage 364 409acute confusional state delirium last updated july 2022 clinical features clinical picture includes symptoms develop rapidly hours days often fluctuate course day agitation delusions behavioural disorders hallucinations often visual may associated symptoms management delirium almost always organic cause also consider use drugs may cause delirium opioid analgesics psychotropic drugs fluoroquinolones etc use toxic substances alcoholdrugs withdrawal substances delirium requires hospitalisation administration diazepam may increase delirium absolutely necessary sedate agitated patient use low dose haloperidol short time 7 days less haloperidol po 05 1 mg 2 times daily haloperidol im 05 1 mg repeated patient still agitated 30 60 minutes first injection necessary administer additional doses every 4 hours exceed total dose 5 mg daily case delirium related alcohol withdrawal delirium tremensdisorientation time space impaired consciousness concentration problems memory impairment infectious meningitis severe malaria encephalitis septicaemia syphilis aids etc metabolic hyperhypoglycaemia electrolyte imbalance niacin vitamin pp b thiamine vitamin b deficiencies etc3 1 endocrine thyroid disorders neurological epilepsy raised intracranial pressure head trauma meningeal haemorrhage brain tumour etc treat underlying cause provide supportive care ie nutrition fluid electrolyte balance ensure bladder function ensure patient receives medications appropriate needs treat pain needed see pain chapter 1 ensure adequate sensory environment low lightening limit noise admit patient intensive care unit administer diazepam iv 10 20 mg 4 6 times daily close supervision ventilation equipment near hand goal achieve mild sedation without provoking respiratory depression doses duration treatment adjusted according clinical progress iv hydration 2 4 litres 09 sodium chloride per 24 hours administer thiamine im slow iv 30 minutes 100 mg 3 times daily 3 5 days monitor vital signs blood glucose levelspage 365 409posttraumatic stress disorder last updated november 2021 event traumatic someone directly confronted death either seeing another person killed seriously injured result violence experiencing serious harm threat hisher life physical integrity eg rape torture exposure one several events causes feelings helplessness horror immediate transitory symptoms disorientation anxiety sadness fleeing etc distinguished secondary longlasting problems appear andor last several weeks months event posttraumatic stress often associated depression depression sometimes acute psychosis psychotic disorders even people history psychotic symptoms posttraumatic stress disorder characterized three types psychological response generally seen combination hypervigilance constant state alert exaggerated startle reaction anxiety insomnia poor concentration sometimes somatic symptoms sweating shaking tachycardia headache etc reexperiencing highly distressing causes disorders may worsen time people isolate behave differently stop fulfilling familysocial obligations experience diffuse pain mental exhaustion management psychological intervention essential reduce suffering disabling symptoms social handicaps resulting ptsd important reassure patient symptoms normal response abnormal event sessions conducted tact patient listened avoid intensely questioning patient emotions leave patient decide far want go associated symptoms anxiety insomnia persistent relieved symptomatic treatment see anxiety insomnia two weeks patient severe symptoms obsessive thoughts pronounced hypervigilance comorbid despression etc pharmacological treatment fluoxetine po 20 mg daily paroxetine po 10 20 mg daily sertraline po 50 mg daily continued 2 3 months symptoms resolve stop gradually 1 persistent reexperiencing patient describes images thoughts perceptions related traumatic experience intrude despite efforts block including night form distressing dreams flashbacks patient relives parts traumatic scene avoidance patient tries avoid places situations people might associated trauma thoughts feelings related trauma patients may use alcohol drugs psychotropic agents purpose persistent perceptions heightened current threat page 366 409references 1world health organization post traumatic stress disorder international classification diseases mortality morbidity statistics eleventh revision icd11 httpsicdwhointbrowse11lmenhttpidwhointicdentity2070699808 accessed 26 january 2021page 367 409depression last updated july 2022 depression characterised set symptoms present least two weeks represent change previous functioning standard criteria diagnosis major depressive disorder features depression vary according patients culture example depressed patient may express multiple somatic complaints rather psychological distress depression may also manifest acute psychotic disorder given cultural context management faced symptoms depression consider underlying organic cause eg hypothyroidism parkinsons disease adverse effects medical treatment corticosteroids cycloserine efavirenz mefloquine etc look triggering event eg sexual violence recent childbirth postpartum depression depressive disorders common mental disorders patients severe chronic infectious diseases hiv infection tuberculosis disorders neglected especially negative impact adherence treatment symptoms depression common major loss bereavement forced displacement etc gradually subside cases social support psychological support may useful pharmacological treatment always offered along counseling patients severe depression patient health questionnaire9 phq9 score 19 severe functional impairment psychotic symptoms andor suicidal risk patients moderately severe depression phq9 score 1519 pharmacological treatment considered improvement 3 counselling sessions outset patients express personal preference prescribing make sure 9month treatment followup psychological support adherence response possible pervasive sadness andor lack interest pleasure activities normally found pleasurable least four following signs significant change appetite weight insomnia especially early waking rarely hypersomnia psychomotor agitation retardation significant fatigue making difficult carry daily tasks diminished ability make decisions concentrate feelings guilt worthlessness loss selfconfidence selfesteem feelings despair thoughts death suicidal ideation attempt page 368 409preferably use serotonin reuptake inhibitor sri particularly older patients preferably use fluoxetine except pregnancy sertraline preferred fluoxetine po 20 mg alternate days one week daily 3 weeks increase dose necessary max 40 mg daily use caution patients severe anxiety disorders immobilised eg wounded paroxetine po 10 mg daily 3 days 20 mg daily 3 weeks increase dose necessary max 40 mg daily especially depression accompanied severe anxiety sertraline po 25 mg daily 3 days 50 mg daily 3 weeks increase dose necessary max 100 mg daily assess tolerance response every week 4 weeks response inadequate 4 weeks optimal dose sri poorly tolerated replace another sri need medicationfree interval two sris available amitriptyline po may used alternative start 25 mg daily bedtime gradually increase 8 10 days 75 mg daily max 150 mg daily therapeutic dose close lethal dose older patients reduce dose half delay 2 3 weeks antidepressant effect sris occurs least 4 weeks amitriptyline period anxiety may exacerbated risk suicide may increase especially fluoxetine hydroxyzine po 25 50 mg 2 times daily max 100 mg daily promethazine po 25 50 mg daily bedtime may given first 2 weeks treatment improvement 1 week change diazepam po 25 5 mg 2 times daily 2 weeks max first 2 4 weeks give patient tablets quantity required week entrust treatment someone patients close entourage initially ensure administration drug severe depression carries risk suicide talking patients increase risk suicide attempt contrary depressed people often anxious ambivalent suicide feel relieved able talk major symptoms improved month treatment increase maximum dose assess 2 weeks improvement refer patient psychiatrist possible try different antidepressant treatment always stopped gradually 4week period inform patient problems associated abrupt treatment discontinuation common paroxetine special situations pregnant breastfeeding women reevaluate need continue treatment treatment still necessary best continue treatment effective rather switching different antidepressant nevertheless woman plans breastfeed taking fluoxetine consider switching another sri least 3 weeks expected delivery reduce adverse effects neonate breastfeeding monitor neonate first days life signs toxicity withdrawal symptoms depression frequent postpartum breastfeeding period pregnancy case severe post partum depression breastfeeding woman use sertraline firstline option available use paroxetine administer fluoxetine case severe depression pregnancy use sertraline avoid paroxetinepregnancy woman antidepressants depression occurring pregnancy postpartum period footnotespage 369 409ahence importance working informant anthropological sense word dealing unfamiliar cultural contextspage 370 409psychotic disorders last updated july 2022 psychoses characterised delusions patient convinced things real accounted persons cultural background hallucinations patient hears voices exist behavioural symptoms eg strange behaviour agitation mutism opposition fleeing management includes psychosocial support antipsychotic medication treatment efficacy prognosis depend largely quality therapeutic relationship established patient family keeping patient home outpatient followup preferred risk selfharm harm others family capable managing disorder interpretation psychotic symptoms vary according cultural context example psychotic disorders may attributed charms ancestor intervention therapeutic approach take beliefs account patients usually already traditional treatments seen obstacle conventional medical treatment acute psychotic episode chronic psychoses bipolar disorder footnotes ahence importance working informant anthropological sense word dealing unfamiliar cultural contextspage 371 409acute psychotic episode last updated july 2022 acute psychotic episode onetime occurrence usually sudden onset occur repeatedly may early phase chronic psychosis occur following adverse life event eg loss acute stress trauma postpartum psychosis delusions frequently related motherchild relationship prescribing antipsychotic medication consider possibility underlying organic cause see acute confusional state delirium substance use check record blood pressure heart rate weight antipsychotic treatment chronic psychoses haloperidol risperidone last least 3 months 3 months patient stable stop treatment gradually 4 weeks monitoring potential relapse acute episode lasted 3 months continue antipsychotic treatment least 2 years severe anxiety agitation shortcourse anxiolytic sedative treatment may added antipsychotic treatment beginning treatmentpage 372 409chronic psychoses last updated july 2022 chronic psychoses schizophrenia paranoid psychosis etc defined specific clinical characteristics longterm nature schizophrenia characterized delusions disorganized thinking hallucinations depersonalisation loss motivation diminished emotional expression impaired cognition abnormal behaviour neglected hygiene patients often anxious goal treatment reduce symptoms improve social occupational functioning offers real benefits even chronic symptoms persist tendency toward social isolation possible relapses periods increased behavioural problems etc prescribing antipsychotic medication consider possibility underlying organic cause see acute confusional state delirium use substances check record blood pressure heart rate weight treatment last least one year possibly life particularly patients schizophrenia uncertainty possibility followup one year beyond reason treat however better start pharmacological treatment patients familysocial support eg homeless provided severe behavioural disorders prescribe one antipsychotic time limit risk adverse effects start treatment low dose gradually increase minimum effective dose reached older patients reduce dose half whichever medication used haloperidol firstline antipsychotic preferably use oral haloperidol view switching longacting haloperidol haloperidol decanoate patient likely need longterm treatment eg patients schizophrenia haloperidol po start 05 mg 2 times daily 3 days 1 mg 2 times daily end first week increase 25 mg 2 times daily second week 2 weeks assess treatment well tolerated effective effective check adherence necessary increase 5 mg 2 times daily max 15 mg daily haloperidol available contraindicated poorly tolerated possible alternative risperidone po 1 mg 2 times daily one week 2 mg 2 times daily one week necessary increase 3 mg 2 times daily third week max 10 mg daily chlorpromazine po especially sedative effect required 25 50 mg daily evening one week necessary increase 50 mg morning 100 mg evening one week necessary 100 mg 3 times daily third week olanzapine po 10 mg daily necessary increase 5 mg every week max 20 mg daily case extrapyramidal symptoms try reducing dose antipsychotic extrapyramidal symptoms severe add biperiden po 2 mg daily increase necessary 2 mg 2 3 times daily biperiden available use trihexyphenidyl po dosage severe anxiety possible add shortcourse anxiolytic treatment days max 2 3 weeks antipsychotic treatment diazepam po 25 5 mg 2 times daily major agitationpage 373 409haloperidol po 5 mg promethazine po 25 mg repeated 60 minutes necessary 60 minutes necessary administer promethazine im 50 mg case hostile agressive behaviour use im route dose repeated 30 minutes necessary 30 minutes necessary administer promethazine im 50 mg high doses haloperidol induce extrapyramidal symptoms add biperiden necessary diazepam po im 10 mg repeated 60 minutes necessary combine two antipsychotics longterm treatment eg patients schizophrenia longacting antipsychotic drug used patient stabilised oral treatment dosage depends oral dose patient taking switch oral longacting antipsychotic gradual according specific protocol information end transition period oral longacting antipsychotic dose haloperidol decanoate im administered every 3 4 weeks approximately patient risperidone po gradually decrease dose risperidone slowly introducing haloperidol po patient stabilised change haloperidol decanoate every 3 4 weeks special situations pregnant breastfeeding womenif patient antipsychotic treatment patient already antipsychotic treatment daily dose haloperidol pomonthly dose haloperidol decanoate im 25 mg 25 mg 5 mg 50 mg 10 mg 100 mg 15 mg 150 mg aif haloperidol decanoate available fluphenazine im 125 50 mginjection every 3 4 weeks event pregnancy woman taking antipsychotics reevaluate need continue treatment treatment still necessary administer minimal effective dose avoid combination anticholinergic biperiden trihexphenidyl monitor neonate extrapyramidal symptoms first days life first symptoms psychosis pregnancy start lowest dose haloperidol increase slowly necessary postpartum psychosis woman breastfeeding haloperidol preferred longacting antipsychotics administeredpage 374 409bipolar disorder last updated july 2022 bipolar disorder characterised alternating manic depressive episodes generally separated normal periods lasting several months years episodes mania characterised elation euphoria hyperactivity accompanied insomnia grandiose ideas loss social inhibitions sexual particular depressive episodes often severe significant risk suicide look family history similar symptoms particularly suicide frequent bipolar patients pharmacological treatment valproic acid po 200 mg 2 times daily week 1 400 mg 2 times daily week 2 500 mg 2 times daily week 3 usually sufficient stabilise patient necessary dose may increased 500 mg weekly max 1000 mg 2 times daily carbamazepine po 100 mg 2 times daily week 1 200 mg 2 times daily week 2 200 mg 3 times daily week 3 usually sufficient stabilise patient necessary dose may increased 200 mg weekly max 1200 mg daily longterm treatment bipolar disorder based continuation treatment led remission manic episode antipsychotic mood stabilizer combination treatment initiated physician trained mental health consultation set soon possible specialist episodes mania treated haloperidol po 5 mg daily 3 days 75 mg one week necessary increase increments 25 mg per week max 15 mg daily possible alternatives risperidone po 2 mg daily necessary increase increments 1 mg per week max 6 mg daily olanzapine po 10 mg daily 3 days necessary increase increments 5 mg per week max 20 mg daily improvement one week treatment continue dose least 8 weeks remission symptoms diazepam po 5 10 mg daily added first 2 3 weeks symptoms resolve 2 weeks antipsychotic treatment maximum tolerated dose 2 different antipsychotics tried add mood stabiliser treatment continued least 8 weeks complete remission symptoms assess together patient benefits risks pursuing longterm treatment decided discontinue antipsychotic treatment medication stopped gradually monitoring possible relapse depressive episodes treated depression see depression patient episode mania antidepressants immediately stop antidepressants treat episode mania episode mania antidepressants indicative bipolar disorder page 375 409valproic acid recommended women childbearing age necessary start treatment use carbamazepine woman childbearing age already taking valproic acid switch carbamazepine gradually decreasing dose valproic acid period 2 weeks stop treatment abruptly gradually starting carbamazepine woman becomes pregnant planning pregnancy essential contact specialist reevaluate whether treatment still necessary adjust dose needed footnotes aunipolar forms characterized recurring episodes depressionpage 376 409chapter 12 conditions sickle cell disease epilepsy diabetes type 2 adults essential hypertension adults heart failure adults chronic heart failure acute heart failure acute pulmonary oedema endemic goitre iodine deficiency page 377 409sickle cell disease homozygous sickle cell disease scd lifethreatening genetic disorder haemoglobin hb abnormal hb hbs results distortion red blood cells sickle shape leading increased destruction haemolysis increase blood viscosity obstruction capillaries vasoocclusion scd common subsaharan africa 1 3 births american continent india mediterranean basin clinical features major acute manifestations painful vasoocclusive crises voc fever look infection particular pneumonia cellulitis meningitis osteomyelitis sepsis patients particularly susceptible infections especially due pneumococcus meningococcus haemophilus influenzae malaria acute severe anaemia strokesymptoms generally begin 6 months age major signs recurrent painful crises chronic anaemia splenomegaly frequently growth retardation malnutrition children serious acute life threatening complications stroke overwhelming infections acute chest syndrome populations disease frequent diagnosis suggested family history similar clinical signs children 2 years present handfoot syndrome dactylitis acute pain swelling hands feet children older 2 years adults present acute pain affecting back chest abdomen resemble acute abdomen extremities young children may nonspecific signs voc refusal walk irritability lack appetite crying whimpering moaning touched etc look associated infection might precipitated voc case bony pain single location unresponsive analgesics persistent limp child associated fever erythema swelling consider osteomyelitis chronic anaemia often complicated acute severe anaemia gradually appearing fatigue pallor conjunctivae palms shortness breath tachycardia syncope heart failure acute anaemia due acute severe haemolysis often secondary malaria fever haemoglobinuria dark urine yellow conjunctivae splenic sequestration trapping blood cells spleen mostly children 1 4 years sudden enlargement spleen severe left upper quadrant pain thrombocytopenia lead shock aplastic crisis transient suspension red blood cell production bone marrow impalpable spleen absence reticulocytespage 378 409acute chest syndrome acs priapism painful prolonged erection absence sexual stimulation also occurring young boys risk necrosis irreversible erectile dysfunction laboratory investigations diagnosis examinations management major acute manifestationsmost often ischaemic due vasoocclusion cerebral vessels stroke also haemorrhagic sudden loss motor function aphasia children adults signs resemble meningitis cerebral malaria headache photophobia vomiting stiff neck alteration consciousness neurologic signs rarely seizures chest pain tachypnoea respiratory distress hypoxia fever frequent children pulmonary infiltrate chest xray often proceeded voc complications multiorgan failure lung liver kidney hb electrophoresis confirms diagnosis often unavailable available positive emmel test sickling test presence clinical signs sickle cell disease supports diagnosis tests indications haemoglobin time diagnosis annually frequently 7 9 gdl case voc fever acute anaemia 5 gdl drop hb 2 gdl patients baseline stroke acs monitoring transfused patients platelets time diagnosis annually case acute anaemia thrombocytopenia platelet count 100 000mm splenic sequestration3 urine dipstick case fever look urinary tract infection case acute severe anaemia look haemoglobinuria malaria test case voc fever acute anaemia stroke lumbar puncture case fever meningeal signs unexplained coma available complete blood count reticulocyte count blood culture case fever xray suspicion pneumonia osteomyelitis acspage 379 409painful vasoocclusive crisis voc treatment pain according intensity see pain chapter 1 fever infection ceftriaxone slow ivinjection 3 minutes iv infusion 30 minutes children 40 kg 50 mgkg every 12 hours children 40 kg adults 2 g every 12 hours cloxacillin iv infusion 60 minutes children 40 kg 50 mgkg every 6 hours children 40 kg adults 3 g every 6 hours administer iv therapy least 14 days patient improved change oral route additional 14 days treatment combination ciprofloxacin po children 35 kg 15 mgkg 2 times daily children 35 kg adults 500 mg 2 times daily amoxicillinclavulanic acid po see ceftriaxone im slow iv injection 3 minutes iv infusion 30 minutes children 20 kg 50 mgkg daily max 2 gday children 20 kg adults 1 2 g daily 48 hours reevaluate patient amoxicillinclavulanic acid coamoxiclav po 7 10 days use formulations ratio 81 71 exclusively dose expressed amoxicillin children 40 kg 50 mgkg 2 times daily moderate pain home generous oral hydration water soup juice coconut water minimum 100 mlkg daily children 50 mlkg daily adults 25 3 litres daily warm compresses application cold contraindicated level 1 paracetamol ibuprofen level 2 tramadol analgesics pain controlled home within 24 hours seek medical attention severe pain pain controlled home hospital po hydration patient unable drink sufficiently iv hydration appendix 1 event dehydration treat according degree dehydration see dehydration chapter 1 level 3 analgesics morphine give routine antibiotics absence fever transfuse voc admit hospital children less 2 years children fever 385 c adults fever 395 c patients critically ill appearingor acute anaemia po iv hydration appendix 1 treat malaria present treat bacterial infections according cause treat patients respiratory symptoms pneumonia acs case osteomyelitis b c source infection unknown b patient improving afebrile drink change topage 380 409children 40 kg adults ratio 81 3000 mg daily 2 tab 500625 mg 3 times daily ratio 71 2625 mg daily 1 tab 875125 mg 3 times daily patients 2 years without acute anaemia continue treatment outpatients patients 2 years acute anaemia cannot monitored treated home family complete po antibiotherapy hospital acute severe haemolysis aplastic crisis splenic sequestration note splenectomy contraindicated high operative mortality strokeif patient improving continue ceftriaxone patient afebrile change po treatment monitor acute anaemia admit hospital treat malaria present transfuse packed red blood cellsif hb 5 gdl drop 2 gdl patients baseline target hb level 9 gdl e start 10 15 mlkg 3 4 hours information 10 mlkg packed red blood cells usually raise hb 25 gdl repeat hb second transfusion needed check signs fluid overload starting transfusion measure hb perform urine dipstick following days transfusions may necessary haemolysis ongoing admit hospital treat associated bacterial infection present transfuse haemolysis repeat hb every day increasing reticulocyte count gradual increase hb indicate improvement follow patient reached baseline hb admit hospital treat hypovolaemic shock present monitor size spleen transfuse hb 5 gdl target hb level 7 8 gdl maximum administer ceftriaxone clinical improvement monitor relapse follow size spleen admit hospital treatment choice ischaemic stroke exchange transfusion lower concentration hbs transfer patient specialized facility management including prophylactic therapy prevent recurrences transfusion program hydroxyurea patient awaiting transfer transfer possible oxygen continuously least 5 litresminute maintain spo 94 98 2 treat seizures present transfuse hb 9 gdl target hb 10 gdl transfusion provide iv hydration appendix 1page 381 409acute chest syndrome ceftriaxone slow iv injection 3 minutes iv infusion 30 minutes 7 10 days children 20 kg 50 mgkg daily max 2 g daily children 20 kg adults 1 2 g daily azithromycin po 5 days children 10 mgkg daily max 500 mg daily adults 500 mg d1 250 mg daily d2 d5 salbutamol aerosol 100 microgramspuff children adults 2 4 puffs spacer every 10 30 minutes needed priapism prevention complications certain complications avoided appropriate health education patientsfamilies routine preventive care regular followup education patients including children familiesadmit hospital measure spo administer oxygen stroke 2 po hydration voc patient unable drink sufficiently iv hydration appendix 1 monitoring fluid overload event fluid overload administer one dose furosemide iv see dehydration chapter 1 antibiotics b transfuse symptoms unresponsive antibiotics hb 9 gdl wheezing present treat encourage deep breathing incentive spirometry hourly treat pain see pain chapter 1 po hydration voc iv hydration necessary appendix 1 treat dehydration present see dehydration chapter 1 encourage urination apply warm compresses treat pain erection 4 hours consider transfusion refer surgerypage 382 409 routine preventive care phenoxymethylpenicillin penicillin v po age 15 years least 5 years children 1 year 625 mg 2 times daily children 1 5 years 125 mg 2 times daily children 5 15 years 250 mg 2 times daily ensure childs immunisations date administer catch vaccines folic acid polifelong treatment children 1 year 25 mg dailybasic knowledge disease treatment monitoringchronic necessarily transmitted parents noncontagious routine see symptomatic pain size spleen temperature baseline hb major precipitating factors painful crisis prevent cold excessive heat tight clothing dehydration excessive effort infectionswear warm clothing avoid bathing cold water example avoid going midday wear wide comfortable clothing without elastics drink plenty fluids moderate physical activity beneficial follow routine treatments including vaccination principal complications requiring patient seek urgent medical advice pain unresponsive analgesia 24 hours severe start fever treat home respiratory problems cough difficulty breathing chest pain diarrhoeavomiting inability drink dehydration dark infrequent urine anaemia pale yellow conjunctivae pale palms enlarged spleen prevention pneumococcal infections immunization children 5 yearsdtp hepatitis b polio measles h influenzae type b vaccines pneumococcal conjugate vaccine pcv13 available pcv10 meningococcal conjugate vaccine endemic areas 2 years pneumococcal 23valent polysaccharide vaccine least 8 weeks last pcv13 10 children 5 yearsdtp td hepatitis b polio measles h influenzae type b vaccines pneumococcal conjugate vaccine pcv13 pcv10 meningococcal conjugate vaccine endemic areas support red blood cell production f page 383 409children 1 year adults 5 mg daily mefloquine po children 6 months 5 years 5 kg 5 mg basekg weekly use treat malaria routine followup patients children 5 years every 1 3 months children 5 years adults every 3 6 months malaria chemoprophylaxis malaria prevalence 5 provide nutritional support hospital discharge crises information crisis often necessary according clinical course footnotes acritically ill appearing child weak grunting crying drowsy difficult arouse smile disconjugate anxious gaze pallor cyanosis general hypotonia bfor administration iv route ceftriaxone powder reconstituted water injection administration iv infusion dilute dose ceftriaxone 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults ccloxacillin powder injection reconstituted 4 ml water injection dilute dose cloxacillin 5 mlkg 09 sodium chloride 5 glucose children less 20 kg bag 100 ml 09 sodium chloride 5 glucose children 20 kg adults dalways inquire many transfusions patient previously received risk iron overload edo transfuse whole blood possible risk fluid overload firon contraindicated patients received multiple transfusions avoid combined preparations iron folic acidpage 384 409epilepsy last updated october 2024 epilepsy chronic neurological disorder characterized recurrent seizures people epilepsy frequently face discrimination stigma well social economic difficulties also risk mental behavioural cognitive disorders well seizurerelated injuries management comorbidities patientfamily education support essential seizures usually short episodes seizure lasting longer 5 minutes 2 seizures 5 minutes without complete restoration baseline consciousness seizures medical emergency see generalised tonic clonic seizures convulsive status epilepticus chapter 1 clinical features manifestations epilepsy ie seizures varied critical recognize type seizure determine patient management seizures classified follows generalized onset seizures focal onset seizures epilepsy clinically diagnosed 2 unprovoked seizures ie seizures caused temporary reversible condition type occur 24 hours apart treatment principles rarely asms may cause paradoxical increase seizure frequency mainly start treatment increase dose 1 tonicclonic seizures contraction muscles including respiratory muscles tonic phase followed rhythmic jerking arms legs clonic phase loss consciousness myoclonic seizures sudden brief contractions muscle group muscles atonic seizures sudden loss muscle tone frequently resulting falls absence seizures brief seconds impairment consciousness cessation activity common children 4 years age start localised symptoms eg jerking movements one body part repetitive lips smacking sometimes spread rest body becoming generalised 2 3 diagnosis epilepsy seizures requiring longterm treatment made antiseizure medication asm prescribed prevent occurrence new seizures treatment prescribed monotherapy ie single asm choosing asm see choice antiseizure medication likelihood continued asm availability also considered making choice treatment taken daily without interruption long term abruptly stopping reducing asm dose likely provoke seizures longterm patient followup required see patient followup change treatment dose increments asm substitution discontinuation requires close clinical monitoring seizures controlled assess adherence treatment consider increasing dose tolerated maximum dose necessarypage 385 409choice antiseizure medication asm selected according seizures still controlled treatment tolerated gradually change another asm slowly increase dose new asm slowly decrease dose first asm complete substitution combination therapy considered two different asms used monotherapy failed stopping antiseizure treatment may considered patient seizurefree least 2 years benefitsrisks stopping asm discussed patient seizures may recur stopping treatment dose slowly tapered eg 10 every 2 weeks period least 3 months patients seek medical attention seizures recur stopping treatment 4 patient family education essential provide information epilepsy disease benefits treatment ways maximize control including adherence treatment first aid seizures explain people epilepsy lead normal lives certain safety measures taken eg swimming alone cooking open flames 4 5 type seizure asms may exacerbate symptoms patients characteristics age sex pregnancy breastfeeding status comorbidities related treatments asms adverse effect profile general newer asms eg levetiracetam safer better tolerated fewer drug interactions older asms eg carbamazepine phenobarbital phenytoin valproic acid agetype seizures first choice second choice third choice children 1 month 2 years motor generalised tonicclonic myoclonic atonic b levetiracetam levphenobarbital pbcarbamazepine cbz phenytoin pht nonmotor generalised absence focal partial lev cbz pb pht girls 2 10 years boys 2 years men motor generalised tonicclonic myoclonic atonic b lev valproic acid vpacbz pb pht nonmotor generalised absence c lev vpa focal partial lev cbz vpa pb pht girls 10 years women motor generalised tonicclonic myoclonics atonic b lev cbz pht pb nonmotoras generalised absence c lev focal partial lev cbz pht pbpage 386 409children patients 65 years pregnant women girls cases women girls childbearing ageafor myoclonic seizures cbz pht recommended risk worsening symptoms bfor atonic seizures cbz recommended risk worsening symptoms cfor absence seizures cbz pb pht recommended risk worsening symptoms vpa contraindicated children less 2 years increased risk hepatotoxicity lev preferred older patients 6 risk major congenital malformations mcm lower monotherapy combined therapy 7 asms used pregnancy include lev firstline safest asm lowest risk mcm 7 8 asms lev lev available cbz pht associated intermediate risk mcm 7 8 pb associated high risk mcm small gestational age 7 8 taking asm treatment pregnancy lev continue treatment closer monitoring asms lev benefitsrisks substitution safer asm discussed patients substitution may beneficial foetus may also risk mother foetus results loss seizure control term pregnancy taken account substitution safer asm see treatment principles substitution frequently takes 2 3 months vpa must prescribed pregnant women girls associated highest risk mcm neurodevelopmental disorders children exposed utero situations vpa would option divide doses day minimize peaks vpa plasma concentrations 7 8 parents informed current knowledge terms risks unborn child particular risk foetotoxicity high administer lower effective dose foetal harms mainly dosedependent asm plasma concentrations may decrease pregnancy dose needs increased antepartum start reducing d3d4 postpartum gradually return dose effective pregnancy start taking high dose folic acid reduce risk mcm 5 mg daily first trimester 9 pregnancy benefits breastfeeding considered outweigh risk adverse effects asms 10 choice asm based criteria per pregnant women girls due possibility undiagnosed future pregnancies preconception andor contraception counselling offered considering pregnancy depending asm currently taken consider safer asm planning pregnancy start taking folic acid conception reduce risk mcm pregnancy planned effective contraception provided patient taking cbz pb pht injectable medroxyprogesterone dmpa levonorgestrelcontaining copper intrauterine device 7 patient taking lev vpa contraceptive implants oral contraceptives also used 7 page 387 409dosage antiseizure medications start low dose increase gradually based patients response seizure control tolerance occurrence adverse effects following doses given guide ajusted individually carbamazepine po levetiracetam po phenobarbital po phenytoin po valproic acid sodium valproate po patient followupin situations vpa would effective option ie confirmation asms ineffective poorly tolerated blood pregnancy test performed starting treatment regularly patient effective contraception pregnancy occurs see pregnant women girls children 1 month 11 years start 5 mgkg daily 25 mgkg 2 times daily increase daily dose increments 25 5 mgkg every 3 7 days 5 mgkg 2 3 times daily necessary max 20 mgkg daily children 12 years start 100 200 mg daily 50 100 mg 2 times daily increase daily dose increments 100 200 mg every week 200 400 mg 2 3 times daily necessary max 1800 mg daily adults start 100 200 mg daily 50 100 mg 2 times daily increase daily dose increments 100 200 mg every week 400 mg 2 3 times daily necessary max 2 g daily children 1 5 months start 7 mgkg daily increase 7 mgkg 2 times daily 2 weeks increments 7 mgkg 2 times daily every 2 weeks necessary max 21 mgkg 2 times daily children 6 months 17 years 50 kg start 10 mgkg daily increase 10 mgkg 2 times daily 2 weeks increments 10 mgkg 2 times daily every 2 weeks necessary max 30 mgkg 2 times daily children 50 kg adult start 250 mg 2 times daily increase 500 mg 2 times daily 2 4 weeks increments 500 mg 2 times daily every 2 4 weeks necessary max 15 g 2 times daily children 1 month 11 years start 2 3 mgkg daily bedtime 1 15 mgkg 2 times daily 2 weeks increase daily dose increments 1 2 mgkg every week 2 6 mgkg daily necessary children 12 years adults start 1 mgkg max 60 mg daily bedtime 2 weeks increase daily dose increments 15 30 mg every week 3 mgkg daily needed max 180 mg daily children 1 month 11 years start 15 25 mgkg 2 times daily increase daily dose increments 5 mgkg every 3 4 weeks 25 5 mgkg 2 times daily necessary max 75 mgkg 2 times daily 300 mg daily children 12 years start 75 150 mg 2 times daily increase daily dose increments 25 mg every 3 4 weeks 150 200 mg 2 times daily necessary max 300 mg 2 times daily adults start 150 300 mg daily 75 150 mg 2 times daily increase daily dose increments 50 mg every 3 4 weeks 200 400 mg daily 100 250 mg 2 times daily necessary max 400 mg daily 300 mg 2 times daily children 2 11 years start 10 15 mgkg daily 5 75 mgkg 2 times daily increase daily dose increments 5 10 mgkg every week 125 15 mgkg 2 times daily necessary max 600 mg 2 times daily children 12 years adults start 500 600 mg daily increase daily dose increments 200 mg every 3 days 500 mg 1 g 2 times daily necessary max 25 g dailypage 388 409the initial followup schedule guided titration prescribed asm seizures controlled least 1 month followup spaced 3 months every 6 months patient stable encourage maintaining seizure diary possible consultation referencesassess growth development children treatment response seizure frequency tolerance adverse effects impact daily life eg time school work adherence treatment comorbidities including associated anxiety depression adjust dose asm necessary case review patient needed case within one month following change dose provide treatment next consultation facilitys dispensing schedule answer questions discuss problems try find solutions patient footnotes athe optimal dose folic acid prevent mcm established first trimester dose reduced use fixeddose combination 60 mg elemental iron400 micrograms folic acid 1fisher rs cross jh french ja et al operational classification seizure types international league epilepsy position paper ilae commission classification terminology epilepsia 2017584522530 httpsdoiorg101111epi13670 2world health organization pocket book primary health care children adolescents guidelines health promotion disease prevention management newborn period adolescence copenhagen regional office europe 2022 httpswwwwhointeuropepublicationsiitem9789289057622 3fisher rs acevedo c arzimanoglou et al ilae official report practical clinical definition epilepsy epilepsia 2014554475482 httpsdoiorg101111epi12550 4world health organization mhgap intervention guide mental neurological substance use disorders non specialized health settings mental health gap action programme mhgap version 20 world health organization 2016 httpswwwwhointpublicationsiitem9789241549790 5nice epilepsies children young people adults published online april 27 2022 httpswwwniceorgukguidanceng217 6piccenna l odwyer r leppik et al management epilepsy older adults critical review ilae task force epilepsy elderly epilepsia 2023643567585 httpsdoiorg101111epi17426 7american college obstetricians gynecologists gynecologic management adolescents young women seizure disorders acog committee opinion 806 obstet gynecol 2020135e21320 httpswwwacogorgclinicalclinicalguidancecommitteeopinionarticles202005gynecologicmanagementof adolescentsandyoungwomenwithseizuredisorders 8meador kj effects maternal use antiseizure medications child development neurol clin 2022 nov404755768 httpswwwncbinlmnihgovpmcarticlespmc9589915page 389 4099royal college obstetricians gynaecologists uk epilepsy pregnancy published online june 2016 httpswwwrcogorgukmediarzldnacfgtg68_epilepsypdf 10pennell pb use antiepileptic drugs pregnancy evolving concepts neurotherapeutics 2016 oct134811820 httpwwwncbinlmnihgovpmcarticlespmc5081129page 390 409diabetes type 2 adults last update november 2023 diabetes metabolic disorder leads hyperglycaemia type 2 diabetes usually occurs adults accounts 90 95 diabetes cases worldwide type 2 diabetes lead acute complications well chronic complications result serious organ damage cardiovascular events diabetic retinopathy neuropathy nephropathy clinical features diagnosis 1 symptoms symptoms hyperglycaemia may present polyuria frequent urination polydypsia excessive thirst drinking rare cases patients may present severe hyperglycaemia impaired consciousness coma acute dehydration look diabetes event symptoms hyperglycaemia cardiovascular disorders stroke myocardial infarction hypertension peripheral neuropathies foot ulcers absence tendon reflexes peripheral pulse diagnosis made one following results 1 2 tests symptomatic patient asymptomatic patient fasting blood glucose a1 fasting blood glucose 7 mmollitre 126 mgdl2 fasting blood glucose 7 mmollitre 126 mgdl random blood glucose b1 random blood glucose 11 mmollitre 200 mgdlsee tablenote b postload blood glucose c1 postload blood glucose venous blood 11 mmollitre 200 mgdl2 postload blood glucose venous blood 11 mmollitre 200 mgdl capillary blood 122 mmollitre 220 mgdlor capillary blood 122 mmollitre 220 mgdl glycated hb hba1c d1 hba1c 65 2 hba1c 65 afasting blood glucose test performed patient fasted least 8 hours values venous capillary blood brandom blood glucose test performed moment day values venous blood asymptomatic patients recommended perform 2 random blood glucose tests first test random blood glucose second test fasting blood glucose cpostload blood glucose test performed 2 hours oral ingestion 75 g glucose one sachet 75 g anhydrous glucose powder dissolved 200 300 ml water drunk within 10 minutespage 391 409or treatment glycaemic targets fasting blood glucose 7 mmollitre 126 mgdl hba1c 7 closer blood glucose levels remain values cardiovascular complications prevented delayed depending context healthcare provision patient profile older patient history severe hypoglycaemia longstanding poorly controlled diabetes hba1c 8 acceptable blood glucose fall 45 mmollitre 80 mgdl hba1c 65 lifestyle dietary advice pharmacological treatment firstline treatment metformin po usual dose 1 2 g daily information week 1 500 mg daily morning breakfast week 2 500 mg 2 times daily morning evening meals increase increments 500 mg per week long drug well tolerated max 2 g daily ie 1 g morning evening glycaemic control acheived administer metformin combination sulfonylurea sulfonylurea doses adjusted increments avoid risk hypoglycaemia based blood glucose results usual dose 5 mg 2 times daily information week 1 25 mg daily morning breakfast week 2 5 mg daily morning breakfast increase increments 25 mg weekly fasting blood glucose reaches target levels max15 mg daily usual dose 40 80 mg 2 times daily information weeks 1 2 40 mg daily morning breakfast increase increments 40 mg every 2 weeks weeks 3 4 80 mg daily morning breakfast fasting blood glucose reaches target levels max 240 mg daily ie 120 mg morning evening dglycated haemoglobin hba1c reflects average glycaemia around 3 months perform urine dipstick analysis ketones fasting blood glucose 15 mmollitre 270 mgdl symptoms hyperglycemia fasting random blood glucose 18 mmollitre 325 mgdl even without symptoms refer patient acute complications hyperosmolar hyperglycaemia ketoacidosis present 3 2 b avoid sugared foods drinks excessive restriction carbohydrates high fibre intake limit animal fats alcohol physical activity weight control bmi 25 try reduce weight 5 10 stop smoking c patients 60 glibenclamide po patients 60 gliclazide po immediate release tablet page 392 409if glycaemic control acheived combination metformin sulfonylurea continue metformin replace sulfonylurea intermediateacting insulin sc start 02 iukg bedtime dose adjusted measuring fasting blood glucose morning blood glucose levels stabilized test levels weekly consultation doses 1 iukgday may necessary reach glycaemic targets necessary dose 05 iukgday administer 2 injections daily adjustment intermediateacting insulin dosage based blood glucose levels example man weighing 79 kg start 16 iu per day 79 kg x 02 iu d4 blood glucose 146 mmollitre add 4 iu daily dose insulin 20 iu d8 blood glucose 104 mmollitre add 2 iu daily dose insulin 22 iu d12 blood glucose 61 mmollitre glycaemic target reached surveillance monitoring laboratory surveillancemorning blood glucose action 4 mmollitre 70 mgdltreat hypoglycaemia see hypoglycaemia chapter 1 reduce daily dose insulin 2 4 units maintain new dose 4 days check blood glucose 4 days readjust dose glycaemic target reached check blood glucose 4 days repeat process glycaemic target reached 4 72 mmollitre 70 130 mgdldo change dose 72 11 mmollitre 130 200 mgdlincrease daily dose insulin 2 units check blood glucose 4 days readjust dose glycaemic target reached check blood glucose 4 days repeat process glycaemic target reached 11 mmollitre 200 mgdlincrease daily dose insulin 4 units check blood glucose 4 days readjust dose glycaemic target reached check blood glucose 4 days repeat process glycaemic target reached perform urine dipstick analysis ketones according criteria defined diagnosis section patients oral hypoglycemic agents blood glucose test month begin monitoring visits patients insulin fasting blood glucose test dose adjustment phase possible weekly insulin dose stabilised hba1c available every 3 months every 6 months well stabilisedpage 393 409clinical monitoring patient education referencesother necessary tests according comorbidities chronic complications routine consultations check blood pressure remain 14080 mmhg weight examine feet consultations month first 6 months individualised frequency consultations depending patients characteristics eg every 6 months diabetes well controlled annual checkup check cardiovascular neurological complications evaluate renal function serum creatinine proteinuria dipstick test examination teeth gums management diabetes complications b lifestyle dietary measures diet physical activity etc patients sulfonylurea insulin therapy signs hypoglycaemiahyperglycaemia management patients insulin therapy autoadministration schedule injection sites techniques storage insulin patients insulin therapy presenting hypoglycaemic episodes selfmonitoring blood glucose adjustment doses home using glucometer 3 patients sensory neuropathy peripheral arterial disease autoexamination feet prevention foot lesions footnotes aeven symptomatic patients preferable perform second blood glucose test confirm result bthese measures concern patients regardless medication prescribed sufficient alone normalize blood glucose levels certain patients cif metformin contraindicated tolerated replace sulfonylurea 1world health organization classification diabetes mellitus world health organization 2019 accessed october 19 2023 httpsiriswhointhandle10665325182 2hearts diagnosis management type 2 diabetes accessed october 19 2023 httpswwwwhointpublicationsdetailredirectwhoucnncd201 3type 2 diabetes adults management guidance nice published december 2 2015 accessed october 19 2023 httpswwwniceorgukguidanceng28page 394 409essential hypertension adults hypertension high blood pressure hbp defined elevated blood pressure bp rest persists time ie measured 3 times 3 separate consultations period three months essential hypertension defined hbp undetermined cause large majority cases global overall prevalence hbp adults aged 25 around 40 serious complications hbp acute hypertensive encephalopathy leftsided heart failure acute renal failure delayed ie occur long period hbp controlled stroke ischaemic heart disease peripheral arterial disease chronic renal impairment pregnancyinduced hypertension see essential obstetric newborn care msf clinical features sbp 180 andor dbp 110 symptoms moderate headaches epistaxis dizziness tinnitus eye floaters signs endorgan damage sbp 180 andor dbp 110 signs endorgan damage paraclinical investigations 1 hbp thresholds hbp classificationblood pressure bp mmhg systolic sbp diastolic dbp mild 140 90 moderate 160 100 severe 180 110 severe hbp defined presence serious endorgan damage blood pressure reading uncomplicated hypertensive crisis hypertensive emergency intense headaches nauseavomitting confusion seizures coma event hypertensive encephalopathy dyspnoea chest pain event heart failure cardiac ischaemia rapid andor irregular heart rate event heart failure anuria oliguria event renal impairment history clinical examination look medications taken cause aggravate hbp focal neurological signs suggestive stroke comorbidities risk factors heart failure diabetes renal impairment excessive smoking consumption alcohol excess weight bmi 25 etc blood test ionogram particularly serum potassium levels serum creatinine necessary laboratory tests according comorbidities eg diabetespage 395 409longterm treatment lifestyle dietary advice recommended hypertensive patients pharmacological treatment start monotherapy one four classes antihypertensive drugs chosen first line treatment according patients characteristics eg age contraindications etc information ecg echocardiogram look signs heart failure coronary disease arrhythmia goal treatment lower bp target bp sbp 140 andor dbp 90 sbp 140 andor dbp 80 diabetic patients sbp 150 andor dbp 90 patients aged 80 years patients mild hbp sbp 140 andor dbp 90 without associated cardiovascular disorders stroke diabetes start lifestyle dietary advice pharmacological treatment indicated following cases sbp 160 andor dbp 100 hbp associated cardiovascular disorder stroke diabetes hbp controlled lifestyle dietary changes alone reduce calorie salt intake regular physical activity weight loss bmi 25 stop smoking alcohol consumptionpage 396 409 patients comorbidity start thiazide diuretic check bp 4 weeks treatment treatment correctly taken improvement 4 weeks add second antihypertensive drug 4 weeks bitherapy reevaluate patients bp remains high consider tripletherapy diabetic patients improvement 4 weeks aec inhibitor treatment taken correctly add calcium channel blocker patients cardiac disorder heart failure coronary heart disease bitherapy usually necessary start aec inhibitor betablocker surveillance monitoring laboratory surveillance according treatment diuretic aec inhibitor etc ionogram serum creatinine every 6 12 months clinical monitoring patient educationpatient comorbidities patient comorbidities thiazide diuretic stroke thiazide diuretic patient 65 years thiazide diuretic calcium channel blocker diabetic patient angiotensin converting enzyme ace inhibitor beta blocker concomitant cardiovascular disorder patient black skin thiazide diuretic calcium channel blocker avoid ace inhibitorsrenal impairment ace inhibitor thiazide diuretic hydrochlorothiazide po 125 25 mg daily morning max 25 mg daily angiotensin converting enzyme inhibitor enalapril po start 5 mg daily gradually increase every 1 2 weeks according bp 10 20 mg daily max 40 mg daily elderly patients patients taking diuretic patients renal impairment start 25 mg daily calcium channel blocker amlodipine po 5 mg daily increase 10 mg daily necessary max 10 mg daily elderly patients patients hepatic impairment start 25 mg daily betablocker contraindicated patients asthma bisoprolol po 5 10 mg daily morning stop treatment abruptly risk malaise angina consultations every 3 months bp weight every 6 months individualised frequency consultations depending patients characteristics management comorbidities eg diabetespage 397 409treatment hypertensive crisis uncomplicated hypertensive crisis frequent reassure patient prescribe rest check bp days later start adapt treatment hypertensive emergency treat intensive care unit aim reduce bp 10 15 within first hour reduce 25 first 24 hours labetalol iv contraindicated patients asthma 20 mg least 1 minute administer another dose 10 minutes bp decreased necessary 40 mg doses administered every 10 minutes hypertension controlled max 300 mg total dose referenceslifestyle dietary advice treatment observance stop treatment abruptly particularly taking beta blockers risk malaise angina consultation event epistaxis tinnitus eye floaters adverse effects treatment eg cough aec inhibitors erectile dysfunction beta blockers oedema calcium channel blockers hypertensive encephalopathy b stroke try decrease bp first 3 days unless sbp 220 andor dbp 120 event administer labetalol acute pulmonary oedema see acute heart failure footnotes aconsider secondary hypertension caused medications taken mainly nsaid corticosteroids opioids oral estroprogestogens etc treatment event consists stopping replacing causative drug bin patient asthma hydralazine iv 5 10 mg diluted 10 ml 09 sodium chloride administered slow iv repeated 20 30 minutes necessary 1world health organization media center high blood pressure public health problem 2018 httpwwwemrowhointmediaworldhealthdaypublichealthproblemfactsheet2013html accessed 12 september 2018page 398 409heart failure adults heart failure hf defined inability heart maintain adequate cardiac output serious condition particularly frequent people 70 years two types chronic hf gradual onset signs hf acute hf sudden onset lifethreatening hf cardiogenic acute pulmonary oedema shock cases patients known cardiopathy chronic heart failure acute heart failure acute pulmonary oedemapage 399 409chronic heart failure clinical features fatigue andor progressive onset dyspnoea occurs exertion rest accentuated decubitus position preventing patient lying peripheral oedema oedema lower limbs hepatomegaly jugular vein distention hepatojugular reflux ascites advanced stages left rightsided signs rightsided signs often prominent evaluate severity hf identify causative aggravating factors paraclinical investigations treatment lifestyle dietary adviceleftsided hf left ventricle failure frequent form rightsided hf right ventricle failure global hf failure ventricles 1 class limitation physical activity symptoms ordinary physical activity class iislight limitation physical activity comfortable rest ordinary physical activity results fatigue palpitation dyspnoea class iiimarked limitation physical activity comfortable rest less ordinary activity causes fatigue palpitation dyspnoea class iv unable carry physical activity without discomfort symptoms heart failure rest coronary valvular heart disease hypertension viral toxic cardiopathy pericarditis anaemia american trypanosomiasis rheumatic fever diabetes thyroid disorder drugalcohol addiction cardiac ultrasound available method choice confirm cardiopathy electrocardiogram ecg diagnose left ventricular cardiomyopathy left ventricular hypertrophy andor left bundle branch block arrhythmia particularly atrial fibrillation af afib signs myocardial ischemia infarction chest xray exclude lung disease patients dyspnoea show cardiomegaly pleural effusion often bilateral alveolarinterstitial syndrome blood test full blood count ionogram serum creatinine necessary laboratory tests according comorbidities eg diabetes thyroid disorder reduce salt intake limit fluid retention normal fluid intake except cases severe oedema stop smoking physical activity adapted patients capacitypage 400 409treatment fluid retention furosemide po start 20 mg daily increase necessary according clinical response certain patients need doses 80 mg 1 2 times daily reduce oedema decrease 20 40 mg daily reabsorption oedema sometimes slow taking 2 3 weeks gradual worsening hf may require increase dosage lifelong treatment diuretics always necessary event resistant oedema add hydrochlorothiazide po 25 mg 1 2 times daily days hospital settings monitoring renal function longterm lifelong treatment treatmentsweight loss bmi 25 ace inhibitors first line treatment start low doses especially patients hypotension renal impairment hyponatraemia increasing dose monitor drug tolerance dry cough blood pressure systolic bp remain 90 mmhg serum potassium creatinine levels patients taking diuretics reduce dose diuretic possible introducing ace inhibitors risk hypotension patient high doses diuretics enalapril po week 1 25 mg daily 3 days 5 mg daily week 2 10 mg daily 3 days 20 mg daily effective dose usually 20 mg daily 10 mg 2 times daily doses 10 mg daily sometimes enough conversely doses 40 mg daily maximum sometimes necessary patient stable least 2 weeks taking ace inhibitors absence contra indications asthma hypotension bradycardia conduction disorders particularly atrioventricular heart blocks add beta blocker bisoprolol po start low dose gradually increase long drug well tolerated monitor signs worsening hf blood pressure heart rate week 1 125 mg daily week 2 25 mg daily week 3 375 mg daily weeks 4 8 5 mg daily insufficient weeks 9 12 75 mg daily week 13 10 mg daily max 10 mg daily event temporarily worsening hf hypotension bradycardia readjust doses associated treatments reduce dose bisoprolol gradually stop treatment stopping abruptly lead acute deterioration patients condition patient stabilized reincreaserecommence bisoprolol antagonist aldosterone serum potassium levels ecg monitored risk severe hyperkalaemia add spironolactone po 25 mg daily longterm treatment particularly cases severe hf classes iii iv nitrates used leftsided global hf patients intolerance ace inhibitors cough tolerated renal impairment severe hypotension isosorbide dinitrate po start 5 40 mg 2 3 times daily increase effective dose usually 15 120 mg dailypage 401 409treatment causative aggravating factors according cause surveillance monitoring laboratory surveillance according treatment ace diuretic etc clinical monitoring patient education referencesdigitalis glycosides administer caution intensive care unit therapeutic dose close toxic dose patients af rapid ventricular response confirmed ecg visible p waves irregularly irregular qrs complex 120160 stabilised consultations month first 6 months individualised frequency consultations depending patients characteristics routine consultations weight curve bp progress signs dyspnoea oedema etc monitoring comorbidities causative aggravating lifestyle dietary measures diet weight control physical activity adapted patients capacity etc warning signs shortness breath oedema lower limbs serious adverse effects treatment management timelyurgent medical consultation 1chop wm jr extending new york heart association classification system jama 1985254505page 402 409acute heart failure acute pulmonary oedema last updated april 2021 clinical features signs severity paraclinical investigations diagnosis mainly clinical available treatment systolic blood pressure 90 mmhg see shock chapter 1 systolic blood pressure 90 mmhgsudden onset exacerbation dyspnoea fatigue increased time recover exercise bilateral peripheral oedema cold extremities elevated jugular venous pressure auscultation bilateral pulmonary crepitations andor extra heart sound gallop rhythm severe respiratory distress intercostal retractions nasal flaring seesaw breathing spo 90 etc cyanosis profuse sweating confusion2 systolic blood pressure 90 mmhg cardiogenic shock rapid excessive increase arterial blood pressure hypertensive emergency heart rate hr 130minute 40minute respiratory rate rr 30minute 12minute chest pain underlying cardiac ischemia ecg look signs myocardial ischemia arrhythmia chest xray signs vary depending severity pulmonary oedema early stage dilation vessels upper lobes perihilar haze thickening septa advanced stage prominent opacities hilar perihilar regions pleural effusion exclude lung disease pulmonary infection pocus perform 12zone lung exam evaluate signs bilateral pulmonary oedema andor pleural effusions perform 5view cardiac exam evaluate signs acute volume overload andor decreased cardiac function monitoring full blood count electrolytes serum creatinine cardiac troponins available 1 2 patient must hospitalised place patient semiseated position legs patients spo 90 administer oxygen mask necessary flow rate maintain spo 95 pulse oximetry available administer oxygen flow rate 6 10 litresminute patients signs of2 2page 403 409isosorbide dinitrate sublingual 5 mg tablet 5 mg per dose necessary 2 doses taken 10 minutes apart isosorbide dinitrate iv 10 ml ampoule 1 mgml 2 mg 2 ml slow iv injection 2 minutes necessary 2 10 mghour continuous infusion electric syringe pump glyceryl trinitrate sublingual 05 mg tablet 05 mg per dose necessary 3 doses taken 5 minutes apart subsequent treatment depends underlying pathology chronic heart failure hypertension acute coronary syndrome etc referenceshypoxia insert iv line signs volume overload andor case hypertensive emergency furosemide iv 40 80 mg may repeated necessary according urine output signs respiratory distress spo patient already taking furosemide doses 40 mg administer preexisting dose iv route2 add shortacting nitrate vasodilator systolic blood pressure 100 mmhg aim gradually lower systolic blood pressure nearbaseline value patients baseline value unknown information lower systolic blood pressure 120150 mmhg diastolic pressure 110 mmhg noninvasive ventilation using continuous positive airway pressure cpap recommended patients persistent hypoxaemia unless contraindicated eg impaired consciousness condition appropriate monitoring available monitoring hr rr bp spo mental status urine output 2 footnotes apocus performed interpreted trained clinicians 1ponikowski p et al 2016 esc guidelines diagnosis treatment acute chronic heart failure task force diagnosis treatment acute chronic heart failure european society cardiology esc developed special contribution heart failure association hfa esc eur j heart fail 2016188891975 httpsacademicoupcomeurheartjarticle372721291748921 accessed 23 march 2021 2ezekowitz justin et al 2017 comprehensive update canadian cardiovascular society guidelines management heart failure j cardiol 20173313421433 httpswwwonlinecjccaactionshowpdfpiis0828282x28172930973x accessed 23 march 2021page 404 409endemic goitre iodine deficiency goitre enlargement thyroid gland endemic goitre occurs iodinedeficient areas goitre also caused aggravated regular consumption goitrogens manioc cabbage turnips millet etc goitre adaptive process iodine essential production thyroid hormones iodine deficiency impairs thyroid hormone synthesis compensate thyroid gland increases volume thyroid function usually remains normal well development goitre iodine deficiency pregnant women serious consequences child foetal perinatal mortality physical mental retardation cretinism risks must prevented providing iodine supplementation iodinedeficient areas clinical features prevention treatment objective prevention reduce consequences iodine deficiency neonates children supplying iodised salt national programmes recommended method prevention prevention populations living iodine deficient areas iodised salt available curative treatment patients goitre use iodised oil according national protocols information according curative preventive singledoses oral treatment preferred target populations pregnant breastfeeding women women childbearing age children children goitre disappears several months disappears slowly never adults despite restoration normal thyroid function 2 weeks surgery indicated patients local mechanical dysfunctionthe proposes simplified classification based significance goitre group 0 normal thyroid palpable visible goitre group 1 enlarged thyroid palpable visible neck normal position group 2 thyroid clearly visible neck normal position possible mechanical complications rare compression deviation trachea oesophagus populationiodised oil po yearly 190 mg capsule children 1 year 1 capsule children 1 6 years 2 capsules children 6 15 years 3 capsules pregnant lactating women women childbearing age2 capsulespage 405 409appendices appendix 1 normal daily maintenance iv fluids children 1 month page 406 409appendix 1 normal daily maintenance iv fluids children 1 month last updated january 2021 indications basic hydration needsfor patients unable drink sufficiently 48 hours essential provide nutrition patient orally nasogastric tube gradually reduce iv fluids protocol used surgical burns patients renal cardiac disease diabetic ketoacidosis fluid administered fluid choice children ringer lactateglucose 5 rlg5 use premixed solution available add 50 ml g50 500 ml rl 100 ml g50 1000 ml rl rl available use 09 sodium chloride instead ease prescription administration daily volumes rates drops per minute rounded weightvolume 24 hoursrate paediatric infusion set 1 ml 60 drops 3 4 kg 350 ml24 h 15 dropsmin 4 5 kg 450 ml24 h 19 dropsmin 5 6 kg 550 ml24 h 23 dropsmin 6 7 kg 650 ml24 h 27 dropsmin 7 8 kg 750 ml24 h 31 dropsmin 8 9 kg 850 ml24 h 35 dropsmin 9 11 kg 950 ml24 h 40 dropsmin 11 14 kg 1100 ml24 h 46 dropsmin 14 16 kg 1200 ml24 h 50 dropsmin 16 18 kg 1300 ml24 h 54 dropsmin 18 20 kg 1400 ml24 h 58 dropsminpage 407 409 weightvolume 24 hoursrate paediatric infusion set 1 ml 60 drops rate standard infusion set 1 ml 20 drops 20 22 kg 1500 ml24 h 63 dropsmin 21 dropsmin 22 26 kg 1600 ml24 h 67 dropsmin 22 dropsmin 26 30 kg 1700 ml24 h 71 dropsmin 24 dropsmin 30 35 kg 1800 ml24 h 75 dropsmin 25 dropsmin 35 kg 2000 ml24 h 83 dropsmin 28 dropsmin paediatric infusion set number drops per minute equal number ml per hour example 15 dropsmin 15 mlhour footnotes adaily needs calculated according following formula children 010 kg 100 mlkg per day children 1120 kg 1000 ml 50 mlkg every kg 10 kg per day children 20 kg 1500 ml 2025 mlkg every kg 20 kg per day adults 2 litres per daypage 408 409main references websites consulted june 2019 december 2022 british national formulary bnf british national formulary children bnfc medicinescomplete martindale complete drug reference medicinescomplete uptodate evidencebased clinical decision support resource bmj group bmj best practice la revue prescrire centre belge dinformation pharmacotherapeutique cbip httpwwwcbipbefrstart centers disease control prevention httpwwwcdcgovdiseasesconditions cochrane library world health organization httpwwwwhointpublicationsenpage 409 409